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ABSTRACT 
 
 
Fibronectin (FN) is a ubiquitous component of the extracellular matrix (ECM).  Its assembly into 3D fibrillar 
matrices is essential during development and tissue repair to maintain tissue architecture and provide 
environmental signals to cells.  However, FN deposition must be tightly regulated as excessive assembly is a 
major hallmark of fibrotic diseases and cancer.   
 
Tenascin-C (TN-C) is a large, multi-domain ECM glycoprotein that co-localizes with newly synthesized FN 
fibrils in vivo during development, wound repair and tumorigenesis.  However, it is not known precisely how 
FN and TN-C interact within the ECM, or whether their interaction has any functional relevance.    
 
I have demonstrated that distinct domains of TN-C inhibit FN matrix assembly by fibroblasts, whereas full 
length TN-C has no effect.  I have identified regions within TN-C domains that are essential for binding to 
fibrillar FN, but not to soluble FN, and mapped where they interact within the FN molecule.  I have found 
that domains containing these regions interfere with inter-molecular FN-FN interactions during 
fibrillogenesis.  I also identified other TN-C domains that interfered with FN matrix assembly by FN-
independent mechanisms.   I demonstrated that one of these TN-C domains was internalized by fibroblasts 
causing morphological changes that may interfere with cytoskeleton organization or cell surface receptor 
availability to prevent the maintenance of a fibrillar FN matrix at the cell surface.   
 
Recently emerging evidence indicates that deposition of FN by epithelial and endothelial cells is absolutely 
vital for tubulogenesis and the formation of new blood vessels.  Without this scaffold, the cells fail to 
generate sufficient tensional force required for the morphogenesis and migration essential for tubule 
formation.  I have shown that specific domains of TN-C can inhibit tubulogenesis by epithelial cells within a 
3D collagen matrix and may also affect angiogenesis of endothelial cells within a 3D collagen matrix 
environment.  
 
These data suggest that proteolysis of TN-C during tissue remodelling may create fragments that act to limit 
FN matrix assembly.  Persistent TN-C expression during fibrosis and tumour growth may contribute to 
uncontrolled FN deposition and angiogenesis during disease progression. 
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1.1   The Extracellular matrix 
The extracellular matrix (ECM) is a highly structured network of secreted proteins, proteoglycans 
and carbohydrates.  Differences in the composition and organization of the ECM lead to an 
amazingly diverse range of matrix structures, each one adapted to the tissue and its function.   For 
example the basement membrane is composed of fibronectin, collagen type IV, laminin, nidogen 
and perlecan arranged in a flat lattice network, which functions to separate the epithelia and 
endothelia, providing cellular cues and signals.   In contrast, in tendons, the predominant ECM 
component is collagen type I organized into long, parallel collagen fibrils, which allows tensile 
force to be transduced to the skeleton.  The ECM is a complex mixture of many different interacting 
molecules and the exact constituents are tissue specific and dependent on the ECM function.   
 
The ECM was originally referred to as ‘ground substance’ and thought to act only as an inert 
support for cells.  Whilst the ECM does play a key structural role by acting as a scaffold that 
maintains tissue architecture, it is also important in actively regulating cellular processes. The ECM 
regulates cell behavior in a number of different ways: it sequesters growth factors to control cell 
signaling but also directly signals to the cell itself either by activation of cell surface receptors via 
interactions with ECM components or by applying external tension on the cell.   
 
The composition of the ECM is important as the resident constituents both determine the rigidity of 
the ECM and define which signaling pathways will be activated.  The 3D nature of the ECM is also 
important in regulating cell activity; cells in vivo are often surrounded in ECM and behave very 
differently when cultured on 2D surfaces compared to a 3D environment (Cukierman et al., 2001) 
(Geiger, 2001).  Furthermore, the ECM is in a constant state of turnover: cells are continuously 
synthesizing and degrading ECM proteins to maintain tissue architecture and regulate cellular 
processes.  Control of this ECM deposition is important during developmental morphogenesis, as 
well as in adult homeostasis to prevent aberrant cell signaling.   
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Figure 1.1   FN matrix assembled by cultured cells
FN matrix assembled by NIH 3T3 fibroblasts cultured for 24 h in serum-free medium.  Cells were fixed 
in 3.8 % paraformaldehyde and stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-
568 conjugated antibody.  Images were taken by confocal microscopy at x60 magnification, scale bar 
= 25 μm.   
 
My aims are to examine how different components of the ECM interact to form 3D matrices, to 
determine how the assembly of complex 3D matrices is regulated by components of the ECM and 
to investigate how these ECM networks affect cell behavior.   I will focus on the assembly of 
fibronectin (FN) – a key ubiquitous component of the ECM.  
 
1.2   Fibronectin 
FN is an abundant and ubiquitously expressed, 220-250-kDa glycoprotein of the ECM (Mao and 
Schwarzbauer, 2005a) (Pankov and Yamada, 2002) (Wierzbicka-Patynowski and Schwarzbauer, 
2003).  Plasma FN is synthesized by hepatocytes and secreted into the blood plasma, where it 
circulates at ~300-400 μg/ml (Zardi et al., 1979) in a soluble, compact inactive form.  Cellular FN is 
synthesized, secreted and assembled locally by many cell types including, but not only, fibroblasts 
(Figure 1.1), endothelial cells, chondrocytes, glial cells, synovial cells and myocytes  (Mao and 
Schwarzbauer, 2005a). 
 
 
 
 
 
 
 
 
 
 
FN assembly into a 3D fibrillar network on the cell surface is vital for establishing and maintaining 
tissue architecture and for influencing cell behavior.  FN  has been shown to regulate a wide variety 
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of cellular functions including adhesion (Manabe et al., 1997) (Sottile and Mosher, 1997) (Wang et 
al., 2005) (Friedland et al., 2009), spreading (Gui et al., 2006), proliferation  (Gui et al., 2006) 
(Jiang et al., 1999) (Sechler and Schwarzbauer, 1998) (Sottile and Mosher, 1997), migration (Clark 
et al., 2003) (Couchman et al., 1982) (Hocking and Chang, 2003) (Rozario et al., 2009), and 
apoptosis (Natal et al., 2006) (Tafolla et al., 2005). 
 
1.2.1   FN function in development 
During development, cellular processes have to be tightly coordinated, requiring signaling events 
from cell-ECM, cell-cell and growth factor-cell interactions.  FN plays a vital role in directing these 
cellular events as FN null mice are embryonic lethal at E10-11.  FN null embryos showed 
increasing abnormalities in mesodermal development including that of the heart and 
extraembryonic vasculature, neural crest, trunk and limb buds (Astrof and Hynes, 2009) (George et 
al., 1993) (George et al., 1997).  FN matrices were shown to be essential for generating polarized 
tension to correctly orient cell division during development (Rozario et al., 2009).  Mice null for FN 
receptors such as α5, αv or β1 integrins were also shown to be embryonic lethal (Yang et al., 1999).     
 
FN also plays an essential role in tubule formation and branching morphogenesis during the 
development of salivary glands, lung and kidney; FN is expressed most strongly in the cleft regions 
of budding salivary gland explant epithelium, which was inhibited by the presence of blocking anti-
FN antibodies and by siRNA expression knockdown (Sakai et al., 2003).  Tubulogenesis requires 
complex coordination of epithelial cell adhesion, spreading, proliferation, migration and 
organization into tubular structures (Borenstein and Cline., 2004) (Montesano et al., 1991) 
(Schoenenberger et al., 1994).  FN is essential for mediating this process in vivo.  FN induces tubule 
formation by ureteric bud cells when grown in 3D collagen type I gels, a model of processes that 
are important during renal development (Ye et al., 2004).  FN has been shown to be essential for 
determining cell polarity in cardiac precursors during heart tube formation; zebrafish with a null 
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mutation in the FN1 gene showed defective adherens junction formation between myocardial 
precursors and poor organization of the myocardial epithelia, which lead to defective cell migration 
and defective heart tube formation (Trinh and Stainier, 2004).  FN-null mice develop lethal vascular 
defects, including impaired heart development and collapsed blood vessel lumens (Astrof and 
Hynes, 2009).   
 
FN plays a role in regulating cell adhesion, migration, proliferation and survival during in vitro 
tubulogenesis (Ilic et al., 1995) (Jiang et al., 1999) (Jiang et al., 2000) (Montesano et al., 1991) 
(Schoenenberger et al., 1994).  Madin-Darby canine kidney (MDCK) epithelial cells express the 
EDA+ isoform of FN (Inoue et al., 2001), which is stimulatory for epithelial cell migration (ffrench-
Constant, 1995) (Jiang et al., 2000).  Both exogenous FN and a certain level of endogenous FN are 
essential for cell migration but excessive FN matrix assembly impedes this process (Couchman et 
al., 1982) (Hocking and Chang, 2003) (Rozario et al., 2009).  This highlights the requirement for 
tightly regulating FN matrix assembly to allow correct cell migration and tubule formation.  FN is 
also an important scaffolding protein, regulating the deposition of other ECM molecules including 
collagen type I and laminin (Dzamba and Peters, 1991) (McDonald et al., 1982) (Sottile and 
Hocking, 2002) (Sottile et al., 2007) (Velling et al., 2002), which are important constituents of the 
basal laminae of tubules. 
 
1.2.2   FN function in tissue repair 
In adults, FN plays a key role in mediating tissue repair after injury.   Plasma FN is deposited in a 
provisional matrix at the wound site which is cross-linked by transglutaminase to fibrin (Armstrong 
and Armstrong, 2000) (Midwood et al., 2004b).  This matrix induces fibroblast and endothelial cell 
migration (Feng et al., 1999a) (Nicosia et al., 1993) (Tonnesen et al., 2000) and invasion from the 
surrounding collagen-rich matrix (Greiling and Clark, 1997) (Knox et al., 1986).  Endothelial cells 
and fibroblasts repopulate the wound and deposit cellular FN, which acts as a scaffold for the 
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deposition of collagen (McDonald et al., 1982) (Sottile and Hocking, 2002) (Sottile et al., 2007) and 
the development of granulation tissue (Lorenz and Longaker, 2003) (Midwood et al., 2004b).  FN in 
the wound site is also vital for regulating specialized tube structure formation during 
neovascularisation of wounds during resolution of tissue injury by angiogenesis, which is the 
formation of neovessels from pre-existing vessels by proliferation and migration of endothelial 
cells.  Angiogenesis is comparable with tubulogenesis, requiring complex coordination of 
endothelial cell processes including cell adhesion, migration and proliferation.  Changes in the 
ECM composition function to regulate wound neovascularisation (Kalluri, 2003) (Tonnesen et al., 
2000).  A FN fibrillar network is required for HUVEC proliferation, migration (Zhou et al., 2008) 
and survival (Kaczmarek et al., 1994) (Khan et al., 2005).   
 
Misregulated angiogenesis occurs in pathologies including cancer, arthritis and psoriasis (Carmeliet, 
2003) (Zetter, 1998).  Angiogenesis is essential for growth and invasion of solid and hematological 
tumors and neovessels within these tumors exhibit strong staining for FN (Carnemolla et al., 1999) 
(Hanamura et al., 1997) (Kaczmarek et al., 1994) (Schnyder et al., 1997) (Zhou et al., 2008) 
demonstrating how important correct FN matrix assembly is for control of these cell processes.   
 
1.2.3   The modular structure of FN 
FN is a modular multi-domain glycoprotein composed of an array of multiple repeated structures: 
twelve FN type I repeats (FNI), two FN type II repeats (FNII), fifteen constitutively expressed and 
two alternatively spliced (EDA and EDB) FN type III repeats (FNIII), and a non-homologous V 
(variable) or IIICS region (type III connecting segment), which are organized into functional 
domains.   This includes the N-terminal 70-kDa domain (FNI 1-9), the 120-kDa central binding 
domain (CBD; FNIII1-12) and the Heparin binding domain HepII (FNIII12-14) (Figure 1.2).  The 
multi-modular structure allows flexibility of the FN molecule which regulates its function (Baneyx 
et al., 2001) (Baneyx et al., 2002) (Erickson et al., 1981) (Erickson and Carrell, 1983) (Johnson et 
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al., 1999) (Rocco et al., 1987).  The multi-domain organization allows FN to interact with multiple 
binding partners including other ECM components and cell-surface receptors (Pickford and 
Campbell, 2004) (Figure 1.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
All three of the modular folds of the FN repeats are highly conserved and found in numerous other 
proteins (Craig et al., 2004).  Although the tertiary fold of FNIII is highly conserved, the sequence 
homology between different FNIII modules within FN is actually less than 20%.  In comparison, 
each FNIII module shows a high homology (80-90%) across species (Craig et al., 2004) suggesting 
each module must have a specific and important function (Chen et al., 2007) (Gao et al., 2003) 
(Krammer et al., 1999) (Smith et al., 2007).  For example, FNIII10 possesses an RGD integrin 
recognition sequence exposed on a β hairpin-like loop to allow integrin binding (Carr et al., 1997) 
(Leahy et al., 1996).  FNIII modules have lower mechanical stabilities than FNI and FNII modules 
as they do not possess disulphide bonds.  This property of FNIII is important to allow module 
Figure 1.2   Schematic showing the modular and domain structure of FN 
Binding partners and the relevant binding domains are shown.  FN intramolecular binding 
sites and sites essential for FN matrix assembly are highlighted in red. 
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unfolding and exposure of cryptic FN binding sites that play a key role in FN fibrillogenesis (Craig 
et al., 2001) (Hocking et al., 1996) (Krammer et al., 1999).   
 
The alternative splicing of EDB and EDA and more complex splicing of the V or IIICS domain 
during transcription allows different isoforms of FN to be expressed in a tissue-dependent, 
temporally regulated and cell-type specific manner (Hershberger and Culp, 1990) (Khan et al., 
2005) (Rybak et al., 2007) (Tressel et al., 1991) (Van Vliet et al., 2001).  In humans, twenty 
potential FN isoforms can be generated (ffrench-Constant, 1995).  These isoforms modulate the 
properties of the ECM: cellular FN shows reduced incorporation into fibrin gels compared to 
plasma FN (Wilson and Schwarzbauer, 1992); EDA+ FN and similarly, EDB+FN enhance cell 
adhesion, spreading and FN matrix assembly (Chen and Culp, 1996) (Guan et al., 1990) (Fukuda et 
al., 2002) (Manabe et al., 1997).  The orientation and rotational interdomain flexibilities of FNIII 
modules are known to be affected by neighboring domains (Altroff et al., 2004) (Bencharit et al., 
2007) (Leahy et al., 1996) (Pickford et al., 2001) (Pickford and Campbell, 2004) (Spitzfaden et al., 
1997) and inclusion of the EDB domain alters the bending and rotational angles at the EDB-FNIII8 
interface compared to FNIII7-8 (Bencharit et al., 2007).  This change in interdomain orientation may 
impact the global conformation of FN, affecting the presentation of FNIII loop structures and 
binding sequences to modulate FN-cell signaling and FN-FN interactions during matrix assembly.     
 
1.2.4   FN matrix assembly 
FN matrix assembly is a step-wise, cell mediated process (Choi and Hynes, 1979) (McKeown-
Longo and Mosher, 1983).  FN in solution alone will not polymerize (Mosher and Johnson, 1983) 
and will not form a 3D matrix in the absence of cells (Mao and Schwarzbauer, 2005b).  FN is 
expressed and secreted in a soluble, compact dimeric form, which is maintained by two disulphide 
S-S bonds at its C-terminal and intramolecular electrostatic interactions between its FNI1-5, FNIII2-3 
and FNIII12-14 domains (Johnson et al., 1999) (Rocco et al., 1983) (Sechler et al., 1996) (Figure 1.3). 
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In low salt conditions, this compact quaternary structure can be observed by electron microscopy 
(Erickson and Carrell, 1983) (Rocco et al., 1987) and recent FRET studies show that the arms of 
soluble FN overlap each other (Smith et al., 2007).  FN mutants lacking FNIII12-14 or where this 
region was replaced by the alternatively spliced FN type III domains A1-A3 from tenascin-C (TN-
C), showed sedimentation coefficient values that were lower than wild type FN, reflecting adoption 
of a more open conformation, highlighting the importance of FNIII12-14 in maintaining these 
intramolecular interactions (Johnson et al., 1999).  FN dimerisation is a pre-requisite for FN 
assembly as mutation of C-terminal cysteines results in the loss of fibrillogenesis (Schwarzbauer, 
1991).  FN appears at the cell surface within 10 min of plating and in the conditioned medium 
within 30 min (Choi and Hynes, 1979).  
 
1.2.4.1    FN matrix assembly initiation 
Initiation of assembly involves FN binding to cell-surface receptors (Figure 1.4).  This cell-
associated FN is soluble upon detergent treatment of cells (Allio and McKeown-Longo, 1988) 
(McKeown-Longo and Mosher, 1983) (McKeown-Longo and Mosher, 1985).  FN first binds to the 
cell surface via FNI1-5 within the 70-kDa N-terminal domain of FN: 70-kDa localizes as short, linear 
arrays on cell peripheries similar to FN at early time points of assembly (McKeown-Longo and 
Mosher, 1985) (Tomasini-Johansson et al., 2006); 70-kDa remains detergent soluble, indicating its 
inability to assemble into a complex matrix (McKeown-Longo and Mosher, 1985) (Schwarzbauer, 
Figure 1.3    Compact structure of FN
FN is secreted as a soluble, globular form maintained by interactions between FNI1-5, FNIII1-2 and 
FNIII12-14 (regions highlighted in green).   
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1991) (Tomasini-Johansson et al., 2006); 70-kDa binding is saturable with a similar binding affinity 
as full-length FN suggesting the involvement of a finite number of binding partners (Allio and 
McKeown-Longo, 1988) (McKeown-Longo and Mosher, 1985) (Tomasini-Johansson et al., 2006) 
and 70-kDa inhibits FN matrix assembly by occupying matrix assembly sites (Bultmann et al., 
1998) (McDonald et al., 1987) (McKeown-Longo and Mosher, 1985) (Morla and Ruoslahti, 1992) 
(Sottile and Mosher, 1997) (Zhang and Mosher, 1996), whereas other regions of FN could bind to 
cells in vivo but this was insufficient to block fibrillogenesis (Rozario et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
FN matrix assembly initiation occurs at focal contacts, which are initial sites of ECM contact on the 
cell periphery rich in paxillin, vinculin, phosphotyrosines, β1 and β3 integrins (Pankov et al., 2000) 
(Zamir et al., 1999) but the receptor(s) for 70-kDa has not yet been clearly elucidated. 70-kDa 
cross-linking to a cell-surface complex is dependent on divalent cations suggesting involvement of 
an integrin (Limper et al., 1991).  The major FN binding integrin, α5β1, is not a receptor for the 70-
kDa domain (Fogerty et al., 1990) (Limper et al., 1991) (Zhang and Mosher, 1996).  Instead αvβ3 
integrin is a possible candidate: it is located and remains in focal contacts of spread cells at the cell 
Figure 1.4   FN unfolding; initiation 
FN initiation involves interactions with cell surface receptors:  (a) FNI1-5 within 70-kDa binds to cell 
surface receptors possibly including integrins, (b) FNIII9-10 binds to integrin α5β1, (c) integrin activation 
by outside-in or inside-out signaling induces integrins to adopt a high affinity state and allow FN 
binding and (d) FNIII12-14 binds to HSPGs. 
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periphery during FN fibrillogenesis (Pankov et al., 2000); it can support FN polymerization of 
confluent cells lacking β1 (Wennerberg et al., 1996); αv and β3 co-localize to the ends of FN fibrils 
(Wennerberg et al., 1996); 70-kDa can interact with αvβ3 by solid phase binding via a novel 
GNGRG motif in FNI1-5, and this sequence motif can also be deamidated and rearranged (a 
physiological ECM protein “ageing” process) to isoDGR, which can interact with high affinity (Kd 
= 0.57 μM) to αvβ3 integrins (Curnis et al., 2006) (Takahashi et al., 2007).  In vivo, the presence of 
pre-existing 3D FN matrices also stimulates αvβ3 activation, which allows FN matrix assembly 
(Mao and Schwarzbauer, 2005b).  Altogether, this data suggests that 70-kDa initiates FN matrix 
assembly by binding to the cell surface at focal contacts, possibly interacting with αvβ3 integrins on 
the cell surface (Figure 1.4 a).   
 
A further essential step in the initiation and assembly of an extensive FN matrix involves α5β1 
integrin binding of the RGD loop on FNIII10 and the neighboring PHSRN sequence in FNIII9 in the 
CBD of FN (Huveneers et al., 2008) (Mao and Schwarzbauer, 2005b) (Wennerberg et al., 1996) 
(Wu et al., 1993) (Wu et al., 1995b) (Figure 1.4 b).  FN mutants with loss of the RGD site or a 
mutation within the RGD site, did not assemble a fibrillar network, and only weakly stained the 
periphery of cells in immunofluorescence studies (Sechler et al., 1996).  Antibodies against the 
RGD domain or small RGD peptides can also inhibit FN matrix assembly (Darribere et al., 1990) 
(McDonald et al., 1987) (Morla and Ruoslahti, 1992) (Takahashi et al., 2007) (Winklbauer and 
Stoltz, 1995).  α5β1 integrin binding to CBD is a high affinity interaction, Kd = 0.2 μM by solid 
phase binding (Altroff et al., 2004).  Recently Huveneers et al., (2008) demonstrated that α5β1 but 
not αvβ3 integrins supported FN matrix assembly because β1 null or α5 null mouse embryonic 
fibroblasts or fibroblasts expressing mutated β1 subunits could not support FN fibrillogenesis.  
However, it is interesting to note that FNRGE/RGE expressing mice showed normal FN-RGE 
distribution, and isolated fibroblasts assembled endogenous FN-RGE into short, thick, fibrils, 
suggesting FNIII10  interactions with α5β1 are not essential for assembly (Takahashi et al., 2007).  In 
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Table 1.1   List of other integrins that can bind to FN 
these studies, the FNRGE/RGE mouse fibroblasts had to be plated onto laminin to allow matrix 
assembly to occur; when plated on vitronectin, no assembly could be observed as the αv integrins 
were involved in binding to the vitronectin and could not be used in assembling FN-RGE 
(Takahashi et al., 2007).  Huveneer’s et al., (2008) plated their fibroblasts on FN, so the αv integrins 
(in the absence of α5) may have been engaged in binding to the coated FN as opposed to the 
exogenous FN, which may account for the lack of FN assembly by αv integrins.  Other integrins 
which bind FN are summarized in Table 1.1 although some e.g. αvβ1, do not support FN 
fibrillogenesis.  Mice engineered to be deficient in FN, α5, β1 or αv, highlight the importance of FN 
fibrillogenesis during development (Yang et al., 1999).  
TABLE 1  (Wu et al., 1995a) (Johansson et al., 1997) (Schnapp et al., 1995) (Zhang et al., 1993) (Magnusson and Mosher, 1998) (Wu et al., 1993) (Kauf et al., 2001) 
 
 
 
 
 
 
 
 
 
 
 
The interaction of integrins such as α5β1 with FN provides “outside-in” signals (Disatnik and 
Rando, 1999), and induces integrin clustering in focal adhesions (Friedland et al., 2009).  Ligation 
of integrins can also induce intracellular signaling and the activation of integrins to a higher affinity 
binding state by “inside-out” signaling.   Phosphorylation of integrin cytoplasmic domains and 
subsequent integrin activation by signaling molecules such as talin requires myosin II dependent 
cell generated tension, which is activated by force-induced conformational changes (Friedland et 
Wu et al., 1993; Kauf, 2001;  
Johansson, 1997Platelets+
FNIII9-10 
(RGD)IIb 3
Magnusson and Mosher, 1998;  
Johansson, 1997
Epithelial cells: development, wound 
healing, tumors—
FNIII10 
(RGD)v 6
Zhang, 1993;  Johansson, 
1997Cell lines—
FNIII10 
(RGD)v 1
Schnapp, 1995;  Johansson, 
1997
epithelial cells, smooth muscle cells, 
myofibroblasts, and embryonic 
neural cells
—FNIII10 (RGD)8 1
Wu, 1995; Johansson, 1997White blood cells and adherent cells—IIICS (V) CS1 region4 1
Wu, 1995; Johansson, 1997
In vivo: epithelial skin cells, 
endothelial digestive tract cells 
kidney mesangial cells.  In vitro: 
most cell lines 
+ (adhesion to 
entactin promotes 
FN fibrillogenesis)
70-kDa 3 1
RefsExpression Supports fibrillogenesisDomain 
FN 
receptors
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al., 2009) (Lee et al., 2007) (Somanath et al., 2007) (Wu et al., 1995b).  “Outside-in” signals can be 
translated into “inside-out” signals via this feedback loop (Disatnik and Rando, 1999) (Green et al., 
2009) (Somanath et al., 2007) to regulate adhesion complex formation, integrin affinity and FN 
matrix assembly (Somanath et al., 2007) (Mao and Schwarzbauer, 2005b) (Wu et al., 1995b) 
(Figure 1.4 c).  
 
Cell surface heparan sulphate proteoglycans (HSPGs) have also been shown to play an important 
role in FN matrix assembly (Figure 1.4 d).  CHO mutant cells defective for heparan sulphate GAG 
synthesis or expressing reduced levels of HSPGs showed loss of or reduced FN matrix assembly 
respectively (Chung and Erickson, 1997).  The HepII domain of FN (FNIII12-14) can interact with 
heparin (Ingham et al., 1990) and the FNIII13 module is the primary binding site (Bloom et al., 
1999) (Ingham et al., 1993) (Busby et al., 1995), suggesting this FN domain is involved in the 
binding of HSPGs.  The HepII domain of FN has also been shown to bind to heparan GAG chains 
of syndecan-4 (Huang et al., 2001) (Woods et al., 2000), and this domain has been shown to be 
essential for the formation of stress fibers and focal adhesions (Wenk et al., 2000) (Bloom et al., 
1999) by fibroblasts in a 3D environment (Midwood et al., 2004a).  Syndecan-4 activation is 
required for cell spreading (Saoncella et al., 1999) and cell contractility (Midwood and 
Schwarzbauer, 2002) including the ability of fibroblasts to contract fibrin-FN gels (Midwood et al., 
2004a).  However, Huveneers et al., (2008) showed that syndecan-4 is not essential for FN matrix 
assembly as syndecan-4 null mouse embryonic fibroblasts still assembled a FN matrix.  Instead, 
syndecan-2, which is the major syndecan of fibroblasts and supports FN matrix assembly (Klass et 
al., 2000), or other cell surface receptors in fibrillar adhesion complexes may compensate.  This 
reflects the complexity and multiple components that can be involved in these signaling complexes 
(Geiger et al., 2001) and level of compensation that occurs on the cell surface or the differences in 
FN assembly mechanisms between different cell types.   
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1.2.4.2   FN unfolding, elongation and fibril formation 
Upon binding to integrins and other cell surface receptors, FN then has to be unfolded from its 
compact structure (Figure 1.5).  This unfolding allows exposure of the different binding domains of 
FN for interactions with other FN molecules and ECM components and can be monitored by 
fluorescence resonance energy transfer (FRET) (Baneyx et al., 2001) (Baneyx et al., 2002) (Smith 
et al., 2007).  FN unfolding has been shown to be dependent on β1-FN translocation from focal 
contacts to central tensin-rich fibrillar adhesion complexes (Pankov et al., 2000) (Figure 1.5 b).  FN 
fibrils are shown to form from the continuous growth and extension of FN molecules (Ohashi et al., 
2002) (Pankov et al., 2000) (Winklbauer and Stoltz, 1995).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell tension is known to be important for initiation of matrix assembly to generate a force that 
induces conformational changes of the cell-surface bound FN and allow integrin translocation.  
Application of tension directly to FN in the absence of cells can expose FN-FN binding sites to 
promote FN-FN intermolecular interactions (Zhong et al., 1998).  An intact actin cytoskeleton is 
Figure 1.5   FN unfolding 
A representation of events during FN unfolding: (a) upon FN ligation 
of integrins, signaling from cell-surface receptors induces actin 
cytoskeletal reorganization and mysoin II dependent contractility, 
which leads to (b) integrin translocation and FN extension.        
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essential for FN matrix assembly: cytochalasin D or inhibitors of contractility (e.g. ROCK inhibitor 
Y-27632) can interrupt FN unfolding (Baneyx et al., 2002) (Smith et al., 2007), FN fibrillar 
extension (Davidson et al., 2008) (Ohashi et al., 2002) and α5β1 integrin cross-linking and 
clustering (Friedland et al., 2009) (Ohashi et al., 2002).  Cell contractility is thought to require a 
submembranous pool of myosin II, controlled by myosin light chain kinase, which can be activated 
by RhoA-ROCK II dependent (Yoneda et al., 2007) (Zhang et al., 1997) (Zhong et al., 1998) or 
RhoA independent pathways (Brenner et al., 2000) (Fernandez-Sauze et al., 2009) (Yoneda et al., 
2007).  Myosin II inhibitors inhibit cell contractility and FN matrix assembly (Zhong et al., 1998).  
The presence of multiple pathways to mediate cell contractility demonstrates the importance of this 
generated force in FN matrix assembly (Figure 1.5).   
FNI1-5 (Aguirre et al., 1994) (Limper et al., 1991) (Sottile and Mosher, 1997) (Schwarzbauer, 1991), 
FNIII1-2 (Aguirre et al., 1994) (Sechler et al., 2001), FNIII4-5 (Maqueda, 2007) and FNIII12-14 
(Bultmann et al., 1998; Sambrook et al., 1989) are important domains for FN fibrillogenesis 
(Sechler et al., 1996) (Schwarzbauer, 1991) (Figure 1.6).  The 29-kDa (FNI1-5) region of the 70-kDa 
domain can complex with FNIII1-2, which also interacts with FNIII10 bound to α5β1 integrins 
(Hocking et al., 1996) (Sottile and Mosher, 1997), demonstrating the complexity of these 
interactions.  FNIII1-7 is important for regulating the rate of fibrillogenesis; FN deletion mutants of 
this domain (FNΔIII1-7) showed rapid incorporation into detergent insoluble material, but slower 
fibrillogenesis (Sechler et al., 1996).  The presence of the EDA or EDB domain also promotes FN 
matrix assembly possibly by exposing integrin binding sites in neighboring domains: FNIII10 (EDB) 
and IIICS region (EDA) (Abe et al., 2005) (Guan et al., 1990).   
 
FN fibrillogenesis progresses by module unfolding and exposure of cryptic FN-FN binding sites to 
further promote FN fibrillogenesis (Smith et al., 2007).  Cryptic binding sites present within the 
folded FNIII module are exposed upon heat or chemical denaturation (Hocking et al., 1994) 
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(Hocking et al., 1996) (Ingham et al., 1997) (Morla et al., 1994), or by force induced unfolding.  
Inherent elasticity of the FN linker domains and the FNIII modules have been demonstrated (Chen 
et al., 2007) (Craig et al., 2001) (Gao et al., 2003).  Domains shown to possess cryptic binding sites 
include FNIII1 (Hocking et al., 1994) (Hocking et al., 1996) (Morla et al., 1994), FNIII10 (Hocking 
et al., 1996), FNIII7 and FNIII15 (Ingham et al., 1997) (Figure 1.6).  A peptide sequence derived 
from FNIII1 (FNIII1-C) at low concentrations can induce the formation of superfibronectin, a high 
molecular weight precipitate mass of highly cross-linked aggregates of FN, which resembled cell-
assembled FN fibrils by light microscopy (Bourdoulous et al., 1998) (Morla et al., 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These intermolecular FN interactions allow fibril formation.  FN fibrils then interact to allow the 
formation of high molecular weight, complex, fibrillar FN matrices, which are detergent insoluble 
Figure 1.6   FN fibrillogenesis
Domains involved in FN-FN interactions exposed upon FN unfolding 
are highlighted in green.  Cryptic FN binding sites exposed upon 
module unfolding are highlighted in purple. 
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(Choi and Hynes, 1979) (McKeown-Longo and Mosher, 1983) (McKeown-Longo and Mosher, 
1985).  FN molecules are organized into thin fibrils of 5 nm diameter, which are then laterally 
associated into thicker fibrils of 6-22 nm diameter (Dzamba and Peters, 1991).  FN fibrils are 
formed from the overlapping of extended FN dimers, and as the fibril matures, these FN dimers 
become staggered within the fibrillar structure (Dzamba and Peters, 1991).  FN molecules also 
become cross-linked into disulphide-stabilized multimers, which may occur via an endogenous 
protein disulphide isomerase activity present in FNI12 (Langenbach and Sottile, 1999).  
 
FN is continuously polymerized and remodeled into a fibrillar matrix on the cell surface (Sottile and 
Hocking, 2002).  This is a dynamic process (Davidson et al., 2008) (Ohashi et al., 1999) (Ohashi et 
al., 2002), where fibrils detach at one end, contract, bend, stretch, move and anneal to neighboring 
fibrils (Davidson et al., 2008) (De Jong et al., 2006) (Ohashi et al., 2002) occurring over a longer 
period of time than de novo fibrillogenesis (Ohashi et al., 1999).   
 
1.2.5   Regulation of FN matrix assembly  
FN matrix assembly has to be tightly regulated.  Cellular FN homeostasis is maintained by 
continual FN assembly and loss from the pericellular matrix (Sottile and Hocking, 2002).  However, 
excessive FN deposition is one of the key characteristics in fibrotic conditions including fibrotic 
renal diseases.  Increased FN levels are often observed in renal glomerulosclerosis and interstitial 
fibrosis (Buyukbabani and Droz, 1994) (Mason and Wahab, 2003) (Oomura et al., 1989) (Van Vliet 
et al., 2001) suggesting that after damage, a misregulated repair system results in unresolved excess 
tissue deposition.  Persistently high levels of FN promote cell proliferation, survival signals and 
strong cell-ECM adhesions.  Conversely, loss of FN matrix assembly is observed by some 
transformed cells and can be caused by aberrant signaling to affect “inside-out” integrin activation 
(Brenner et al., 2000) (Sakai et al., 2003).  In addition, loss of FN deposition, which is a scaffold for 
other ECM components (McDonald et al., 1982) (Sottile and Hocking, 2002) would accentuate the 
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loss of ECM within wound beds, as observed in chronic non-healing wounds such as in diabetic leg 
ulcers, even though FN expression persists and is actually increased in the surrounding dermis 
(Loots et al., 1998) (Ongenae et al., 2000).   
 
FN expression and assembly is stimulated in a cell-specific manner by a multitude of signaling 
molecules: TGF-β (Hocevar et al., 1999) (Oh et al., 1998) (Qi et al., 2006) (Roberts et al., 1988), 
CTGF (Gore-Hyer et al., 2002) (Weston et al., 2003), PDGF-BB (Zhang and Lo, 1995), IGF-1 
(Zhang and Lo, 1995), HGF (Liu et al., 1998),  glucose (Lam et al., 2003) (Oh et al., 1998) 
sphinogsine-1-phosphate (Zhang et al., 1999), glucocorticoids (Babu et al., 1989) (Oliver et al., 
1992), plasminogen activator inhibitor type I (PAI-1), (Vial et al., 2006) (Vial and McKeown-
Longo, 2008) and cell contractility promoting agents such as LPA (Zhang et al., 1997) (Zhong et 
al., 1998).  Stimulation of FN expression, secretion and assembly by these agents emphasizes the 
complexity and requirement for tight regulation of this process.  
 
In contrast, FN deposition can be inhibited by inhibitors of cell contractility and RhoA inhibitors 
(Baneyx et al., 2002) (Smith et al., 2007) (Yoneda et al., 2007) (Zhang et al., 1997) (Zhong et al., 
1998).  FN can also be degraded by multiple proteases including MMP-9 (Kusubata et al., 1999).  
FN fragments and individual FN modules such as high concentrations of FNIII1-C can then inhibit 
FN matrix assembly by competing for FN assembly sites (Bourdoulous et al., 1998), which would 
act as a feedback system to regulate FN levels on the cell surface.  The increased levels of proteases 
such as neutrophil elastase in chronic wound exudate, which degrade FN (Grinnell and Zhu, 1996) 
(Latijnhouwers et al., 1998a) (Palolahti et al., 1993) (Rao et al., 1995) (Trengove et al., 1999) 
contribute to this condition.  Aged clots in chronic wounds contain highly cross-linked fibrin, which 
are stripped of other functional proteins by the highly proteolytic environment illustrating the 
importance of FN in regulating wound healing processes (Clark, 1996).    Loss of FN is mediated 
via an endocytic mechanism which is caveolin-1 dependent and LRP-independent and FN becomes 
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targeted to the lysosomes and degraded intracellularly (Sottile and Hocking, 2002) (Sottile and 
Chandler, 2005).  As FN is assembled into high molecular weight multimers by endogenous 
disulphide isomerase activity (Langenbach and Sottile, 1999), some reverse proteolytic activity 
must occur to allow FN to be endocytosed (Sottile and Hocking, 2002) (Sottile and Chandler, 
2005).   
 
Other ECM components also influence FN matrix assembly.  Low levels of vitronectin (VN) have 
been shown to enhance FN matrix assembly by increasing the expression of matrix assembly sites 
on the cell surface (Zheng et al., 2007) (Pankov et al., 2000).  However, high concentrations of VN 
are inhibitory for FN matrix assembly (Zheng et al., 2007) (Rivera-Torres, 2001) (Hocking et al., 
1999).   The HepII domain of VN has been shown to interact with αvβ3 and αvβ5 integrins, which 
prevents actin microfilament reorganization and loss of FN matrix assembly sites (Hocking et al., 
1999).  Loss of collagen type VI, impairs complex FN matrix assembly, with FN fibrils oriented 
parallel to the long axis of the cell (Sabatelli et al., 2001).  As discussed before, the individual FN 
domains including 70-kDa can also inhibit FN matrix assembly by interfering with fibril formation 
by the full-length molecules.  This highlights how ECM composition and breakdown can also act as 
another level of control.  In this study, I aim to determine how the ECM protein TN-C affects FN 
matrix assembly. 
 
1.3   Tenascin-C structure  
TN-C is also a large, modular, multi-domain protein (Figure 1.7).  TN-C forms a hexabrachion via 
associations at its N-terminal via its TN-C association (TA) domain (Chiquet-Ehrismann et al., 
1988) (Fischer et al., 1997).  The TA domain possesses different regions which are involved in 
hexabrachion formation: a heat shock protein 33 (HSP33) homologous domain followed by a 
heptad repeat region.  The HSP33 region is involved in regulating TN-C hexamer formation (Pas et 
al., 2006) and the heptad repeats are thought to form coiled coil structures, which cluster into a 
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trimeric organization and then associate into a hexameric structure stabilized by disulphide bonding 
(Chiquet et al., 1991) (Kammerer et al., 1998).  
 
 
 
 
 
 
 
 
 
 
The TA domain is followed by 14.5 epidermal growth factor-like (EGF-L) repeats, which are one of 
the most frequent and conserved modular folds present in modular proteins (Pickford and Campbell, 
2004) and are highly conserved within TN-C (Pas et al., 2006).  Each EGF-L module is maintained 
by 3 disulphide bonds formed from 6 conserved cysteine residues, which fold into a more compact 
structure than EGF (Pas et al., 2006).     
 
Adjacent to these EGF-L domains is an array of FNIII-like repeats: 8 conserved FNIII-like repeats 
and 9 alternatively spliced FNIII-like repeats.  To distinguish these FNIII repeats from those found 
in FN, these will be referred to as TNfn repeats.  Profile alignments of TNfn sequences show that 
tryptophan, leucine, tyrosine and threonine residues are 100% conserved in all TNfn modules (Pas 
et al., 2006).  Unlike FN, TNfn modules all have similar mechanical stabilities (Cao and Li, 2006), 
and upon repeated stretching, TNfnALL, which is composed of all TNfn domains including the 
alternatively spliced domains had low unfolding forces (Cao and Li, 2006) and rapid refolding 
processes (Oberhauser et al., 2002).  The elasticity of TNfn domains is necessary to impart 
Figure 1.7   Schematic domain structure of TN-C 
Binding partners and relevant binding domains are shown 
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mechanical support to the TN-C molecule as TN-C is expressed in environments subject to high 
tensile load or undergoing remodeling (See Table 1.2 and 1.3).   
 
The structure of TNfn3 has been highly studied due to its RGD sequence, which is in the same 
location as on the FNIII10 module (Akke et al., 1998) (Cao and Li, 2006) (Carr et al., 1997) (Craig 
et al., 2004) (Leahy et al., 1992), however, this domain only shares 27% amino acid sequence 
identity with FNIII10 (Carr et al., 1997), the RGD loop is not as exposed (Leahy et al., 1992) (Carr et 
al., 1997) and TNfn3 demonstrates much higher mechanical stability (Craig et al., 2004).  This 
suggests the structure of TNfn3 may limit its recognition of integrin binding partners, and maintain 
its structure better under stress.   
 
Finally, the C-terminal fibrinogen globe shares 40% homology with fibrinogen and is homologous 
to the β and γ chains (Doolittle, 1981) (Clark et al., 1997).  It forms an asymmetrical, dimeric 
structure, with a putative EF-hand calcium binding site maintained by a hydrophobic core and 
disulphide bonds (Milev et al., 1997) (Pas et al., 2006).   
 
Human TN-C monomers can have a molecular weight of between 200-300-kDa (Hsia and 
Schwarzbauer, 2005) and multiple isoforms can be expressed by selective splicing of the TN-C 
mRNA.  The number of TNfn repeats is dependent on the species, cell type and is temporally 
regulated.  In mice, alternative splicing of TNfnA1/A2/A4/B/C/D could potentially generate 64 TN-
C isoforms but only certain splice variants are expressed:  neural stem/progenitor cells expressed 20 
different TN-C isoforms (von Holst et al., 2007), whilst 27 TN-C isoforms were detected during 
mouse brain development (Joester and Faissner, 1999).  In humans, this splicing becomes even 
more complex as up to 9 alternatively spliced TNfn domains TNfnA1/A2/A3/A4/B/AD2/AD1/C/D 
can be included or excluded (Pas et al., 2006) (Figure 1.7).  Larger TN-C isoforms often include the 
TNfnA1/A2/(A3)/A4, TNfnB and TNfnD modules (Adams et al., 2002) (Bell et al., 1999) (Berndt  
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Table 1.2   Expression of TN-C during development
Derr, 1997E10: Large isoform, containing TNfnAD1: base of feather buds, bronchial tips, perichondrium of sternum, 
periostium of ribs, spinal cord
E10: Large isoform, containing TNfnAD2: weak staining of lung bronchioles, base of feather buds at 
epithelial-mesenchymal interactions
E14: Large isoform, containing TNfnAD1: optic tectum, tendons, mesenchyme and osteocytes of 
developing collar bone
Chick embryo
Tucker, 1993E3: large TN-C staining of lens vesicle
E7: small and large TN-C isoforms in endothelium, spinal nerves, media mesenchyme of ki dney, gizzard, 
mesoderm derived liver, highly expressed by notochord, smooth mu scle cells of aorta, epithelium near 
bronchial tips, spinal cord ependymal layer
E10: smaller isoform in areas of chondrogenesis
E10: larger isoform in developing central nervous system; glial cells
E14: smaller isoform in cartilagenous vertebrae, inner perichondrium
E14: larger isoform in vertebrael laminae, regions of bone development, spinal cord white matter
E18: small isoform in cartilagenous tissues
E18: larger isoform in spinal cord and areas of osteogenesis
Chick embryo
Tucker, 1994E7 stage, TN-C containing TNfnA and B modules: kidney mesenchyme, bronchial tips, aorta endothe lium 
and spinal cord ependyma
E7 stage, TN-C containing TNfnC module: bronchial tips, weaker staining of the aorta endotheliu m and 
spinal cord
E10 stage, TN-C containing TNfnA and B modules: perichondrium , tendons, base of feathers buds, spinal 
cord
E10 stage, TN-C containing TNfnC module: tendons and base of feather buds
Chick embryo
Crossin, 1986Developing cartilage, in perichondrium of more mature cartilage,smooth muscle of developing gut, smooth 
muscle and plexus of tendinous tissue, arterial smooth muscle and valvular tissues, basement membrane 
of lung and kidney
Chick embryo 
(non-nervous 
system)
Crossin, 1986Spinal cord and brain, dorsal root ganglion, sciatic nerve, alon g radial migratory pathway of glial cells, 
radial glial fibers, along migratory pathway of axons of the optic fiber  
Chick embryo 
(nervous 
system)
Crossin, 19862 d: basement membrane of the neural tube and notochord in anter ior regions
3 d: developing neural tube, notochord, basement membrane of somites and aorta
5 d: neural crest cell mass and along neural crest migratory pat hways
Chick embryo 
(neurulation)
Prieto, 1990Large isoform (220-kDa): glia and glial precursors throughout the nervous system; staining of glial fibers, 
spinal cord, around notochord and in cerebellum
Small isoform (180 -kDa): chondroblasts, smooth muscle,  tendinous tissues and some lung mesenchyme 
tissues
Small and large isoforms: mesenchyme and epithelium; expression by epithelial cells (choroid plexus) , 
mesenchymal cells (kidney) or  by both cell types (lungs) 
Chick embryo
Tucker, 1991Mesenchyme during feather morphogenesis
Early stages (feather rudiments): highly expressed in mesenchyme and epidermal-dermal junction
Later stages (early feather buds): highly expressed in mesenchyme and within the epidermis and dermis
:ate stage (elongating feather bud): highly stained in mesenchyme and dermis, not epidermis
Chick 
embryos
Chiquet and 
Fambrough, 
1984
Developing chick wing bud
Stage 20 (day 3): basement membrane around notochord and aorta; staining in head region
Stage 24 (day 4): developing vertebrae; perichondria of humerus
Stage 27/28 (day 5): merichondrial mesenchyme extending from radius and ulna to developing premuscle
masses; around vertebrae and ligaments; ECM of aortic wall; ECM of developing lung buds, esophagus 
and gizzard
Stage 29: tendon primodia between individual muscles.
Chick 
embryos
Riou, 1988Dorsal expression pattern; co -localizes with some regions of FN staining
Stage 22 (Tailbud stage): ECM between dorsal epidermis and neural tube; 
Stage 24: neural crest cell migration path; regions of high cell migration; ECM of developing brain; cephalic 
mesoderm; ECM of intersomitic regions 
Stage 24+  (Late tailbud stage): ECM at periphery of aortic arches and endocardial tube
Spawnings of 
Pleurodeles
waltl (ribbed 
newt)
RefDevelopmental stage/Expression patternOrganism.
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Table 1.3   Expression of TN-C in normal healthy tissue  
Table 1.2   Expression of TN-C during development
Sasano, 2000High expression in mesenchyme and mesenchymal cell condensations of the dentary of mandibles and 
perichondrial mesenchyme of the tibia; minimal TN-C staining in calcified bone matrix 
Wistar rat 
embryos, d 14-
d 20 of 
gestation
RefDevelopmental stage/Expression patternOrganism.
Bell, 1999Major isoforms contain TNfnD module or TNfnA1 -TNfnB domains +/- TNfnA3 moduleHuman fetal 
membrane
von Holst, 
2007
20 detected isoforms expressed
TNfnD, TNfnA1/D, TNfnC/D, TNfnA1/C/D, TNfnA1/A2/A4/B, TNfnA1/A2/A4/B/C/D combinations preferably 
expressed
Mouse neural 
stem 
cell/progenitor 
cells
Joester, 1999P0: isoforms containing TNfnA1/A2 or AD1 show increased expression (38% and 20% respectively); 
isoforms containing TNfnC/D show decreased expression (38%)
P6: isoforms containing TNfnC/D strongly expressed (59%), isoforms containing TNfnA1/A2 are weakly 
expressed (7%), isoforms containing TNfnAD1slightly increased (32%)
Postnatal 
mouse
Joester, 199927 detected isoforms expressed 
E16: isoforms containing TNfnC/D strongly expressed (93%)
Mouse CNS
Gebb, 2005In vivo and explants grown in 3% Oxygen, TN-C stained strongly at epithelial-mesenchymal interface at 
tips and clefts of branching epithelium; 3 distinct TN-C isoforms expressed: 220, 200 and 180 -kDa
Rat embryonic 
lung and rat 
embryonic lung 
explants
Young, 1994Gestational d 14: weak staining in basal laminae, primitive airways and around capillaries; associated with 
fibrillar collagen near basement membrane
Postnatal d 7: strong slightly irregular staining around airways and alveolar walls; concentrated at septal
alveolar tips
Rat embryonic 
lung
Aufderheide, 
1988
E17: TN-C expressed in primitive villi structures and in the mesenchyme; small TN-C isoforms expressed 
from E15-18
Mouse small 
intestines
Mackie, 1988Discontinuous staining at dermal-epidermal junction; basement membrane of capillaries, hair 
follicles and collagen fibrils
Rat skin biopsies
Koyama, 1996Staining in the perichondrium of the inner side of the earMouse ear
Koyama, 1996Some expression at epidermal basement membrane and around hair f olliclesMouse dorsal 
skin
Aufderheide, 
1988
Expressed in lamina propria of gut villi; small and large isoform expressedMouse small 
intestines
Schwarzbauer, 
1991
Small TN190 isoform: tendon of the gizzard, elastic connective tissue bands and stroma around 
crypts
TN200 isoform: smooth muscle tissue
TN230 isoform: stroma beneath villous epithelium
Chick gizzard
Chiquet and 
Fambrough, 
1984
ECM between muscle fibers, capillaries, perineurium tendon fascicles, myotendinous junctions; stain 
as coarse ECM fibrils only partial overlap with FN fibrils
Adult chick 
anterior 
longissimus dorsi
(ALD) muscle
Riou, 1988Brain: extracellular spaces between neuronal cell bodies
Lung: smooth muscle cells; border of alveoli
Stomach: smooth muscle cells; muscularis mucosae; mucous coat
Liver: no staining
Adult 
Pleurodeles waltl
(ribbed newt)
RefExpression patternOrganism
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et al., 2006),  whereas inclusion of TNfnC, TNfnAD1 and TNfnAD2 modules are more rare (Berndt 
et al., 2006) (Carnemolla et al., 1999) (Derr et al., 1997) (Meiners and Geller, 1997) (Mighell et al., 
1997).  In many reports, TN-C isoforms are merely reported as “small isoform” or “large isoform”, 
although the reported molecular weights of these can vary for each species, suggesting different 
populations of TN-C are observed.  In a similar manner as FN, the presence of alternatively spliced 
domains modulates the properties of TN-C, and the high number of combinations possible suggests 
these domains may have subtle effects on TN-C function.   
 
1.3.1   TN-C expression  
Unlike FN, expression of TN-C is not constitutive.  It is expressed highly during development, 
down-regulated in the adult and highly but transiently re-expressed at sites of tissue remodeling and 
pathological stress in adults (Chiquet-Ehrismann and Chiquet, 2003) (Jones and Jones, 2000b) 
Table 1.3   Expression of TN-C in normal healthy tissue  
Schalkwijk , 1991Discontinuous staining at dermal-epidermal junction; basement membrane of capillaries, hair 
follicles and sweat glands 
Human adult skin 
biopsies
Latijnhouwers, 
2000
Large isoforms containing TNfnA1, TNfnA2, TNfnA4, TNfnB and TNfnD are expressed around 
basement membrane of subepidermal capillaries, sweat ducts, hair follicles and discontinuously 
expressed in the adjacent to the basal laminae.
Human adult skin 
biopsies
Maseruka, 1997Staining of the sclera Human corneas
Berndt, 2006Small TN-C isoform found at epithelial border; large TN -C isoforms containing TNfnB, TNfnA1 or 
TNfnD modules only found sporadically near the epithelium.  
Normal human 
urothelial
epithelium
Riley, 1996Weak staining of ECM around parallel collagen fibre bundles and intense pericellular staining of 
round cells in the disorganized, non -fibrous regions of the matrix; stained infiltrating blood vessel s
Human tendons
Dalkowski, 1999Weak staining in secretory vesiclesNormal human 
dermal fibroblast 
cultures
Dalkowski, 1999Dermal-epidermal junction; basement membrane of blood vessels, sebaceous glands and hair 
follicles
Human adult skin 
biopsies 
RefExpression patternOrganism
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(Jones and Jones, 2000a).  TN-C shows spatially and temporally restricted expression patterns, 
suggesting it has a specific albeit transient role, which is important for tissue remodeling events. 
 
TN-C is first expressed upon gastrulation (Crossin et al., 1986) and is strongly expressed throughout 
development (See Table 1.2) in processes including branching morphogenesis (Gebb et al., 2005) 
(Inaguma et al., 1988) (Roth-Kleiner et al., 2004) (Young et al., 1994), tubulogenesis (Inaguma et 
al., 1988), neovascularization, angiogenesis (Ballard et al., 2006) (Canfield and Schor, 1995) 
(Schenk et al., 1999) (Zagzag et al., 2002) and the development of the central nervous system 
(CNS) including the brain (Joester and Faissner, 1999) (Prieto et al., 1990) (Tucker, 1993) (von 
Holst et al., 2007).  The larger TN-C isoforms are associated with migratory processes especially 
those involved in CNS development (Derr et al., 1997) (Prieto et al., 1990) (Meiners and Geller, 
1997) (Meiners et al., 1999), whereas the smaller isoform is expressed in processes such as 
chondrogenesis (Prieto et al., 1990) (Tucker, 1993), suggesting different isoforms are spatially 
expressed to support different cell activities.  TN-C expression is also temporally regulated with 
differential expression patterns dependent on the tissue and organism involved (Aufderheide and 
Ekblom, 1988) (Crossin et al., 1986) (Prieto et al., 1990) (Young et al., 1994). 
 
In adults, TN-C expression shows a limited expression pattern in healthy tissues (Table 1.3).  It is 
expressed in a very restricted manner in normal healthy tissue but highly expressed and transiently 
up-regulated at sites of physiological or pathological tissue remodeling (See Table 1.4 -1.5 for 
summary).  During wound healing, TN-C is strongly and transiently expressed at the wound edge 
and highly expressed throughout the wound healing process but not in the scar tissue (Table 1.4) 
(Betz et al., 1993) (Latijnhouwers et al., 1996) (Latijnhouwers et al., 1997) (Latijnhouwers et al., 
2000) (Loots et al., 1998) (Mackie et al., 1988) (Whitby and Ferguson, 1991).  TN-C is up-
regulated in pathological skin conditions (Table 1.5) and persistently expressed in chronic non-
healing wounds and fibrotic conditions (Table 1.5).  It is highly expressed in hypertensive  
Introduction 
 27
Table 1.5   Expression of TN-C in pathological conditions
Yamamoto, 
2005
d 7: Staining around adventitia and media, expressed by cells inthe adventitia and 
media
d14: Staining in the neointima and media, expressed in the neointima
d 28: staining in the neointima, reduced staining in the media
Mouse aorta after 
surgical incision to 
stimulate intimal
hyperplasia
Matsumoto, 
2002
3 d: strong staining in periglomerular regions around Bowman's capsules
7d : strong staining around Bowman's capsules, glomeruli, periglomerular and 
interstitial regions
Mouse model of 
glomerulonephritis
induced by Habu
snake venom
Other 
fibrotic 
conditions
El-Karef, 2007Increased TN-C deposition; in inflammatory regions including peri-portal and central 
vein areas and in liver parenchyma
Mouse model of liver 
fibrosis; 
concanavalin A 
induced
Schalkwijk , 
1991
Strong staining in dermis beneath epidermal cellsSolar kerotosis
biopsy
Jones and 
Rabinovitch, 
1996
14 d: high focal staining in outer medial and adventitial layers; small and large 
isoforms expressed
21 d: staining throughout medial layer
28 d: staining in developing neointima
Mouse 
monocrotaline
induced pulmonary 
hypertension
Schalkwijk , 
1991
Highly expressed in tumor stroma; most prominent expression adjacent to basal 
membrane lining tumor cell nests
Basal cell carcinoma 
biopsy
Schalkwijk , 
1991
Increased and continuous TN-C expression along the basement membrane lining 
dermis and extending deep into dermis
Psoriatic skin 
biopsies
Filsell, 1999Increased TN-C expression in basement membrane, extending deep into the 
dermis and throughout papillary dermis; large isoform expressed by keratinocytes in 
epidermis
Photodamaged skin 
biopsies
Strong staining in secretory vesicles; normal FN staining and normal morphologyHuman keloid
fibroblast cultures
Dalkowski, 
1999
Diffuse expression throughout affected dermis; associated with c ollagen bundles 
and along collagen fibres
Human keloids
Latijnhouwers, 
1996
Increased staining in papillary dermis, deeper into dermis, strong but diffusely 
distributed in granulation tissue
Chronic venous leg 
ulcers
Loots, 1998Persistent levels in dermis under wound bed; strong expression s till detected 3-12 
months after
Human chronic 
diabetic ulcers and 
venous leg ulcers
Koyama, 19961-3 d (after challenge with hapten):  TN-C staining in allergic edema, 
8 d: TN-C in dermis on inner and outer sides of the ear
14 d: no detectable TN-C
Mouse model of 
chronic contact 
dermatitis: ear 
biopsy, sensitized 
mouse
Koyama, 19963 d (after hapten application): weak staining within dermis on inner and outer sides 
of the ear
6 d: stronger staining within dermis on inner and outer sides of the ear
Mouse model of 
chronic contact 
dermatitis: ear 
biopsy, non-
sensitized mouse
Koyama, 199624 h (after hapten application): staining around infiltrated cells, deep in the dermis
3-6 d: re-epitheliazation, strong staining throughout the dermis 
13 d: reduced staining, present in subepithelial dermis
Mouse model of 
chronic contact 
dermatitis: dorsal 
skin biopsy, non-
sensitized mouse
Kusubata, 
1999
Acute phase (d 6): deposited in connective tissue and basement membrane of the 
inner and outer sides of the ear
Chronic phase (d 30): under epidermal basement membrane, weak st aining in the 
inner and outer sides of the ear
Mouse model of 
chronic contact 
dermatitis: ear 
biopsy 
Dalkowski, 
1999
Acute phase: increased in connective tissue and basement membrane
Chronic phase: increased in epidermal basement membrane
Mouse model of 
chronic contact 
dermatitis: ear 
biopsy 
Skin 
disorders
RefExpression patternOrganism
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Table 1.5   Expression of TN-C in pathological conditions
Hanamura, 
1997
Stroma of adenoma and vasculature, expressed by stromal cells near tumor 
surfaces
Human colon 
adenomas
Hanamura, 
1997
Stroma and at edge of invading tumors, expressed by stromal fibroblasts, vascular 
cells and tumor cells
Human colon 
carcinoma
Carnemolla, 
1999
Large isoform (containing TNfnC): around blood vessels, in stroma around tumor 
nests and within proliferating cells, expressed by tumor cells
Human glioblastomas
Talts, 1999Staining in a streak-like pattern around large tumor cell nests Transgenic mice: 
spontaneous 
mammary gland 
tumors
Cancer
Berndt, 2006Small isoform: found in carcinoma stroma and papillary stroma.  
Larger isoforms containing TNfnA1/B/D modules: expressed in superficial 
connective tissue, muscle and blood vessels and at tumor margins.
Human urothelial non-
invasive carcinoma
Berndt, 2006Large isoforms containing TNfnB expressed in intratumoral tissue, areas of 
inflammation; large isoforms containing TNfnA1 or TNfnD are restricted to muscle 
fibers and blood vessels; large isoforms containing AD1+ only expressed in 
carcinomas with compact invasive pattern 
Human urothelial
invasive carcinoma
Katenkamp, 
2004
Large isoform: strong staining in the tumor stroma; around neoplastic glands; tumor 
blood vessels; expressed by carcinoma cells and endothelial cells 
Smaller isoform: basement membranes; around normal and hyperplastic benign 
glands; around inflammatory infiltrate; tumor blood vessels
Human prostate 
adenocarcinomas
Tsunoda, 
2003
Large isoform: strongly stain invasion front of invasive ductal carcinomas Human breast cancers: 
fibroadenomas and 
invasive ductal
carcinomas
Adams, 2002Small isoform strongly expressed (70%), large isoform weakly exp ressed (5%); 
stained around basement membrane of acini and ducts, blood vessel walls
Human benign breast 
carcinoma
Adams, 2002Small isoform expressed in 7% of cases, large isoform containing TNfnB/D 
expressed in 75% of cases, large isoform containing TNfnB expressed in 35% of 
cases; strong stromal staining; expressed by peritumoral stromal cells
Human invasive breast 
carcinoma
Adams, 2002small isoform, large isoforms containing TNfnB/D or TNfnB expressed in 46% of 
cases; small isoform and large isoform containing TNfnB expressed in 31% of 
cases; located in the basement membrane and periductal stroma; expressed by 
myoepthelial cells
Human ductal
carcinoma in situ
Matsuda, 
2005
Subepithelial deposition beneath bronchial epithelium; Single Nucleotide 
polymorphism (SNP) associated with asthma patients encode an ami no acid 
substitution within TNfnD module
Human asthmatic lung 
tissues
Maseruka, 
1997
Strong staining adjacent to perforation; especially in the subepithelial scar tissue 
that had formed
Perforated rheumatoid 
arthritic cornea
Maseruka, 
1997
Staining in stroma, areas of acute inflammation and active ulceration; increased 
subepithelial staining; staining around inflammatory cell infiltrate
Human corneas with 
bacterial keratitis
Yang, 2001Strong staining of mesangiumDiffuse human  
mesangial sclerotic 
lesions
RefExpression patternOrganism
Ihida-
Stansbury, 
2006
staining of occlusive vascular lesions and vascular walls of rem odeled pulmonary 
arteries
Human lung tissue 
sections with familial 
pulmonary 
hypertension
Maseruka, 
1997
Staining in stroma and around areas of acute inflammationHuman corneas with 
herpes simplex 
keratitis , rosacea
keratitis , herpes zoster 
opthalmicus
Jeong, 2000Weak, granular staining of mesangium, strong staining of subendothelial region of 
thickened capillary walls, blood vessels, interstitium and perivascular connective 
tissue
Human renal allografts
with transplant 
glomerulopathy
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pulmonary arteries and during neointimal hyperplasia (Ihida-Stansbury et al., 2006) (Jones and 
Rabinovitch, 1996) (Yamamoto et al., 2005) and in many cancers (summarized in Table 1.5).  
Isoform expression can also change during disease progression: normal breast tissue and benign 
breast tumors express the small TN-C isoform (Adams et al., 2002) (Berndt et al., 2006), whereas 
the presence of larger TN-C isoforms were increased in malignant and invasive breast carcinomas 
(Adams et al., 2002).  The general, but not exclusive, pattern of expression suggests that the larger 
TN-C isoforms are predominantly associated with areas of physiological and pathological tissue 
remodeling, whereas smaller TN-C isoforms are predominantly associated with regions of normal 
or quiescent tissue (Cai et al., 2002) (Chiquet-Ehrismann et al., 1991) (Latijnhouwers et al., 2000) 
(Tsunoda et al., 2003).   
 
TN-C expression is induced by a multitude of growth factors and inflammatory cytokines including 
those summarized in table 1.6.  Cell tension and ECM integrity have also been shown to modulate 
Table 1.5   Expression of TN-C in pathological conditions
Sillacci , 2006Large isoform (containing TNfnC) strongly stained all lung tumors: vascular 
staining in squamous cell carcinoma and stromal staining in lung adenocarcinoma
Human lung 
adenocarcinoma, 
bronchial alveolar 
carcinoma, small cell 
carcinoma, large cell 
carcinoma and 
mesothelioma sections
Dang, 2006Papillary dermis and reticular dermis of invasive specimens, at invasive front of 
tumor at the epidermal -dermal junction
Human cutaneous
squamous cell 
carcinoma
RefExpression patternOrganism
Ramos, 1998Mild-moderate dysplasia: expressed in the basement membrane 
Carcinoma: high expression throughout stroma
Human SCC oral 
biopsies from ventral 
surface of the tongue or 
the mouth
Hindermann, 
1999
Large isoform (TNfnA1-A4) stained whole stromal compartment, mainly expressed 
by carcinoma cells and also some myofibroblasts
Human oral squamous 
cell carcinoma
Dang, 2006Large isoform containing TNfnAD2 or AD1 (88% of specimens)
Sparse staining of papillary dermis
Large isoform containing TNfnAD2 or AD1 (63% of specimens)
Human actinic keratosis
Latijnhouwers, 
2000
Strong stromal staining of large isoforms of TN -C containing TNfnA1, TNfnA2, 
TNfnA4, TNfnB and TNfnD
Human basal cell 
carcinoma
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TN-C expression (Chiquet et al., 2004) (Chiquet-Ehrismann et al., 1994) (Feng et al., 1999b) (Jones 
et al., 1997) (Maier et al., 2008); an intact collagen type I matrix inhibits TN-C expression whereas 
a degraded collagen type I matrix enhances TN-C expression (Jones et al., 1995).  When these 
collagen type I matrices are attached to the culture dish or when cyclic strain is applied to produce a 
tensed collagen gel environment, this induces proteinase expression, which degrades fibrillar 
collagen to expose β3 specific RGD epitopes, (Chapados et al., 2006) (Cowan et al., 1999) (Jones et 
al., 1997) and the denatured matrix signals via integrin-linked kinase (ILK), RhoA/ROCK, ERK1/2 
and homeobox transcription factors Prx1 and Prx2 to induce TN-C expression (Chapados et al., 
2006) (Chiquet et al., 2004) (Jones et al., 2001) (Maier et al., 2008) (Sarasa-Renedo and Chiquet, 
2005).  This cyclic strain can signal independently but also synergistically with growth factor 
signaling to further enhance expression (Chiquet et al., 2004).  Certain MMPs including MMP-2 
and MMP-7 can degrade TN-C (Siri et al., 1995) (Wallner et al., 2004).  MMP-3 and MMP-9 have 
also been shown to regulate TN-C matrix incorporation as suppression of these enzymes inhibits 
TN-C staining of the FN matrix, suggesting TN-C degradation is required before it can be 
incorporated (Dang et al., 2004).  This acts as a level of control to regulate and modify TN-C 
activity within matrix environments that are undergoing remodeling.   
 
 
 
 
 
 
 
 
 
 Latijnhouwers, 1998; Ogawa, 2005Keratinocytes IFN-
Latijnhouwers, 1998; Nakoshi, 2008Keratinocytes, squamous cell carcinoma, chondrocytes from 
OA cartilage
TNF-
Chiquet, 2004Chick embryonic fibroblastsPDGF-BB
Tucker, 19933T3 Swiss cellsbFGF
Ogawa, 2005KeratinocytesIL-13
Latijnhouwers, 1998; Makhluf, 1996; 
Ogawa, 2005
Keratinocytes; human dermal fibroblasts, sclerodermal
fibroblasts
IL-4
McCachren, 1992Human synovial fibroblastsIL-1
Gore-Hyer, 2002human proximal tubule epithelial cellsCTGF
Zhao, 1995; Jinnin, 2004; Gore-Hyer, 
2002; Chiquet, 2004
human dermal fibroblasts, human proximal tubule epithelial 
cells, chick embryonic fibroblasts; fetal rat lung
TGF-
Chiquet, 2004; Latijnhouwers, 2000Squamous cell carcinoma; chick embryonic fibroblastsSerum
ReferenceCell typeInducers of TN-C 
expression
Table 1.6   Stimulators of TN-C expression
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1.3.2   TN-C and FN co-localize in vivo 
TN-C is often co-expressed temporally and spatially with areas of active FN matrix remodeling.  
During development both FN and TN-C are highly expressed.  During chick wing development, 
TN-C and FN staining overlap around the radius and ulna and around the developing humerus, 
although FN expression is much more extensive throughout the mesenchyme and developing 
connective tissue, whereas TN-C expression is more concentrated at the base of the developing 
structures (Chiquet and Fambrough, 1984).  During wing bud development, TN-C and FN showed 
co-localization in the mesenchyme, although FN also stained other structures (Tucker, 1991).  
During Pleurodeles waltl (ribbed newt) development TN-C expression was more restricted to the 
dorsal end and co-distributed with FN in this region (Riou et al., 1988).  Furthermore, 
microinjection of TN-C into blastocoel cavities of Pleurodeles waltl spawnings showed TN-C 
localization to FN fibrils within 15 min (Riou et al., 1990).    
 
During wound healing, FN and TN-C are up-regulated and co-localize at the wound edges and in 
the granulation tissue (Loots et al., 1998) (Mackie et al., 1988) (Whitby and Ferguson, 1991).  In 
chronic non-healing wounds, TN-C and FN expression persists in the dermis around the ulcer bed 
(Latijnhouwers et al., 1996) (Loots et al., 1998) suggesting excess and uncontrolled TN-C 
expression may be detrimental for wound healing.  Similarly, in pathological skin conditions such 
as contact dermatitis, FN and TN-C were abundant in the dermis early after hapten induction, and 
when applied to the ear, FN and TN-C were up-regulated in the connective tissue, with a more 
restricted expression of TN-C on the inner side of the ear.  In chronic conditions, FN was up-
regulated in the connective tissue but TN-C appearance was delayed resulting in a delay in the 
resolution of the allergy (Koyama et al., 1996) (Kusubata et al., 1999).  In fibrotic transplant 
glomerulonephropathy, both TN-C and FN prominently localized to capillary walls, blood vessels, 
the mesangium of glomeruli and the interstitium (Jeong et al., 2000).  In cancers, FN and TN-C are 
highly up-regulated in the tumor ECM (Hanamura et al., 1997) (Kaariainen et al., 2006): in 
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melanomas, FN and TN-C formed tubular like structures within the dermis, which ensheath 
melanoma cells (Kaariainen et al., 2006); in colon adenomas, TN-C and FN expression are up-
regulated in the stroma and the vasculature within the adenoma (Hanamura et al., 1997). In colon 
carcinomas, TN-C and FN expression were also up-regulated, although FN expression was 
associated with the tumor centre whereas TN-C expression was localized to the stroma (Hanamura 
et al., 1997).  This suggests in some conditions TN-C and FN expression spatially and temporally 
overlap, whereas in other conditions, the expression patterns are spatially similar but not identical.   
 
1.3.3   TN-C can interact with FN in vitro 
TN-C is often associated with FN fibrils in in vitro cell cultures.  Myogenic cell cultures which 
accumulated FN fibrils showed increased staining of TN-C (Chiquet and Fambrough, 1984).  
Confluent chick embryonic fibroblasts, which assembled a dense FN matrix also showed partial 
TN-C co-distribution with broad FN fibrils, although a complete overlap was not observed.  In 
subconfluent cultures only some cells showed patchy TN-C staining, which co-localized or were 
independent of FN staining (Chiquet and Fambrough, 1984).  This has also been observed with 
CHO-K1 cultures, which assemble a prominent FN matrix on which TN-C shows partial co-
localization (Chung and Erickson, 1997).  Peritumor fibroblasts and squamous cell carcinoma cell 
co-cultures can assemble TN-C into a matrix, but only in the presence of a FN matrix (Ramos et al., 
1998).  This suggests TN-C requires FN as a scaffold.  However, TN-C is often shown to form 
fibrillar structures independently of FN fibrils, suggesting it may assemble on other ECM 
components, which are also dependent on the presence of FN, such as laminin or collagen type I 
(Dzamba and Peters, 1991) (Sottile and Hocking, 2002) (Sottile et al., 2007) (Velling et al., 2002).   
 
TN-C and FN interactions have also been demonstrated by various binding assays.  This has been 
demonstrated using purified or recombinant proteins: by solid phase binding (Chiquet-Ehrismann et 
al., 1988) (Chiquet-Ehrismann et al., 1991) (Chung et al., 1995) (Chung and Erickson, 1997) (Ghert 
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et al., 2001), glycerol gradient sedimentation (Chung et al., 1995) (Lightner and Erickson, 1990), 
affinity chromatography (Chiquet-Ehrismann et al., 1991) and incubation of TN-C and FN coated 
covasphere beads (Hoffman and Edelman, 1987).  The small TN-C isoform shows increased 
binding to FN compared to the large TN-C isoform (Chung and Erickson, 1997) (Ghert et al., 2001) 
(Schwarzbauer, 1991) and small TN-C isoforms also showed increased fibrillar staining of the ECM 
from NIH 3T3 cell cultures, whereas the large isoform of TN-C did not (Chung et al., 1995).  Using 
individual recombinant TN-C domains, TNfn3 has been shown to be the minimum unit for FN 
interactions, but TNfn3-5, TNfn1-5 and TNfn1-8 showed much stronger binding (Chung et al., 
1995) (Hauzenberger et al., 1999) (Ingham et al., 2004).  These TN-C domains have been shown to 
be able to interact with the N-terminal 70-kDa domain of FN (Ingham et al., 2004).   
 
1.3.4   TN-C function  
TN-C itself, plays a major role in regulating cell adhesion, spreading, migration and proliferation 
(See Table 1.7).  However, the effect of TN-C on different cell processes is complex and dependent 
on many factors including cell type (See Table 1.4-1.5).  TN-C also alters the adhesive properties of 
FN.  TN-C coated onto immobilized BSA-blocked FN could not support chondrosarcoma adhesion 
whereas a mixed TN-C/FN substratum showed increased chondrosarcoma adhesion compared to 
FN alone (Ghert et al., 2001).  However, in other studies, a TN-C/FN substratum or mixed TN-C 
and native ECM substratum reduces cell adhesion (Huang et al., 2001) (Lightner and Erickson, 
1990) (Riou et al., 1990).  The presence of TN-C interferes with the strong cell adhesive 
interactions with FN by interfering with focal adhesion formation.  TN-C has been shown to reduce 
FAK and RhoA activation, paxillin focal organization and stress fibre formation (Midwood and 
Schwarzbauer, 2002) (Orend et al., 2003) (Wenk et al., 2000) (Zagzag et al., 2002), which is 
dependent on inhibition of syndecan-4 interactions with FN via direct interactions of TN-C to this 
receptor (Huang et al., 2001).  This inhibition reduces rat fibroblast proliferation (Orend et al., 
2003) but conversely, induces glioblastoma proliferation (Huang et al., 2001) demonstrating how  
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Kaariainen, 
2006
Induction of cell migration on 3D collagen gel in the 
presence or absence of FN
Primary melanoma cells 
(PMEL29)
U251 human 
glioblastoma
Lightner, 1990Inhibition of cell adhesion to FN either by adding soluble TN-
C or coating TN-C on FN 
NIL.8M hamster fibroblasts and 
U251MG glioma cells
U251MG human 
glioma TN-C
Meiners, 1997(Large isoform) Promotion of neurite outgrowth via TNfnD or 
TNfnB-D
(Large isoform) Promotion of neurite outgrowth via TNfnD or 
TNfnB-D
(Small isoform) Inhibition of neurite outgrowth
Rat embryonic cerebral cortical 
and hypothalamic neuronal 
cultures
U251MG TN-C 
and recombinant 
large and small 
TN-C
Meiners, 1999(Large isoform) promotion of neurite guidance and crossing, 
dependent on TNfnB-D domains
(Small isoform) Inhibition of neurite guidance and crossing
Cerebellar granule neuronal 
cultures
U251MG TN-C 
and recombinant 
large and small 
TN-C
Latijnhouwers, 
1997
Inhibition of keratinocyte adhesion on TN-C substratum
Low adherence of fibroblasts
Human keratinocytesU251MG human 
glioma TN-C
Ghert, 2001TN-C coated onto BSA blocked FN
(220-kDa isoform) Inhibition of cell adhesion 
(320-kDa isoform) no effect on adhesion
BSA blocked TN-C/FN mixed substrate
(220-kDa isoform) enhancement of cell adhesion 
(320-kDa isoform) no effect on adhesion
Human chondrosarcoma JJ012 
cells
U251 MG human 
glioma cells 320-
kDa and 220-kDa
Huang, 2001Inhibition of adhesion on TN-C substratum
Reduced cell adhesion and spreading on TN-C/FN mixed 
substratum
T98G (gliobastoma), MDA-
MB435 (breast carcinoma), 
CHO-B2, CHO-K1, CHO-B2a27
Full-length chicken 
TN-C TN260
Orend, 2003Inhibition of proliferation and adherence on TN -C 
substratum
Increase of cdk inhibitor levels
Reduction of cyclin E-cdk2 activity 
Inhibition of proliferation on TN -C/FN substratum
Loss of focal adhesions, paxillin staining and FAK 
phosphorylation
Reduction of cyclin E-cdk2 activity by a cdk inhibitor 
independent mechanism
Blockage of syndecan-4 dependent actin cytoskeletal
organization.
Human fibroblasts: HDF, HS68, 
MRC-5
Immortalized rat embryo 
fibroblasts: REF5
Immortalized mouse embryonic 
fibroblasts: NIH 3T3 
Chicken TN260 or 
TN190
Riou, 1990Inhibition of cell adhesion to FN and cell spreading
Reduction of cell migration on gastrula derived ECM 
Isolated mesodermal cells from 
dorsal marginal zone
Wenk, 2000Inhibition of stress fire formation
Reorganization of actin cytoskeleton into filopodia
Suppression of RhoA activation
Maintenance of Cdc42 activation
NIH 3T3 fibroblasts cultured on 
3D fibrin-FN matrices
U251 glioma cells; 
70Ten
Riou, 1990Inhibition of further mesodermal cell migrationInjection into late stage 
Pleurodeles waltl (ribbed newt) 
embryos (stage 9)
Riou, 1990Abnormal embryogenesis
Arrested development, endoderm mass, loss of mesoderm
Addition of anti -TNfn6-8 rescues embryogenesis 
Heat denaturation of TN-C rescued embryogenesis 
Injection of excess TN-C into 
late stage Pleurodeles waltl
(ribbed newt) embryos (stage 
7)
Chick embryo 
fibroblast
RefEffect/activ itiesExplant/cell line 
culture/source
TN-C source
Table 1.7   Reported TN-C functions 
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TN-C effects on FN-dependent adhesion are cell specific.  Furthermore, TN-C may also inhibit FN 
matrix assembly: a recombinant TN-C protein showed reduced FN matrix assembly by fibroblasts 
(Midwood and Schwarzbauer, 2002).  FN plays an essential role in directing cell processes, so the 
Table 1.7   Reported TN-C functions 
Kiernan, 1996Repulsive boundary
Inhibition of cell migration over protein strip 
Inhibition of cell migration as homogenous substratum
Mouse primary oligodendrocyte
precursors from optic nerve and 
forebrain
Neonatal mouse 
brain 
Kiernan, 1996Repulsive boundary
Inhibition of cell migration over protein strip
Promotion of cell migration as homogenous substratum
CG-4 oligodendrocyte precursor
Holley, 2005Induction of quiescent phenotype: reduced expression of 
eNCAM, EGFR and bFGFscar (activated) astrocyte
markers and ECM protein nestin on TN-C substratum
Reduction of cell proliferation
Human astrocytesCommercial TN-C 
(Chemicon)
Schmidinger, 
2002
Reduction of fibroblast adhesion and migration 6 h - 12 h 
but distance migrated was recovered to control levels by 
24 h
Human corneal fibroblastsCommercial TN-C 
(Biomol
Feinchimikalien
GmbH) 
Jang, 2005Promotion of chondrosarcoma cell survival on TN -C 
substratum
Induction of survival signals via PI -3-K/Akt pathway
Human chondrosarcoma JJ012 
cells
Human TN-C
Chiquet-
Ehrismann, 
1988
TN-C substratum promotes cell adhesion but inhibits cell 
spreading
Soluble TN-C inhibits cell adhesion and spreading to FN 
substratum
Chick embryo fibroblasts and L929 
cells
Unknown
Midwood, 2002Reduction of focal adhesion formation
Inhibition of FAK phosphorylation, matrix contraction, actin 
stress fiber formation and FN matrix assembly
NIH 3T3 fibroblasts cultured on 3D 
fibrin-FN matrices
70Ten
RefEffect/activ itiesExplant/cell line culture/sourceTN-C source
Transwell migration assay: reduced cell adhesion and 
migration
Zagzag, 2002Aggregate migration assay: adhesion, round morphology, 
reduction in cell processes
U251MG glioblastomasUnknown
Transwell migration assay: adhesion and migration on TN-
C coated filters
Zagzag, 2002Aggregate migration assay: adhesion, spreading and 
formation of elongated processes on TN-C substratum 
after 1 h culture
Bovine retinal endothelial cells 
(BRECs)
Unknown
(Large (TN230) chick isoform) Promotion of cell migrationQuail fibrosarcoma (QT6)Endogenous cell 
expression
Derr, 1997(Small (TN190), intermediate (TN200) and large (TN230) 
chick isoforms) Reduction of cell migration
Chicken embryo fibroblast (SL -29)Endogenous cell 
expression
Tsunoda, 2003(Large isoform TN-C containing TNfnB) Promotion of cell 
migration
Enhancement of cell proliferation. 
Mouse mammary cancer cell line 
GHOM5E 
Endogenous cell 
expression
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loss of a FN matrix may contribute to changes in cell adhesion, spreading, migration and 
proliferation.          
 
The isoform of TN-C involved also affects cell activities and modifies its interactions with other 
ECM components, which may be the reason why often contradictory observations are reported for 
the function of TN-C.  For example, the large isoform of TN-C containing TNfnD or TNfnB-D can 
promote neurite outgrowth and migration, whereas the small isoform of TN-C inhibits neurite 
outgrowth and migration (Meiners and Geller, 1997) (Meiners et al., 1999).  Chondrosarcoma cells 
could adhere to a mixed substratum of the small isoform of TN-C and FN but not to the larger 
isoform of TN-C and FN by solid phase binding (Ghert et al., 2001).  The fact that different TN-C 
isoforms are expressed in a spatially and temporally regulated manner, exhibit different FN binding 
abilities, and can have opposing effects on cell processes, suggests these different TN-C isoforms 
possess multiple and differential functions. 
 
1.3.5   TN-C null mice 
Despite these key effects of TN-C on cell activities and high levels of TN-C expression observed 
during development, TN-C KO mice were shown to develop properly, were viable at birth and did 
not show any gross phenotypic, anatomical abnormalities (Forsberg et al., 1996) (Saga et al., 1992), 
with normal peripheral nerve regeneration, normal collagen type I deposition in granulation tissue 
of wounds (Forsberg et al., 1996) and normal myocardial repair after injury (Tamaoki et al., 2005).  
TN-C null mice developed similar mammary tumors and metastases as wildtype mice (Talts et al., 
1999).  FN deposition in the thymus and brain were also unaltered (Saga et al., 1992).  However, 
further investigations demonstrated TN-C null mice exhibited subtle differences in their behavior 
(poor swimming abilities, increased hyperlocomotion) (Mackie and Tucker, 1999) (Fukamauchi et 
al., 1996) (Fukamauchi et al., 1997) and responses to pathological conditions or wounding.  The 
loss of TN-C on ECM assembly during resolution of these conditions or wounding also shows quite 
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convoluted effects.  In some cases, the loss of TN-C resulted in the loss of FN and ECM deposition: 
reduced FN deposition in the granulation tissue of TN-C null mice (Forsberg et al., 1996); 
compacted corneal wounds with reduced ECM deposition and with reduced FN staining (Matsuda 
et al., 1999);  reduced tumor growth (Tanaka et al., 2004); reduced angiogenesis of transplanted 
cardiac tissue allograft or transplanted melanoma tumor tissue (Ballard et al., 2006) (Tanaka et al., 
2004); delayed and aberrant glomeruli restoration after Habu snake venom induction of 
glomerulonephritis (Matsumoto et al., 2002); diminished liver fibrosis and cellular infiltrate upon 
concanavalin A induced chronic hepatitis (El-Karef et al., 2007) and reduced neointimal hyperplasia 
in the mouse model of stenosis (narrowing of the aorta) (Yamamoto et al., 2005).  This suggests the 
presence of TN-C would promote ECM assembly in these conditions.  However, loss of TN-C can 
also lead to increased ECM deposition: TN-C null mice had altered matrix tumor stroma 
organization and increased ECM deposits around tumor nests (Talts et al., 1999) suggesting that 
here the presence of TN-C would act to inhibit ECM assembly. 
 
1.3.6   Potential functions of TN-C in tubulogenesis and angiogenesis 
Although other developmental processes appear unaffected by the absence of TN-C, recent studies 
demonstrated a reduction of lung branching during development in TN-C null mice, indicating that 
TN-C plays an important role in the tubulogenesis process (Roth-Kleiner, 2004).  The high 
expression of TN-C at the tips and within the clefts of developing buds (Gebb et al., 2005) (Young 
et al., 1994), in contrast to FN, which is more prominently expressed in cleft regions (Sakai et al., 
2003), suggests TN-C may provide spatial cues to modify cell behavior as well as altering ECM 
properties.  TN-C is highly expressed in the mesenchyme adjacent to the epithelium of developing 
and maturing mammary glands (Inaguma et al., 1988).  FN is also essential for tubulogenesis and 
epithelial cell survival.  The ability of TN-C to modify cell-matrix contacts suggests TN-C 
expression regulates levels of cell adhesion to FN to promote cell migration and proliferation 
essential for tubule formation. 
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The prominent localization of TN-C around vascular structures in both normal and especially 
pathological tissues suggests that TN-C is important for angiogenesis.  TN-C has been shown to 
regulate cardiac endothelial cell adhesion in a temporally controlled manner (Ballard et al., 2006), 
promote cardiac endothelial cell migration (Ballard et al., 2006) (Zagzag et al., 2002), induces 
endothelial cell elongation and the sprouting phenotype (Canfield and Schor, 1995) (Schenk et al., 
1999) and promotes neovascularization of cardiac tissue allografts in mice in vivo (Ballard et al., 
2006).  Tumor vascularization is also reduced in TN-C null mice (Tanaka et al., 2004).   Endothelial 
cells highly express αvβ3 integrins, α2β1 integrins and syndecan-4 during angiogenesis, and as well 
as being receptors for TN-C (see Figure 1.7 and Table 1.8) these are also receptors for FN and 
collagen.  FN has been shown to be vital for angiogenesis (Zhou et al., 2008) and TN-C can 
interfere with cell adhesions to FN by blocking binding to syndecan-4 (Huang et al., 2001) 
(Midwood and Schwarzbauer, 2002) suggesting TN-C may inhibit endothelial cell adhesions and 
plays a regulatory role in angiogenesis.   
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.8    TN-C receptors 
Weber, 1996NeuronsTNfn5-7contactin/F11
Milev, 1997Astrocytes; olfactory neuronsFBGPhosphocan, neurocan
Joshi, 1993; Chung, 1997; 
Aukhil, 1993; Huang, 2001Adherent cellsFBG
HSPGs; 
syndecan-4
Yokosaki,1998EpitheliumTNfn39 1
Schnapp, 1995; Varnum-
Finney, 1995
epithelial cells, smooth muscle 
cells, myofibroblasts, and 
embryonic neural cells
TNfn3, TNfn6-88 1
Srirarmarao, 1993Tumor endothelial cellsTNfn32 1
Yokoyama, 2000; 
Srirarmarao, 1993; 
Johansson, 1997
Endothelial cells, osteoclasts, 
tumor cells, cultured in vitro cellsTNfn3, FBGv 3
Chung, 1994Tumor cellsTNfnA-DAnnexin II
RefsExpressionDomainTN-C receptors
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1.3.7   Potential functions of TN-C fragments 
Full-length TN-C expression is co-expressed in regions of high MMP expression (Cowan et al., 
1999) (Imai et al., 1994) (Jones et al., 1995) (Jones et al., 1997) (Kalembeyi et al., 2003) (Mai et al., 
2002) including during angiogenesis (Tokes et al., 1999).  TN-C itself can also induce the 
expression of MMPs (Kalembeyi et al., 2003) (Tremble et al., 1994) (Wallner et al., 2004).  MMP-
1, MMP-2, MMP-3, MMP-7, serine proteases, cathepsin B, cathepsin G and leukocyte elastase can 
all degrade TN-C (Imai et al., 1994) (Latijnhouwers et al., 1998a) (Mai et al., 2002) (Siri et al., 
1995), suggesting a highly proteolytic environment will regulate TN-C protein levels and feedback 
to regulate MMP expression levels.  Full-length TN-C is a large multi-domain protein, and like FN, 
many of these domains possess independent activities compared to the full-length structure (Table 
1.9).  Degradation of TN-C may also reveal activities by individual TN-C domains, which are 
buried or encoded in the full-length protein.  Degraded TN-C fragments have been shown to induce 
aggrecanase activity in cartilage, whereas the full-length TN-C molecule has no effect (Sofat, 
2006).  Activated T-lymphocytes secrete urokinase type plasminogen activator, which cleaves 
plasminogen to plasmin, which then proteolyses TN-C converting it from an anti-adhesive substrate 
to an adhesive substrate for T-lymphocytes (Gundersen et al., 1997).  
 
Other cryptic functions of TN-C have been revealed with the use of recombinant TN-C domains 
(See Table 1.9).  Some domains have the same activity as the full-length molecule and may be 
responsible for the overall observed effect of the full-length molecule: the FBG domain of TN-C 
interacts with T-lymphocyte receptors to tether the cells and induce cell rolling (Clark et al., 1997); 
the FBG domain is also responsible for changes in endothelial cell shape (Schenk et al., 1999).  In 
some cases, multiple domains within TN-C have the same effect as the full-length molecule: TN-C, 
TNfn1-5, TNfnA-D and TNfnALL inhibit β-casein protein synthesis in a concentration dependent 
manner (Jones et al., 1995).  Other domains have opposing activities: full-length TN-C acts like a 
boundary to inhibit oligodendrocyte crossing over a protein strip whereas the FBG domain 
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promotes cell crossing (Kiernan et al., 1996).  Conversely, individual domains may possess unique 
activities not present in the full-length molecule: TN-C fragments containing EGF-L domains have 
been shown to induce human smooth muscle cell apoptosis whereas intact TN-C has no effect 
(Wallner et al., 2004); TN-C domains EGF-L, TNfn3-5, TNfn5-7 and TNfn6-8 induce GAG release 
in porcine cartilage explants whereas full-length TN-C has no effect (Sofat, 2006).  The presence of 
neighboring domains can also affect the exposure of the cryptic function:  TN-C deletion mutants 
lacking both EGF-L and TNfn domains (TA/FBG) or TNfn and FBG domains (TA/EGF-L) 
promote chick embryo fibroblast adhesion and spreading, whereas TN-C mutants lacking only the 
EGF domain (TA/TNfn/FBG) or only the FBG domain (TA/EGF- L/TNfn) showed reduced 
adhesion and cell rounding (Fischer et al., 1997); the presence of neighboring TNfnA1-A4 domains 
buries the TNfnA2 pro-adhesive effect (Saito et al., 2007).  This suggests within TN-C, individual 
domains also possess unique biological activities, which may only be exposed upon proteolytic 
cleavage.  This effect has been seen with other modular proteins including FN and collagens, and 
these biologically active domains or fragments have been termed matricryptins (Tran et al., 2005).   
 
 
 
 
 
 
 
 
 
 
 
 
Schnapp, 1995α8β1 integrin mediated RGD-dependent adhesion to TN-CHEK293
Yokosaki, 1998RGD-independent, IDG-dependent α9β1 mediated adhesion
RGD-dependent, αvβ3 mediated adhesion
Human colon cancer cells 
(SW480)
Joshi, 1993Mediates cell adhesion and spreading; mediated via αvβ3; RGD-
dependent
Bovine aortic endothelial cellsTNfn3
Krishnan, 2007Activates cell migration; signaling via EGFR, PLC -γ and m-
calpain
internalization of EGFR not required to mediate signaling
NR6WT murine fibroblastsEGF-L 
(Ten14)
Tsunoda, 2003No effect on cell migration (Boyden chamber), no effect on cell 
proliferation
Mouse mammary cancer cell line 
GHOM5E 
Fischer, 1997Mediates cell adhesion and spreading in hexameric construct 
lacking TNfn and FBG domains; reduces adhesion to FN; in the 
presence of TNfn domains, abolishes adhesion to FN
Chick embryo fibroblast
Kiernan, 1996Repulsive boundary; inhibits cell migration over protein strip; 
allows cell migration as substratum
Primary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
Prieto, 1992Inhibits NIH 3T3 adhesion to FNNIH 3T3
Prieto, 1992No cell adhesionNeuroblastoma, NIH 3T3, 
U251MG
Wallner, 2004Induction of apoptosis via activation of caspase -3Human SMCsEGF-L
RefLigands/activitiesExplant/cell line culture/sourceTN-C 
domain
Table 1.9   TN-C domain functions 
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Young, 1994Inhibition of branching morphogenesisRat fetal lung explantTNfnA-D
Jones, 1995Inhibition of B-casein milk protein productionMammary epithelial cells cultured 
on 2D EHS matrix
Meiners, 1999Promotion of neurite outgrowth, migration and guidanceCerebellar granule neuronal 
cultures
Meiners, 1997Enhancement of neurite outgrowth via more than one binding 
site
Rat embryonic Cerebral cortical 
and hypothalamic neuronal 
cultures
Prieto, 1992Inhibition of NIH 3T3 adhesion to FNNIH 3T3
Kiernan, 1996Promotion of cell migrationPrimary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
TNfn7-8
Tamaoki, 2005Promotion of migration Cardiac fibroblastsTNfn1-8
Tamaoki, 2005Up-regulates α-SMA expressionCardiac myofibroblasts
Meiners, 1997Enhancement of neurite outgrowth (via TNfn6 -8)Rat embryonic Cerebral cortical 
and hypothalamic neuronal 
cultures
Tsunoda, 2003No effect on cell migration (Boyden chamber), no effect on cell 
proliferation
Mouse mammary cancer cell line 
GHOM5E 
Tremble, 1994Induction of FN dependent MMP expression Rabbit synovial fibroblasts
Prieto, 1992Inhibition of NIH 3T3 adhesion to FNNIH 3T3
Prieto, 1992Trypsinization reveals cell surface binding sites
Promotion of cell adhesion
L-929
Prieto, 1992Inhibition of cell adhesionNeuroblastoma, NIH 3T3, 
U251MG
Seiffert, 1998Promotion of cell adhesion
Reduction of proliferation compared to large isoform of TN-C; 
HSPG dependent
Haematopoietic stem cells: 
Myeloblastic KGla cells
Erythroleukemic K562 cells 
Promonocytic U937 cells 
Meiners, 1997Enhancement of neurite outgrowth via a single site (within 
TNfn6-8)
Rat embryonic Cerebral cortical 
and hypothalamic neuronal 
cultures
Meiners, 1999Promotion of neurite outgrowth but not neurite migration or 
guidance
Cerebellar granule neuronal 
cultures
Young, 1994Inhibition of branching morphogenesisRat fetal lung explantTNfn6-8
Kiernan, 1996Promotion of cell migrationPrimary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
TNfn4-5
Hauzenberger, 
1999
Inhibition of α4β1 and α5β1 mediated cell adhesion to FNMOLT-4 T lymphocytes
Joshi, 1993Mediates cell adhesion but not spreading; mediated via αvβ3 Bovine aortic endothelial cells
Aukhil, 1993Heparin binding: affinity chromatographyRat embryo skin fibroblasts
Jones, 1995Inhibition of β-casein milk protein productionmammary epithelial cells cultured 
on 2D EHS matrix
Young, 1994Inhibition of branching morphogenesisRat fetal lung explantTNfn1-5
Aukhil, 1993Heparin binding: affinity chromatographyRat embryo skin fibroblastsTNfn3-5
Kiernan, 1996Promotion of cell migrationPrimary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
Meiners, 1999Promotion of neurite outgrowth but not neurite migration or 
guidance
Cerebellar granule neuronal 
cultures
Jones, 1995Inhibition of B-casein milk protein productionmammary epithelial cells cultured 
on 2D EHS matrix
TNfn1-3
RefLigands/activ itiesExplant/cell line culture/sourceTN-C 
domain
Table 1.9   TN-C domain functions 
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Table 1.9   TN-C domain functions 
Tamaoki, 2005Promotion of migration 
Up-regulation of α-SMA expression
Cardiac fibroblastsFBG
Seiffert, 1998Promotion of cell adhesion
Promotion of proliferation compared to large isoform of TN -C 
HSPG dependent
Haematopoietic stem cells: 
Myeloblastic KGla cells
Erythroleukemic K562 cells 
Promonocytic U937 cells 
Yokoyama, 2000Promotion of αvβ3 mediated adhesion via 2 sequences within FBG 
(γC346-358 and γC190-202)
β3-CHO 
Schenk, 1999Promotion of bFGF induced cell elongation and bipolarization; 
Reduction in the adhesive properties of TN-C
Bovine aortic endothelial cells
Clark, 1997Promotion of T lymphocyte rolling via novel β1, β3, RGD, heparin 
independent TN-C receptor
SKW3 T lymphoblastoid cells
Fischer, 1997Mediates cell adhesion and spreading in hexameric construct 
lacking EGFL and TNfn domains
Reduction of adhesion to FN
Chick embryo fibroblast
Aukhil, 1993Mediates cell adhesion but not cell spreading; HSPG dependent Rat embryo skin fibroblasts
Fischer, 1995Heparin binding: affinity chromatography with pronase digestion; 
ImmunoEM; TN-C mutants
Rat embryo skin fibroblasts
Joshi, 1993Mediates cell adhesion but not spreading; HSPG -dependentHamster fibroblast NIL.8M
Joshi, 1993Mediates cell adhesion but not spreading; integrin dependent but
not αvβ3, α5β1; no adherence if FBG coated onto nitrocellulose 
rather than plastic
Bovine aortic endothelial cells
Tsunoda, 2003No effect on cell migration (Boyden chamber), no effect on cell 
proliferation
Mouse mammary cancer cell line 
GHOM5E 
Kiernan, 1996Promotion of cell migration and distribution on protein strip
Promotion of cell migration as substratum
Primary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
Tsunoda, 2003Promotion of cell migration (Boyden chamber)
Enhancement of cell proliferation
Mouse mammary cancer cell line 
GHOM5E 
RefLigands/activ itiesExplant/cell line culture/sourceTN-C 
domain
Joshi, 1993Mediates cell adhesion but not spreading via αvβ3Bovine aortic endothelial cells
Meiners, 1997Enhancement of neurite outgrowth via more than one binding siteRat embryonic Cerebral cortical 
and hypothalamic neuronal 
cultures
Tamaoki, 2005Promotion of migration Cardiac fibroblasts
Jones, 1995Inhibition of β-casein milk protein productionMammary epithelial cells cultured 
on 2D EHS matrix
TNfnALL
Kiernan, 1996Repulsive boundary
Inhibition of cell migration over protein strip
Promotion of cell migration as substratum
Primary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
TNfnB/D
Kiernan, 1996Repulsive boundary
Inhibition of cell migration over protein strip
Promotion of cell migration as substratum
Primary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
TNfnA1/A2/
A4
Kiernan, 1996Repulsive boundary
Inhibition of cell migration over protein strip
Promotion of cell migration as substratum
Primary oligodendrocyte
precursors and oligodendrocyte
precursor cell CG-4
TNfnA1/A2/
A4/B/D
Saito, 2008Inhibition of angiogenesis Chick embryo chorioallantoic
membrane (CAM)
Saito, 2008Inhibition of cell migration on FN substrate 
Inhibition of cell proliferation
Human dermal microvascular
endothelial cells
Saito, 2007Promotion of cell adhesion and spreading; interacts with HSPG to
activate β1
SV40 transformed human 
embryonic lung 
fibroblastsWI38VA13
TNfnA2
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TN-C fragmentation has been observed in vivo.  TN-C degradation products are observed in chronic 
non-healing wound exudate (Latijnhouwers et al., 1998a), which are highly proteolytic 
environments, and have been shown to be mediated by serine proteases (Latijnhouwers et al., 
1998a).  TN-C fragmentation is observed in cancers including small cell lung cancers (Cai et al., 
2002) and this was shown to correlate with the metastatic potential of these cancers.  TN-C 
fragmentation has also been observed in atherosclerotic plaques (Wallner et al., 2004), in ruptured 
tendons (Riley et al., 1996) and in RA and OA cartilage (Sofat, 2006).   
 
Larger TN-C isoforms are more susceptible to MMP-2 and MMP-3 degradation (Siri et al., 1995), 
suggesting the expression of these splice variants during physiological and pathological conditions 
will result in the release of TN-C fragments.  These fragments may expose TN-C domains with 
independent functions from the full-length molecule and signal to the cell to signify the progression 
or subsequent resolution of the condition. These TN-C fragments may also differentially change the 
properties of the ECM or the extent of ECM assembly, which may explain the differences observed 
in TN-C null mice.  
 
1.4   Possible functions for TN-C to promote or inhibit FN matrix assembly 
FN and TN-C are both temporally and spatially co-expressed and up-regulated during development, 
in wound healing and in pathological conditions in vivo.  TN-C can also interact with FN fibrils in 
vivo as well as in vitro and modifies the properties of the FN matrix.  This close interaction between 
FN and TN-C suggests TN-C may also play a role in regulating FN matrix assembly and may be a 
unique mechanism by which ECM proteins and their degradation products can influence the 
composition of the ECM.  However the precise effect of TN-C on FN assembly is not clear. 
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1.4.1   TN-C may promote FN matrix assembly 
TN-C null mice exhibit reduced FN deposition during wound healing (Forsberg et al., 1996) 
(Matsuda et al., 1999); diminished liver fibrosis upon concanavalin A induced chronic hepatitis (El-
Karef et al., 2007) and reduced neointimal hyperplasia in the mouse model of stenosis (narrowing 
of the aorta) (Yamamoto et al., 2005) suggesting TN-C promotes FN matrix deposition in these 
conditions.  TN-C and a close family member TN-R have been shown in electron micrographs to 
cross-link with aggrecan-hyaluronan complexes (Lundell et al., 2004).  TN-R forms trimer 
complexes and interacts with the aggrecan CLD domains via its TNfn3-5 domains (Lundell et al., 
2004) (Diao and Tajkhorshid, 2008).  A pentameric multi-domain protein that also has a stabilizing 
and catalytic function is cartilage oligomeric matrix protein (COMP), which binds collagen type I 
and II molecules, to bring them close together and facilitate their fibril formation (Halasz et al., 
2007).  The close spatial and temporal expression of hexameric TN-C with FN and the ability of 
TN-C to form fibrillar structures but only when in the presence of fibrillar FN matrix, could indicate 
a similar catalytic role for TN-C in the stabilization of FN.  
 
1.4.2   TN-C may inhibit FN matrix assembly 
TN-C null mice had increased ECM deposits around tumor nests (Talts et al., 1999) suggesting the 
presence of TN-C would act to inhibit ECM assembly.  During development of the dentary of rat 
mandibles and tibias, FN localization to the mesenchyme, and TN-C localization to mesenchymal 
cell condensations overlapped at early time points, but later in the process, TN-C and FN become 
segregated with TN-C staining almost encasing the FN staining regions (Sasano et al., 2000).  This 
suggests that the presence of TN-C results in a loss of FN deposition in that region to segregate 
specific areas during development (Sasano et al., 2000).  Furthermore a recombinant TN-C protein, 
70-Ten, which has the same effect on cell morphology and focal adhesion formation as full-length 
TN-C, was observed to inhibit FN matrix assembly by fibroblasts (Midwood and Schwarzbauer, 
2002).   
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1.5   Aims of this thesis 
• Determine whether TN-C or any of its individual domains have any effect on FN matrix 
assembly.  I will initially use two well characterized methods to assay FN matrix assembly 
by NIH 3T3 fibroblasts in monolayer culture.   
• Map which specific domains within TN-C are required to mediate any effects observed  
• Investigate the mechanisms by which these domains are acting.   
• Determine whether individual domains of TN-C are involved in affecting FN dependent 
physiological processes such as tubulogenesis and angiogenesis. 
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2.1 Regents 
2.1.1 General reagents 
General reagents were purchased from the following sources: 10×phosphate buffered saline 
(PBS), sodium carbonate, sodium chloride, calcium chloride (CaCl2), methanol, isopropanol and 
acetic acid from VWR International GmbH (Darmstadt, Germany); sulphuric acid from BDH 
(VWR International); Trizma base (minimum 99.9% titration), glycine, 
ehtylenediaminetetraacetic aicd (EDTA), Tween-20, magnesium chloride (MgCl2), bovine 
serum albumin (BSA),  sodium n-dodecyl sulphate (SDS) and 38% paraformaldehyde 
(BioChemika) from Sigma-Aldrich (Dorset, UK).  
 
2.1.2 Tissue culture reagents 
All reagents used were of tissue culture grade and sterile.  Reagents were purchased from the 
following sources: Dulbecco’s modified Eagle’s medium (DMEM) with high Glucose 4.5 g/l, 
L-Glutamine and Sodium Pyruvate, Ham’s F-12 medium with L-glultamine, 1xRPMI-1640 
with L-Glutamine, 100 X penicillin and streptomyocin (1000 U/ml penicillin and 10 mg/ml 
streptomycin), 1xTrypsin-EDTA solution and Heat Inactivated Fetal Calf Serum (FCS) from 
PAA Laboratories Ltd. (Somerset, UK); Heat Inactivated Fetal Calf Serum from Biosera 
(Sussex, UK); gelatin sepharose from GE Healthcare (Buckinghamshire, UK); 10xRPMI-1640 
medium, endothelial cell growth supplement, sterile dimethyl sulphoxide (DMSO) and E64 
from Sigma-Aldrich Ltd (Dorset, UK); Heat Inactivated Newborn Calf Serum (NCS) from 
Gibco (Invitrogen, Paisley, UK); Versene (EDTA) from Biowhittaker; Type I collagen 
(Cellmatrix type I-A) from Nitta Gelatin Inc. (Osaka, Japan); Recombinant human hepatocyte 
growth factor (HGF) from Peprotech (London, UK); vascular endothelial growth factor 
(VEGF), Suramin and Optimised medium for HUVEC culture from TCS Cellworks 
(Buckingham, UK);  50 U/ml heparin from PD Pharmaceuticals Ltd. (Hampshire, UK); 
GM6001 (Ilomastat) from Elastin Products Company (Missouri, USA); 8 well chamber slides 
from BD Biosciences (Oxford, UK); Glass slides from Menzel-Glaser (Braunschweig, 
Germany); Glass coverslips from VWR International; all plastic-ware for tissue culture from 
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Invitrogen (Paisley, UK), BD Biosciences (Oxford, UK) and Corning BV  (Amsterdam, The 
Netherlands). 
 
2.1.3   SDS-PAGE reagents 
Reagents were purchased from the following sources: N, N, N’, N’-Tetramethylethylenediamine 
(TEMED), bromophenyl blue, glycerol from Merck Biosciences (UK); 30% (w/v) 
acrylamide/bis-acrylamide from Severn Biotech Ltd.; ammonium persulfate (APS) from Acros 
Organics; dithiothreitol (DTT) from AXXORA, Nottingham, UK;  Prestained Precision Plus 
Protein standards from Bio-Rad Laboratories, Hemel Hempstead, UK. 
 
2.1.4   Coomassie Blue and silver staining reagents 
Reagents were purchased from the following sources: Coomassie Brilliant Blue R-250, formic 
acid from Merck Biosciences BDH (VWR International); silver nitrate solution from Fisher 
(Landsmeer, The Netherlands); sodium thiosulphate from VWR International GmbH 
(Darmstadt, Germany).  
 
2.1.5   Immunoblotting reagents 
Reagents were purchased from the following sources: Dot blotting filter paper from Bio-Rad 
Laboratories, Hemel Hempstead, UK; nitrocellulose from GE Healthcare, Buckinghamshire, 
UK; Western blue substrate from Promega, UK; polyvinylidene difluoride (PVDF) membrane, 
ECL substrate and Hyperfilm™ from Amersham Pharmacia Biotech, Little Chalfont, UK; dried 
skimmed milk from Tescos (UK). 
 
2.1.6   DOC solubility assay reagents 
Reagents were purchased from the following sources: deoxycholate, general protease inhibitor 
(PI), iodoacetic acid  and  N-ethylamaleimide from Sigma-Aldrich (Dorset, UK); cell scrapers 
from Corning BV  (Amsterdam, The Netherlands); G26 × ½ blunt stainless steel hypodermic 
needles (Coopers needle works) from ; 1 ml syringes from Terumo (Tokyo, Japan). 
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2.1.7   Protein fluorescence labelling reagents 
Reagents were purchased from the following sources: Alexa Fluor-488 and Alexa Fluor-568 
dyes were from Invitrogen molecular probes; dimethylformamide (DMF) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) from Sigma-Aldrich, Dorset, UK and 
added to the protein solution.   
 
2.1.8   General indirect immunofluorescence staining reagents  
Reagents were purchased from the following sources: Alexa Fluor-488 phalloidin (A12379), 
Alexa Fluor-568 phalloidin (A12380), Alexa Fluor-660 (A22285) phalloidin, Alexa Fluor-488 
reactive dye, Alexa Fluor-568 reactive dye and Prolong Gold Antifade reagent from Invitrogen 
(Paisley, UK); DAPI staining for cell nuclei, 3.8% paraformaldehyde from Sigma-Aldrich 
(Dorset, UK); Triton X-100 from BDH (VWR International GmbH, Darmstadt, Germany); 
Alexa Fluor-568 labelled concanavalin A was a kindly provided by Kathryn Owen.   
 
2.1.9   FACs analysis reagents  
Reagents were purchased from the following sources: Annexin V binding buffer, Annexin V, 
FACs buffer from BD pharmingen, BD Biosciences, Oxford, UK; versene (EDTA) from 
Biowhittaker.   
 
2.1.10    RT-PCR reagents 
Reagents were purchased from the following sources: dATP, dCTP, dTTP, dGTP, random 
primers and UltraPure™ agarose from Invitrogen, Paisley, UK; Stratascript buffer, RNAse 
block, Stratascript reverse transcriptase from Stratagene, UK; ethidium bromide from BDH, 
(VWR International GmbH, Darmstadt, Germany); Loading sample buffer, 500 bp and 1 kb 
DNA ladders from Bio-Rad, Hemel Hempstead, UK.   
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2.2   Purified proteins 
Alpha-chymotryptic FN fragments 120-kDa Central Binding Domain (CBD; F1904) and 40-
kDa domain (HepII; F1903) were purchased from Chemicon (Millipore, Watford, UK); 70-
kDa and 70-Ten was kindly provided by Jean Schwarzbauer (Princeton University, NJ).   
 
2.3   Recombinant proteins 
TN-C expressing HEK 293 cells were kindly provided by Gertraud Orend (INSERM, 
Strasbourg) and TN-C purified by Emma Chan.  Recombinant TN-C domains TA, TNfn1-3, 
TNfn3-5, TNfn1-5, TNfn5-7, TNfn6-8 and FBG were expressed in E. coli and purified by 
Annette Trébaul, Emma Chan and Kim Midwood as described in (Midwood et al., 2009) and 
made available for this study.  FLAG-tagged FBG was expressed in HEK 293 cells and purified 
by Emma Chan following the protocol for expression of FLAG-tagged EGF-L expression by 
(Sofat, 2006).  FLAG-tagged EGF-L was expressed in HEK 293 cells by Nidhi Sofat and 
purified by me from the conditioned medium of these cells by anti-FLAG affinity 
chromatography and gel filtration (Sofat, 2006) (Figure 2.1 A).  The TNfn1-8 construct was 
expressed in Rosetta DE3 E. coli and purified from the soluble supernatant of the bacterial 
lysate by Annette Trébaul.  I established the purification procedure for TNfn1-8 (Figure 2.1 B).   
 
 
 
 
 
 
 
 
 
 
Figure 2.1    Purification schemes for EGF-L and TNfn1-8
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2.4   Antibodies 
Antibodies used in this study are summarized in Table 2.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invitrogen, A21472Chicken1000FACsPAbRatAlexa Fluor-647 anti-rat
Invitrogen, A11036Goat200 (2D), 300 (3D)IFPAbRabbit
Alexa Fluor-568 anti-
rabbit
Invitrogen, A11034Goat200 (2D), 300 (3D)IFPAbRabbit
Alexa Fluor-488 anti-
rabbit
Sigma, A1949Mouse5000WBMAbRabbitHRP conjugated anti-rabbit
Promega, S3721Goat5000WBPAbMouseAnti-Mouse IgG (Fc), AP conjugate
Promega, S3731Goat5000WBPAbRabbitAnti-Rabbit IgG (Fc), AP conjugate
AbCam, ab32084Rabbit200IFMAbHuman, mouse, ratPaxillin [Y113]
Chemicon, MAB2514Rat100FACsMAbMouseAnti-mouse integrin 5 1
200ELISA
Sigma, F3165Mouse
1000WB
MAbFLAG tagAnti-FLAG ® M2
Chemicon, MAB1908Mouse1000WBMAbHumanAnti-TN-C N-terminus
200ELISA
QIAGEN, 34670Mouse
1000WB
MAbHis tagTetra-His 
200ELISA
Chemicon, MAB1918Mouse
1000WB
MAbHumanTNfn6-8
200ELISA
Chemicon, MAB1911Mouse
1000WB
MAbHumanTNfn1-3
Jean Schwarzbauer, 
R40Rabbit200IFMAbHuman, mouseFNIII1-6
Jean Schwarzbauer, 
R457Rabbit200IFMAbHuman, mouse70-kDa
Jean Schwarzbauer, 
F184Rabbit200IFPAbHuman, mouseFibronectin
Jean Schwarzbauer, 
R39Rabbit200IFPAbHuman, mouseFibronectin
200IHC
200IF
200ELISA Sigma, F3648Rabbit
1000WB
PAb
Human, mouse, 
rat, goat, pig, 
chicken
Fibronectin
Company, # no. or 
sourceRaised inDilutionsUse
Antibody 
typeSpecificityAntigen
Table 2.1 Antibodies used in this study 
AP, alkaline phosphatase; HRP, hydrogen peroxide; MAb, monoclonal antibody; PAb, polyclonal antibody; WB, 
Western blot; IF, immunofluorescence; ELISA, enzyme linked immunosorbant assay; IHC, 
immunohistochemistry; FACs, fluorescence activated cell sorting  
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2.5   Protein purification 
2.5.1 Ni-NTA purification of His-tagged proteins 
1 ml Ni-NTA agarose (QIAGEN, Crawley, UK) was packed into a chromatography column 
(Bio-Rad ECONOPAC columns) for every 5-10 mg/ml of protein loaded.  The column then 
went through a series of wash and elution steps:  
 
Table 2.2   Steps involved in Ni-NTA purification 
Step Solution Column volume 
Wash TBS 10 
Application of protein Applied in TBS 1 ml Ni-NTA agarose for every 
5-10 mg/ml 
Wash TBS 10 
Wash 60% isopropanol 20 
Wash  TBS 10 
Wash 20 mM imidazole in TBS or 
gradient of imidzole 
10 
Elute 100 mM imidazole in TBS 10 
Wash 100 mM imidazole in TBS 5 
Wash H2O 10 
Storage 20% ethanol Washed through 
 
Imidazole was from Sigma-Aldrich.  Each wash and eluted fractions was collected and run on 
coomassie or silver stained gels to detect presence of protein of correct band size.   
 
TBS 
0.05 M Tris pH 8.0 
0.15 M NaCl 
0.02% sodium azide 
 
 
2.5.2   Anion exchange: HiTrap Q HP column and Cation exchange: HiTrap SP HP 
column 
The 5 ml HiTrap Q HP column (Q-column) or 5 ml HiTrap S HP (S-column) column (GE 
Healthcare, Buckinghamshire, UK) was attached to the ÄKTA Fast Protein Liquid 
Chromatography (FPLC) system (Amersham Pharmacia Biotech, Little Chalfont, UK).  The 
columns were initially washed with a high salt buffer (1M NaCl) then equilibrated in a low salt 
buffer (0.05M NaCl).  TN1-8 was diluted to the required NaCl concentration (0.05 M) and 
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passed over the columns.  Protein was eluted on a salt gradient of 0.5 M NaCl for 1 h and 
fractions collected.   
 
Low salt buffer 
50 mM Tris-HCl  pH 8.0 
50 mM NaCl 
 
High salt buffer 
50 mM Tris-HCl  pH 8.0 
1 M NaCl 
 
 
2.5.3   Affinity chromatography: Anti-FLAG affinity column 
Anti-FLAG® M2 affinity agarose (Sigma-Aldrich, Dorset, UK) was used to isolate FLAG-
tagged EGF-L and eluted by competition with a FLAG peptide (Advanced Biotechnology 
Centre, Imperial College, UK). 
 
Table 2.3   Steps involved in anti-FLAG affinity chromatography 
Step Solution Volume/Time 
Apply Anti-FLAG resin 2 ml 
Wash TBS 30 min 
Load Sample  0.5 ml/min 
Wash 1 M NaCl buffer 30 ml 
Load FLAG peptide (200 μg/ml) 3 ml; with pipette, re-suspend beads 
in column 
Elute FLAG peptide (200 μg/ml) 3 ml 
Elute FLAG peptide (200 μg/ml) 3 ml 
Elute FLAG peptide (200 μg/ml) 3 ml 
Elute FLAG peptide (200 μg/ml) 3 ml 
Elute  FLAG peptide (200 μg/ml) 3 ml 
Wash Pipette washed in elution buffer 3 ml 
Wash/store TBS with sodium azide 10 min 
  
 
2.5.4   LPS testing 
To check the concentration of LPS present, the LAL test from Cambrex (Lonza Biologics, 
Slough, UK) was used according the manufacturers’ instructions.   
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2.5.5   HiLoad 16/60 superdex 75 column gel filtration 
The HiLoad 16/60 superdex 75 column (Amersham Pharmacia Biotech, Little Chalfont, UK) 
was inverted, attached to the ÄKTA FPLC and washed through to remove any hydrophobic 
proteins or contaminants. 
 
Table 2.4   Steps involved in HiLoad 16/60 superdex 75 column gel filtration 
Step Solution Column volume 
Wash 1 M NaOH 4 
Wash H2O 4 
Wash 30% isopropanol 0.5 
Wash H2O 2 
Equilibrate  TNC buffer Overnight wash 
Elute TNC buffer 1 
 
The column was re-inverted and sample was injected directly onto the column.  TNC buffer was 
then run in at 0.8 ml/min.  Fractions were collected for analysis. 
 
TNC Buffer 
0.05 M Tris-HCl, pH8.0 
0.15 M NaCl 
0.01 M CaCl2 
 
 
2.5.6   XK 26/100 sephacryl S200 column gel filtration 
The XK 26/100 sephacryl S-200 column (Amersham Pharmacia Biotech, Little Chalfont, UK) 
was packed with sephacryl S-200 HR slurry (Amersham Pharmacia Biotech, Little Chalfont, 
UK) re-suspended with TNC buffer and packed by running buffer through.  It was then 
thoroughly washed through with 60% isopropanol to ensure no LPS contamination.   
 
Table 2.5   Steps involved in XK 26/100 sephacryl S200 column gel filtration 
Step Solution Column volume 
Wash 60% isopropanol 3 
Wash H2O 3 
Equilibrate  TNC buffer 2 
Elute TNC buffer 1 
 
Sample was injected directly onto the column.  TNC buffer was then run through at 0.8 ml/min, 
and fractions collected for analysis.   
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2.5.7   Protein dialysis 
Large volumes of protein were dialysed in Spectrum molecular porous membrane tubing 
(Spectrum Laboratories, Breda, The Netherlands).  Smaller volumes of protein were dialysed in 
Slide-a-Lyzer cassettes (Pierce Biotechnology, Rockford, IL, USA).  Both methods involved the 
submergence of the tubing or cassette in dialysis buffer at 4°C with stirring, which was replaced 
after 2 h, and left overnight.  
 
2.5.8   Protein concentration 
Protein was concentrated by either a Vivacell 250 ultrafiltration concentrator system 
(VivaScience) for large volumes of solution >100 ml or a spin column system (Vivaspin, Viva 
Science, Gloucestershire, UK). 
 
2.6   Cells and tissue culture 
2.6.1   Cell lines 
Cell lines used in these studies: NIH 3T3 fibroblasts from ATCC; Madin-Darby canine kidney 
(MDCK) cells were kindly provided by Noriko Itoh and Brit Wolters; Human endothelial cells 
used in the 2D human angiogenesis model were pre-plated and provided by TCS CellWorks, 
Buckingham, UK (ZHA-1000); human umbilical vein endothelial cells HUVECs used in 3D gel 
experiments were isolated from human umbilical cord veins and kindly gifted to us at Passage 3 
by Leigh Madden. 
 
2.6.2   Cell culture 
All cells were cultured in a 37ºC humidified incubator supplied with 5% CO2. 
 
NIH 3T3 fibroblasts were cultured in DMEM supplemented with penicillin-streptomycin (1x) 
and 10% FCS at 37˚C.  The fibroblasts were passaged upon ~70-80% confluence by 
trypsinisation.  For use in experiments, NIH 3T3s fibroblasts were cultured in serum-free 
DMEM supplemented with penicillin-streptomycin (1x).   
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For DOC solubility experiments, indirect immunofluorescence studies and RT-PCR, NIH 3T3 
fibroblasts were plated in 24 well plates at a density of 4x105/ml (unless stated), on sterilised 13 
mm diameter glass coverslips cultured in DMEM supplemented with only Penicillin-
Streptomycin (1x) and incubated at 37˚C, 5% CO2.  To monitor TN-C or TN-C domain 
interactions over time, NIH 3T3 fibroblasts were incubated for 2 h, before TN-C, TN-C 
domains or an equivalent buffer volume without recombinant protein was added directly to the 
media at the specified concentration and incubated for the required time period.  The dishes 
were then removed from incubation and examined under x10 magnification on a light 
microscope and changes in cell shape or confluence were noted.  To examine TN-C or TN-C 
domains interactions with cells possessing a mature FN matrix, 4x105/ml NIH 3T3 fibroblasts 
were cultured for 24 h before addition of TN-C, TN-C domains or an equivalent buffer volume 
without recombinant protein.  
 
Where required, cells were also cultured in the presence of 10 μM general MMP inhibitor, 
GM6001 or an equivalent volume of carrier solution DMSO.   These were added directly to the 
conditioned medium after 2 h plating.   
 
MDCK cells were cultured in DMEM supplemented with penicillin-streptomycin (1x) and 5% 
FCS.  MDCK cells were passaged upon confluence by trypsinisation.  For use in experiments, 
MDCK cells were cultured in DMEM supplemented with penicillin-streptomycin (1x) and 10% 
FCS.        
 
For tubulogenesis assays (Bird, 2006) collagen gel was prepared by mixing 10 volumes of ice-
cold Collagen Type I (Cellmatrix type I-A) supplemented with 1 volume 10xRPMI, 0.022M 
NaOH to adjust the solution to a neutral pH and 50 ng/ml HGF.  Mixing was done rapidly on 
ice.  MDCK cells were harvested and re-suspended to a density of 1.6x104/ml in DMEM 
supplemented with 10% FCS and penicillin-streptomycin (1x).  750 μl of this cell solution 
(1.28x104 cells) was suspended in the collagen gel preparation. 100 μl of the collagen mix was 
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pipetted per well in an 8 well chamber slide and left to polymerise at 37ºC for 20 minutes.  Gels 
were then overlaid with 500 μl DMEM supplemented with 10% FCS and penicillin-
streptomycin (1x).  The medium was supplemented with 50 ng/ml HGF and the medium 
supplemented with 1 μM, 0.1 μM or 0.01 μM of each TN-C domain or an equivalent volume of 
buffer without recombinant protein.  MDCK cells were cultured for 5 days with a media change 
at day 3.  To monitor tubulogenesis over time, MDCK cells were imaged over time at x10 
magnification with a light microscope (Olympus CKX41). 
 
Human endothelial cells used in the 2D human angiogenesis model (TCS CellWorks 
AngioKit) were cultured in Optimum medium as provided and described by the suppliers.   
 
HUVECs used in the 3D human angiogenesis model were cultured in HUVEC Full Medium  in 
75 cm2 flasks coated with 1% sterile, filtered gelatin.  For use in experiments, cells were 
trypsinised and cultured in HUVEC experimental medium supplemented with 100 ng/ml VEGF. 
 
HUVEC Full Medium 
10% (v/v) heat inactivated Fetal Calf Serum  
10% (v/v) heat inactivated Newborn Calf Serum 
15 μg/ml endothelial cell growth supplement 
50 U/ml heparin  
100 U/ml streptomycin, 100 μg/ml penicillin) 
 
HUVEC experimental medium  
10% (v/v) heat inactivated Fetal Calf Serum 
10% (v/v) heat inactivated Newborn Calf Serum 
100 U/ml streptomycin, 100 μg/ml penicillin 
 
 
For angiogenesis assays, a sandwich collagen gel (Deroanne et al., 1996) was prepared by 
coating the base of a 24-well plate with 200 μl collagen mix: 10 volumes of ice-cold Cellmatrix 
type I-A supplemented with 1 volume 1xDMEM and 0.022 M NaOH to adjust the solution to a 
neutral pH.  This was incubated for 1 h at 37ºC, 5% CO2 to allow the collagen to set.  1x105/ml 
HUVECs were overlaid on this collagen gel and incubated in HUVEC experimental medium for 
2 h at 37ºC, 5% CO2.  These cells were then overlaid with 300 μl collagen mix.  Finally, 500 μl 
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HUVEC experimental medium supplemented with 100 ng/ml VEGF and 1 μM TN-C domain or 
an equivalent buffer volume without recombinant protein was added to these cultures before 
culturing the cells for 2 d.   
 
2.7   Tris-glycine Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
For gel recipes, please see section 18.53 of Molecular cloning (Sambrook et al., 1989).  Proteins 
were separated by 6 %, 10 % or 12 % Tris-glycine SDS-PAGE dependent on the size of the 
protein band being investigated.  Samples were added to 2x SDS loading sample buffer with 0.2 
M dithiothreitol (DTT) in a 1:1 ratio with sample and boiled for 5 min before loading.  7 μl 
Prestained Precision Plus Protein standards were loaded alongside the samples to allow 
determination of protein band sizes.  Gels were run in protein gel tanks (Mighty Small II, 
Amersham) 1x tris-glycine running buffer for approximately 1 h at 180 mV.   
 
2x loading sample buffer 
1.7 % (w/v) SDS 
42.52 % (v/v) upper gel buffer 
8.5 % (v/v) bromophenol blue (0.1%) 
34.01 % (v/v) glycerol 
0.25 M EDTA 
 
10x Tris-glycine running buffer  
0.06 M Tris base 
0.48 M glycine 
1 % (w/v) SDS 
 
 
2.8   Coomassie and silver staining 
To detect protein bands directly on the gel, gels were either stained by coomassie blue or for 
higher sensitivity, with a silver stain.  For coomassie blue staining, gels were submerged in 
coomassie blue solution on a shaker for 15 min, before rinsing and destained in destainer until 
bands are clear above the background.  Once de-stained, the gels were washed in dH2O and then 
dried.   
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Coomassie Blue solution  
0.1% (w/v) coomassie blue 
50% (v/v) methanol 
20% (v/v) acetic acid 
In H2O 
 
Destainer 
30% (v/v) methanol 
1% (v/v) formic acid 
 
 
For silver staining, gels were fixed (50% methanol; 5% acetic acid) for 30 mins, washed (50% 
methanol for 10 mins then dH2O for 10 mins) and sensitized in sensitizer solution (0.02% 
sodium thiosulphate) for 1 min.  Gels were washed in dH2O, then submerged in cold silver 
reagent (0.1% silver nitrate solution) and incubated for 1 h at 4°C then further washed with 
dH2O.  The gel bands were developed with developer (0.04% paraformaldehyde in 2% sodium 
carbonate) for 1 min, then fresh developer applied until bands appeared.  The reaction was 
stopped with 5% acetic acid, washed in dH2O and dried.   
 
2.9   Immunoblotting methods 
2.9.1   Dot blotting  
Filter paper and nitrocellulose were soaked for a minimum of 5 mins in TN buffer before 
placement into the Bio-Dot® SF Microfiltration Apparatus (Bio-Rad, Hemel Hempstead, UK) 
system and assembly of the apparatus.  Protein samples were diluted in TN buffer.  10 µl sample 
was applied directly onto the nitrocellulose membrane under suction.  The membrane was then 
removed and immediately blocked in 5% BSA at room temperature for 1 h or at 4ºC overnight.  
Blocking solution was removed and primary antibody diluted in 1% BSA applied directly and 
incubated at room temperature for 1 h.  The membranes were washed in wash buffer: 3x10 
mins.  Alkaline phosphatase (AP)-conjugated secondary antibodies were diluted in 1% BSA and 
incubated at room temperature for 1 h.  The membranes were washed in wash buffer 3 x 10 
mins.  Bands were visualized with Western blue substrate.  A shaker was used to ensure optimal 
antibody coverage and washing. 
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TN Buffer 
50 mM Tris-HCl, pH8.0 
150 mM NaCl 
 
 
 
2.9.2   Western blotting 
Bands on the gel were transferred onto a PVDF membrane in transfer buffer using the X cell II 
blot module (Invitrogen, Paisley, UK) for a minimum of 2 h at 25 mV, or the mini-blot transfer 
unit (Bio-Rad, Hemel Hempstead, UK) for 1 h at 125 mAmps.   
 
Membranes were blocked at room temperature for 1 h in: 5% BSA for AP; 10 % milk for HRP.  
Blocking solution was removed and primary antibody solution applied directly.  The primary 
antibody was diluted in: 1% BSA for AP; 10% milk for HRP, and incubated at room 
temperature for 1 h or at 4ºC.  The membranes were washed in wash buffer:  3 x 10 mins for 
AP; 3 x 15 mins for HRP.  Diluted secondary antibody was then applied to the membrane.  AP-
conjugated secondary antibodies or horse radish peroxidase (HRP) conjugated secondary 
antibodies were diluted in: 1% BSA for AP; 10% milk for HRP and incubated at room 
temperature for 1 h.  The membranes were washed in wash buffer:  3 x 10 mins for AP; 3 x 15 
mins for HRP.  The respective substrate was then added: Western Blue substrate for AP 
visualisation, ECL substrate for HRP visualisation and bands detected by film.  A shaker was 
used to ensure optimal antibody coverage and membrane washing. 
 
Transfer buffer  
0.72% (w/v) glycine 
0.15% (w/v) Trizma base 
20% (v/v) methanol 
Water up to 1 litre  
 
Wash buffer  
0.25 M Tris pH7.5 
1.5 M NaCl 
1% Tween-20 
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2.10   Deoxycholate (DOC) solubility assay 
NIH 3T3 fibroblasts were plated as described above.  Cultured medium was aspirated and 
collected.  The wells were washed gently with 500 μl ice-cold PBS and aspirated off.  On ice, 
200 μl DOC lysis buffer was added to each well and left on ice for a minimum of 10 min.  The 
wells were scraped thoroughly to ensure all cell material was collected.  The DOC lysis buffer 
was then passaged through a 26G stainless steel, hypodermic needle and sheered on the side of a 
1.5 ml eppendorf.  The eppendorf was spun down at 13000rpm for 15 min to collect the DOC 
insoluble material as a pellet.  The supernatant (DOC soluble material) was transferred to a fresh 
eppendorf tube.  The insoluble pellet was re-suspended in 25 μl SDS-containing buffer, and then 
heated at 100°C for 5 min to ensure total solubilisation of the pellet.  Samples were stored at -
20°C until required. 
 
DOC lysis buffer 
2% (w/v) DOC 
0.02 M Tris-HCl pH8.8 
0.002 M EDTA 
0.002 M Protease Inhibitor (PI) 
0.002 M Iodoacetic acid 
0.002 M N-ethylmaleimide 
 
SDS-containing buffer  
1% (w/v) SDS 
0.025 M Tris-HCl pH8.0 
0.002 M EDTA  
0.002 M PI 
0.002 M Idoacetic acid 
0.002 M N-ethylmaleimide 
 
 
2.11   Immunofluorescence 
Microscopes used: Nikon TE2000-E light/fluorescent microscope (Nikon Co., Japan) with a 
Hamamatsu camera (Hertfordshire, UK) and Ultraview Nipkow scanning disc Nikon TE2000-U 
confocal microscope (Nikon Co., Japan).   
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2.11.1   Fluorescent labelling of FN, TN-C and TN-C domains 
The protein to be fluorescently labelled was dialysed into HEPES buffer with at last three buffer 
changes to ensure no residual Tris remained.  Alexa Fluor-488 or Alexa Fluor-568 dye 
(Invitrogen molecular probes) was reconstituted in 50 μl dimethylformamide (DMF; Sigma-
Aldrich, Dorset, UK) and added to the protein solution.  The fluorescent solution was rotated for 
1 h at room temperature and then labelling reaction was stopped by addition of 100 μl 0.5M 
glycine.  Fluorescent solution was then dialysed into TNC buffer with three buffer changes to 
ensure no free fluorescent dye remained.  Fluorescence was confirmed by resolving proteins by 
SDS-PAGE and scanning silver stained gels on the phosphoimager (FLA-5100; FujiFilm, 
Bedford, UK).  
 
The efficiency of labelling was determined by measuring the O.D. at the wavelength of the dye 
(e.g. 568 nm) and at the wavelength to determine protein concentration (280 nm).  Using the 
stated equations (Figure 2.2), the concentration of dye and the concentration of protein present 
in the solution was determined and from this the dye:protein ratio was calculated.   
 
HEPES Buffer 
20 mM HEPES 
150 mM NaCl 
pH 8.2 
 
 
 
 
 
 
 
The extinction coefficient of Alexa Fluor-488 dye is 71000 cm-1M-1 and the correction factor is 
0.11.  The extinction coefficient of Alexa Fluor-568 dye is 91300 cm-1M-1 and the correction 
factor is 0.46.  
 
 
Figure 2.2   Equations used to determine Alexa Fluor-488 labelling efficiency  
Equations to determine the concentration of dye [Label] and the concentration of TN-C or the TN-C 
domains after labelling [protein].  A(568), absorbance at 568 nm; A(280), absorbance at 280 nm; 
E(Alexafluor), extinction coefficient of Alexafluor dye; E(protein), extinction coefficient of protein; 
CF(Alexafluor 488), correction factor for Alexafluor dye. 
 
Materials and Methods 
 
 
63
2.11.2   Immunofluorescent staining of NIH 3T3 cultures 
NIH 3T3 fibroblasts were plated as described above.  After the required period of incubation, 
cells were gently washed in 1xPBS, fixed in 3.8% (w/v) paraformaldehyde for 15 minutes at 
room temperature.  Cells fixed onto coverslips were washed three times in 1xPBS and 
permeabilised in 0.2% Triton X-100 for 10 minutes at room temperature and washed again in 
1xPBS as required.  Coverlips were then incubated with primary anti-fibronectin antibody 
(1/200) diluted in 2% BSA-PBS for 30 minutes at 37ºC.  Coverslips were washed three times in 
1xPBS before applying Alexa Fluor-488 or 568 conjugated secondary anti-rabbit antibody, 
Alexa Fluor-488, -568 or -660 phalloidin (1/300) and DAPI (1/250) diluted in 2% BSA-PBS.  
Coverlips were then washed three times in 1xPBS and three times in water and left to air dry in 
the dark.  Coverlips were mounted onto glass slides with ProLong Gold Antifade Reagent and 
sealed with nail polish.  The coverslip was visually scanned before random fields of view were 
selected for imaging.  Low magnification images (x20) were captured by fluorescence 
microscopy, whilst high magnification images (x60, x100) were captured on the confocal 
microscope.  Images were processed using the Volocity® 3D Imaging Software (Invitrogen, 
Paisley, UK).   
 
To quantify image intensity, images were converted to 8-bit grayscale images whereby each 
pixel is assigned an intensity from 0 (black) to 255 (white) (Figure 2.3 A) (Hinz et al., 2001).  
Images were analysed by ImageJ image processing software (http://rsbweb.nih.gov/ij/), and 
from the histograms for each image (Figure 2.3 B) the number of pixels with each assigned 
intensity value could be determined (Figure 2.3 C).  From this pixel count, the total number of 
pixels greater than 100 was determined, which represents the overall fibrillar coverage of the 
image.  The average pixel intensity was also calculated to represent the fibril complexity – 
thicker fibrils are more intensely stained compared to thinner, less densely packed fibrils.  The 
background value was selected manually as the grey value of 100 as the cut-off to distinguish 
between background and fibrillar FN because pixels that contributed to faint fibrillar structures 
showed pixel intensities above 100.   
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These images were corrected against the number of nuclei per field of view (modified from (Cai 
et al., 2009) (Hinz et al., 2001)), determined from phase contrast images of cell nuclei as the 
confocal microscope did not have the capacity to detect DAPI stained nuclei (Figure 2.4 A-C).   
As cells were cultured at a fairly high confluence (4x105/ml), cell number was very consistent 
within each experiment (Figure 2.4 C).   
 
The pixel intensity data was then plotted on GraphPad Prism version 4.03 for Windows 
(GraphPad Software, San Diego, California, USA).  One-way ANOVA (non-parametric) one-
way analysis of variance statistical test was applied to the data with Dunnett post tests to 
Figure 2.3 Quantification of FN matrix assembly from immunofluorescent images.   
(A) Immunofluorescent images were analysed by Image J image analysis software.  (B) Each 
pixel in the image is assigned a pixel intensity value: 0, black Æ 255, white.  These pixels can 
then be plotted on a histogram, which totals the number of pixels that have the same pixel 
intensity value.  (C) This can then be listed for analysis.  A pixel intensity greater than 100 was 
considered to be involved in the matrix structure whereas values less than 100 were considered 
to be background.  By totalling the number of pixels greater than 100, this represents the overall 
FN matrix coverage of the image, whereas the average pixel intensity represents the fibrillar 
complexity i.e. the brightness of the fibrils.      
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compare pixel intensities with control images.  P-values are plotted on the data; *; P<0.05; **; 
P<0.01; ***P<0.001.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.11.3   Paxillin staining 
NIH 3T3 fibroblasts were plated as described above.  After the required period of incubation, 
cells were gently washed in 1xPBS, fixed in 3.8% (w/v) paraformaldehyde for 15 minutes at 
room temperature.  Cells fixed onto coverslips were washed three times in 1xPBS and 
permeabilised in 0.2% Triton X-100 for 10 minutes at room temperature and washed again in 
1xPBS as required.  Coverlips were then incubated with primary anti-paxillin antibody 
(ab32084) (1/300) diluted in 2% BSA-PBS for 30 minutes at 37ºC.  Coverslips were washed 
three times in 1xPBS before applying Alexa Fluor-488 conjugated secondary anti-rabbit 
antibody and Alexa Fluor-568 phalloidin (1/300) diluted in 2% BSA-PBS.   
 
Figure 2.4  Quantification of FN matrix assembly corrected to the number of cell nuclei per field of view.  
NIH 3T3 fibroblasts were cultured for 24 h before fixing and staining for cell nuclei with DAPI. The number of 
cell nuclei were determined from phase microscopy images.  As an example, phase images were taken on a 
fluorescent microscope (A-B) and the number of nuclei determined and compared to the number of nuclei 
observable by DAPI staining (C). The arrow denotes a cell nucleus that was not noted.   Fluorescent and DIC 
dry phase images were taken at x60 magnification, scale bars = 50 μm. The number of cell nuclei per field of 
view are consistent within independent experiments as shown in (D).  Total number of nuclei per field of view 
are denoted by the numbers in the central corners.  These images are representative of four individual cell 
cultures within one experiment.  
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Coverlips were then washed three times in 1xPBS and three times in water and left to air dry in 
the dark.  Coverlips were mounted onto glass slides with ProLong Gold Antifade Reagent and 
sealed with nail polish.  The coverslip was visually scanned before random fields of view were 
selected for imaging.  High magnification images (x60) were captured on the confocal 
microscope.  Images were processed using the Volocity® 3D Imaging Software (Invitrogen, 
Paisley, UK). 
 
2.11.4   Immunofluorescent cell surface staining 
NIH 3T3 fibroblasts were cultured as described above.  For re-plated cells, cells were then 
treated with EDTA for a minimum of 5 min before gentle lifting and collection, three washes in 
DMEM supplemented with only Penicillin-Streptomycin (1x) and re-plating onto sterile glass 
coverslips.  Cells were incubated for a further 2 h at 37˚C, 5% CO2.  Coverslips were gently 
washed in 1xPBS and cells fixed in 3.8% (w/v) paraformaldehyde for 15 minutes at room 
temperature.  Coverlips were then incubated with Alexa Fluor-568 labelled concanavalin A 
(0.28 μg/ml) diluted in 2% BSA-PBS for 30 minutes at 37ºC.  Coverslips were washed three 
times in 1xPBS, three times in water and left to air dry in the dark.  Coverlips were mounted 
onto glass slides with ProLong Gold Antifade Reagent and sealed with nail polish.  The 
coverslip was visually scanned before random fields of view were selected for imaging.  High 
magnification images (x60) were captured on the confocal microscope.  Images were processed 
using the Volocity® 3D Imaging Software (Invitrogen, Paisley, UK). 
 
2.11.5   Immunofluorescent staining of MDCKs embedded in 3D collagen gels 
Collagen gels were washed three times in 1xPBS with the final wash left for 10 minutes.  Gels 
were then  fixed in 3.8% (w/v) paraformaldehyde for 30 minutes at room temperature, 
permeabilised with 0.2% Triton X-100 for 15 minutes at room temperature and washed three 
times, 5 minutes per wash in 1xTBS.  Gels were blocked O/N in 5% BSA-TBS at 4ºC.  Primary 
anti-FN antibody (1/200) was applied at 1:200 dilution in 5% BSA-TBS and incubated at room 
temperature for 30 minutes with gentle rocking.  Gels were washed three times in IF buffer, 5 
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minutes per wash before incubation with Alexa Fluor-488 anti-rabbit antibody (1/300), Alexa 
Fluor-488 or Alexa Fluor-568 phalloidin (1/300) and DAPI (0.75 μg/ml) in 5% BSA-TBS and 
incubated for a further 30 minutes with gentle rocking.  Gels were again washed three times in 
IF buffer, 5 minutes per wash, once in 1xPBS for 5 minutes and once in water for 5 minutes.  
Collagen gels were then embedded in ProLong Gold Antifade Reagent protected with a glass 
coverslip and imaged under a fluorescent microscope at x60 magnification.   
 
IF Buffer 
7.7 mM sodium azide 
0.1% (w/v) BSA 
0.2% (w/v) Triton X-100 
0.05% (w/v) Tween-20 
In 1xPBS 
 
 
2.11.6   Immunofluorescent staining of HUVECs sandwiched between 3D collagen gels 
Cells were cultured as described above.  Cells embedded in the collagen gel sandwiches were 
then washed three times in 1xTBS before fixing in 3.8 % (w/v) paraformaldehyde, 
permeabilizing in 0.2 % Triton X-100 and washing three times, 5 minutes per wash in 1xPBS.   
Gels were blocked O/N in 5% BSA-TBS at 4ºC.  Gels were incubated with Alexa Fluor-568 
labelled phalloidin (1/500) and DAPI (0.75 μg/ml) in 5% BSA-TBS and incubated at room 
temperature for 30 minutes with gentle rocking.  Gels were washed three times in IF buffer, 5 
minutes per wash, once in 1xPBS for 5 minutes and once in water for 5 minutes.  Collagen gels 
were then embedded in ProLong Gold Antifade Reagent protected with a glass coverslip and 
imaged under a fluorescent microscope at x20 magnification.          
 
2.12   Immunohistochemistry  
Collagen gels were fixed in 10% neutral buffered formalin (Cellstor, Cellpath, Powys, UK).  
Samples were then processed by David Essex at the Charing Cross Hospital Histopathology 
Department and stained with anti-FN antibodies and counterstained with Harris’ Haematoxylin.  
Sections were also stained with haematoxylin and eosin (H&E) to determine cellular structures.  
 
Materials and Methods 
 
 
68
Where required, sections were also treated by pressure-cooking or protease treatment before 
staining.    
 
2.13   Solid phase binding assay 
25 μg/ml human plasma FN, 25 μg/ml TN-C or 78 nM TN-C domains were diluted in TBS 
containing 1 mM CaCl2 and 1 mM MgCl2 and 50 μl applied to each well of a 96 well EIA/RIA 
flat bottomed ELISA plate (Corning Inc., Costar, Amsterdam, The Netherlands) and left 
overnight at 4ºC.  Wells were washed in PBS-T three times before blocking in 100 μl 5% 
skimmed milk in PBS and incubating for 1 h at 37ºC.  Wells were washed in PBS-T three times 
before addition of different concentrations of human plasma FN, TN-C or TN-C domains 
diluted in TBS containing 1 mM CaCl2 and MgCl2.  50 μl of this ligand solution was applied to 
each well and incubated for 1 h at 37ºC.  Primary antibody was diluted in 1xPBS, 50 μl applied 
to each well and incubated for 2 h at room temperature gently shaking.  Wells were washed 
three times in PBS-T before application of 50 μl secondary antibody diluted in 1xPBS, 
incubated for 2 h at room temperature gently shaking.  Wells were finally washed again three 
times in PBS-T before addition of TMB substrate (KPL, Gaithersburg, MD, USA).  Colour 
development was stopped with 50 μl ELISA stop solution and the plate O.D. read at 450 nm.    
 
Wash buffer PBS-T 
0.05 % Tween-20 
In 1xPBS 
 
ELISA stop solution 
6% sulphuric acid  
 
 
2.14   Fluorescence activated cell sorting (FACs) 
To examine early cell apoptosis events, 4x105/ml NIH 3T3s were plated in a 24-well dish NIH 
3T3s plated for 2 h before culture before addition of an equivalent buffer volume or 0.1 μM of 
each of the individual TN-C domains directly to the conditioned medium.  One set of cells was 
removed for UV irradiation (5 minutes).  Cells were cultured for a further 22 h before 
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trypsinisation and harvesting of cells.  Cells were washed in 1xPBS before resuspending in 100 
μl Annexin V binding buffer containing 4 μl Annexin V and incubated for 10 min at room 
temperature.  100 μl Annexin V binding buffer was added to stop the labelling before cells were 
sorted on BD LSR II System (BD Biosciences, Oxford, UK). 
 
To determine cell surface levels of α5β1, 4x105/ml NIH 3T3s were plated in a 24-well dish and 
cultured for 2 h, before Cells were then cultured for a further 12 h before cells were collected by 
gentle dissociation with versene (EDTA).  The collected cells were washed in FACs wash 
buffer (1% BSA, 0.05% sodium azide in 1xPBS) before re-suspending in 100 μl FACs buffer 
containing 10 μg/ml anti-α5β1 antibody (MAB2514).  This was incubated on ice for 30 min, 
before washing in FACs wash buffer and re-suspending cells in 100 μl FACs buffer containing 
2 μg/ml APC-conjugated anti-rat antibody or IgG from rat serum (Sigma-Aldrich, Dorset, UK) 
and incubated for 30 mins on ice in the dark.  Cells were finally washed again in FACs wash 
buffer before fixing in 1% paraformaldehyde in 1xPBS and retained at 4ºC.  Cells were sorted 
on a BD FACSCanto Flow Cytometer (BD Biosciences, Oxford, UK).   
 
2.15   Reverse transcription polymerase chain reaction  
2.15.1   mRNA isolation  
The QIAmp RNA blood mini kit (QIAGEN, Crawley, UK) was used – see kit manual for full 
details.  NIH 3T3 fibroblasts were cultured as described above.  Conditioned medium was 
aspirated off and cells were lysed with lysis buffer RLT containing β-mercaptoethanol 
(QIAGEN, Crawley, UK).  The lysate was either frozen at -80°C for processing later or it was 
processed where RNA is bound onto the membrane of the QIAmp spin column and washed in 
different buffers and finally eluted in RNAse free water (QIAGEN, Crawley, UK).  The RNA 
was then stored immediately at -80°C or underwent a reverse transcriptase reaction.  The quality 
of the isolated RNA was determined by measuring the OD of a 3:7 dilution of the RNA at 230, 
260, 280 and 320 nm.  By determining the 260/280 ratio > 1.7, this ensures low protein 
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contamination and 260/280 >2 indicates pure RNA isolation.  230 and 320 measure small 
peptide contamination and hence should be low.   
 
2.15.2   RT-PCR 
The reverse transcriptase reaction was performed as described in the scheme below.  The dNTP 
mix was made by mixing dATP, dCTP, dTTP and dGTP to a total concentration of 100 mM.   
 
Table 2.6   Steps involved in RT-PCR 
Step Reagent Volume (μl) 
0.5 μg RNA X 
300 ng random primers  3 
Incubate at 65°C for 5 min 
then cool at RT for 10 min 
Autoclaved H2O 50-(X+3) 
                              
Stratascript buffer (10x) 5 
RNAse block (40U/μl) 1 
dNTP mix 2 
Heat in 42°C for 1 h then 
heat in 100°C heatblock for 
5 min. 
Stratascript reverse transcriptase (50U/μl) 1 
                              Aliquot and store at -20°C 
 
The RNA was then used in PCR reactions with primers specific for the GAPDH house-keeping 
gene and primers designed specifically against mouse FN.  For PCR, puReTaq Ready-To-Go 
PCR beads (Amersham Pharmacia Biotech, Little Chalfont, UK) were used.  Beads were 
reconstituted in 21 μl water, 1 μl of the forward primer, 1 μl of the reverse primer and 2 μl of 
cDNA template or water (negative control) or  cDNA from glioblastoma U251MG cell line 
(positive control).  5 μl aliquots of each PCR product was then loaded in loading sample buffer 
and resolved on 1% agarose gels containing ethidium bromide.  500 bp and 1 kb DNA ladders 
were included on each gel.   
 
Primers were designed specific for the GAPDH housekeeping gene and mouse FN gene.  For 
each primer set, the optimum annealing temperature was determined by a temperature gradient 
reaction for 40 cycles.  The optimum cycle number was determined by a cycle curve to ensure 
the reaction occured within the linear range of the PCR:  the GAPDH primer required 26 cycles 
and the FN primer required 25 cycles for optimal amplification within the linear range.   
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Table 2.7   Primer sequences 
Primer Sequence 
GAPDH forward primer catggagaaggctggggctc 
 
GAPDH reverse primer atgaggtccaccaccctgtt 
 
FN forward primer aatggacgcatcacctgtacc 
FN reverse primer gcacagagcaccattggaat 
 
 
2.16   MTT assay 
NIH 3T3 fibroblasts were plated at 4x105/ml in 96 well dishes for 2 h before addition of buffer 
in the absence of recombinant protein, the required concentration of TN-C domain or 0.2 μM 
sodium nitroprusside (SNP, Sigma-Aldrich).  To confirm that the buffer alone was not affecting 
cell viability, cells were also cultured in the absence of both buffer and recombinant protein.  
Cells were cultured for a further 22 h.  HUVECs were plated at 1x104/ml in 96 well dishes for 2 
h before addition of buffer in the absence of recombinant protein before addition of 1 μM of 
each TN-C domain or 0.2 μM SNP.  To confirm that the buffer alone was not affecting cell 
viability, cells were also cultured in the absence of both buffer and recombinant protein.  Cells 
were cultured for a further 5 d with a change in media at d 3.  After the required period of 
incubation at 37ºC, 5% CO2, conditioned medium was aspirated and 100 µl fresh serum-free 
medium containing 0.5 mg/ml MTT (Sigma-Aldrich) was applied and cells incubated for 2 h 
before addition of 100 µl MTT stop solution and incubation overnight at 37ºC.  Plates were then 
read at 574 nm. 
 
MTT stop solution 
10% SDS 
0.01M HCl  
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CHAPTER 3 
Determining if FN matrix assembly is 
regulated by TN-C and its individual domains 
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3.1   Introduction 
FN is a ubiquitous component of the ECM and its expression and assembly has to be tightly and 
dynamically regulated.  A FN matrix is essential for maintaining tissue architecture and for 
regulating cell behavior including migration (Couchman et al., 1982) (Herard et al., 1996) (Hocking 
and Kowalski, 2002), proliferation (Couchman et al., 1982) (Gui et al., 2006) (Khan et al., 2005) 
(Jiang et al., 1999) (Sechler and Schwarzbauer, 1998) and survival (Farias et al., 2005) (Jiang et al., 
1999).  Loss of FN matrix synthesis and assembly is a hallmark of transformed cells (Brenner et al., 
2000).  Conversely, excess FN matrix synthesis is characteristic of fibrotic conditions (Babu et al., 
1989) (Buyukbabani and Droz, 1994) (Mason and Wahab, 2003) (Okuda et al., 1990) (Oomura et 
al., 1989) (Van Vliet et al., 2001).  FN levels on the cell surface are regulated by rates of FN 
biosynthesis (Dean et al., 1988) (Lam et al., 2003) (Scita et al., 1996) degradation and its 
conversion from initial surface bound FN into a complex 3D, fibrillar matrix (Choi and Hynes, 
1979) (McKeown-Longo and Mosher, 1983).   
   
TN-C is spatially and temporally co-expressed in areas of FN expression and assembly in vivo 
during embryonic development (Chiquet and Fambrough, 1984) (Riou et al., 1990) and in regions 
of tissue remodeling such as wound healing (Kusubata et al., 1999) (Whitby and Ferguson, 1991).  
This co-localization suggests it may interact with FN in vivo as demonstrated by in vitro studies 
(Chiquet-Ehrismann et al., 1991) (Chung et al., 1995) (Huang et al., 2001) (Lightner and Erickson, 
1990).  However, it is not known whether TN-C has any functional effect on FN matrix assembly. 
This could be a novel mechanism to regulate FN cell surface levels during development and tissue 
remodeling.  Previously, Midwood et al., (Midwood and Schwarzbauer, 2002) had shown that a 
recombinant protein, 70Ten, containing some TN-C domains inhibited FN matrix assembly by NIH 
3T3 fibroblasts.  However, full-length TN-C was not tested for its ability to inhibit FN matrix 
assembly.   In this first chapter, I explore the effects of TN-C and individual domains within TN-C 
on FN matrix assembly.  
Results: Regulation of FN matrix assembly by TN-C and TN-C domains 
 
 74
3.2   Results 
 
3.2.1   Synthesis and purification of recombinant TN-C and TN-C domains  
The following recombinant human proteins were used in these studies: full-length TN-C,   
individual TN-C domains TA, EGF-L, TNfn1-8, TNfn1-5, TNfn1-3, TNfn3-5, TNfn5-7, TNfn6-8, 
FBG, 70Ten; a chimeric protein comprising domains of both FN and TN-C, and the 70-kDa N-
terminal domain of FN (Figure 3.1).  I focused initially on domains within the TNfn1-8 module, 
which has been shown to possess FN binding activity (Chung et al., 1995) (Ingham et al., 2004), in 
order to compare its activity with the other TN-C domains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1   Schematic of TN-C, recombinant TN-C proteins and the 70-kDa domain of FN.  
TN-C comprises a TA domain (triangle     ), EGF-L repeats (grey ovals   ), constitutively expressed FN 
type III repeats (white rectangles     ), alternatively spliced FN type III repeats (grey rectangles     ) and 
the FBG (dark circle       ).  70Ten recombinant protein is composed of the 70-kDa N-terminal of FN: FN 
type I repeats (dark ovals     ) and FN type II repeats (light ovals     ), and the C-terminal TNfn and FBG 
domains of TN-C.   
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Full-length his-tagged TN-C expressed in mammalian HEK 293 cells was purified as described in 
Lange et al., (Lange et al., 2007) by Emma Chan.  FLAG-tagged EGF-L was expressed in HEK 293 
cells by Nidhi Sofat and purified by me from the conditioned medium of these cells by anti-FLAG 
affinity chromatography and gel filtration as described in (Sofat, 2006).  All other recombinant TN-
C domains were his-tagged and expressed in E.coli.  TA, TNfn1-3, TNfn3-5, TNfn1-5, TNfn5-7, 
TNfn6-8 and FBG were purified by Annette Trébaul and Kim Midwood (described in (Midwood et 
al., 2009)) and made available for this study. 
 
The TNfn1-8 construct was expressed in Rosetta DE3 E. coli and purified from the soluble 
supernatant of the bacterial lysates by Annette Trébaul.  I then established the purification 
procedure by screening a number of different methods.  The final, established procedure is shown 
as a schematic in Materials and Methods (Figure 2.1 B).  In brief, nickel affinity chromatography, 
positively charged ion exchange S-column chromatography and gel filtration with a 2.6 cm x 100 
cm (XK 26/100) sephacryl column with a high fractionation range were used to isolate a single 
band of the correct molecular weight (Figure 3.2 A, and B).   Results from each purification step are 
shown in appendix figure A1. 
 
Each recombinant protein was purified to homogeneity as determined by the presence of a single 
band of the correct MW when resolved on silver stained gels (Figure 3.2 A).  The identity of the 
purified proteins were also confirmed by Western blotting with an anti-His (Figure 3.2 B) or anti-
FLAG antibody as appropriate (Figure 3.2 C). 
 
3.2.2   The TNfn1-8 and FBG domains of TN-C inhibit fibronectin matrix assembly 
FN matrix assembly has been shown to be inhibited by the 70-kDa N-terminal domain of FN 
(Bultmann et al., 1998) (Hocking et al., 1994) (McKeown-Longo and Mosher, 1985) (Takahashi et 
al., 2007) and the recombinant 70Ten molecule (Midwood and Schwarzbauer, 2002).     
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However, because 70Ten is composed of the 70-kDa N-terminal domain of FN and the C-terminal 
FN type III repeats and FBG domain of TN-C (Figure 3.1), its inhibitory activity may not originate 
from the TN-C domains but from the FN domain.  Therefore I screened full-length TN-C and 
individual TN-C domains for any effect on FN matrix assembly.   
 
 
 
Figure 3.2   Silver stain and Western blot analysis of TN-C and TN-C fragments.  
1 μg of each purified protein was resolved by SDS-PAGE (10% total acrylamide) and subjected to (A) silver 
staining, or (B) Western blot analysis with a monoclonal anti-His antibody (34670) or (C) with an anti-FLAG 
antibody (F3165).  The arrowhead in (B) denotes the TA domain and the arrow in (C) denotes EGF-L. 
Molecular weight markers are in kDa. 
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3.2.2.1   TNfn1-8 and FBG reduce FN matrix complexity and fibrillar structure 
NIH 3T3 fibroblasts were used in these studies as a homogenous cell population, which synthesize 
and assemble a complex FN matrix on the cell surface (Midwood and Schwarzbauer, 2002) but do 
not express any endogenous TN-C (Midwood unpublished observations).  Fibroblasts were cultured 
in serum free medium to avoid the exogenous supplementation of growth factors that could affect 
intracellular signaling.  Fibroblasts were cultured in the presence or absence of TN-C and TN-C 
domains, at a high cell density (2x105/well) for 24 h.  I used these conditions because confluent 
fibroblasts produce optimal levels of FN by 24 h (Senger et al., 1983).  Cells were then fixed and 
FN matrix visualized by indirect immunofluorescence using an anti-FN antibody and secondary 
Alexa Fluor-568 conjugated antibody.   
 
Compared to cells cultured in the absence of any recombinant protein full-length TN-C and the TA 
or EGF-L domains had no effect on FN matrix assembly (Figure 3.3 B, C, D respectively).  
However, TNfn1-8 (Figure 3.3 E), FBG (Figure 3.3 F) and 70-kDa (Figure 3.3 G) reduced the 
complexity, density and 3D fibrillar structure of the FN matrix.  70-kDa (Figure 3.3 G) was 
included as positive controls as a known inhibitor of FN matrix assembly.  Fluorescence intensity 
was quantified using the ImageJ analysis program as described in materials and methods (modified 
from (Cai et al., 2009) (Hinz et al., 2001)) and demonstrated that TNfn1-8, FBG and 70-kDa 
significantly reduced the overall FN matrix assembled and the density of fibrils covering the cell 
surface to a similar extent compared to cells cultured in the absence of recombinant protein (Figure 
3.4 A) or with addition of TN-C, TA and EGFL (Figure 3.4 A).  TNfn1-8, FBG and 70-kDa also 
significantly reduced the average pixel intensity compared to the control (Figure 3.4 B), suggesting 
these domains additionally inhibit fibril thickness.  Curiously, TN-C, TA and EGF-L showed a 
significant increase in the average pixel intensity compared to the control (Figure 3.4 B), suggesting 
these domains may affect fibril thickness without affecting the overall FN matrix density.      
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3.2.2.2   TNfn1-8 and FBG inhibit FN conversion to a DOC insoluble matrix 
The deoxycholate (DOC) detergent solubility assay is commonly used to monitor FN matrix 
assembly (McKeown-Longo and Mosher, 1983).  During the assembly process, FN progresses from 
a cell-surface bound, DOC soluble state to a dense, complex, fibrillar DOC insoluble state.  To 
confirm the effect of TN-C domains on FN matrix assembly, NIH 3T3 fibroblasts were cultured in 
the presence or absence of 0.1 μM TN-C or TN-C domains for 24h after which time the solubility of 
the FN matrix was assessed.  Levels of FN in the DOC soluble or insoluble fractions and the 
conditioned medium were assessed by Western blotting using anti-FN antibodies and detected using 
ECL.  TN-C, TA and EGF-L had no effect on levels of DOC insoluble FN (Figure 3.5).  TNfn1-8, 
FBG, 70-kDa and 70Ten showed a consistent reduction in FN levels in the DOC insoluble fraction 
(Figure 3.5), suggesting these domains affect FN assembly into higher molecular weight, dense 
detergent insoluble matrices.  This supports the results from the immunofluorescent studies, which 
Figure 3.4 Quantification of immunofluorescence images to determine the effects of TN-C and TN-C 
domains on FN matrix assembly. 
ImageJ software was used to calculate (A) the total pixel intensities greater than 100 to determine the overall 
matrix assembly, or (B) average pixel intensity calculated to represent the three-dimensional fibrillar structure.  
Values were corrected for the number of nuclei per field of view and normalised to the control where no 
recombinant protein was added (-). Three random fields of view were analysed per experiment. Results are 
shown as mean +/- SEM of 3 independent experiments. *, p<0.05; **, p<0.01 determined by one-way ANOVA 
statistical analysis using Dunnett’s test compared to the control (-).   
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show these domains also reduce the FN matrix fibrillar density.  Furthermore, TNfn1-8, FBG and 
70-kDa dose dependently reduced FN levels in DOC insoluble material (Figure 3.6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Western blot of FN in DOC insoluble material isolated from 
fibroblasts cultured in the presence or absence of TN-C and TN-C domains. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium at 37ºC before 
being further cultured for 22 h with buffer alone in the absence of recombinant 
protein (-) or in the presence of 0.1 μM full-length TN-C, TA domain, EGF-L 
domain, TNfn1-8, FBG, the 70-kDa domain of FN, or 70Ten.  Fibroblasts cultured 
in medium alone in the absence of recombinant protein and buffer were included 
for comparison (N). DOC insoluble material was isolated and 3 µg was resolved 
by SDS-PAGE (6% total acrylamide), and Western blotted with an anti-FN 
antibody (F3648) and secondary HRP-conjugated antibody. 0.1 μg human 
plasma FN as a positive control (pFN).  A blot from a single experiment is shown, 
which is representative of results from 4 independent experiments.  Molecular 
weight markers are in kDa. 
Figure 3.6   Western blots of FN in the DOC insoluble material isolated from fibroblasts cultured in 
the presence of increasing doses of TN-C domains 
NIH 3T3 fibroblasts were plated for 2 h at 37ºC before being further cultured for 22 h with buffer alone in 
the absence of recombinant protein (-) or in the presence of 1, 0.1, 0.01 or 0.001 μM of TNfn1-8, FBG and 
70-kDa.  DOC insoluble material was then isolated.  3 µg DOC insoluble material was resolved by SDS-
PAGE (6% total acrylamide), which was Western blotted and probed with an anti-FN antibody (F3648) and 
secondary HRP-conjugated antibody. 0.05 μg human plasma FN (hpFN) was included as a control. 
Molecular weight markers are in kDa. 
 
Results: Regulation of FN matrix assembly by TN-C and TN-C domains 
 
 81
The levels of FN in the DOC soluble fraction, which represents cell surface bound and intracellular 
FN, and FN in the conditioned medium, representing secreted protein, showed no consistent 
changes in the presence of TN-C or any TN-C domain (Figure 3.7).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm the levels of FN in the soluble and condition medium I sought an alternative method of 
quantifying FN in each fraction.  ECL Western blotting allows sensitive determination of band 
intensities and it has been reported to be used for quantifying protein levels (Green et al., 2009), but 
the film-based detection method suffers from the problem that it is only sensitive across one order 
of magnitude so the linearity of the technique is limited; a threshold level of signal is required 
Figure 3.7  Western blots of FN in DOC soluble material and conditioned medium isolated from 
fibroblasts cultured in the presence or absence of TN-C and TN-C domains. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium at 37ºC before being further cultured for 
22 h with buffer alone in the absence of recombinant protein (-) or in the presence of 0.1 μM full-length 
TN-C, TA domain, EGF-L domain, TNfn1-8, FBG, the 70-kDa domain of FN, or 70Ten.  Fibroblasts 
cultured in medium alone in the absence of recombinant protein and buffer were included for 
comparison (N). DOC soluble material was isolated and conditioned media collected. 6 µg DOC soluble 
material and 20 μl conditioned medium were resolved by SDS-PAGE (6% total acrylamide), and 
Western blotted with an anti-FN antibody (F3648) and secondary HRP-conjugated antibody. 0.1 μg 
human plasma FN as a positive control (pFN).  Blots from a single experiment are shown, which are 
representative of results from 4 independent experiments.  Molecular weight markers are in kDa. 
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before an image is generated and film darkening is not linear to the amount of light produced by the 
chemiluminscent reaction (Dickinson and Fowler, 2002).  To accurately quantify protein 
concentration, a linear curve of either known protein concentrations or diluted samples must be 
developed simultaneously.  This method therefore also places limitations on the number of samples 
that can be resolved on polyacrylamide gels.  Dot blotting, where the sample is applied directly to 
nitrocellulose membrane and bound to the membrane by an applied suction pressure is rapid, allows 
up to 36 samples simultaneously and has a linear range of three orders of magnitude and so was 
used in preference for protein quantification.   
 
The total amount of FN in DOC insoluble and soluble material and conditioned media was 
quantified using a dot blot system.  Samples were diluted to ensure that they were resolved within 
the linear range of the system and 10 μl of each loaded onto a nitrocellulose membrane together 
with a series of FN standards of known concentration.  Bands were probed with an anti-FN 
antibody and detected using a secondary alkaline phosphatase (AP)-conjugated antibody, and band 
intensity was quantified using Phoretix software (1D v2003.02, Nonlinear Dynamics).  Using the 
FN standard curve, the amount of FN in each sample was then calculated.   
 
The quantity of FN detected in this system by dot blotting was ~ 0.6 – 2.9 μg/ml in the conditioned 
medium and ~0.95 – 3.63 μg “cellular FN” (sum of both DOC soluble and DOC insoluble 
material)/200000 cells for cells cultured for 24 h at 37ºC in buffer alone.  This is slightly lower than 
the range reported by Morykwas (Morykwas and Marks, 1998) for human neonatal dermal 
fibroblasts: 1.4-10 μg/ml in the conditioned medium and 0.8-9.8 μg cellular FN/10000 cells, but is 
consistent with the fact that human fibroblasts are known to express higher levels of FN than NIH 
3T3 fibroblasts and that the human fibroblasts were cultured in 10% FBS supplemented medium.   
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The dose dependent effect of TNfn1-8, FBG and 70-kDa on DOC insoluble FN was confirmed by 
this method (Figure 3.8 A).  TNfn1-8 had no consistent effect on FN in DOC soluble material 
(Figure 3.8 B).  Conversely, FBG consistently increased levels of FN in the DOC soluble fraction 
by ~50%, whilst 70-kDa reduced FN levels in the DOC soluble fraction at the two highest 
concentrations used (Figure 3.8 B).  Furthermore, TNfn1-8 showed a  1.5 - 2 fold increase in FN 
levels within the conditioned medium at higher concentrations, whilst FBG and 70-kDa had no 
consistent effect on FN in the conditioned medium (Figure 3.8 C).  This data is consistent with that 
already published for 70-kDa, which has been shown to reduce levels of both DOC soluble and 
insoluble FN (McKeown-Longo and Mosher, 1985).  
 
In these experiments, TN-C was included as a negative control but actually appeared to slightly 
reduce levels of FN in DOC insoluble material at the lower concentrations but not at higher 
concentrations (Figure 3.8 A).  It also slightly increased FN levels in the DOC soluble material at 
higher, but not lower, concentrations (Figure 3.8 B).  There was a trend for increased FN levels in 
the conditioned medium at lower concentrations tested (Figure 3.8 C).   
 
TN-C domains were added to cells at 500, 50 or 5 pmoles (1, 0.1 or 0.01 μM).  Using the values of 
FN calculated above I was able to determine that the highest concentrations of TN-C used are in 
excess of the 6 – 26 pmoles (8.3 – 35.9 nM) of FN present in my system.  This means all binding 
should be saturating.  The fact that not all TN-C domains have an effect on FN matrix assembly 
demonstrates that the presence of excess protein is not affecting the assembly process by non-
specific interactions with the FN.         
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Figure 3.8   Pmoles of FN determined from dot blots of DOC insoluble and soluble material and conditioned 
medium isolated from NIH 3T3 fibroblasts after culture with increasing concentrations of TN-C and TN-C 
domains.  
NIH 3T3 fibroblasts were plated for 2 h at 37ºC before being further cultured for 22 h with buffer alone in the absence of  
recombinant protein (-) or in the presence of 1, 0.1, 0.01 or 0.001 μM TN-C, TNfn1-8, FBG, 70-kDa.  (A) DOC insoluble 
material, (B) DOC soluble material and (C) conditioned medium was then isolated. These different fractions were directly 
dot blotted onto nitrocellulose membrane and the pmoles of FN calculated from a standard curve of known FN 
concentrations.  Results were then normalised as a percentage of the control (-) and plotted as above.  Data are shown 
as mean +/- SEM from 2 independent experiments. 
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3.2.3   Mapping the inhibitory domains within TNfn1-8 
TNfn1-8 is a large multi-modular domain, within which the TNfn3 module has been shown to 
possess FN binding activities (Chung et al., 1995) (Ingham et al., 2004).  To map the active region 
of TNfn1-8 involved in FN assembly inhibition, smaller TNfn domains were tested for their effect 
on FN matrix assembly.  Domains possessing the TNfn3 domain (TNfn1-3, TNfn3-5, TNfn1-5) 
were compared with domains that do not have this TNfn module (TNfn5-7 and TNfn6-8).   
 
3.2.3.1   TNfn1-3 and TNfn6-8 reduce matrix complexity and FN fibrillar structure 
Compared to cells cultured in the absence of recombinant protein, (Figure 3.9 A), TNfn1-3 (Figure 
3.9 C) and TNfn6-8 (Figure 3.9 G) reduced FN matrix density and complexity to a level comparable 
with that observed with TNfn1-8 (Figure 3.9 B).  In contrast TNfn3-5 (Figure 3.9 D), TNfn1-5 
(Figure 3.9 E) and TNfn5-7 (Figure 3.9 F) had no effect on the FN matrix.  Quantification of FN 
staining intensities showed that TNfn1-8, TNfn1-3 and TNfn6-8 significantly reduced the density 
and coverage of FN fibrils per field of view, compared to cells cultured in the absence of 
recombinant protein (Figure 3.10).   
 
3.2.3.2   TNfn1-3 and TNfn6-8 reduce FN levels in DOC insoluble fractions 
TNfn1-3 and TNfn6-8 showed a consistent reduction of FN levels in the DOC insoluble fraction 
(Figure 3.11), suggesting that these domains also inhibit FN assembly into higher molecular weight, 
complex matrices.  The levels of FN in the DOC soluble fraction and in the conditioned medium did 
not show any consistent reduction in FN levels (Figure 3.11) as detected by ECL Western blotting.   
TNfn1-3 and TNfn6-8 also dose-dependently inhibited FN levels in DOC insoluble material (Figure 
3.12).  Quantification by dot blotting confirmed that TNfn1-3 and TNfn6-8 inhibited FN levels in 
DOC insoluble material dose dependently (Figure 3.13 A).   
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Figure 3.10  Quantification of immunofluorescence images to determine 
effects of TNfn domains on FN matrix assembly. 
ImageJ software was used to calculate (A) total pixel intensities greater than 
the 100 to determine the overall matrix assembly, or (B) average pixel intensity 
calculated to represent the three-dimensional fibrillar structure.  Values were 
corrected for the number of nuclei per field of view and normalised to the 
control where no recombinant protein was added (-). Three random fields of 
view were analysed.  Results are shown as mean +/- SEM of 3 independent 
experiments. *, p<0.05; **, p<0.01 determined by one-way ANOVA statistical 
analysis using Dunnett’s test compared to the control (-).   
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Figure 3.11   Western blots of FN in DOC insoluble and soluble material, 
and conditioned medium isolated from fibroblasts cultured in the 
presence of TNfn domains. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium at 37ºC before 
being further cultured for 22 h with buffer alone in the absence of recombinant 
protein (-), or in the presence of 0.1 µM TNfn1-8, TNfn1-3, TNfn1-5, TNfn3-5, 
TNfn6-8 or TNfn5-7 to the media.  Then DOC insoluble and DOC soluble 
material was isolated and conditioned media collected.  3 µg DOC insoluble 
material, 6 µg DOC soluble material and 20 μl conditioned medium was 
resolved by SDS-PAGE (6% total acrylamide) and Western blotted with an anti-
FN antibody (F3648) and secondary HRP-conjugated antibody.  0.05 μg human 
plasma FN was included as a positive control (pFN) Blots from a single 
experiment are shown, which are representative of results from 3 independent 
experiments. Molecular weight markers are in kDa. 
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Figure 3.12   Western blots of FN in DOC insoluble material from fibroblasts cultured in the 
presence of increasing doses of TNfn domains 
NIH 3T3 fibroblasts were plated for 2 h at 37ºC before being further cultured for 22 h with buffer alone 
in the absence of recombinant protein (-) or in the presence of 1, 0.1, 0.01, 0.001 μM TNfn1-3, TNfn6-
8 and TNfn1-8.  DOC insoluble material was then isolated. 3 µg DOC insoluble material was resolved 
by SDS-PAGE (6% total acrylamide), which was Western blotted and probed with an anti-FN antibody 
(F3648) and secondary HRP-conjugated antibody. 0.05 μg human plasma FN (hpFN) was included 
as a positive control. Molecular weight markers are in kDa. 
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Figure 3.13  Pmoles of FN determined from dot blots of DOC insoluble and soluble material and 
conditioned medium isolated from fibroblasts after culture with increasing concentrations of TNfn 
domains.   
NIH 3T3 fibroblasts were plated for 2 h at 37ºC before being further cultured for 22 h with buffer in the absence of 
recombinant protein (-) or in the presence of 1, 0.1, 0.01 or 0.001 μM TNfn1-8, TNfn1-3, TNfn3-5 and TNfn6-8.  
(A) DOC insoluble material, (B) DOC soluble material and (C) conditioned medium was then isolated.  These 
different fractions were directly dot blotted onto nitrocellulose membrane and the pmoles of FN calculated from a 
standard curve of known FN concentrations.  Results were then normalised as a percentage of the control (-) and 
plotted as above.  Data are shown as mean +/- SEM from 2 independent experiments.  
 
Results: Regulation of FN matrix assembly by TN-C and TN-C domains 
 
 91
TNfn1-3 and TNfn6-8 had no effect on FN levels in the DOC soluble material (Figure 3.13 B), nor 
on FN levels in the conditioned medium (Figure 3.13 C).  In contrast, TNfn3-5 had no effect on FN 
levels in DOC insoluble or soluble material or in the medium (Figure 3.13 A-C).   
 
3.2.4   TNfn1-8, TNfn1-3, TNfn6-8 and FBG demonstrate temporally distinct effects on FN 
matrix assembly   
FN matrix assembly occurs as a stepwise process.  By monitoring FN matrix assembly over time, it 
could be determined whether TN-C or its individual domains affect the rate of FN assembly.  For 
example, although TN-C does not affect FN matrix assembly after 24 h culture, it could be 
accelerating the assembly process before this time point.  This experiment would also provide 
further information on the possible mechanisms by which TNfn1-8 and FBG are inhibiting FN 
matrix assembly.  This process is routinely monitored by immunofluorescence (Mao and 
Schwarzbauer, 2005) (Sechler et al., 1996) (Takahashi et al., 2007) (Tomasini-Johansson et al., 
2006).  In the absence of recombinant protein, punctate FN staining is associated with the cell 
surface within 2 h of culture.  Short FN fibrils start to form within 4-6 h of culture, and these begin 
to thicken and elongate after 10 h of culture.  By 24 h of culture a thick, fibrillar matrix can be 
observed (Figure 3.14; -).   
 
Addition of TN-C (Figure 3.14) had no effect on the rate of FN matrix assembly compared to the 
control (-).  Likewise, addition of TA (Figure 3.14), EGF-L (Figure3.14), TNfn3-5 (Figure 3.15), 
TNfn1-5 (Figure 3.15) or TNfn5-7 (Figure 3.15) did not affect matrix assembly.  
 
TNfn1-8 inhibited FN assembly at a very early stage of the process.  4 h after addition of TNfn1-8 
(6 h total culture time), progression of the initial surface bound fibrils into thicker, elongated fibrils 
was strikingly inhibited.  The attenuation of this assembly process resulted in a less extensive FN 
matrix assembled after 24 h culture compared to the control (Figure 3.16).    
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Conversely, TNfn1-3 attenuated FN matrix assembly only after 10 h of culture.  FN matrix 
assembly was similar to that of the control before 10 h, with thick fibrils clearly developing.  
However, after 24 h of culture, the fibrillar matrix was much less extensive than the control (Figure 
3.16).  TNfn6-8 did not affect the earliest stages of FN matrix assembly but inhibited FN fibrillar 
progression 6-8 h after culture; the stage at which FN begins to thicken and elongate. By 24 h, the 
FN fibrils appeared thinner and the matrix density was much reduced (Figure 3.16).  FBG affected 
late FN assembly processes (Figure 3.17).  Initial FN matrix assembly was similar to the control, 
with fibril thickening and elongation observed after 10-12 h culture.  After 18-24 h culture, the FN 
matrix was much reduced in complexity compared to the control; the fibrils did not progress in 
complexity from that observed at 12 h (Figure 3.17).   
 
70-kDa is known to inhibit FN matrix assembly at the initiation stage (Bultmann et al., 1998) 
(McDonald et al., 1987) (Spiegel et al., 1986).  This was confirmed by my observations; it was clear 
after 4 h of culture, FN association to the cell surface was reduced.  The initial formation of short, 
thick fibrils was strikingly inhibited, so only very short, punctate staining of FN was observed at 6-8 
h of culture.  By 24 h, only very thin fibrils and disordered aggregates of FN were observed (Figure 
3.17).   
 
These data suggest that  TNfn1-8 and TNfn6-8 act at an early stage of FN matrix assembly before 
FN associates into thicker fibrils and begins elongating, whereas TNfn1-3 and FBG act at a later 
stage of FN fibrillogenesis after fibrils have already formed. 
 
3.2.5   TN-C and TN-C domains have no effect on FN mRNA levels 
FN is constitutively expressed by fibroblasts but its expression can be altered by cell stimulation for 
example TGF-β enhances FN expression levels (Hocevar et al., 1999).  TN-C or TN-C domains 
could affect FN matrix assembly by altering the level or rate of FN biosynthesis.  To examine the  
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effect of TN-C domains on FN expression levels, total RNA was isolated from cells cultured in the 
absence of protein (-), 0.1 μM TN-C or individual TN-C domains.  FN mRNA levels were 
monitored over time to see if the distinct temporal effects of TNfn1-8, TNfn1-3, TNfn6-8 or FBG 
on FN assembly are due to changes in FN expression levels.  Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA was used as a ubiquitous housekeeping gene to allow for 
comparison of FN mRNA levels.  cDNA product was excluded from the PCR reaction as a negative 
control for the PCR (-).  cDNA isolated from human glioma cells was used as a positive control (+) 
for the PCR as this cell type is known to express high levels of FN.   
 
None of the recombinant proteins had any consistent effect on FN mRNA levels at any time point 
tested (Figure 3.18) and GAPDH mRNA levels were also constant (Figure 3.18) suggesting that 
inhibition of FN matrix assembly by TNfn1-8, TNfn1-3, TNfn6-8 and FBG is not due to effects on 
FN expression.   
 
3.2.6 TNfn1-8 and FBG inhibition of FN matrix assembly is not due to FN degradation  
TN-C can induce the expression of proteases such as MMP-9 in breast cancer cells and rabbit 
synovial fibroblasts (Kalembeyi et al., 2003) (Tremble et al., 1994).  MMP-9 is known to degrade 
FN (Marom et al., 2007).  The addition of TN-C domains such as TNfn1-8 or FBG may inhibit FN 
matrix assembly by causing an increase the expression of FN degrading proteases.  I next 
determined whether proteolytic degradation is involved in the loss of FN matrix assembly caused by 
TN-C domains.   
 
Given that Western blots for DOC insoluble, DOC soluble or conditioned medium were probed 
with a polyclonal anti-FN antibody and did not show the presence of any small degradation 
products, it is unlikely that FN degradation is responsible for the reduction in FN matrix assembly.   
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Figure 3.18   RT-PCR to determine the effects of TN-C, TNfn1-3, TNfn6-8, TNfn1-8 and FBG 
on GAPDH and FN mRNA levels over time.   
NIH 3T3 fibroblasts were plated in serum-free medium for 2 h at 37ºC before being further 
cultured with buffer alone in the absence of recombinant protein (1) or in the presence of 0.1 μM 
full-length TN-C (2), TNfn1-3 (3), TNfn6-8 (4), TNfn1-8 (5) or FBG (6). Cells were cultured for a 
further 2, 4, 6, 8, 16 and 22 h before isolation of RNA, which was reverse transcribed and the 
cDNA amplified by PCR with specific FN and GAPDH primers.  Time points are labelled as 2, 4, 
6, 8, 10, 18 and 24 h to describe the total time of culture for the cells.  A negative control (- ; 
without template cDNA) and a positive control (+; cDNA isolated from human glioma cells) were 
included in the PCR reactions.    
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A representative full-length blot for DOC insoluble material Western blotted for FN is shown in 
figure 3.19, which reflects the absence of degraded FN products.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To confirm that TNfn1-8 and FBG are not enhancing protease expression or activity, I examined the 
effect of MMP inhibition on TNfn1-8 and FBG inhibition of FN assembly.  I first confirmed FN 
matrix assembly in the absence of recombinant domains was not affected by inhibition of protease 
activity.  The protease inhibitor GM6001, a general MMP inhibitor was added to the conditioned 
medium to inhibit protease degradation at a concentration which does not affect FN matrix turnover 
(Sottile and Hocking, 2002).  GM6001 was shown not to affect FN levels in the DOC insoluble 
matrix of control cells after 24 h culture (Figure 3.20). An equivalent DMSO volume, which is a 
carrier for GM6001 was also shown not to affect FN levels in DOC insoluble material (Figure 
3.20).  
Figure 3.19   Western blotting to confirm the absence of FN degradation products. 
NIH 3T3s were plated in serum-free medium for 2 h before being further cultured for 22 h with 
buffer alone in the absence of recombinant protein (-) or in the presence of 0.1 μM 70Ten, 70-
kDa, TNfn1-8, FBG, EGF-L and TA.  DOC insoluble material was then isolated. 3 μg DOC 
insoluble material  was resolved by SDS-PAGE (6% total acrylamide) and Western blotted with an 
anti-FN antibody (F3648) and a secondary HRP-conjugated antibody. 0.05 μg human plasma FN 
(+) was included as a positive control.  A representative Western blot of DOC insoluble material is 
shown above. Molecular weight markers are in kDa; F indicates gel front. 
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Addition of GM6001 to fibroblasts, which were  simultaneously cultured with 0.1 μM TNfn1-8 or 
FBG did not result in the rescue of FN levels in isolated DOC insoluble material to those observed 
in the controls where fibroblasts were  cultured in the absence of recombinant protein  but in the  
presence of GM6001 (Figure 3.20).  Together these results confirm TNfn1-8 and FBG are likely to 
be affecting specific steps of FN matrix assembly by interfering with the fibrillogenesis process 
rather than inducing protease activity or affecting FN expression. 
 
3.3   Discussion 
I have demonstrated that full-length TN-C does not inhibit FN matrix assembly.  I have also shown 
that the N-terminal TA and EGF-L domains of TN-C do not inhibit FN matrix assembly.  However, 
two domains within TN-C, TNfn1-8 and FBG, do inhibit FN matrix assembly.  This suggests that 
inhibition of FN matrix assembly is cryptic within the full-length molecule.  It is also clear that 
TNfn1-8 and FBG act via very different mechanisms to affect FN matrix assembly:  TNfn1-8 
Figure 3.20   Western blot of DOC insoluble material to determine if inclusion 
of GM6001 protease inhibitor can rescue effect of TNfn1-8 and FBG on FN 
levels in this fraction.  
NIH 3T3 fibroblasts were plated for 2 h at 37ºC before being further cultured for 22 
h with buffer alone in the absence of recombinant protein (–) or in the presence of 
0.1 μM TNfn1-8 or FBG, with the exclusion (-) or inclusion (+) of 10 μM general 
MMP inhibitor GM6001 or 5 μl DMSO.  As a control, no protease inhibitor or DMSO 
was added to the medium (no addition).  DOC insoluble material was then isolated.  
3 μg DOC insoluble material and 0.05 μg human plasma FN (first and last lanes) 
were resolved by SDS-PAGE (6% total acrylamide) and Western blotted with an 
anti-FN antibody (F3648) and HRP-conjugated secondary antibody. Molecular 
weight markers are in kDa. 
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affects early matrix assembly events whereas FBG acts on later fibrillogenesis processes.  Within 
TNfn1-8 TNfn1-3 and TNfn6-8 can also inhibit FN matrix assembly, but these domains also 
possess potentially different mechanisms of action to TNfn1-8. 
 
To monitor FN matrix assembly, NIH 3T3 fibroblasts were fixed and the FN matrix was examined 
by indirect immunofluorescence.  This allowed the visualisation of the FN fibrillar structure and at 
higher magnification, the fibril thickness and the three-dimensionality of the FN matrix could be 
clearly discerned.  The DOC solubility assay is another well-established method to monitor FN 
matrix assembly (Choi and Hynes, 1979) (Kuznetsova et al., 2008) (Midwood and Schwarzbauer, 
2002) (McKeown-Longo and Mosher, 1983) (McKeown-Longo and Mosher, 1985).  Using this 
method, a DOC containing buffer is added to lyse the cells and then centrifuged to separate out the 
DOC soluble components in the supernatant from the DOC insoluble components in the pellet.  The 
conditioned medium was also collected to determine levels of FN secreted by the fibroblasts.  The 
level of FN in each fraction was determined either by Western blotting or dot blotting and bands 
visualized using an anti-FN antibody and HRP-conjugated (Western blotting) or alkaline 
phosphatase-conjugated (dot blotting) secondary antibodies.  FN assembled into higher molecular 
weight fibrils and complexes is partitioned into the DOC insoluble fraction, whereas cell-surface 
receptor-bound and intracellular FN is retained in the DOC soluble fraction (Kuznetsova et al., 
2008).  Using these blotting methods, FN levels in each fraction could be monitored and point to 
possible mechanisms involved in FN matrix assembly regulation.   
 
ECL Western blotting has been widely used to allow sensitive determination of FN levels in DOC 
insoluble and soluble material (Mao and Schwarzbauer, 2005) (Midwood and Schwarzbauer, 2002) 
(Sechler et al., 1996) (Sechler et al., 2001) (Yoneda et al., 2007).  Band intensities have been 
determined from the film-based detection method for quantifying protein levels (Green et al., 2009) 
(Sechler et al., 2001), but the linearity of the technique is limited; film darkening does not develop 
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linearly with the amount of light produced (Dickinson and Fowler, 2002).  Dot blotting is more 
rapid, allows up to 36 samples to be analyzed simultaneously and has a wider linear range (103) and 
so was used in preference for protein quantification.  As no non-specific protein bands are detected 
in the conditioned medium or DOC soluble or insoluble samples from cultured fibroblasts and no 
FN degradation products can be observed by Western blotting (Figure 3.19) this suggests the anti-
FN antibody (F3648) is specific for FN and band intensities observed by dot blotting should only be 
detecting intact FN molecules.   
 
I observed some differences between FN levels assessed by the two methods (ECL versus dot 
blotting).  The DOC insoluble material resolved by both methods and quantified by dot blotting was 
very consistent.  However, in the DOC soluble material detected by Western blotting none of the 
TN-C domains showed a consistent effect out of 4 independent experiments tested.  However, using 
the dot blotting method there are clear dose dependent differences in DOC soluble material for FBG 
and for 70-kDa.  Likewise, differences in the conditioned medium were seen for TNfn1-8 by dot 
blotting, which were not consistently shown by Western blotting.  The bands detected by ECL 
Western blots may be above the linear range accurate detectable by film.  The increased linear 
range of the dot blotting method compared to ECL Western blotting and the ability to calibrate band 
intensities with known protein concentration standards may enhance the sensitivity of the dot 
blotting method.  
 
However, despite this, the dot blotting method often resulted in very large SEM, particularly for the 
soluble fraction and the conditioned medium.  The high concentration of FN in these fractions 
required the medium to be highly diluted so it could be detected within the linear range of the assay.  
This may contribute to the variability reflected by the large SEM values, making these results 
unreliable.  In addition, due to time constraints, only two independent repeats of each experiment 
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were quantified meaning that significance cannot be calculated and only trends can be reported.  
Further repeats are needed to confirm these results and to reduce SEM values. 
 
Alternative methods to determine FN levels in the conditioned medium are discussed below.  
Previously I tried to quantify FN levels from the conditioned medium by sandwich ELISA, but I 
found this was not sensitive enough to reproducibly determine the quantities of FN in my system (6-
26 pmoles).   
 
To determine FN levels more accurately, 125[I]-FN could have been used to monitor exogenous FN 
assembly on FN-null embryonic fibroblast cultures and the levels of 125[I] partitioned into DOC 
insoluble, DOC soluble fractions and remaining in the conditioned medium could be determined 
(Bultmann et al., 1998) (Maqueda et al., 2007) (McKeown-Longo and Mosher, 1983) (McKeown-
Longo and Mosher, 1985).  The limitation during my PhD was that we did not have the available 
facilities at the time I did these investigations.  However, this method may not be as physiologically 
relevant as it would measure the binding of exogenous 125[I]-labelled soluble plasma FN to the cell 
surface, which is both functionally and structurally distinct from cellular FN, which is due to the 
presence of alternatively spliced domains, as discussed in the Introduction chapter, section 1.2.3 
(The modular structure of FN).  
 
Finally, reverse transcription-PCR with specific FN and GAPDH primers was used to confirm that 
TN-C domains are not affecting FN matrix assembly by reducing the expression of FN.  
Unfortunately, unlike real time PCR, this method is not directly quantitative with a limited dynamic 
range due to the relative insensitivity of ethidium bromide; results can only be compared 
qualitatively via this PCR method.  To determine whether the presence of the TN-C domains was 
causing increased activation of proteases, which would lead to FN matrix degradation, cells were 
cultured in the presence of the general MMP inhibitor, GM6001 as previously described (Sottile 
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and Hocking, 2002).  The levels of FN in the DOC insoluble fractions were not rescued by the 
MMP inhibitor suggesting this mechanism is not involved.   
 
3.3.1   70-kDa inhibits an early stage of FN matrix assembly 
I have demonstrated that 70-kDa showed a strong, dose dependent inhibition of FN matrix 
assembly.  It prevented FN incorporation into both DOC soluble and insoluble material.  70-kDa 
inhibition was observed as early as 2 h after addition to the conditioned medium (4 h total culture).  
FN did not progress beyond sparse punctate staining on the cell surface.    
 
My data are consistent with that already published: 70-kDa is a known inhibitor of matrix assembly 
that inhibits early matrix assembly (Bultmann et al., 1998) (Hocking et al., 1994) (Maqueda et al., 
2007) (McDonald et al., 1987) (McKeown-Longo and Mosher, 1985) (Spiegel et al., 1986) 
(Takahashi et al., 2007) (Tomasini-Johansson et al., 2006) (Zhang and Mosher, 1996).  It reduces 
the binding of FN to the cell surface and association into the DOC soluble pool, and therefore, 
inhibited the conversion of FN into DOC insoluble material (McKeown-Longo and Mosher, 1985).  
 
The 70-kDa domain of FN was previously reported to completely inhibit FN matrix assembly 
(Bultmann et al., 1998) (Maqueda et al., 2007), but in my studies, a sparse FN matrix can still be 
observed on the surface of the confluent fibroblasts.  Experiments by Bultmann et al. (Bultmann et 
al., 1998) used a 13x higher concentration (1.3 μM) and Maqueda et al., (Maqueda et al., 2007) 
used a 28x higher concentration (2.8 μM) than used in my immunofluorescence studies (0.1 μM).  
These groups were also looking at exogenous plasma FN binding overnight to cycloheximide 
treated fibroblasts, which may have lower affinities for FN matrix assembly receptors compared to 
endogenous cellular FN.   The polyclonal anti-FN antibody used in my immuofluorescence studies 
also recognise the 70-kDa domain of FN and could be recognising exogenously added 70-kDa 
bound to the fibroblast surface.   
Results: Regulation of FN matrix assembly by TN-C and TN-C domains 
 
 105
 
70-kDa is thought to be acting in two ways to prevent FN matrix assembly (Figure 3.21 A and B).  
It can bind to cell-surface matrix assembly sites at the cell periphery in linear arrays and thus may 
inhibit FN interactions with FN matrix assembly receptors (Bultmann et al., 1998) (McKeown-
Longo and Mosher, 1985) (Tomasini-Johansson et al., 2006) (Zhang and Mosher, 1996).  70-kDa 
can also bind directly to FN via its FNIII1 or FNIII12-14 domains (Aguirre et al., 1994) (Bultmann et 
al., 1998), which could also inhibit intermolecular FN-FN interactions during fibrillogenesis.   
 
3.3.2   70Ten inhibits FN matrix assembly whereas TN-C has no effect 
Previously, the recombinant 70Ten molecule had been used in place of full-length TN-C, because 
attempts to express full-length TN-C in a Hi5 insect cell system were unsuccessful; intracellular 
aggregation killed the cells before sufficient amounts of protein could be secreted.  70Ten was 
designed as a recombinant, chimeric molecule that could be expressed in Hi5 cells (Wenk et al., 
2000).  70Ten contains the 70-kD N-terminal domain of FN and the C-terminal TNfn and FBG 
domains of TN-C and has been shown to have identical effects on cell adhesion, actin cytoskeleton 
organization and cell signaling pathways as full-length TN-C (Midwood and Schwarzbauer, 2002) 
(Schwarzbauer, 1991) (Wenk et al., 2000).  Consistent with previous reports (Midwood and 
Schwarzbauer, 2002), I showed that 70Ten is an inhibitor of FN matrix assembly.  
 
However, contrary to the effects of 70Ten, full-length TN-C itself has no effect on FN matrix 
assembly, but did increase fibril thickness.  Analysis of immunofluorescence images with ImageJ 
software showed TN-C and its N-terminal domains TA and EGF-L significantly increased the 
average FN pixel intensity, suggesting it may affect the fibrillogenesis process.  However, there was 
no obvious difference in the total number of FN pixels (overall FN matrix coverage) or in FN levels 
in the DOC insoluble material at 0.1 μM, suggesting these domains may be affecting the 
organisation of the fibrils in the matrix rather than affecting the levels of FN in the matrix.   
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Figure 3.21   Mechanisms by which 70-kDa inhibit FN matrix assembly 
(A) The 70-kDa domain inhibits initiation of FN matrix assembly by binding to the cell surface at 
matrix assembly sites, which may include integrins to inhibit FN from binding.  (B) 70-kDa can also 
interact with FN at its FNIII12-14 and FNIII1 domains to inhibit FN-FN interactions.   
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Cartilage oligomeric matrix protein (COMP), the pentameric multi-domain catalyst of collagen 
fibrillogenesis brings together multiple collagen molecules to facilitate fibrillogenesis before 
dissociating from the mature collagen fibres (Halasz et al., 2007).  TN-C and another tenascin 
family member tenascin-R (TN-R) have been shown by electron microscopy to cross-link together 
hyaluronan-aggrecan complexes.  TN-R was shown to bind to aggrecan via its TNfn3-5 domain and 
may have a key function in hyaluronan-aggrecan complex stabilisation (Diao and Tajkhorshid, 
2008) (Lundell et al., 2004).  It would be tempting to speculate that TN-C could play a role in 
facilitating FN fibrillogenesis in a similar manner.  It is possible that TN-C alters FN remodelling 
by stabilising FN fibrils.  Dot blotting showed increased FN levels in conditioned medium except at 
the highest concentration of TN-C, but due to the large SEM values, this data is not as reliable.  It is 
curious that TN-C caused a reduction in DOC insoluble FN levels at lower concentrations tested.  It 
may be that low concentrations of TN-C actually act in a destabilising manner on the matrix and it 
requires a threshold concentration of TN-C for optimum FN stabilisation.  This is supported by the 
observation that at higher TN-C concentrations, levels of FN in the DOC soluble material are 
increased.   
 
3.3.3   FBG inhibits later stages of FN matrix assembly 
FBG showed a strong dose-dependent inhibition of FN matrix assembly.  It reduced the levels of 
FN assembled into high molecular weight, cross-linked and detergent insoluble matrices but 
stimulated levels of DOC soluble FN.  FBG acted late in FN matrix assembly.  Initial FN binding to 
the cell surface, fibril thickening and elongation were unaffected by the presence of FBG.  Instead, 
FBG acted on FN matrix assembly after 10 h culture so FN fibrillogenesis did not advance any 
further even after 24 h culture.  FBG did not show any effect on FN mRNA levels, so it is unlikely 
to be affecting FN biosynthesis.  FBG also did not affect FN levels in the conditioned medium, so it 
is not likely to be affecting FN secretion.  GM6001 (a general MMP inhibitor) could not rescue the 
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reduction of FN levels in DOC insoluble fractions caused by FBG, suggesting FN degradation by 
MMPs is also not a major mechanism.  
 
These data suggest that FBG may prevent the conversion of soluble FN into higher order DOC 
insoluble fibrils.  It may do this by increasing the number of cell surface FN receptors available, by 
stabilising cell surface bound FN or by inhibiting the association of FN fibrils.  Alternatively, FBG 
may cause disassembly of already formed DOC insoluble fibrils. It may do this by interfering with 
continuous FN polymerisation required to maintain the FN matrix at the cell surface (Sottile and 
Hocking, 2002) or by affecting actin cytoskeletal tension, which is a prerequisite for maintenance of 
a FN matrix (Baneyx et al., 2002) (Davidson et al., 2008) (Ohashi et al., 2002) (Smith et al., 2007) 
(Zhong et al., 1998).  Both disassembly of DOC insoluble FN or lack of conversion from soluble 
into DOC insoluble matrix may cause an accumulation of soluble FN on the cell surface or it may 
lead to internalization of FN to account for the increase in DOC soluble FN.  However, FBG 
reduced the density of cell-surface FN as observed by immunofluorescence, suggesting that it is 
unlikely to be acting to increase cell surface soluble FN.   
 
3.3.4   TNfn1-8 inhibits an early stage of FN matrix assembly 
TNfn1-8 also showed a strong dose-dependent inhibition of FN matrix assembly.  It reduced FN 
incorporation into higher molecular weight, detergent insoluble structures, but had no effect on 
DOC soluble FN, although it increased FN levels in the conditioned medium.  TNfn1-8 affected 
early events of FN matrix assembly as progression of initial surface bound FN fibrils into thicker 
and elongated fibrils was impeded after only 4 h culture in the presence of TNfn1-8 (6 h total 
culture) suggesting TNfn1-8 attenuated FN fibrillogenesis events at this early stage.  By 24 h, the 
sparsely assembled FN matrix was composed of much thinner and shorter fibrils.  TNfn1-8 did not 
show any effect on FN mRNA levels or FN degradation, so it is unlikely to be affecting FN 
biosynthesis or breakdown. 
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The TNfn3 module of TNfn1-8 has been shown to be involved in binding FN (Chung et al., 1995) 
(Ingham et al., 2004) and TNfn1-8 has been shown to interact with FN by competition solid phase 
binding and glycerol sedimentation assays (Chung et al., 1995).  TNfn1-8 has also been shown to 
localize to a FN fibrillar matrix (Chung et al., 1995).  The TNfn3-5 domain has also been shown to 
bind to heparin, which may mediate binding to cell surface heparan sulphate proteoglycans (Busby 
et al., 1995) (Chung and Erickson, 1997) (Weber et al., 1995).   So TNfn1-8 may inhibit FN matrix 
assembly by binding to cell surface receptors or FN itself to prevent early FN-FN or FN-cell 
interactions to impede FN fibrillogenesis.  This would reduce FN incorporation into the DOC 
insoluble matrix and FN may instead be released into the medium.   
 
3.3.5   TNfn1-3 and TNfn6-8 inhibit FN matrix assembly but act differently to TNfn1-8 
TNfn3 has been shown to interact with FN, and the adjacent TNfn4-5 domains were implicated as a 
requirement for higher affinity binding (Chung et al., 1995) (Ingham et al., 2004). Using smaller 
TNfn domains containing the TNfn3 FN-binding module or domains lacking this module, the active 
sites within TNfn1-8 were mapped for their effects on FN matrix assembly.  This would determine 
whether TNfn3 is the module responsible for TNfn1-8 interactions to inhibit FN fibrillogenesis.  
However, only TNfn1-3 and TNfn6-8 showed inhibition of FN matrix assembly.  TNfn3-5, TNfn1-
5 and TNfn5-7 did not show any effect on FN matrix assembly.  This suggests that TNfn3 is not the 
consensus “inhibitory” TNfn module responsible for FN matrix assembly inhibition.    
 
TNfn1-3 did not show FN matrix assembly inhibition profiles identical to TNfn1-8.  Similar to 
TNfn1-8, TNfn1-3 inhibited formation of DOC insoluble FN but had no effect on FN levels in DOC 
soluble material.  However, unlike TNfn1-8, TNfn1-3 inhibited later events of FN matrix assembly 
after 8 h in culture (10 h total culture).  No previous studies have been done to look at TNfn1-3 
interactions with FN, but the ability of TNfn3 to interact with FN, albeit at lower affinity than 
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TNfn3-5 suggests TNfn1-3 could interact directly with FN to inhibit FN fibrillogenesis.  The 
absence of domains TNfn4-8 may result in weaker interactions with FN than TNfn1-8, resulting in 
less efficient inhibition of FN matrix assembly.   
 
Although TNfn6-8 does not possess the TNfn3 module, it inhibited FN matrix assembly in a dose-
dependent manner and acted at an early time point similar to TNfn1-8; FN fibril thickening and 
elongation is inhibited after 4 h culture (6 h total culture).    Again, TNfn6-8 like both TNfn1-8 and 
TNfn1-3 has no effect on FN levels in DOC soluble material.  TNfn6-8 showed a similar effect on 
the kinetics of FN matrix assembly as TNfn1-8 suggesting this domain may be responsible for the 
inhibitory activity exhibited by TNfn1-8.  Previous studies have demonstrated that TNfn6-8 does 
not interact with FN (Chung et al., 1995) (Ingham et al., 2004), although some studies suggest that 
TNfn6-8 has some weak FN binding activity (Chung et al., 1995).  In addition, TNfn6-8 has been 
shown to interact with the [α5]β1 integrins (Liao et al., 2008) (Varnum-Finney et al., 1995) and 
promotes heparin dependent adhesion (Seiffert et al., 1998).  This suggests that TNfn6-8 may 
inhibit FN fibrillogenesis by binding to matrix assembly receptors and inhibiting FN interactions 
with these receptors.   
 
The importance of the 3D structure of the TNfn domains and the effects of neighbouring domains 
on the orientation and rotational interdomain flexibilities of FNIII modules (Altroff et al., 2004) 
(Bencharit et al., 2007) (Leahy et al., 1992) (Leahy et al., 1996) (Pickford et al., 2001) (Pickford 
and Campbell, 2004), resulting in the masking or exposure of functional sites within FNIII modules 
(Chen and Culp, 1996) (Fischer et al., 1997) (Saito et al., 2007) meant that the probing of individual 
TNfn modules was not explored further as this would be unlikely to yield any further mechanistic 
details.  The importance of the overall 3D structure of the domain and its effects on FN matrix 
assembly are also highlighted by the fact that inhibition of FN matrix assembly by TNfn1-8 and 
FBG is a cryptic activity buried within full-length TN-C.   
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3.3.6   Matricryptic sites within TN-C and TNfn1-8 
Since full length TN-C does not inhibit FN matrix assembly, the TNfn1-8 and FBG inhibitory effect 
must be masked by the overall structure of the hexameric TN-C molecule.  This supports the theory 
of matricryptins, where smaller domains of multi-domain proteins possess cryptic biologically 
active functions not present in the full-length molecule (Tran et al., 2005).  This is illustrated by the 
effect of FBG on matrix assembly.  The full-length TN-C associates into a native hexabrachion 
structure, which would result in 6 FBG ligands presented per complex. However, within the 
complete TN-C structure, these FBG domains do not exhibit an inhibitory effect on FN matrix 
assembly.  This reflects work previously demonstrating that other domains within TN-C can 
attenuate or modulate the effect of FBG.  Hexameric deletion constructs possessing only the TA and 
FBG domains are good substrates for fibroblast adhesion and spreading.  However, the presence of 
the adjacent EGF-L or TNfn domains reduces the adhesive properties of FBG and inhibits cell 
spreading (Fischer et al., 1997).  The large hexabrachion structure may sterically hinder these cell-
FBG interactions or influence the conformation of the FBG fold.   Recently, there have been many 
reports where individual domains of TN-C exhibit differential activities from the full-length TN-C 
molecule: EGF-L, TNfn3-5, TNfn5-7 and TNfn6-8 induced GAG release in porcine cartilage 
explants whereas full-length TN-C has no effect (Sofat, 2006); EGF-L but not full-length TN-C 
induced apoptosis of human smooth muscle cells (Wallner et al., 2004); alternatively spliced 
TNfnA2 module stimulation of β1-mediated cell adhesion is buried within TNfnA1-A4 
alternatively spliced structure (Saito et al., 2007);  TNfn3-5, TNfn6-8 and FBG had no effect on β-
casein milk protein expression whereas TN-C, TNfn1-3, TNfn1-5, TNfnA-D and TNfnALL 
inhibited β-casein expression by Scp2 mouse epithelial cell line (Jones et al., 1995).  There have 
also been reports of different domains derived from the same multi-domain protein with different 
cell activities: EGF-L domain of TN-R is anti-adhesive for microglial and hippocampal neurons, 
whereas TNfn6-8 is adhesive; both domains show differential effects on neural stem cell 
differentiation (Liao et al., 2008). 
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The presence of cryptically encoded activities within TN-C could be an important mechanism to 
regulate FN matrix assembly in regions of remodeling where TN-C is spatially and temporally co-
expressed.  As regions of remodeling often have high levels of proteolytic activity, the degradation 
of TN-C into smaller domains that affect FN matrix assembly could act as an indicator of the phase 
and progress of the remodeling process.  In fact there are many reports of TN-C fragments in 
tissues, indicating that they are physiologically relevant forms of this ECM molecule for example in 
atherosclerotic plaques (Wallner et al., 2004), small cell lung cancers (Cai et al., 2002) and in RA 
and OA cartilage (Sofat, 2006). 
 
3.4   Summary 
Here, I have demonstrated that full-length TN-C does not inhibit FN matrix assembly whereas 
specific smaller domains of TN-C: TNfn1-8, TNfn1-3, TNfn6-8 and FBG do have inhibitory effects 
on FN matrix assembly.  This suggests that inhibition of FN matrix assembly is cryptic within the 
full-length TN-C.  Each of the inhibitory domains affects FN matrix assembly at different time 
points and differentially alters the partitioning of FN into DOC insoluble material, DOC soluble 
material and conditioned medium, suggesting they act via different mechanisms.  The possible 
mechanisms of their action are explored further in the next two chapters in an attempt to elucidate 
the mechanisms by which these domains are acting to affect FN matrix assembly. 
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4.1   Introduction 
In the previous chapter, I showed that full-length TN-C did not inhibit FN matrix assembly, but 
smaller domains within TN-C: TNfn1-8, TNfn1-3, TNfn6-8 and FBG did specifically inhibit FN 
matrix assembly.  This was not caused by changes in FN biosynthesis or degradation but was due to 
an inhibition in the assembly of a detergent insoluble, fibrillar matrix at the cell surface.    
 
The aim of this chapter is to investigate the mechanisms by which TN-C domains inhibit FN matrix 
assembly.  TN-C domains may potentially act (1) by binding directly to FN and interrupting FN-FN 
interactions, (2) by binding to FN to interrupt FN-cell surface receptor interactions, (3) by binding 
to cell surface receptors involved in FN matrix assembly to interrupt FN-cell surface receptor 
interactions or (4) by binding to other cell surface receptors, independent of the FN assembly 
process, which feedback to affect FN matrix assembly. 
 
TN-C has been shown to bind to FN purified from plasma, as described in Introduction chapter 1, 
section 1.3.3 (TN-C can interact with FN in vitro).  However a systematic analysis of TN-C and 
TN-C domain binding to cellular FN at the cell surface has not been undertaken.  Here I will 
confirm the binding of TN-C and TN-C domains to purified soluble plasma FN and compare this 
with the ability of TN-C and TN-C domains to bind to cell-associated, fibrillar FN.  I will also map 
where TN-C binds to within the FN molecule.  These data will provide information as to whether 
TNfn1-8, TNfn1-3, TNfn6-8 and FBG might inhibit FN-FN intermolecular interactions or FN-cell 
binding during matrix assembly by binding directly to the FN molecule. 
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4.2  Results 
 
4.2.1   Synthesis and purification of plasma FN and FN domains 
The structure of FN and its individual domains is shown in the schematic (Figure 4.1 A). Human 
plasma FN was purified by Emma Chan as described in (Mosher et al., 1980).  The 70-kDa N-
terminal domain of FN was a kind gift from Jean Schwarzbauer (Schwarzbauer, 1991).  The 120-
kDa central binding domain (CBD) and the 40-kDa HepII domain were both obtained from 
Millipore.  Purity was assessed by silver staining (Figure 4.1 B) and reactivity with a polyclonal 
anti-FN antibody (F3648) verified (Figure 4.1 C).  All proteins showed a single band at the correct 
molecular weight except for 40-kDa, which had two strong contaminating bands, and CBD, which 
had some fainter smaller contaminating bands.  These are likely to be degradation products as they 
are recognised by Western blotting with the anti-FN antibody (Figure 4.1 C).  The specificity of the 
polyclonal anti-FN antibody was confirmed as it did not recognise purified full-length TN-C and 
only recognised a single band of the expected MW of FN in NIH 3T3 cell lysates (Figure 4.1 D).  
 
4.2.2   Solid phase binding assays to determine interactions of TN-C and TN-C domains with 
full-length FN 
Solid phase binding assays were used to systematically screen interactions between full length 
purified FN and recombinant TN-C or TN-C domains. 
 
4.2.2.1   Soluble FN binds to immobilised TNfn1-5, TNfn1-3, TNfn3-5 and TNfn1-8  
Full length TN-C was immobilized at 25 μg/ml (78 nM) to give 4.2 μg/cm2 per ELISA well (area = 
0.3 cm2) as described in Huang et al., (Huang et al., 2001).  Equimolar amounts of TN-C domains 
(78 nM) were also immobilized to ELISA wells.  Western blots confirmed TN-C and TN-C 
domains were effectively adsorbed to the ELISA dish (Appendix figure A2).    
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Soluble human plasma FN was added to TN-C coated dishes at increasing concentrations and 
immobilised FN that remained bound after washing was detected using the polyclonal anti-FN 
antibody (F3648) at 1:200 dilution (3 μg/ml).    The antibody was confirmed to be in excess for  
Figure 4.1   FN and recombinant FN domains. 
(A) Schematic structure of full-length FN and FN fragments composed of: FN type I repeats (FNI; narrow 
dark ovals    ), FN type II repeats (FNII; wide grey ovals      ), conserved FN type III repeats (FNIII; light 
rectangles      ), alternatively spliced FN type III repeats (dark rectangles      ).  The 70-kDa domain is 
composed of FNI1-9 and FNII1-2, the CBD (120-kDa) is composed of FNIII1-11, whereas the 40-kDa (HepII) of 
FN is composed of FNIII12-14.  (B) 1 μg of FN or individual FN domains were resolved by SDS-PAGE (10% 
total acrylamide) and silver stained or (C) Western blotted with an anti-FN antibody (F3648) and secondary 
alkaline phosphatase conjugated antibody.  (D) To confirm the specificity of the anti-FN antibody for FN 
alone, (i) 1 μg purified FN and TN-C and (ii) 1 μg purified FN and 3 μg detergent (DOC) insoluble material 
isolated from NIH 3T3 fibroblasts cultured for 24 h (cell) were resolved by SDS-PAGE (6% total acrylamide) 
and probed with an anti-FN antibody (F3648) and secondary alkaline phosphatase conjugated antibody.  
Molecular weight markers are in kDa.   
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recognizing full length FN and each FN domain so that saturation of binding in each assay could 
not be due to a limitation in antibody concentration and its specificity for FN immobilized on 
ELISA plates was also confirmed (Appendix figure A3).   
 
FN bound to immobilized TNfn1-8, TNfn1-5, TNfn1-3 and TNfn3-5 in a saturable manner (Figure 
4.2 A and B) indicating that specific FN binding sites exist within these TN-C domains.  Assuming 
that the polyclonal anti-FN antibody recognizes all FN conformations, as it is able to detect FN by 
immunofluorescence, immunoblotting and when adsorbed to an ELISA plate, these results suggest 
that soluble FN has the highest affinity for TNfn1-3 and TNfn1-5 and lower affinities for TNfn1-8 
and TNfn3-5 (Figure 4.2 B).  FN showed low levels of binding to full-length TN-C and did not bind 
to TA, EGF-L, TNfn5-7, TNfn6-8 or FBG (Figure 4.2 A and B).   
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Figure 4.2   Solid phase binding assays to determine the binding of FN to immobilised TN-C and TN-C 
domains.  
ELISA plates were coated with 78 nM TN-C or individual TN-C domains (A) or TN-C and individual TNfn domains 
(B) and incubated overnight at 4ºC.  Wells were blocked in 5% skimmed milk before incubating with increasing 
concentrations of human plasma FN for 1 h at 37ºC.   Binding was detected with an anti-FN antibody (F3648) and 
secondary HRP-conjugated antibody (NA9340) applied at 1:4000 dilution and colour developed with TMB substrate.  
Results are shown as an average from triplicate repeats +/- SEM and are representative of 2 independent 
experiments. 
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4.2.2.2    Soluble TN-C and TN-C domains bind to immobilised FN 
To confirm the interaction of TN-C or specific TN-C domains with FN, the converse solid phase 
binding assay was set-up.  Coating of FN at 25 μg/ml (0.1 μM) to a 96 well ELISA plate was 
carried out as described in (Chung et al., 1995).  FN was confirmed to be efficiently adsorbed to the 
ELISA plates (Appendix figure A4).   Four antibodies were used individually to detect binding of 
each TN-C protein to immobilized FN.  The ability of all the antibodies to specifically detect TN-C 
and TN-C domains was first assessed by coating TNC and TN-C domains directly onto ELISA 
plates and by Western blotting (Appendix figure A5 and A6).    
 
4.2.22.i   The anti-TNfn1-3 antibody (MAB1911) should detect all TNfn domains containing the 
TNfn1-3 epitope and specifically detected TN-C, TNfn3-5 and TNfn1-5 by solid phase ELISA 
(Appendix figure A5) and by Western blotting (Appendix figure A6).  However, it did not detect 
TNfn1-3 itself, but it did recognize TNfn5-7 (Appendix figure A5 and A6), which suggests its 
epitope may not actually be within the TNfn1-3 region as claimed by the manufacturer, but closer to 
the TNfn5 domain.    
 
Specific and saturable binding of full length TN-C, TNfn1-8, TNfn1-5 and TNfn3-5 to immobilized 
FN was detected using the anti-TNfn1-3 antibody (MAB1911).  TNfn6-8 was included as a 
negative control (Figure 4.3 A).   
 
4.2.2.2.ii  The anti-TNfn6-7 antibody (MAB1918) specifically detected full-length TN-C and all 
domains containing the TNfn6-7 epitope: TN-C, TNfn1-8, TNfn5-7 and TNfn6-8 by solid phase 
ELISA and Western blotting (Appendix figure A5 and A6).  
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Figure 4.3   Solid phase binding assays to determine the binding of TN-C and TN-C domains to 
immobilized FN 
ELISA plates were coated with 25 μg/ml human plasma FN overnight at 4ºC and blocked in 5% skimmed milk, 
before incubating with increasing concentrations of TN-C or TN-C domains for 1 h at 37ºC.   Binding was 
detected with a 1:200 dilution of: (A) anti-TN1-3 antibody (MAB1911), (B) anti-TNfn6-7 antibody (MAB1918) or 
(C) anti-tetra His antibody (34670) or (D) an anti-FLAG antibody (F3165).  Secondary HRP-conjugated antibody 
(NA9310) was applied at 1:4000 dilution and colour developed by addition of TMB colorimetric substrate.  
Representative results are shown as an average from triplicate repeats +/- SEM from two independent 
experiments.  
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Specific and saturable binding of full-length TN-C and TNfn1-8, but not TNfn5-7 or TNfn6-8 to 
immobilized FN was detected using the Anti-TN6-7 antibody.  This antibody did not recognize 
TNfn3-5 which was included as a negative control (Figure 4.3 B).   
 
4.2.2.2.iii   The anti-tetra His antibody recognised all recombinant proteins expressing a His tag by 
Western blotting (Figure 3.2).  By solid phase ELISA, the anti-His antibody detected TN-C and all 
TN-C domains except FBG (Appendix figure A5).  This suggests that the FBG His-tag becomes 
buried upon adsorption to the ELISA dish.    
 
Only binding of full length TN-C to immobilized FN was detected using the anti-His antibody.  No 
binding of any of the TN-C domains was detected (Figure 4.3 C).  This suggests that the His-tag 
epitope on the TNfn domains may become buried and inaccessible to this antibody upon 
interactions with the immobilized FN, because binding can be detected using alternative antibodies 
as described above (Figure 4.3 A and B).   
 
4.2.2.2.iv  The anti-FBG antibody (MAB19101) FBG domain could not detect the FBG domain by 
either Western blotting or ELISA (Appendix figure A7), and the anti-His antibody could not detect 
FBG upon adsorption to the ELISA plate.  So FLAG-tagged FBG was expressed in HEK 293 cells 
and used in these solid phase binding experiments.  No binding of FBG to immobilized FN was 
detected using the anti-FLAG antibody (Figure 4.3 D).    
 
The affinities of the monoclonal antibodies to the different domains are variable (as observed in 
appendix figure A5) so it is not possible to make any conclusions about affinity in these assays.  
This difference may be due to the accessibility of the antibody to its specific epitope upon 
adsorption.  FN was not detected by any of the anti-TN-C antibodies used either by ELISA or by 
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Western blotting (Examples with antibodies MAB1908 and MAB1918 shown; appendix figure A5) 
showing the anti-TNfn1-3 and TNfn6-7 antibodies are specific for the FNIII domains in TN-C. 
 
4.2.2.3   Summary:  All protein domains containing the TNfn3 module can interact with FN in 
solid phase binding assays 
Soluble FN could interact with immobilized TNfn1-8, TNfn1-5, TNfn1-3 and TNfn3-5 and 
conversely, TNfn1-8, TNfn1-5 and TNfn3-5 can also interact with immobilized FN.  I was unable 
to assess TNfn1-3 binding to immobilized FN due to the inability of the TNfn1-3 antibody to detect 
TNfn1-3.   Full-length TN-C bound to immobilized FN but not vice-versa.  FN did not bind to TA, 
EGFL, TNfn5-7, TNfn6-8 or FBG.   
 
4.2.3   Mapping the TN-C and TN-C domain binding sites on FN 
To determine where TN-C domains bind to within the FN molecule, I examined the binding of 
smaller FN fragments: 70-kDa, 120-kDa central binding domain (CBD) and the 40-kDa Hep II 
domain to immobilised TN-C or TN-C domains.  Binding of FN fragments was detected with a 
polyclonal anti-FN antibody (F3648).  This antibody specifically recognises each FN domain by 
Western blot (Figure 4.1 C).  The dilution of the anti-FN antibody (1:200) was again in excess for 
70-kDa, CBD and 40kDa detection, so any saturable binding observed is not due to a limitation in 
the concentration of antibody used (Appendix figure A3).  
 
4.2.3.1   The 70-kDa and CBD domains bound specifically to TNfn3 containing domains 
 70-kDa interacted with immobilised TNfn1-3, TNfn3-5, TNfn1-5 and TNfn1-8 in a specific and 
saturable manner.  Each TNfn3 containing domain, excluding TN-C, had a similar affinity for 70-
kDa (Figure 4.4 A).  The CBD also interacted with immobilised TNfn1-3, TNfn3-5 and TNfn1-5 
(Figure 4.4 B) specifically and saturably, but showed lower affinity binding to TNfn1-8 and TNfn5-
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7.  Full-length TN-C, TNfn6-8 or FBG, which did not bind to immobilized full-length FN were 
included as negative controls.  These domains did not bind to 70-kDa or CBD. 
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Figure 4.4   Solid phase binding assays and competition solid phase binding assays  
(A and B)  ELISA plates were coated with 78 nM TN-C or individual TN-C domains overnight at 4ºC and blocked 
in 5% skimmed milk before incubating with increasing concentrations of 70-kDa (A) and CBD (B) for 1 h at 37ºC.  
(C and D)  ELISA plates were coated with 25 μg/ml FN overnight at 4ºC and blocked in skimmed milk before 
incubating with 0.1 μM TN-C, TNfn3-5, TNfn1-5 and TNfn1-8, which had been pre-incubated for 1 h at 37 ºC with 
increasing concentrations of 70-kDa (C) or CBD (D).  ELISA plates were incubated for 1 h at 37ºC.  Binding 
experiments were detected with a 1:200 dilution of (A and B) anti-FN antibody or (C and D) anti-TNfn1-3 antibody 
(MAB1911) and secondary HRP-conjugated antibody applied at 1:4000 dilution and colour developed with TMB 
substrate.  Representative results are shown as an average from triplicate repeats +/- SEM. 
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4.2.3.2   The 40-kDa HepII domain showed high background binding  
40-kDa bound to 5% skimmed milk blocked ELISA wells even in the absence of TN-C domain 
immobilisation resulting in high background absorbance values.  Due to the high background, 
results would not have been reliable as any saturable binding detected could also be partially 
attributed to 40-kDa binding to blocked ELISA plates independently of the presence of TN-C or 
TN-C domains.  
 
4.2.3.3   Competition binding assays  
To map where TN-C or TN-C domains bind on FN, competition binding experiments were carried 
out.  In these experiments, 0.1μM TN-C, TNfn3-5, TNfn1-5 and TNfn1-8, were pre-incubated with 
increasing concentrations of 70-kDa or CBD for 1 h at 37ºC before adding to FN coated ELISA 
plates and binding was detected with the anti-TNfn1-3 antibody.  Unfortunately, because TNfn1-3 
cannot be detected by any of the antibodies available it had to be excluded from these competition 
assays.  
 
70-kDa completely inhibited full length TN-C binding to FN, suggesting that TN-C binds to 70-kDa 
within FN (Figure 4.4 C).  In contrast, 70-kDa partially inhibited TNfn1-8 (by 40%) and TNfn1-5 
and TNfn3-5 (by 70%) binding to FN (Figure 4.4 C) suggesting that whilst these domains can bind 
to 70-kDa, they can also bind to another site within FN.   
   
The CBD did not inhibit TN-C binding to full-length FN, even at concentrations in 10 times excess 
(Figure 4.4 D), confirming that TN-C binds only to 70-kDa in FN.  CBD partially inhibited binding 
to TNfn3-5 (by 70%), to TNfn1-8 (by 40%) and to TNfn1-5 (by 50%) (Figure 4.4 D).  Both 70-kDa 
and CBD more strongly inhibited TNfn3-5, followed by TNfn1-5 and only very weakly inhibited 
TNfn1-8.  The weak inhibition of TNfn1-8 and TN-C by CBD confirmed the weaker affinity of 
these two proteins to CBD observed in figure 4.4 B.  
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4.2.3.4   Summary: TN-C domains contain multiple binding sites for FN that can interact with 
both the 70-kDa and CBD domains  
Full-length TN-C can bind to only the 70-kDa domain in FN however additional binding sites for 
CBD exist in the smaller domains TNfn3-5, TNfn1-5 and TNfn1-8.  TNfn3-5, TNfn1-5 and TNfn1-
8 bound to 70-kDa with similar affinity.  In contrast, whilst TNfn3-5 and TNfn1-5 bound to CBD 
with similar affinity, TNfn1-8 binding to CBD was weaker.  40-kDa binding could not be 
determined as the background absorbance of 40-kDa was too high.  These data are summarised in 
Table 4.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Binding to Immob FN
% inhibition 
Sol 
FN
Sol 
70-
kDa
Sol 
CBD
Immob
FN
70-kDa CBD
TN-C + - - +++ 100 0
TNfn1-8 ++ +++ + ++ 40 40
TNfn1-5 +++  +++ +++ + 70 50
TNfn1-3 +++ +++ +++ nd nd nd
TNfn3-5 ++ +++ +++ + 70 70
TNfn5-7 - - + nd nd nd
TNfn6-8 - - - nd nd nd
FBG - - - nd nd nd
Table 4.1   Summary of solid phase binding studies
Soluble human plasma FN (Sol FN), FN domains 70-kDa (Sol 70-kDa) and CBD (Sol CBD) interactions with 
immobilized TN-C and TN-C domains is rated: +++; high affinity, ++ moderate affinity; +; weak affinity or  -; no 
detectable binding.  
 
Soluble TN-C and TN-C domain interactions with immobilized (Immob FN) human plasma FN detected with 
anti-TNfn1-3 is rated: +++; high affinity, ++ moderate affinity; +; weak affinity or  -; no detectable binding.  
Percentage reduction (% inhibition) of soluble TN-C and TN-C domain interactions with immobilized FN after 
pre-incubation with increasing concentrations of 70-kDa or CBD was compared to total binding of TN-C and 
TN-C domain in the absence of 70-kDa or CBD (100%).   Binding was detected with the anti-TNfn1-3 antibody 
(MAB1911). Due to the inability of the anti-TNfn1-3 to detect TNfn1-3, competition binding could not be 
determined (nd).  TNfn5-7, TNfn6-8 and FBG did not show any interaction with immobilized FN so competition 
binding was also not determined (nd). 
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However, the ability to detect protein-protein interactions via these solid phase binding assays is 
affected by epitope availability, protein presentation upon immobilization on plastic and protein 
presentation in its soluble form.   
 
In vivo, FN is unlikely to be presented as a soluble molecule immobilised onto two-dimensional 
planar surfaces as presented in solid phase binding assays.  Also solid phase binding experiments 
used plasma FN as the binding partner, rather than cellular FN which is synthesised and assembled 
locally on the cell surface.  Important structural differences exist between these two isoforms of FN: 
plasma FN possesses only one FN subunit that contains a IIICS (V) domain and no EDA or EDB 
alternatively spliced domains; cellular FN subunits all contain some portion of the  IIICS (V) 
domain and under certain conditions the EDA and EDB domains (ffrench-Constant, 1995) (Wilson 
and Schwarzbauer, 1992).  These differences in FN structure also reflects differences in FN matrix 
assembly (Abe et al., 2005) (Guan et al., 1990) (Sechler et al., 1996), interactions with other ECM 
components (Wilson and Schwarzbauer, 1992) and exposure of functional sites (Chen and Culp, 
1996).  Cellular FN is secreted locally by cells in a soluble form that is assembled into a complex 
three dimensional fibrillar matrix on the cell surface (Mao and Schwarzbauer, 2005a) (Wierzbicka-
Patynowski and Schwarzbauer, 2003).  Therefore, my next aim was to determine whether TN-C and 
TN-C domains can bind to fibrillar, cell-assembled FN.   
 
4.2.4   TN-C and TN-C domain binding to fibrillar FN 
To determine binding to fibrillar cellular FN, TN-C and TN-C domains were fluorescently labelled 
and monitored by immunofluorescence for co-localization with FN fibrils.  This method avoids 
issues that may be a problem using indirect immunofluorescence due to the possibility that antibody 
epitopes may be masked upon TN-C and TN-C domain interactions with the FN matrix.  This 
labelling method will also reveal how the TN-C domains interact with the matrix architecture (i.e. 
does it form aggregates at fibril branches or decorate the fibril length) and the cell surface (i.e. does 
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it isolate to discrete patches on the cell surface suggesting interactions with specific cell surface 
receptors), giving some insight into the possible mechanism(s) involved.  
 
4.2.4.1   Fluorescent labelling of TNfn domains  
TN-C domains were directly labelled with an Alexa Fluor-488 fluorescent dye (absorbance at 495 
nm; emission at 519 nm), which labels primary amines on the surface of proteins.  To confirm 
successful labelling, unlabelled and labelled proteins were resolved by SDS-PAGE and 
fluorescence detected by phosphor-imaging (Appendix A8 A).  The same gels were also silver 
stained (Appendix A8 B) and additional gels Western blotted and analysed with specific antibodies 
(Appendix A8 C) to confirm the presence and identity of each protein.  The dye and protein 
concentrations were calculated from absorbance values at 280 nm (to determine protein 
concentration) and 495 nm (to determine the dye concentration from the dye absorbance maximum) 
as detailed in materials and methods.  The labelling efficiency was calculated as the number of dye 
molecules per protein molecule and expressed as [Dye] : [Protein] ratio (Appendix Table A1).  
None of the proteins were heavily labelled, which could alter the protein structure and accessibility 
of binding sites on the protein (Gajraj and Ofoli, 2000). 
 
4.2.4.2   Binding of TN-C domains to fibrillar FN matrix  
To determine whether TN-C or the TN-C domains could bind to fibrillar FN, NIH 3T3 fibroblasts 
were cultured for 24 h to permit the assembly of a fibrillar matrix on their cell surface.  By 24 h, FN 
has assembled into a complex, three-dimensional matrix as described before (Schwarzbauer and 
Sechler, 1999) (Sechler et al., 1996) (Sechler et al., 2001) (Takahashi et al., 2007) (Tomasini-
Johansson et al., 2006).  FN fibrils and the matrix architecture can be clearly defined at x100 
magnification (Figure 3.14).  Fluorescently labelled TN-C domains were then added directly into 
the medium and incubated for a further 1, 4 or 8 h at 37ºC at which time cells were fixed and 
stained with an anti-FN antibody (F3648) and Alexa Fluor-568 (absorbance at 578 nm; emission at 
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603 nm) conjugated secondary antibody.  No fluorescence at 488 nm was seen in the absence of 
labelled TN-C or TN-C domains and the fibrillar FN matrix is maintained after a further 1, 4 and 8 
h culture (-; Figure 4.5).   
 
TNfn1-8 co-localized with FN fibrils as early as 1 h after addition to the conditioned medium.  At 1 
h, binding was observed along the length of fibrils with some fibrils showing a continuous staining 
pattern and other fibrils showing a discontinuous staining pattern (Figure 4.5).   This staining was 
not ubiquitous: TNfn1-8 did not co-localize to all FN fibrils and showed varying staining intensity; 
some TNfn1-8 also showed punctate staining independent of FN fibrils.  TNfn1-8 co-localization to 
the FN fibrils increased over time, but TNfn1-8 maintained an irregular punctate fibrillar staining 
pattern and a FN-independent punctate staining even after 8 h culture.  TNfn1-8 also caused a slight 
reduction in the FN matrix density after 1 h incubation (Figure 4.5). 
 
TNfn1-5 also showed clear co-localization with FN fibrils in the matrix as early as 1 h after 
addition, which increased over time, but unlike TNfn1-8, this staining extended along the FN fibrils 
continuously and unlike TNfn1-8, very few FN fibrils did not have TNfn1-5 associated (Figure 4.5).  
Some of the TNfn1-5 staining was also independent of the FN matrix scaffold, but unlike TNfn1-8, 
this staining highlighted fibrillar structures, suggesting TNfn1-5 either forms fibrillar structures 
itself, or that TNfn1-5 co-localizes with other fibrillar ECM components.  TNfn1-5 binding 
increased over time as the FN matrix density increased and after 8 h TNfn1-5 was prominently 
associated with the FN fibrillar matrix and fewer FN independent fibrillar structures could be 
observed (Figure 4.5).   
 
Conversely, despite detectable binding interactions with soluble FN by solid phase binding, TNfn1-
3 showed only weak and sparse patches of staining after 1 h culture, with only a few sparse patches  
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co-localizing with the FN fibrillar matrix, which did not increase over time (Figure 4.5).  In 
contrast, TNfn3-5 did not bind at all to fibrillar FN (Figure 4.5). 
 
The other domains of TN-C, TNfn5-7, TNfn6-8 and FBG, which did not show binding to soluble 
FN, also did not bind to fibrillar FN.  However, whilst TNfn6-8 showed no staining at all even after 
8 h in culture, TNfn5-7 localised to the cell layer after 4 h (Figure 4.6).  FBG also localized to the 
cell layer as early as 1 h after culture and this localization increased over time and was more 
prominent than that observed for TNfn5-7 (Figure 4.6).  TNfn5-7 and FBG showed discrete, 
globular or vesicular staining, which was particularly obvious for FBG.  FBG, like TNfn1-8, also 
reduced the FN matrix density after just 1 h culture with the mature FN matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6   Immunofluorescent staining of FN with Alexa Fluor-488 labelled TNfn5-7, TNfn6-8 and FBG.  
NIH 3T3 fibroblasts were plated in serum-free medium for 24 h at 37ºC before being further cultured with (-) 
buffer alone in the absence of recombinant protein or in the presence of 0.1 μM Alexa Fluor-488 fluorescently 
labelled TNfn5-7, TNfn6-8 and FBG.  Cells were incubated for a further 1, 4 or 8 h at 37ºC, then fixed in 3.8% 
(w/v) paraformaldehyde and stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated 
antibody. Representative images from 3 random fields of view and 2 independent experiments are shown.  
Images were taken by confocal microscopy at x100 magnification, scale bar = 25 μm.   
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4.2.4.3   A FN matrix is not required for FBG or TNfn5-7 localization to the cell layer 
To determine if a FN matrix is required for (a) the localisation of TNfn1-5 or TNfn1-8 to fibrillar 
structures and (b) localization of FBG and TNfn5-7 to the cell layer fluorescently labelled TN-C 
domains were incubated with CHO cells.  CHO cells express very low levels of endogenous FN.  In 
the absence of exogenous FN, CHO cells still attach to plastic substrates and spread but lack a FN 
matrix.  These cells can assemble exogenously added FN into a fibrillar matrix on their cell surface 
(Wu et al., 1993).   
 
CHO cells cultured for 24 h in 10% FBS supplemented medium assembled exogenous FN present 
in the serum into a sparse matrix (Figure 4.7; +).  In CHO cells cultured in medium containing FN-
depleted serum, only a few scattered cell-surface fibrils were assembled (Figure 4.7; -).   
Fluorescently labelled TN-C domains were added directly into the FN-depleted conditioned 
medium and cells cultured for a further 4 h. 
 
No TNfn1-5 staining was observed, which suggests TNfn1-5 may require the presence of a more 
extensive FN matrix to support binding (Figure 4.7).  Some TNfn1-8 did co-localize to the minimal 
FN fibrils assembled on the cell surface (Figure 4.7).  Neither domains formed fibrillar structures 
independent of FN, although this does not exclude the possibility that TNfn1-5 and TNfn1-8 can 
associate with other fibrillar ECM components not expressed or not assembled by CHO cells or 
other cell surface receptors not expressed by CHO cells.  However, the presence of a FN matrix was 
not required for TNfn5-7 or FBG cellular localization, as both domains associated with CHO cells 
(Figure 4.7).  The strong, vesicular staining pattern, particularly for FBG suggests that these TN-C 
domains are possibly internalized into discrete vesicular structures or binding to specific clusters of 
cell surface receptors.   TNfn1-3, TNfn3-5 and TNfn6-8 did not show any localization either to the 
sparse FN fibrils present or to the cell surface (Figure 4.7). 
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4.2.4.4   Summary: TNfn3 is required, but not sufficient, for binding to mature fibrillar FN 
TNfn1-5 and TNfn1-8 bound to FN fibrils with distinctive patterns of localization: TNfn1-5 closely 
and continuously co-localized with FN fibrils, whereas TNfn1-8 showed more discontinuous, 
punctate co-localization along each fibril.  This co-localization required FN assembly as neither 
TNfn1-5 nor TNfn1-8 bound to fibrillar structures in the absence of FN.   In contrast, FBG and 
TNfn5-7 localized to discrete vesicular regions in the cell layer, in a FN-independent manner.  
TNfn5-7 however, showed less prominent staining compared to FBG.  TNfn1-3, TNfn3-5 and 
Figure 4.7   Immunofluorescent staining of FN with Alexa Fluor-488 labelled TN-C domains 
in the absence of an extensive FN matrix. 
CHO cells were plated for 24 h in medium containing serum (+) or in medium containing FN-
depleted serum (- and all TN-C domains) before incubation with buffer alone in the absence of 
recombinant protein (-) or in the presence of 0.1 μM Alexa Fluor-488 fluorescently labelled TNfn1-
3, TNfn3-5, TNfn1-5, TNfn5-7, TNfn6-8, TNfn1-8 and FBG.  Cells were incubated for a further 4 h 
at 37ºC, then fixed in 3.8% (w/v) paraformaldehyde and stained with an anti-FN antibody (F3648) 
and secondary Alexa Fluor-568 conjugated antibody.  Representative images from 3 random 
fields of view are shown.  Images were taken by confocal microscopy at x100 magnification, scale 
bar = 25 μm.   
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TNfn6-8 did not bind either to fibrillar FN matrix or localize to the cell layer.  This demonstrates 
that the TNfn3 domain, required for interactions with soluble or immobilised FN by solid phase 
binding does not necessarily confer the ability of TN-C domains to interact with fibrillar FN.  
Furthermore, TNfn1-8 and FBG reduced FN matrix density suggesting these TN-C domains may 
also cause the disassembly of a mature FN matrix or inhibit continuous FN polymerization on the 
cell surface.   
 
4.2.4.5   Mapping the TNfn binding sites on fibrillar FN 
To determine which FN domains are important for TN-C domain interaction with fibrillar FN, a 
competition experiment was used.  Increasing concentrations of soluble 70-kDa, CBD and 40-kDa 
were pre-incubated with 100 nM of each Alexa Fluor-488 labelled TN-C domain for 1 h at 37ºC 
before adding to fibroblasts that had been cultured for 24 h to assemble a fibrillar matrix.  Cells 
were incubated for a further 1 h at 37ºC before fixing and staining for FN with an anti-FN antibody 
(F3648) and an Alexa Fluor-568 conjugated antibody as described in materials and methods.  250 
nM 70-kDa, CBD or 40-kDa alone were included as negative controls to show that incubation of 
the mature FN matrix with these proteins had no effect on FN matrix architecture during the time 
period of the experiment.   
 
4.2.4.5.1   Pre-incubation with 70-kDa  
Low concentrations of 70-kDa reduced TNfn1-5 binding to FN fibrils and TNfn1-5 fibrillar 
structures independent of the FN matrix scaffold (Figure 4.8 E) but inhibition was incomplete:  
TNfn1-5 co-localization with FN fibrils could still be observed even when TNfn1-5 was pre-
incubated with 20 times excess 70-kDa (Figure 4.8 G and I).   
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Low concentrations of 70-kDa had no effect on TNfn1-8 binding to the FN matrix (Figure 4.8 F) 
but binding to FN fibrils and the TNfn1-8 binding independent of FN was almost completely 
abolished by excess concentrations of 70-kDa (Figure 4.8 H and J).    
 
TNfn1-3, TNfn3-5 and TNfn6-8 did not co-localize to FN fibrils in the absence of 70-kDa (Figure 
4.9 C, D, E respectively) but upon pre-incubation with excess 70-kDa, TNfn1-3 and TNfn3-5 were 
induced to bind to the fibrillar matrix (Figure 4.9 I and J respectively).  These data suggest that the 
absence of detectable TNfn1-3 and TNfn3-5 binding to fibrillar FN was not due to insufficient 
labelling of these proteins, and that these domains can be recruited to FN fibrils by 70-kDa.  
Increasing concentrations of 70-kDa with TNfn6-8 in comparison had no effect (Figure 4.9 H, K) 
confirming that enhanced binding in the presence of 70-kDa was specific to TNfn1-3 and TNfn3-5.   
 
4.2.4.5.2   Pre-incubation with CBD  
Pre-incubation of TNfn1-8 and increasing concentrations of CBD dose dependently inhibited 
TNfn1-8 binding to fibrillar FN and reduced TNfn1-8 staining of FN independent structures and the 
cell surface (Figure 4.10 F, H), and pre-incubation with 2000 nM of CBD binding completely 
inhibited TNfn1-8 binding to fibrillar FN (Figure 4.10 J).    
 
The binding of TNfn1-5 to fibrillar FN was also reduced with increasing concentrations of CBD 
(Figure 4.10 E and G) but complete inhibition was not observed even in the presence of 20 times 
excess CBD (Figure 4.10 I).  2000 nM CBD also seemed to induce an increase of TNfn1-5 binding 
to FN independent fibrillar structures (Figure 4.10 I).   
 
Pre-incubation of TNfn1-3, TNfn3-5 or TNfn6-8 with increasing concentrations of CBD did not 
promote binding to fibrillar FN (Appendix figure A9).   
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4.2.4.5.3   Pre-incubation with 40-kDa  
40-kDa had no effect on TNfn1-8 co-localization to FN and FN independent, punctate structures 
even at ten times excess concentration (Figure 4.11 F, H).   The fibrillar co-localization of TNfn1-5 
(Figure 4.11 C) was reduced dose dependently by excess 40-kDa and almost complete inhibition of 
the fibrillar co-localization can be observed at the highest concentration of competitor (Figure 4.11 
G), but some punctate and globular association with the fibrillar FN can be observed (Figure 4.11 E, 
G).  This staining contrasts the strong continuous staining observed for TNfn1-5 in the absence of 
40-kDa (Figure 4.11 C).   
 
Low concentrations of 40-kDa had no effect on TNfn1-3, TNfn3-5 or TNfn6-8 interactions with 
fibrillar FN.  Increasing concentrations of 40-kDa pre-incubated with TNfn1-3 induced very sparse 
and punctate TNfn1-3 localization independent of the FN matrix, suggesting it may be  interacting 
with specific clusters of receptors on the cell surface (Appendix figure A10 L).  Surprisingly 40-
kDa also induced very weak, sparse and punctate TNfn6-8 localization to the cell layer and matrix 
(Appendix figure A10 N), but this staining is much weaker than that for TNfn1-3.  In contrast, 40-
kDa had no effect on TNfn3-5 (Appendix figure A10), which suggests the effect is specific to these 
domains and not just a general effect of the 40-kDa FN domain.   
 
4.2.4.6   Summary: Multiple TNfn binding sites exist on fibrillar FN 
TNfn1-8 binding to fibrillar FN was completely inhibited by 70-kDa and by the CBD but was 
unaffected by 40-kDa, indicating that TNfn1-8 can bind to either 70-kDa or CBD but not 40-kDa 
and that it cannot bind to 70-kDa and CBD both at once.  TNfn1-5 co-localization with fibrillar FN 
was reduced by 70-kDa, CBD and 40-kDa, but never completely, suggesting that TNfn1-5 can 
interact with multiple sites on fibrillar FN at the same time.   
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Figure 4.8   Mapping the FN domains involved in TNfn1-5 and TNfn1-8 interactions with 
pre-assembled FN matrix by immunofluorescent staining in the presence of increasing 
concentrations of unlabelled 70-kDa. 
NIH 3T3 fibroblasts were plated in serum-free medium for 24 h before being further cultured 
with: buffer alone in the absence of recombinant protein (A), 250 nM 70-kDa (B) or 100 nM 
fluorescently labelled TNfn1-5 (C, E, G, I) or TNfn1-8 (D, F, H, J).  TNfn1-5 and TNfn1-8 were 
pre-incubated for 1 h at 37ºC with either buffer in the absence of 70-kDa (C, D), 100 nM 70-kDa 
(E, F), 1000 nM 70-kDa (G, H) or 2000 nM 70-kDa (I, J).  Cells were incubated for a further 1 h 
at 37ºC then fixed in 3.8% (w/v) paraformaldehyde and stained with an anti-FN antibody 
(F3648) and secondary Alexa Fluor-568 conjugated antibody.  Representative images from 3 
random fields of view are shown.  Images were taken by confocal microscopy at x100 
magnification, scale bar = 25 μm.   
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Figure 4.9   Mapping the FN domains involved in TNfn1-3, TNfn3-5 and TNfn6-8 interactions with 
pre-assembled FN matrix by immunofluorescent staining in the presence of increasing 
concentrations of unlabelled 70-kDa. 
NIH 3T3 fibroblasts were plated for 24 h before incubation being further cultured with: buffer alone in 
the absence of recombinant protein (A), 250 nM 70-kDa (B) or 100 nM fluorescently labelled TNfn1-3 
(C, F, I), TNfn3-5 (D, G, J) or TNfn6-8 (E, H, K).  TNfn1-3, TNfn3-5 and TNfn6-8 were pre-incubated for 
1 h at 37ºC with buffer in the absence of 70-kDa (C, D, E), 100 nM 70-kDa (F, H), 500 nM 70-kDa (G), 
1500 nM 70-kDa (I) and 1000 nM 70-kDa (J, K). Cells were incubated for a further 1 h at 37ºC then 
fixed in 3.8% (w/v) paraformaldehyde and stained with an anti-FN antibody (F3648) and secondary 
Alexa Fluor-568 conjugated antibody.  Representative images from 3 random fields of view are shown.  
Images were taken by confocal microscopy, scale bar = 25 μm. 
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Figure 4.10   Mapping the FN domains involved in TNfn1-5 and TNfn1-8 interactions with pre-
assembled FN matrix by immunofluorescent staining in the presence of increasing concentrations of 
unlabelled CBD. 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium before being further cultured with: buffer 
alone in the absence of recombinant protein (A), 250 nM CBD (B) or 100 nM fluorescently labelled TNfn1-5 
(E, G, I) or TNfn1-8 (F, H, J).  TNfn1-5 and TNfn1-8 were pre-incubated for 1 h at 37ºC with either buffer in 
the absence of CBD (C and D), 100 nM CBD (E, F), 250 nM CBD (G), 500 nM CBD (H) or 1000 nM CBD (I, 
J).  Cells were incubated for a further 1 h at 37ºC then fixed in 3.8% (w/v) paraformaldehyde and stained 
with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody.  Representative 
images from 3 random fields of view are shown.  Images were taken by confocal microscopy at x100 
magnification, scale bar = 25 μm.   
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Figure 4.11   Mapping the FN domains involved in TNfn1-5 and TNfn1-8 interactions with pre-
assembled FN matrix by immunofluorescent staining in the presence of increasing concentrations 
of unlabelled 40-kDa. 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium before being further cultured with:  buffer 
alone in the absence of recombinant protein (A), 250 nM 40-kDa alone (B) or 100 nM fluorescently labelled 
TNfn1-5 (C, E, G) or TNfn1-8 (D, F, H).  TNfn1-5 and TNfn1-8 were pre-incubated for 1 h at 37ºC with 
either buffer alone (C, D), 100 nM 40-kDa (E, F), or 1000 nM 40-kDa (G, H).  Cells were incubated for a 
further 1 h at 37ºC then fixed in 3.8% paraformaldehyde and stained with an anti-FN antibody (F3648) and 
secondary Alexa Fluor-568 conjugated antibody.  Representative images from 3 random fields of view are 
shown.  Images were taken by confocal microscopy at x100 magnification, scale bar = 25 μm.   
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Pre-incubation of 70-kDa with TNfn1-3 and TNfn3-5 specifically induced their binding to fibrillar 
FN, in a similar pattern to TNfn1-8.  In contrast, the CBD had no effect on TNfn1-3, TNfn3-5 and 
TNfn6-8.  However, excess 40-kDa induced some weak and sparse localization of TNfn1-3 and 
TNfn6-8 to fibrillar FN and cell layer although this co-localization of TNfn1-3 and TNfn6-8 is very 
weak compared to the co-localization induced by 70-kDa on TNfn1-3 and TNfn3-5.  These results 
are highlighted in table 4.2.   
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.5   No combinatorial synergistic binding effects can be observed with the TNfn domains 
Combinations of smaller TNfn domains were incubated together to ascertain whether these domains 
can synergistically reproduce binding patterns observed by larger TNfn domains.   
 
Binding to mature fibrillar FN
No addition 70-kDa CBD 40-kDa Cell 
association
TNfn1-8 +++ - - +++ -
TNfn1-5 +++  + + + -
TNfn1-3 - ++ - + -
TNfn3-5 - ++ - - -
TNfn5-7 - nd nd nd +
TNfn6-8 - - - + -
FBG - nd nd nd +++
Table 4.2   Summary of immunofluorescence binding studies to mature cellular FN 
TN-C domain interactions with mature fibrillar FN  matrix in the absence (no addition) or in 
the presence of competing soluble FN domains: 70-kDa, CBD or 40-kDa. For comparison, 
binding to the cell layer is also summarized (cell association).  Binding of TN-C domains to 
a fibrillar FN matrix or association with the cell layer is rated: +++, strong co-localization; ++, 
moderate co-localization; +, weak co-localization; -, no localization.  TNfn5-7 and FBG 
competition assays with FN domains were not determined (nd). 
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Equimolar concentrations of fluorescently labelled TNfn1-3 and TNfn3-5 pre-incubated together for 
1 h, did not induce binding to the FN fibrillar matrix (Figure 4.12 A).  This suggests that pre-
incubation of both these TNfn domains did not result in binding similar to TNfn1-5.   
 
Similarly, when equimolar concentrations of fluorescently labelled TNfn1-5 and TNfn6-8 (Figure 
4.12 B) were pre-incubated, no differences in TNfn1-5 co-localization could be observed compared 
to TNfn1-5 alone.  The discontinuous FN fibril co-localization observed with TNfn1-8 was not 
replicated by combining these individual domains.   
 
This demonstrates that the overall structure of TNfn1-5 and TNfn1-8 are required for the 
characteristic co-localisations to the FN fibrillar matrix. 
 
4.2.6   TNfn domain interaction with the FN matrix during fibrillogenesis 
TNfn1-8, TNfn1-3, TNfn6-8 and FBG inhibited newly synthesized and secreted FN from 
assembling into a 3D matrix on the cell surface (See Chapter 3).  It is likely that the FN presented 
during the initial events of matrix assembly will not have the same structure or conformation as FN 
in a mature pre-assembled matrix.  For this reason I examined the localization of TNfn domains on 
FN fibrils as they developed over time.  FN matrix assembly was monitored by 
immunofluorescence as in chapter 3: fibroblasts were initially plated at a high cell density 
(2x105/well) for 2 h before addition of TN-C and TN-C domains to the conditioned medium and 
culturing for the required time period.   However in this case, fluorescently labelled TN-C proteins 
were included in the culture medium.  Full-length TN-C, TNfn3-5, TNfn1-5 and TNfn5-7 were 
included as controls; none of these domains inhibit FN matrix assembly.  Cells were then fixed and 
FN matrix visualized by indirect immunofluorescence using an anti-FN antibody and secondary 
Alexa Fluor-568 conjugated antibody.   
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Figure 4.12   Immunofluorescent staining of combinations of Alexa Fluor-488 labeled and 
unlabeled domains to determine synergistic interactions for binding to a pre-assembled FN 
matrix. 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium.  Combinations of fluorescently labeled 
proteins were pre-incubated for 1 h at 37ºC: buffer alone in the absence of recombinant protein (-); (A) 
buffer containing 100 nM fluorescently labeled TNfn1-3, TNfn3-5, TNfn1-3 and TNfn3-5 or TNfn1-5; (B) 
buffer containing 100 nM fluorescently labeled TNfn1-5, TNfn6-8, TNfn1-5 and TNfn6-8 or TNfn1-8. 
After pre-incubation, these were added directly to the conditioned medium of NIH 3T3 fibroblasts with a 
pre-assembled FN matrix. Cells were incubated for a further 1 h at 37ºC then fixed in 3.8% (w/v) 
paraformaldehyde and stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 
conjugated antibody. Representative images from 3 random fields of view are shown.  Images were 
taken by confocal microscopy at x100 magnification, scale bar = 25 μm. 
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4.2.6.i   Full-length TN-C showed weak staining of the cell layer, which increased over time 
(Figure 4.13).  However, this is likely to be non-specific, because TN-C also showed strong non-
specific coating to exposed regions of the cover slip (Figure 4.14 B and C) even in the presence of 
cells (*; Figure 4.14 D) suggesting it may be non-specifically coating the cell layer.  TN-C also had 
no effect on matrix assembly (Figure 4.13). 
 
4.2.6.ii   TNfn3-5 exhibited no detectable binding at any time point (Figure 4.13) suggesting that 
this domain does not bind to FN, even during early fibrillogenesis.  This domain also had no effect 
on matrix assembly (Figure 4.13). 
 
4.2.6.iii   TNfn1-8 showed punctate co-localisation to the initial short FN fibrils that had assembled 
after 4 h total culture; only 2 h after addition of TNfn1-8.  Increased co-localization to the 
developing FN fibrils occurred over time (Figure 4.13) and by 24 h, discontinuous co-localisation to 
the FN fibrils could be seen (Figure 4.13) with a similar staining pattern observed with mature pre-
assembled FN (Figure 4.5).  2 h after addition of TNfn1-8 (4 h total culture time), lots of punctate 
staining could be observed which is independent of the short FN fibrils assembled on the cell 
surface.  This staining occurred throughout the time course suggesting that TNfn1-8 may be 
continuously interacting with either exposed cell surface receptors or other ECM components that 
are also being assembled simultaneously (Figure 4.13).  From 4 h (total culture time) onwards FN 
deposition was reduced and by 10 h (total culture time), the FN fibrils were obviously thinner as 
described in the previous chapter (Figure 3.16) confirming FN matrix assembly is inhibited by 
fluorescently labelled TN1-8 (Figure 4.13).  TNfn1-8 non-specifically coated glass coverslips 
(Figure 4.14 F and G), but not when in the presence of cells, even on exposed areas of the coverslip 
(*, Figure 4.14 H) showing this staining is specific for the FN fibrils.   
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4.2.6.iv  TNfn1-3 showed increased punctate staining over time, with some localization to FN 
fibrils but most of the punctate staining occurring independent of the FN matrix (Figure 4.15).  
TNfn1-3 staining peaked 4-8 h after addition to the conditioned medium (6-10 h total culture time).  
However, after 10 h culture (total culture time) and as the FN fibrils developed further, this 
localization was reduced suggesting that TNfn3 binds to a domain of FN that is only exposed during 
fibrillar development, but masked within the mature FN fibril, causing a loss of staining over time, 
or to a cell surface receptor that is highly expressed during fibrillar development.  This loss of 
TNfn1-3 localization after 10 h culture also correlates with the time point at which TNfn1-3 acts to 
inhibit FN fibrillogenesis (as described in chapter 3), so after 24 h, even though there are only very 
low levels of TNfn1-3 localized to FN fibrils, the FN density is obviously reduced (Figure 4.15).   
 
4.2.6.v    TNfn6-8 exhibited no detectable binding to either the cell surface or the FN fibrils at any 
time point but reduced the FN matrix density by 24 h culture (Figure 4.15).  In the previous chapter, 
inhibition of FN matrix assembly was obvious after 6-8 h (total culture time) (Figure 3.16), but 
inclusion of fluorescently labelled TNfn6-8 did not show such an obvious effect until 10 h (total 
culture time), suggesting that fluorescently labelled TNfn6-8 may have differential effects on FN 
matrix assembly. 
 
4.2.6.vi   TNfn1-5 was observed as discrete punctate staining on the cell layer and co-localized to 
short, cell-surface associated FN fibrils only 2 h after addition to the medium (4 h total culture time) 
(Figure 4.15).  Increased co-localization to the FN fibrils occurred over time as the FN fibrils 
developed, so by 24 h, strong, intense staining of the fibrils was obvious.  Increased localization of 
TNfn1-5 to FN independent structures could also be observed over time, and these became defined, 
thin fibrillar structures after 10 h culture as highlighted by TNfn1-5 staining, suggesting these 
TNfn1-5 fibrillar structures developed at a later stage than FN fibril maturation (Figure 4.15).   
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Figure 4.14   Immunofluorescent staining to determine background coverslip coating of  
Alexa Fluor-488 labelled TN-C, TNfnTNfn1-8 and TNfn3-5 in the absence and presence of 
cells   
Glass coverslips incubated in the absence of fibroblasts (A-C; E-G; I-K) or in the presence of 
fibroblasts (D, H, L) in serum-free medium supplemented with buffer in the absence of 
recombinant protein (A, E, I) or 0.1 μM fluorescent TN-C (B-D), TNfn1-8 (F-H) or TNfn3-5 (J-L).  
Coverslips and cells were incubated for a further 22 h then fixed in 3.8% (w/v) paraformaldehyde 
and stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated 
antibody.  Representative images from 3 random fields of view are shown. (A, B, E, F, I, J) 
Images were taken by fluorescence microscopy at x20 magnification, scale bar = 100 μm.  (C, D, 
G, H, K, L) Images were taken by confocal microscopy at x100 magnification, scale bar = 25 μm.  
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TNfn1-5 had no effect on FN matrix assembly as demonstrated previously in chapter 3 (Figure 
3.15). 
 
4.2.6.1   Summary: TNfn1-3 binds specifically to immature FN fibrils  
The major difference from binding studies with mature and immature FN matrices is the ability of 
TNfn1-3 to co-localize with FN early during FN matrix assembly, and that this co-localization is 
lost as FN matrix assembly progresses.  Overall, after 24 h culture, fluorescent TN-C and TN-C 
domains localized to the developing FN matrix or cell layer in an identical manner as observed with 
a mature FN matrix.  TNfn1-8 and TNfn1-5 still showed distinctive FN dependent and independent 
fibrillar staining patterns, TNfn1-3 showed little staining with the assembled FN matrix, TNfn3-5 
and TNfn6-8 showed no detectable staining whereas FBG, TNfn5-7 and TN-C showed localization 
with the cell surface.  These results are summarised in the table 4.3.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immature 
fibrillar FN Cell layer
Time course
of binding 
Time point of 
inhibition
TN-C - + - -
TN1-8 +++ - 4h  onwards 6h
TN1-5 +++ - 4h onwards -
TN1-3 ++ -
4h onwards 
peak at 12 h,  
decreased by 
24 h
10h
TN3-5 - - - -
TN5-7 - + 4h onwards -
TN6-8 - - - 8-10h
FBG - +++ 4h onwards 12h
Table 4.3   Summary of immunofluorescence binding studies to immature developing FN  
TN-C and TN-C domain localization to developing fibrillar FN (immature fibrillar FN) or cell layer were semi-
quantified from the immunofluorescence images.  Fibrillar and cell layer localization after 22 h culture is 
rated:  +++, strong co-localization; ++, moderate co-localization; +, weak co-localization; -, no fibrillar 
localization. The time point at which this localization is observed with cells developing an immature FN 
matrix (time course of binding) and comparison with the time point at which FN fibrillogenesis inhibition is 
observed (time point of inhibition) are shown as the total time of incubation i.e. 6 h = cells plated for 2 h 
before addition of Alexa Fluor-488 labeled protein domains and culturing for a further 4 h before fixing and 
imaging. 
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4.3   Discussion 
In chapter 3, I demonstrated that the TNfn1-8, TNfn1-3, TNfn6-8 and FBG domains of TN-C, but 
not full-length TN-C, inhibited FN matrix assembly.  In this chapter, I set out to determine how 
these domains may be inhibiting matrix assembly by examining the interaction of FN with TN-C 
and TN-C domains.  My data indicated that different TN-C domains exhibit distinct mechanisms of 
inhibition of FN assembly that are both dependent on and independent of direct interactions with 
FN.   
 
4.3.1   Is TNfn3 a major FN binding site in TN-C? 
Many papers report the interaction of purified TN-C with purified plasma FN in vitro (Chiquet-
Ehrismann et al., 1988) (Chiquet-Ehrismann et al., 1991) (Chung et al., 1995) (Hoffman and 
Edelman, 1987).   Here I confirmed that full-length TN-C was able to bind to immobilized plasma 
FN in solid phase binding assays.  I also systematically analyzed binding of each domain within 
TN-C to plasma FN.  I demonstrated that TNfn1-8, TNfn1-5, TNfn1-3 and TNfn3-5 interact with 
FN, but TA, EGF-L, TNfn5-7, TNfn6-8 and FBG do not.  The presence of the TNfn3 domain is the 
consensus module present in all FN binding domains and this is consistent with data published by 
other groups that imply that TNfn3 is important for interactions with FN:  TNfn1-5 interacted with 
FN by solid phase binding (Hauzenberger et al., 1999); TNfn1-8, TNfn1-5 and TNfn3-5 could 
compete with TN-C for binding to FN by competition solid phase binding assays, but TNfn6-8 and 
FBG had no effect (Chung et al., 1995); TNfn3 and TNfn3-5, but not TNfn6-8 or TNfnAD could 
displace TN-C:FN complexes by glycerol gradient sedimentation (Chung et al., 1995); surface 
plasmon resonance demonstrated that TNfn3-5, TNfn1-5 and TNfn1-8 were able to bind strongly to 
the 70-kDa and 29-kDa fragments of FN whereas TNfn6-8 did not bind (Ingham et al., 2004).   
 
It has been proposed that TNfn3 is the major binding site in TN-C for FN and TNfn3-5 is the key 
minimal unit required for optimal binding to FN: TNfn3 was a weaker competitor than TNfn3-5 or 
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TNfn1-5 for TN-C:FN interactions by solid phase binding (Chung et al., 1995) and TNfn3 did not 
bind to 70-kDa or 29-kDa by surface plasmon resonance whereas TNfn3-5 and TNfn1-5 did 
(Ingham et al., 2004).  These studies suggest that TNfn3 alone was not maximally effective for 
interactions with FN and the presence of TNfn4-5 domains is required for optimal FN binding.    
Furthermore, the presence of domains TNfn4-5 was sufficient for maximal binding to FN domains 
as additional domains in TN1-5 and TN1-8 conferred no enhancement of binding or displacement 
or competition over TNfn3-5.  However, the reported dissociation constants (KD) for TNfn3:FN 
interactions (1 μM) (Chung et al., 1995), TNfn1-5:29-kDa FN domain (0.9 μM) and TNfn1-8:29-
kDa FN domain (1.1 μM) (Ingham et al., 2004) are in a similar range, although this may be more 
reflective of the different methods used to measure affinities.    
 
Although TNfn3-5 was reported to be the optimal structure for binding to FN, binding of TNfn1-3 
was not examined in any of these studies.  I showed that TNfn1-3 was also able to bind to FN, as 
well as TNfn1-5 and with a higher affinity than TNfn3-5 and TNfn1-8.  These data indicate that, if 
TNfn3 is the major FN binding site in TN-C, TNfn1-2, as well as TNfn4-5, are sufficient to 
facilitate maximal binding to soluble FN.   However, it is not known if TNfn1, TNfn2, TNfn4 or 
TNfn5 can bind to FN.  If so these domains may enhance the affinity of their neighboring TNfn3 
domain for FN by possessing additional FN binding sites. Alternatively they may act independently 
of direct FN binding in a structural manner by maintaining the FNIII fold of TNfn3 for maximal 
exposure of the FN binding site or exposing or creating multiple FN binding sites present within 
TNfn3.  To definitively determine how TN-C binds to soluble FN requires a systematic analysis of 
the binding of individual TNfn domains (TNfn1, TNfn2, TNfn3, TNfn4 and TNfn5) and paired 
domains (TNfn1-2, TNfn2-3, TNfn3-4, and TNfn4-5), as well as mutagenesis studies of potential 
key residues in TNfn1-3, TNfn3-5 and TNfn1-5.    
 
4.3.2   Full-length TN-C contains cryptic FN binding sites 
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I also mapped where TN-C and TN-C domains bind to within the FN molecule.   Using competition 
assays I demonstrated that TN-C interacted with the 70-kDa domain but not the CBD.  In contrast 
the smaller domains of TN-C that interacted with FN in solid phase binding assays (TNfn1-8, 
TNfn1-5, TNfn1-3 and TNfn3-5) were able to bind to both 70-kDa and CBD when these FN 
domains were presented as isolated fragments or within the FN molecule.  Competition assays 
showed that the smaller TN-C domains contained multiple binding sites that could interact with 
both 70-kDa and CBD.  These data suggest that full length TN-C adopts a conformation where the 
70-kDa binding site(s) is freely available but the CBD binding site(s) is obscured.  Smaller domains 
however exist in a conformation where both binding sites are available.  These data also suggest 
that removal of increasing numbers of additional TN-C domains increasingly reveals the CBD site 
buried within the full-length TN-C; TN-C cannot bind CBD at all, TNfn1-8 exhibits weak binding 
and TNfn1-5, TNfn1-3 and TNfn3-5 bind strongly to CBD.  
 
4.3.3   Immobilization confers unnatural conformations on ECM proteins 
My data confirm studies that have shown that TN-C binds immobilized FN but not vice versa 
(Chiquet-Ehrismann et al., 1991).  These data indicate that the artificial immobilization of FN to 
plastic reveals cryptic domains that allow soluble TN-C binding and/or that the immobilization of 
TN-C to plastic conceals binding sites for soluble FN.  The problem with masking epitopes and 
alterations on protein conformation by adsorption of protein domains to different substrates has 
been previously demonstrated.  Several studies show changes in FN conformation when adsorbed to 
plastic (Narasimhan and Lai, 1989) (Ugarova et al., 1995) and endothelial cell adhesion to FBG was 
abolished if FBG was coated to nitrocellulose rather than to plastic (Joshi et al., 1993).  
Furthermore, surface plasmon resonance experiments were unable to demonstrate an interaction 
between covalently coupled TNfn1-8 or TNfn1-5 with soluble full-length FN or vice versa (Ingham 
et al., 2004); the large size of dimeric FN may not be able to access TNfn domains bound to the 
three-dimensional surface of the carboxymethylated dextran (CMD) sensor chips or conversely 
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covalent coupling of full-length FN to the sensor chip may cause it to adopt a conformation in 
which TNfn binding sites are unavailable or altered by the binding procedure.  Solvent composition 
may also affect protein interactions: glycerol gradient binding experiments showed (large and small 
splice) TN:FN interactions (Chung et al., 1995) and this may be because glycerol favors the 
extended conformation of FN allowing exposure of TN-C binding sites on FN (Rocco et al., 1983).    
 
Similarly, surface plasmon resonance studies did show strong binding of TNfn3-5, TNfn1-8 and 
TNfn1-5 to immobilized 70-kDa (FNI1-9, FNII1-2) and 29-kDa (FNI1-5) (Ingham et al., 2004). These 
results support my own observations that 70-kDa can interact with TNfn3-containing domains.  
Binding of immobilized TNfn1-5 and TNfn1-8 however, showed no binding to the 42-kDa HepII 
domain, the 110-kDa CBD, the N-terminal 42-kDa (FNI6-9+FNII1-2) or 20-kDa (FNI10-12) domains 
of FN (Ingham et al., 2004).  This contrasts with my own studies, where the CBD did show specific 
and saturable interactions with TNfn1-3, TNfn3-5 and TNfn1-5 and weaker interactions with 
TNfn1-8.  Huang et al., (Huang et al., 2001) also showed full length TN-C could interact with the 
42-kDa HepII domain by solid phase binding.   
   
These data are summarized in table 4.4 and reflect the complexity in interpretation of TN-C:FN 
interactions from different in vitro methods.  The results from this study have also been inserted in 
italics for comparison.  The differences in results obtained by these different methods reflect the 
need for careful interpretation of such binding data, which is subjective to the assay set-up and 
method of protein presentation. 
 
Such binding assays are ideal for determining purified FN:TN-C and TN-C domain interactions and 
allow for quantification of these interactions e.g. by surface Plasmon resonance or by 125[I] labeling 
proteins and determining the bound versus unbound ratio.  This is also a homogenous system as it 
determines binding of a set concentration of ligand to a set concentration of binding partner.  
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However, proteins do not exist in isolation in vivo and these assays may be assessing a phenomenon 
that does not reflect physiological situations.  For these reasons I focused on examining TN-C 
domain interactions with fibrillar FN and I did not investigate TN-C domain interactions with 
soluble FN any further via these methods (i.e. quantifying TN-C domain interactions with FN or 
mapping of individual TNfn1-5 modules for binding to FN).   
 
4.3.4   Interactions with FN in the solid phase do not correlate with interactions to fibrillar FN 
or FN matrix assembly inhibition 
In vivo, soluble FN is not likely to be presented in an immobile and planar manner as when 
adsorbed onto an ELISA dish.  Cultured cells assemble FN into a complex, 3D fibrillar matrix on 
the cell surface.   Here I demonstrate TN-C domains interact in a distinct manner with 3D, fibrillar 
cellular FN matrices compared to soluble plasma FN and that the ability of TN-C domains to bind 
either presentation of FN does not necessarily correlate with its ability to inhibit FN matrix 
assembly.  This is summarized in table 4.5.  Both TNfn1-8 and TNfn1-5 bound to newly 
synthesized FN fibrils in addition to a mature FN matrix, whereas TNfn1-3 bound specifically to the 
developing FN matrix and to distinct regions on the cell layer during initial assembly events.   
However, TNfn1-5 does not inhibit FN matrix assembly.  Full-length TN-C and TNfn3-5 did not 
bind to fibrillar FN although they did bind to plasma FN.  TNfn5-7, TNfn6-8 or FBG, also did not 
bind to fibrillar FN or plasma FN, but both TNfn6-8 and FBG showed inhibition of FN matrix 
assembly.   
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4.3.4.1   TNfn1-8 and TNfn1-5 
TNfn1-8 and TNfn1-5 both showed striking co-localization with FN fibrils in mature and immature 
FN.  However each domain exhibited a distinct pattern of binding: TNfn1-5 showed continuous 
staining along the length of fibrils, whereas TNfn1-8 showed a more discontinuous co-localization.   
 
Binding to 
soluble FN
(SPBA)
Binding to 
mature fibrillar 
FN
(IF)
Binding to 
immature 
fibrillar FN
(IF)
Cell 
layer
(IF)
Inhibition of FN 
matrix 
assembly
TN-C + - - - -
TN1-8 ++ +++ +++ - +
TN1-5 +++  +++ +++ - -
TN1-3 +++ - ++ - +
TN3-5 ++ - - - -
TN5-7 - - - + -
TN6-8 - - - - +
FBG -
-
- +++ +
Table 4.5   Comparison of TN-C domain interactions with different FN conformations 
and the cell layer and their effects on FN matrix assembly 
Summary of direct solid phase binding assays (SPBA) demonstrating binding of soluble 
plasma FN to immobilized TN-C and TN-C domains: +++, strong binding; ++, moderate 
binding; +, weak binding; -, no binding. Summary of immunofluorescent (IF) co-localization of: 
Alexa Fluor-488 fluorescently labeled TN-C or TN-C domains to a 3D mature  fibrillar cellular 
FN matrix after 22 h culture; Alexa Fluor-488 fluorescently labeled TN-C or TN-C domains to 
the immature developing FN matrix; Alexa Fluor-488 fluorescently labeled TN-C or TN-C 
domains localization to the cell layer. These interactions are rated  : +++, strong co-
localization; ++, moderate co-localization; +, weak co-localization; -, no fibrillar localization.   
The ability of TN-C and TN-C domains to inhibit FN matrix assembly are summarised: +, 
inhibited assembly; -, no effect. 
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TNfn1-5 binding to mature fibrils was reduced by pre-incubation with all three FN domains (70-
kDa, HepII and CBD), suggesting that TNfn1-5 can bind to each of these domains in fibrillar FN 
(Figure 4.16 A).  However, inhibition was incomplete, indicating that TNfn1-5 contains multiple 
FN binding sites that allow interaction with other FN domains even when interaction with one 
domain is prevented.  This may explain the high levels of TNfn1-5 observed along the entire length 
of FN fibrils.   
 
Conversely, TNfn1-8 binding to fibrillar FN was completely inhibited by pre-incubation with 70-
kDa or CBD alone but was unaffected by 40-kDa.  These data suggest that TNfn1-8 contains one or 
more binding sites that can interact with either 70-kDa or CBD within fibrils but not 40-kDa (Figure 
4.17 A).   My results suggest that 40-kDa binding sites that exist in TNfn1-5 are unavailable in 
TNfn1-8.  These binding sites may be obscured by the presence of the TNfn6-8 modules.  This may 
explain the discontinuous pattern of co-localization of TNfn1-8 compared to TNfn1-5.   
 
TNfn1-8 binding to FN fibrils was detected 2 h after addition.  This domain inhibited early FN 
matrix assembly (4 h after addition).  70-kDa and CBD within FN are required for early FN-FN and 
FN-integrin receptor interactions that mediate FN unfolding during fibrillogenesis (Mao and 
Schwarzbauer, 2005a) (Wierzbicka-Patynowski and Schwarzbauer, 2003).  This suggests TNfn1-8 
is interacting directly with FN, during initiation of FN matrix assembly to block key FN-cell 
receptor interactions and intermolecular FN-FN interactions involved in fibrillogenesis (Figure 4.17 
B).   
 
Conversely, TNfn1-5 bound well to the fibrillar FN but did not inhibit FN matrix assembly.  The 
presence of multiple binding sites for TNfn1-5 in FN may mean that TNfn1-5 can interact with 
different domains of FN in neighboring fibrils to cross-link the matrix and facilitate or increase 
fibrillogenesis (Figure 4.16 B) – this was sometimes seen by immunofluorescence where increased  
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Figure 4.16   TNfn1-5 co-localizes with FN fibrils but does not inhibit FN matrix assembly 
(A)  TNfn1-5 binds to mature fibrillar FN via its 70-kDa, CBD and 40-kDa domains.  (B)  TNfn1-5 also shows 
co-localization to developing FN fibrils.  Its ability to bind to different domains within FN simultaneously 
suggest s that it may act to link multiple FN molecules without affecting FN matrix assembly.   
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Figure 4.17   Mechanisms by which TNfn1-8 may inhibit FN matrix assembly 
(A)  TNfn1-8 binds to mature fibrillar FN at its CBD or 70-kDa FN domains.  (B)  TNfn1-8 also shows co-
localization to developing FN fibrils.  It contains fewer FN fibril binding sites than Tnfn1-5 suggesting that the 
presence of the TNfn6-8 domains may result in interference of Tnfn1-5-FN interactions.  Since Tnfn1-8 cannot 
act to link multiple FN molecules, but instead occupies key domains required for FN-FN intermolecular 
interactions and FN-intergin interactions, FN matrix assembly is blocked. 
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FN matrix fibrillogenesis was observed (although this was not significant upon quantification).  
TNfn1-5 interactions with FN may also affect the structure of FN and expose cryptic binding sites 
to aid fibrillogenesis.  In contrast the inability of TNfn1-8 to bind to several FN domains at once 
would mean that no further cross-linking interactions could occur resulting in inhibition of FN 
matrix assembly (Figure 4.17). 
 
4.3.4.2   TNfn1-3 and TNfn3-5 
In contrast to the solid phase binding data, TNfn1-3 and TNfn3-5 were not able to bind to mature 
fibrillar FN.  These results imply that these domains interact with epitopes that are buried within the 
mature matrix structure and/or that additional TN-C domains are required to bind mature fibrils.  
Only TNfn1-3 showed co-localization with immature, developing fibrils and showed high punctate 
staining with FN independent structures early in fibrillogenesis.  The punctate staining of TNfn1-3 
occurred after 4 h of culture (total culture time i.e. 2 h after addition), and peaked at 6 h (total 
culture time), but decreased after 10 h (total culture time).  This correlates with the time point (10 h 
of total culture time) at which TNfn1-3 inhibited FN matrix assembly (Chapter 3, Figure 3.16).  The 
delay between detectable binding to the developing matrix (4-8 h) and the inhibitory effect on FN 
matrix assembly suggests that either a threshold level of TNfn1-3 binding to FN and/or the cell 
surface is required, or that it interferes with a particular step required for the progression from early 
fibrillogenesis events to late fibrillogenesis events e.g. FN-FN inter-fibrillar interactions (Figure 
4.18 B).  These results also indicate that TNfn1-2 may contain essential FN fibril binding sites or 
that it is vital for affecting the conformation or exposure of TNfn3, since TNfn3-5 cannot bind to 
FN of the cell surface at any time point.  Lack of binding to fibrillar FN by TNfn3-5 would explain 
why this domain did not inhibit FN matrix assembly, despite being able to bind to plasma FN.   
 
The TNfn3 domain of FN also contains an RGD sequence presented on a loop structure that extends 
outside the fold of the domain, which is not as exposed or flexible as the RGD sequence found in 
Results: FN and TN-C interactions 
 
 159
FN (Altroff et al., 2004) (Akke et al., 1998) (Carr et al., 1997), but has been shown to bind to 
specific integrins including αvβ3 (Carr et al., 1997) (Joshi et al., 1993)  (Sriramarao et al., 1993) 
(Yokosaki et al., 1996), which is a cell surface receptor expressed on fibroblasts and involved in FN 
matrix assembly (Mao and Schwarzbauer, 2005b) (Takahashi et al., 2007) (Wennerberg et al., 
1996).  At early initial stages of FN matrix assembly, TNfn1-3 especially, but also TNfn1-5 and 
TNfn1-8 show punctate associations (dotted staining pattern), which do not co-localize with FN 
staining, suggesting these domains could be interacting with the cell surface.  This presents an 
alternative mechanism by which TNfn1-3, TNfn1-5 and TNfn1-8 may be actively incorporated into 
the FN matrix by interacting with cell surface receptors.  However, this mechanism may be unlikely 
for TNfn1-8 and TNfn1-5 because the binding of TNfn1-5 and TNFn1-8 occurs rapidly (within 1 h 
culture) to a mature FN matrix with an identical pattern of binding as observed after 24 h culture 
with a developing, immature FN matrix suggestive of a direct binding mechanism rather than cell-
surface receptor mediated.  In addition TNfn1-8 and TNfn1-3 had no effect on FN levels in DOC 
soluble, surface bound material suggesting they do not affect FN interactions with matrix assembly 
receptors.  TNfn1-8 binding is also completely inhibited by pre-incubation with FN domains 70-
kDa and CBD.  To determine whether cell surface integrins are involved in incorporation of these 
domains into the FN matrix, TNfn domains could be tested for interactions with a cell-free FN 
matrix (Mao and Schwarzbauer, 2005b).   
 
Surprisingly, incubation of TNfn1-3 and TNfn3-5 with excess 70-kDa, but not CBD or 40-kDa, 
resulted in these domains co-localizing to the mature fibrillar matrix in a similar pattern as TNfn1-8.  
We know that TNfn1-3 and TNfn3-5 can bind to 70-kDa and that 70-kDa (but not CBD and HepII) 
can be incorporated into the FN matrix (Aguirre et al., 1994) (Limper et al., 1991) (Schwarzbauer, 
1991) (Sottile and Mosher, 1997) (Zhang and Mosher, 1996).  Thus TNfn1-3 or TNfn3-5 may bind 
to isolated 70-kDa and this 70-kDa:TNfn complex may bind to FN, mediated by 70-kDa:FN 
binding interactions (Figure 4.18 A).  Alternatively binding of these TNfn domains with 70-kDa in  
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Figure 4.18   Mechanisms by which TNfn1-3 and TNfn6-8 may inhibit FN matrix assembly 
(A)  Neither TNfn1-3 or TNfn6-8 bind to mature fibrillar FN matrix alone.  TNfn1-3 can only interact with 
fibrillar FN in the presence of excess 70-kDa.  Both Tnfn1-3 and 6-8 show weak cell layer binding in 
the presence of excess 40-kDa.   (B)  TNfn1-3 exhibits early co-localization to developing FN fibrils 
possibly via unexposed FN binding sites in the 70-kDa (or 40-kDa domains).  Its occupation of these 
sites may inhibit FN-FN interactions.  Tnfn1-3 also shows intense punctate cell association, suggesting 
that it could also be binding to cell surface integrins to prevent FN-cell interactions.  It is unknown how 
TNfn6-8 is acting.  It could be binding to cell surface receptors to inhibit FN matrix assembly directly or 
indirectly.   
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the soluble phase may expose cryptic binding sites in TNfn1-3 and TNfn3-5 for FN and/or 70-kDa 
binding to FN may expose binding sites for these domains. 
 
There is a very weak and punctate staining of TNfn1-3 after pre-incubation with 40-kDa indicating 
there may be some weak interactions with 40-kDa and/or the cell layer (Figure 4.18 A).  However, 
this interaction is very weak and requires further repeats to confirm this is not an artifact.  
 
4.3.5   Inhibiting FN matrix assembly independently of FN binding 
4.3.5.1   TNfn5-7 and FBG 
These studies raised an interesting disparity: the ability to interact with fibrillar FN does not always 
correlate with the ability to inhibit FN matrix assembly.  Table 4.5 highlights this data and 
demonstrates that whilst TNfn1-8 and TNfn1-3 may be preventing FN-FN or FN-cell interactions 
during fibrillogenesis, it is not clear how TNfn6-8 and FBG inhibition of FN matrix assembly is 
mediated.    
 
Both TN5-7 and FBG do not associate with FN at all but specifically localize to the cell, however 
only FBG inhibits FN matrix assembly.  I continue to examine this further in the next chapter. 
 
4.3.5.2   TNfn6-8 
The most intriguing domain is TNfn6-8.  Unlabelled TNfn6-8 showed similar kinetics of FN matrix 
assembly inhibition as TNfn1-8: it showed attenuated FN fibrillogenesis after 4 h culture with 
fibroblasts (6h total culture) (Figure 3.16).  TNfn6-8 had no effect on DOC soluble FN although 
effects on FN levels in the conditioned medium were inconclusive.  This suggested it was 
responsible for the inhibitory effects of TNfn1-8.  However, TNfn6-8 does not possess the TNfn3 
FN-binding module and previous competition solid phase binding assays, ultracentrifugation 
sedimentation or surface plasmon resonance experiments did not show any binding of TNfn6-8 to 
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FN (Chung et al., 1995) (Ingham et al., 2004).  In the context of TNfn1-8, it would appear that the 
presence of this domain interferes with co-localization of the TNfn1-5 domains with fibrillar FN.  
However, fluorescently labeled TNfn6-8 did not localize to either the FN matrix or to the cell layer.  
TNfn6-8 also did not bind to soluble human plasma FN, supporting previous reports (competition 
solid phase binding assays and surface Plasmon resonance) that show TNfn6-8 interactions with FN 
could not be detected (Chung et al., 1995) (Ingham et al., 2004).  There was a suggestion that 
TNfn6-8 bound FN because the TNfnALL of TN-C (TNfn1-8 possessing the alternatively spliced 
domains) did not localize to the FN matrix whereas TNfn1-8 did (Chung et al., 1995), suggesting 
that in the context of TNfn1-8, it may possess weak FN binding activity.   
 
One possibility is that TNfn6-8 may be binding to cell surface receptors (Figure 4.18 B).  TNfn6-8 
domain of tenascin-R (TN-R), which has 38.49% identity (determined by CLUSTALW sequence 
comparison), has been shown to associate with [α5] β1 integrin subunits in rat brain lysates (Liao et 
al., 2008).  TNfn6-8 of TN-C has also has been reported to interact with α8β1 (Varnum-Finney et 
al., 1995) and promotes heparin dependent cell adhesion (Seiffert et al., 1998) suggesting this 
domain does possess integrin and HSPG binding activities.  This suggested TNfn6-8 could be 
interacting with cell surface receptors to inhibit FN matrix assembly either directly by competition 
for HSPG binding, or indirectly by inducing cell signalling, which then affects the activation status 
or expression of FN assembly receptors.  However, although labeled TNfn6-8 still actively inhibited 
FN matrix assembly no TNfn6-8 staining could be observed to the cell layer.  The only staining that 
could be observed was in the presence of excess 40-kDa, which induced very punctate staining co-
localizing with the mature FN matrix or its associated cell layer of cells (Figure 4.18 A).  The non-
specific binding of 40-kDa by solid phase binding casts a little doubt as to the reliability of this 
interaction, although excess 40-kDa had no effect on TNfn3-5 staining suggesting its effects are 
specific to this domain.  This would suggest TNfn6-8 can poorly interact with the cell layer and/or 
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FN matrix upon exposure to the 40-kDa domain.  However, further repeats of this experiment will 
need to be done to confirm this observation is not an artefact. 
 
Another possibility is that TNfn6-8 could be sequestering soluble FN in the conditioned medium.  
Attempts to pull-out TNfn6-8:FN complexes from the medium using gelatin sepharose were 
unsuccessful as the gelatin beads were also found to non-specifically bind to the purified TNfn6-8 
as well.  Instead, pull-down studies with the anti-TNfn6-7 antibody (MAB1918) could be used to 
determine more specifically whether FN is complexed with TNfn6-8.   
 
Iodinated TNfn6-8 could also be used to monitor the location of TNfn6-8 after addition to the cell 
culture in case the fluorescent tag is affecting TNfn6-8 interactions.  This may be a possibility as 
fluorescent TNfn6-8 did not show an obvious effect on FN matrix assembly until after 8 h 
incubation (10 h total culture) contrasting with observations from the previous chapter where FN 
matrix assembly appeared reduced after 4-6 h incubation (6-8 h total culture) (Chapter 3, figure 
3.16).  Further work will need to be done to determine whether TNfn6-8 is correctly folded after 
labeling and whether the fluorescent tag is stably attached to this domain.  The mechanism by 
which this domain is acting requires further investigation.   
 
4.3.6   Neighboring domains influence TNfn function within full-length TN-C 
Despite being able to bind to soluble FN, I showed that full-length TN-C was unable to bind to 
cellular, fibrillar FN.  This lack of TN-C binding to FN fibrils may explain the inability of TN-C to 
inhibit FN matrix assembly.  In this study, the large TN-C isoform was used.  Previous in vitro 
studies by Chiquet-Ehrismann et al., (Chiquet-Ehrismann et al., 1991) and later, Chung et al., 
(Chung et al., 1995) have shown that the large isoform of TN-C has a much lower affinity for 
soluble FN compared to the smaller isoform where no alternatively spliced domains are present.  
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Furthermore, by immunofluorescence, the small TN-C isoform showed prominent fibrillar FN 
staining but the large isoform of TN-C did not (Chung et al., 1995).   
 
The presence of TNfn alternatively spliced domains may obscure the fibrillar FN binding sites in 
TN-C.  This may occur by their conformationally affecting the exposure of the CBD binding site, or  
by allowing the formation of looping structures that allows other TNfn domains to interact with the 
CBD binding site or sterically interfere the CBD binding site to inhibit interactions with FN.  As 
such removal of alternatively spliced domains in the small splice variants may allow exposure of 
the CBD binding site in TNfn1-8.  The ability of alternatively spliced TNfn domains to mask 
binding sites has been previously reported where TNfnA1-A4 domains have been shown to bury the 
pro-adhesive effects of the TNfnA2 module (Saito et al., 2007).   
   
 The presence of other TN-C domains was also shown to alter the pro-adhesive abilities of the EGF-
L and FBG domain (Fischer et al., 1997).   Hexameric TN-C mutants lacking either the EGF-L and 
TNfn domains (TA/FBG) or TNfn and FBG domains (TA/EGF-L) could promote chick embryo 
fibroblast adhesion and spreading; TN-C mutants lacking only the EGF-L domain (TA/TNfn/FBG) 
or the FBG domain (TA/EGF-L/TNfn) showed reduced adhesion and cell rounding (Fischer et al., 
1997).  This shows how important the structure of the different modular TN-C domains can affect 
the exposure or masking of cryptic binding sites.   
 
Mapping which domains within TNfn1-8 were required to inhibit FN matrix assembly proved to be 
a complex issue.  Both TNfn1-3 and TNfn6-8 were inhibitory but they did not behave like TNfn1-8.  
The differential binding activities of TN-C, TNfn1-3, TNfn1-5, TNfn3-5, TNfn6-8 and TNfn1-8 to 
fibrillar FN and their effects on FN matrix assembly demonstrate how the presence or absence of 
neighbouring TNfn domains is key to influencing domain function.  Furthermore, the requirement 
for an intact domain structure to confer co-localisation with FN fibrils is reflected in the fact that 
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smaller domains in combination do not mimic the overall effect by the full-length molecule: TNfn1-
3 and TNfn3-5 do not synergise to cause co-localization similar to TNfn1-5 and the binding of 
TNfn1-5 is not affected by the presence of independent TNfn6-8 domains.  
 
The modular composition and the subsequent tertiary structure is likely to play a major role in 
dictating the availability of binding sites within TNfn domains.  Each TNfn module may influence 
its neighbouring modules by restricting their torsional and rotational flexibilities (Altroff et al., 
2004) (Pickford and Campbell, 2004) (Vakonakis et al., 2007).  This may allow intermolecular 
interactions between non-contiguous domains to form globular structures, as observed with FNI6--
FNII2 from the collagen binding domain of FN (Pickford et al., 2001).   The ability of homologous 
FN type III repeats to self-associate has been clearly demonstrated in FN type III domains FNIII5.5-9 
and FNIII5.5-6 (Carnemolla et al., 1996).  The thermostability of different FNIII domains is 
dependent on the context by which they were presented, and it is thought that some long range 
stabilizing interactions may exist between FNIII3, 6, 7, 9, 10 (Litvinovich and Ingham, 1995).  FNIII 
domains from neural cell adhesion molecules (NCAM) have been shown to aggregate when 
attached to microsphere beads (Ranheim et al., 1996). The human TAX-1 neural adhesion 
molecule, which is involved in early axonogenesis has also been shown to associate via interactions 
between its FNIII domains in adjacent molecules (Tsiotra et al., 1996).  This homophilic interaction 
is also thought to occur in the TAX-1 avian/rat homologue axonin-1/TAG-1, allowing cell surface 
receptor clustering during cell-cell interactions (Kunz et al., 2002).  However, the mechanism and 
the sequence motifs involved by which FNIII domains interact has yet to be elucidated. It is also not 
known if isolated TNfn domains can interact with each other and how the domain structure 
influences this binding interaction.  It would be interesting to compare the 3D structures of TNfn1-
8, TNfn1-3 and TNfn6-8 with that of non-binding domains such as TNfn1-5 and TNfn3-5.  
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4.4     Summary 
In examining TN-C interactions with soluble plasma FN, I confirmed that the TNfn3 domain is 
required for FN binding.  I also found that domains TNfn1-2 are equally as effective in promoting 
optimal FN binding as the previously reported TNfn4-5 domains.  In mapping the binding sites for 
TN-C within plasma FN I demonstrated that full length TN-C can bind only to the 70-kDa domain 
of FN and that smaller TNfn domains contain additional cryptic binding sites for the CBD of FN.  
In comparison, TNfn3 was not sufficient for maximal binding to 3D fibrillar cellular FN.  TNfn3-5 
could not bind to fibrils at all and TNfn1-3 could bind only to an immature matrix.  These data 
suggest that TNfn1-2, but not TNfn4-5, play a role in interactions with the fibrillar matrix, and also 
that other domains are required.  Binding to fibrillar FN was optimal with TNfn1-5 which possessed 
several fibrillar FN binding sites, whereas the presence of TNfn6-8 in TNfn-8 reduced FN binding 
site availability.  
 
Previously, I identified four inhibitory domains within TN-C: TNfn1-8, TNfn1-3, TNfn6-8 and 
FBG.   Although these domains all inhibited FN matrix assembly and reduced FN incorporation into 
detergent insoluble material (assembly into highly cross-linked multimeric matrix), they showed 
differential effects on the kinetics of the assembly process and different effects on FN partitioning 
into, detergent soluble material (cell surface binding and intracellular FN) and conditioned medium.  
In this chapter, I show that inhibition of FN matrix assembly relied on both direct FN-binding 
dependent and FN independent mechanisms.   
 
My data indicates that TNfn1-8 inhibits FN matrix assembly by binding to FN fibrils to inhibit FN-
FN and FN-cell interactions.  TNfn1-3 may also mediate its inhibitor effects by directly binding to 
FN, or alternatively to cell surface receptors.  Conversely, TNfn6-8 and FBG appear to inhibit FN 
matrix assembly independent of FN binding; neither domain can interact with soluble or fibrillar 
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FN.  However, FBG was localized to the cell layer suggesting it may act by affecting cell 
phenotype.  This will be explored further in the next chapter.   
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CHAPTER 5 
Inhibiting FN matrix assembly independently 
of binding to FN 
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5.1   Introduction 
In chapter 3, I demonstrated that FBG inhibited FN matrix assembly and that it acted late during FN 
fibril development (after 10-12 h culture). These data suggest that initial matrix assembly proceeds 
unhindered in the presence of FBG but that FBG may prevent later events in matrix assembly such 
as lateral FN-FN fibril interactions.  Alternatively, FBG may interfere with the maintenance of a 
fully mature matrix at the cell surface by preventing continual FN unfolding and polymerization or 
fibril remodelling, or it may promote the disassembly of a mature matrix.  In chapter 4, I showed 
that FBG did not interact with plasma FN by solid phase binding and did not co-localize with FN 
fibrils in a 3D cell-assembled matrix.  Instead, it localized to discrete regions of the cell layer with a 
distinctive vesicular pattern, in a FN independent manner.  These data suggest that FBG mediates 
its effects by influencing fibroblast phenotype.  In this chapter, I further examined the mechanism 
by which FBG inhibits FN matrix assembly. 
 
5.2   Results 
 
5.2.1   FBG localizes to the cell layer in a specific and vesicular manner 
Previously, NIH 3T3 cells were cultured for 24 h to enable assembly of a mature fibrillar FN matrix 
before addition of Alexa Fluor-488 labelled FBG.  FBG localized to the cell layer in a vesicular 
manner after just 1 h incubation with cells possessing a mature matrix (Figure 4.6 and Figure 5.1 
A).   When FBG was incubated for increasing lengths of time (4 h and 8 h) with fibroblasts that had 
been cultured for 24 h, this localization increased over time up to 8 h by which time the majority of 
cells stained positively for FBG (Figure 4.6).  The FN matrix over these time points was also 
significantly reduced compared to the control (Figure 4.6).  These data suggest that FBG can 
promote disassembly of an already established, mature FN matrix. 
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FBG also localized to the cell layer during FN fibrillogenesis.  NIH 3T3 fibroblasts were plated for 
2 h before incubation with Alexa Fluor-488 labelled FBG over time up to a further 22 h (Figure 5.1 
B and 5.2).  FBG localization was minimal 4 h after incubation with fibroblasts (6 h total culture) 
with a prominent increase in staining at 10-12 h total culture time (Figure 5.2).  This correlated with 
the time point at which FN matrix density was becoming affected by FBG (Figure 3.17 and 5.2).  
By 24 h, more FBG was associated with the cell layer in a vesicular manner, by which time, the FN 
matrix density was much reduced compared to the control (Figure 5.1 B and 5.2). Furthermore, this 
decrease in FN was specifically associated with cells that stained positive for FBG; FN matrix was 
unaffected in cells that did not stain for FBG (Figure 5.1 and 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1   Immunofluorescent staining to determine localization of FBG in fibroblast cultures 
(A) NIH 3T3 fibroblasts were cultured for 24 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (-) or 0.1 µM Alexa Fluor-488 labelled FBG (FBG).  Cells were then 
further incubated for 1 h. (B) NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before 
addition of buffer in the absence of recombinant protein (-) or 0.1 µM FBG (FBG) to the conditioned 
medium and further incubated for 22 h at 37ºC.  (C-E) Glass coverslips were incubated in the absence of 
fibroblasts or (F) in the presence of fibroblasts in serum-free medium supplemented with (C) buffer in the 
absence of recombinant protein or (D-F) 0.1 μM fluorescent FBG.  Coverslips and cells were incubated 
for a further 22 h.   (A- F) Coverslips were then fixed in 3.8% (w/v) paraformaldehyde and stained with 
an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody.  (C, D) Images were 
taken by fluorescence microscopy at x20 magnification, scale bar = 100μm. (A, B, E, F) Images were 
taken by confocal microscopy at x100 magnification, scale bar = 25 μm.   
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FBG shows minimal background coating of the coverslip in the absence (Figure 5.1 D, E) or in the 
presence of fibroblasts (Figure 5.1 F) suggesting its localization to the cell layer is cell specific.  
These data also suggest that FBG can only associate with cells after they have been cultured for at 
least 10 h.   
Figure 5.2   Immunofluorescent staining to determine localization of FBG over time. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (-) or 0.1 µM Alexa Fluor-488 labelled FBG. Cells were further 
incubated for 4, 6, 8, 10 or 22 h at 37ºC.  Cells were then fixed in 3.8% (w/v) paraformaldehyde and 
stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody.  
Representative images from 3 random fields of view are shown.  Images were taken by confocal 
microscopy at x60 magnification, scale bar = 25 μm. 
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TNfn5-7 also exhibited cellular staining, although FN matrix structure was maintained in the 
presence of this TN-C domain (Figure 4.6 and 5.3).  In comparison to FBG, when TNfn5-7 was 
incubated with cells already possessing a mature matrix, localization to the cell layer was minimal 
after 1 h incubation but increased slightly over time (Figure 4.6).  When incubated with newly 
plated cells TNfn5-7 localization was observable after 4 h incubation (6 h total culture), and 
increased marginally over time.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.3   Immunofluorescent staining to determine localization of TNfn5-7 over time. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (-) or 0.1 µM Alexa Fluor-488 labelled TNfn5-7.  Cells were further 
incubated for 2, 4, 6, 8 or 22 h at 37ºC.  Cells were then fixed in 3.8% (w/v) paraformaldehyde and 
stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody.  
Representative images from 3 random fields of view are shown.  Images were taken by confocal 
microscopy at x100 magnification, scale bar = 25 μm. 
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However, TNfn5-7 (Figure 5.3) localized to fewer cells than FBG (Figure 5.1 B).  This suggests 
that TNfn5-7 only interacts weakly with cells at early time points after plating, in contrast to FBG, 
but this interaction reduces over time, and hence, has no effect on FN fibrillogenesis.    
 
5.2.2   FBG binds to the cell surface and can be internalized  
The results described above indicate that FBG does not bind to FN, but localizes to the cell layer.  
The vesicular pattern observed suggests that FBG may be internalized.  To confirm this, I next 
examined more closely the localization of FBG in cultures of fibroblasts.   
 
Cells were cultured for 2 h before incubation in the presence or absence of Alexa Fluor-488 labelled 
FBG for 22 h.  Cells were then fixed and stained with anti-FN antibodies as well as with phalloidin 
to delineate the actin cytoskeleton of the cell.  In the absence of FBG, cells were well spread and 
flattened, with actin organized into stress fibres throughout each cell (Figure 5.4, 647nm channel).  
The dense fibrillar FN matrix was intact (Figure 5.4, 568nm channel).   Upon addition of FBG, this 
TN-C domain was distributed in two different ways.  It was observed either at or near the plasma 
membrane (Figure 5.5 cell a) and in the cell cytoplasm (Figure 5.5 cell b).  In cells in which FBG 
was localized to the cytoplasm, striking alterations in cell shape were observed; these cells were 
very rounded.  At the cell membrane FBG did not completely co-localize with the actin 
cytoskeleton or FN.  However, using phalloidin, it is still quite difficult to distinguish where the cell 
membrane is located as the actin cytoskeleton is directly below the cell membrane.     
 
To distinguish the cell membrane more clearly, cells were not permeabilized and the cell surface 
was stained with Alexa Fluor-568 labelled concanavalin A, a lectin which binds to cell surface 
glycoproteins.  When cultured for 22 h in the absence of FBG, cells were well spread and from the 
XY and the XZ transections, cells could be seen to adopt a flattened morphology (Figure 5.6 A).  
When cells were cultured for 22 h with Alexa Fluor-488 FBG, I again observed two different 
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distributions of FBG.  It localized to the plasma membrane where it co-localized with the 
concanavalin A staining suggesting it is binding to the cell surface (Figure 5.6 B).  In these cells, 
morphology and spreading is similar to the control.   
 
I also observed cells that contained fluorescent FBG in the cytoplasm (Figure 5.7 A and B).  FBG 
exhibited a vesicular pattern and the cross section of the lower cell body clearly shows the 
fluorescence is within the confines of the plasma membrane (Figure 5.7; XZ and YZ side profiles).  
These cells are less flattened in shape compared to control cells cultured in the absence of FBG 
(Figure 5.6 A).  I also observed cells containing more intense FBG staining localized intracellularly 
and this intense staining correlated with much more prominent rounding of the cell (Figure 5.7 B).  
This suggests that FBG binds to the surface of cells that are well spread, and is internalized by 
fibroblasts and also causes changes in cell morphology.   
 
Another interesting note is that internalization of FBG also increases intracellular FN levels (Figure 
5.5) compared to control cells cultured in the absence of recombinant protein (Figure 5.4) 
suggesting a direct correlation between uptake of FBG and loss of a cell surface FN matrix.  FN has 
been shown to be internalized via the caveolin-1 dependent, RAP independent endocytosis 
mechanism (Sottile and Hocking, 2002).  Intracellular pools of FN did not co-localize with 
intracellular pools of FBG, suggesting FBG and FN are not internalized within the same endocytic 
vesicles and also may not be internalized via the same endocytic mechanism.   
 
FBG treated cells also show the presence of what appear to be non-cellular clumps of Alexa Fluor-
568 fluorescent aggregates (Figure 5.6 B and 5.7 A and B).  This could be membrane debris from 
cells that have apoptosed or undergone necrotic cell death, or shedding of clustered glycoproteins.   
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Figure 5.4   Confocal Z scan images showing the actin cytoskeleton and FN matrix in the 
absence of FBG. 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before addition of buffer in the absence 
of recombinant protein.  Cells were incubated for a further 22 h and then fixed in 3.8% (w/v) 
paraformaldehyde, permeabilized with 0.2% Triton X-100 and stained with an anti-FN antibody 
(F3648), secondary Alexa Fluor-568 antibody and Alexa Fluor-647 conjugated phalloidin.  0.1 μm z-
stack scans were taken by confocal microscopy and images analysed by Volocity 3D imaging software 
(Invitrogen). Flattened stack images of merged, and individual channels (488 nm, 568 nm and 647 nm) 
are depicted on the left of the figure.  A single slice through the z-stacks (XY) is shown with the 
corresponding side profiles (YZ and XZ).  The location of the side profiles are indicated by the dotted 
white lines. Images were taken at x100 magnification, scale bar = 12 μm. This image is a 
representative from 3 fields of view from 2 independent experiments. 
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Figure 5.5   Confocal Z scan images showing the distribution of FBG relative to the actin 
cytoskeleton and FN matrix.   
NIH 3T3 fibroblasts were cultured for 2 h in serum-free medium before addition of 0.1 μM Alexa Fluor-
488 labelled FBG.  Cells were incubated for a further 22 h and then fixed in 3.8% (w/v) 
paraformaldehyde, permeabilized with 0.2% Triton X-100 and stained with an anti-FN antibody 
(F3648), secondary Alexa Fluor-568 conjugated antibody and Alexa Fluor-647 conjugated phalloidin.  
0.1 μm z-stack scans were taken by confocal microscopy and images analysed by Volocity 3D 
imaging software (Invitrogen). Flattened stack images of merged, and individual channels (488 nm, 
568 nm and 647 nm) are depicted on the left of the figure.  A single slice through the z-stacks (XY) is 
shown with the corresponding side profiles (YZ and XZ).  The location of the side profiles are indicated 
by the dotted white lines. Images were taken at x100 magnification, scale bar = 12 μm.  This image is 
a representative from 3 fields of view from 2 independent experiments. 
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Figure 5.6   Confocal Z scan images showing the distribution of FBG relative to the plasma 
membrane.   
NIH 3T3 fibroblasts were cultured for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (A) or 0.1 μM Alexa Fluor-488 labelled FBG (B).  Cells were 
incubated for a further 22 h. Cells were then fixed in 3.8% (w/v) paraformaldehyde and stained with 
Alexa Fluor-568 labelled concanavalin A.  0.1 μm z-stack scans were taken by confocal microscopy 
and images analysed by Volocity 3D imaging software (Invitrogen).  Flattened stack images of 
merged, and individual channels (488 nm, 568 nm and 647 nm) are shown.  A single slice through the 
z-stacks (XY) is shown with the corresponding side profiles (YZ and XZ) with the location of the side 
profiles indicated by the dotted white lines. Images were taken at x60 magnification, scale bars = 25 
μm.  A representative image from three different fields of view is shown.   
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Figure 5.7   Confocal Z scan images showing the distribution of FBG relative to the plasma 
membrane.   
NIH 3T3 fibroblasts were cultured for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (A) or 0.1 μM Alexa Fluor-488 labelled FBG (B).  Cells were 
incubated for a further 22 h. Cells were then fixed in 3.8% (w/v) paraformaldehyde, and stained with 
Alexa Fluor-568 labelled concanavalin A.  0.1 μm z-stack scans were taken by confocal microscopy 
and images analysed by Volocity 3D imaging software (Invitrogen).  Flattened stack images of 
merged, and individual channels (488 nm, 568 nm and 647 nm) are shown.  A single slice through the 
z-stacks (XY) is shown with the corresponding side profiles (YZ and XZ) with the location of the side 
profiles indicated by the dotted white lines and cells of interest denoted (a and b). Images were taken 
at x60 magnification, scale bars = 25 μm.  A representative image from 3 different fields of view is 
shown. 
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5.2.3   FBG remains within the cell after trypsinization 
To confirm that FBG is internalized, cells were cultured in the presence or absence of 0.1 μM Alexa 
Fluor-488 labelled FBG, TNfn3-5 or TNfn5-7 for 22 h before cells were trypsinised.  FACs analysis 
demonstrated no increase in fluorescence intensity when cells were cultured in the presence of 
TNfn3-5 (Figure 5.8 B) or TNfn5-7 (Figure 5.8 C) compared to cells cultured in the absence of 
recombinant protein (Figure 5.8 A and E).  However, cells did stain positively when cultured in the 
presence of FBG, as indicated by the increase in fluorescence intensity in figure 5.8 D.  This is also 
shown in an amalgamated histogram (Figure 5.8 F) where the relative shift in the presence of FBG 
has been highlighted, and in the scatter diagram (Figure 5.8 G) showing almost half of the cells 
(43.41%) are located in the right quadrants i.e. fluorescently labelled. These data indicate that FBG, 
but not other TN-C domains, remain associated with the cells after trypsinization, as would be 
expected upon internalization.   
 
To visualize FBG localization after trypsinization, cells cultured with Alexa Fluor-488 labelled 
FBG for 22 h were trypsinized and re-plated for 2 h before fixing and staining the cell surface with 
concanavalin A.  In the absence of recombinant protein, cells remained rounded and were beginning 
to spread at the edges (Figure 5.9 A).  Cells that had been cultured with FBG show fluorescence 
located intracellularly (Figure 5.9 B; a, b) but also some low levels of FBG on the cell-surface 
(Figure 5.9 B; a) after re-plating.  There was no noticeable difference in cell shape in the presence 
of FBG, but again, clumps of Alexa Fluor-568 fluorescent aggregates were observed.  These data 
confirm that the majority of FBG is retained within the cell after trypsinzation and show that a small 
amount remains associated with the plasma membrane.   
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Figure 5.8   FACs analysis showing specific FBG labelling of cells after trypsinization    
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (A; -), 0.1 μM Alexa Fluor-488 labelled TNfn3-5 (B), TNfn5-7 (C) or  
FBG (D). Fibroblasts cultured in medium alone in the absence of recombinant protein or buffer were 
included for comparison (E).  Cells were incubated for a further 22 h before trypsinization and 
collection for FACs analysis.  Cells were monitored and sorted with a 488 nm filter (FITC-A).  The 
individual histogram plots for each condition are amalgamated and the FBG data highlighted by 
orange shading (F).  A scatter diagram representation of the histogram D (cells cultured with 0.1 μM 
Alexa Fluor-488 FBG) (G).   
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Figure 5.9   Confocal Z scan images showing the distribution of FBG after cell trypsinization 
and re-plating.  
NIH 3T3 fibroblasts were cultured for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (A) or 0.1 μM fluorescent FBG (B).  Cells were then incubated for a 
further 22 h. Cells were then trypsinized, washed in 1xPBS and re-plated onto glass slides and 
cultured for 2 h in fresh serum-free medium.  Cells were then fixed in 3.8% (w/v) paraformaldehyde 
and stained with Alexa Fluor-568 labelled concanavalin A.  0.1 mm z-stack scans were taken by 
confocal microscopy and images analysed by Volocity 3D imaging software (Invitrogen).  Flattened 
stack images of merged, and individual channels (488 nm and 568 nm) are shown.  A single slice 
through the z-stacks (XY) is shown with the corresponding side profiles (YZ and XZ) with the location 
of the side profiles are indicated by the dotted and dashed white lines. Cells of interest are denoted (a 
and b).  Images were taken at x60 magnification, scale bars = 25 μm. 
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5.2.4   Reducing cell membrane fluidity by cooling to 4ºC prevents FBG localization to the cell 
layer 
FBG could be taken up by fibroblasts by a number of mechanisms.  Endocytosis mechanisms 
include macropinocytosis (fluid phase endocytosis), phagocytosis, clathrin dependent, caveolin 
dependent or clathrin and caveolin independent receptor mediated endocytosis (Doherty and 
McMahon, 2009).  Receptor mediated endocytosis and fluid phase endocytosis are inhibited upon 
culture of cells at 4ºC (Mellman, 1996) (Besterman and Low, 1983) and reduction of membrane 
fluidity, which is required for the movement of phospholipids and cell surface receptors (Pastan and 
Willingham, 1985) (Holtzmann, 1989).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10   Immunofluorescent localization of FBG upon reduction of membrane 
fluidity.   
NIH 3T3s were cultured at 37ºC for 24 h in serum-free medium before culture for a further 1h 
at 37ºC in the presence of 1 µM Alexafluor-488 FBG (A) or in the absence of recombinant 
protein (B).  In parallel, cells were cultured for 24h in serum free medium at 37ºC, then pre-
cooled  at 4ºC for 30 min (C), 1 h (D) or 2 h (E) before incubation in the presence of Alexa 
Fluor-488 labelled FBG for a further 1 h at 4ºC.  An additional set of cells were pre-cooled for 1 
h before incubating with Alexa Fluor-488 labelled FBG for 1h at 4ºC and then incubated at 
37ºC for a further 1h (F).  All cells were fixed in 3.8% (w/v) paraformaldehyde.  Representative 
images from 3 random fields of view are shown.  Images were taken by fluorescence 
microscopy at x20 magnification, scale bar = 100 μm. 
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To determine if this is a possible mechanism by which FBG is being internalized, fibroblasts were 
pre-incubated at 4ºC for 30 min, 1 h or 2 h, to reduce cell membrane fluidity, before incubation with 
Alexa Fluor-488 labelled FBG for a further 1 h at 4ºC.  Cell membrane fluidity is required for 
invaginations of the cell membrane and thus should prevent uptake of FBG.  Indeed, internalization 
was inhibited in cells cooled at 4ºC for 30 min (Figure 5.10 C), 1 h (Figure 5.10 D) or 2 h (Figure 
5.10 E).  In fact, cooling inhibited all FBG association with the cell membrane – no fluorescence 
was observed at any time point.    
 
Warming of cells to 37ºC has been shown to restore endocytosis (Larrick et al., 1985).   
Correspondingly, FBG localization was rescued back to control levels (Figure 5.10 A) when cells 
were transferred from 4ºC back to 37ºC for 1 h (Figure 5.10 F).  The complete loss of FBG staining 
at 4ºC shows that FBG binding to the cell surface is prevented at low temperatures and that FBG 
internalization may be hindered by loss of membrane movements.    
 
5.2.5   Localization of FBG to the cell layer is altered by addition of excess unlabeled FBG  
To determine whether FBG binds to specific and saturable cell surface receptors, an increasing 
concentration of unlabelled FBG was simultaneously added with 0.1 μM Alexa Fluor-488 labelled 
FBG to determine whether this unlabelled protein could compete out binding to the cell layer and 
thus reduce the detectable Alexa Fluor-488 binding.  This association with the cell layer was 
monitored by immunofluorescence.  When FBG was added to fibroblasts that had been plated for 2 
h, and then cultured for a further 22 h, addition of 10 times excess (1μM) unlabelled FBG (Figure 
5.11 B) enhanced the level of fluorescently labelled FBG staining on the cell layer compared to 
fluorescent FBG alone (Figure 5.11 A).  However, inclusion of 0.1 μM (Figure 5.11 C) or 0.01 μM 
unlabelled FBG (Figure 5.11 D) reduced FBG staining levels compared to fluorescent FBG alone.  
In all cases where unlabelled FBG was added, large aggregates of fluorescent FBG were observed.  
FBG aggregation occurred in a dose dependent manner.  This FBG aggregation also seems to occur  
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Figure 5.11   Immunofluorescent localization of Alexa Fluor-488 labelled FBG in the 
presence of excess unlabelled FBG in fibroblasts assembling a de novo FN matrix 
NIH 3T3 fibroblasts were plated for 2 h in serum-free medium before addition of: 0.1 μM Alexa 
Fluor-488 labelled FBG in the absence of any other recombinant protein (A), or in the presence 
of 1 μM unlabeled FBG (B), 0.1 μM unlabeled FBG (C) or 0.01 μM unlabeled FBG (D).  0.1 μM 
unlabeled FBG with buffer in the absence of recombinant protein was included as a background 
control (E). Cells were cultured for a further 22 h then fixed in 3.8% (w/v) paraformaldehyde and 
stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody.  
Representative images from 3 random fields of view are shown.  Images were taken by 
fluorescence microscopy at x20 magnification, scale bar = 100 μm. 
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Figure 5.12    Immunofluorescent localization of Alexa Fluor-488 labelled FBG in the 
presence of excess unlabelled FBG in fibroblasts with a mature FN matrix. 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium before addition of: 0.1 μM 
Alexa Fluor-488 labelled FBG the absence of any other recombinant protein (A), 1 μM 
unlabeled FBG (B), 0.1 μM unlabeled FBG (C) or 0.01 μM unlabeled FBG (D). Unlabeled 
FBG with buffer in the absence of recombinant protein (E) was included as a background 
control. Cells were cultured for a further 1 h then fixed in 3.8% (w/v) paraformaldehyde and 
stained with an anti-FN antibody (F3648) and secondary Alexa Fluor-568 conjugated 
antibody.  Representative images from 3 random fields of view are shown.  Images were 
taken by fluorescence microscopy at x20 magnification, scale bar = 100 μm. 
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in a cell-dependent manner as incubating FBG with coverslips alone in medium over 24 h did not 
result in aggregates of FBG coating the coverslip (Figure 5.1 D and E).  
 
In contrast, excess unlabelled FBG reduced fluorescent FBG levels on cells with a pre-assembled 
matrix (Figure 5.12 B) in a dose dependent manner (Figure 5.12 C and D).   
 
Together these data suggest that FBG may be binding distinct, saturable cell surface receptors, 
which can be competed for by unlabelled FBG and that at high concentrations and over long periods 
of incubation, FBG aggregation occurs, which is a cell dependent process.   
 
5.2.6   FBG does not affect cell viability 
To determine whether incubation of cells with FBG was causing cell death, which ultimately 
resulted in the reduced FN matrix assembly observed, an MTT assay was used to assess cell 
viability in the presence of increasing doses of FBG.  TNfn1-8 and TNfn3-5 were included as 
controls.  The MTT substrate was incubated with untreated cells for increasing periods of time to 
confirm the linear range of the assay (Figure 5.13 A).  No significant difference in cell viability 
could be observed after culture of the cells with any of the TN-C domains tested when compared to 
control cells cultured in the absence of recombinant protein (Figure 5.13 B).  Treatment with 0.2 
μM sodium nitroprusside (SNP) induced cell death, and was used as a negative control for MTT 
uptake.   
 
Although cells were viable within the 24 h period monitored above, this does not rule out the 
possibility that early apoptosis events may be occurring.  Early apoptotic cells undergo changes in 
their cell membrane resulting in the flipping of phosphotidylserine phospholipids from the inner 
leaflet of the cell membrane to the outer leaflet of the cell membrane, which can be detected with 
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annexin V.  Allophycocyanin (APC)-conjugated annexin V was used to identify apoptotic cells by 
FACs analysis (APC fluorophore excites at 633 nm and emits at 660 nm).   
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Figure 5.13   MTT assay showing the effect of TNfn1-8, TNfn3-5 and FBG on cell 
viability  
(A)  NIH 3T3 fibroblasts were cultured in 96 well dishes for 24 h in serum-free medium.  
Fresh serum-free medium with MTT reagent (0.5 mg/ml) was added to cells and incubated 
for 0.5, 1, 2, 4, 6, 8 and 10 h at 37ºC before addition of 100 µl stop solution (0.01 M HCl in 
10% SDS) and incubation overnight.  Plates were then read at 574 nm. Results show the 
average of triplicate repeats from 2 independent assays +/- SEM.  (B) NIH 3T3 fibroblasts 
were cultured for 2 h in serum-free medium before addition of increasing concentrations of 
TNfn1-8, TNfn3-5, FBG, buffer in the absence of recombinant protein (-) or 0.2 μM SNP 
(killed). Fibroblasts cultured in medium alone in the absence of recombinant protein and 
buffer were included for comparison (No add).  Cells were then incubated for a further 22 
h.  Medium was aspirated before fresh serum-free medium with MTT reagent (0.5 mg/ml) 
was applied to cells and incubated for 2 h before addition of 100 µl stop solution and 
incubation overnight.  One set of cells was left untreated (No MTT).  Plates were then read 
at 574 nm.  Results show an average of triplicate repeats from 3 independent assays +/- 
SEM.  One-way ANOVA statistics were applied to compare all conditions with (No add) 
and (-) controls, ***; p<0.001.   
                                                Results: Inhibiting FN matrix assembly independent of FN binding 
 
 188
Fi
gu
re
 5
.1
4 
  F
A
C
s 
an
al
ys
is
 s
ho
w
in
g 
th
e 
ef
fe
ct
s 
of
 T
N
fn
3-
5,
 T
N
fn
5-
7 
an
d 
FB
G
 o
n 
ea
rly
 c
el
l a
po
pt
os
is
 
N
IH
 3
T3
 fi
br
ob
la
st
s 
w
er
e 
pl
at
ed
 fo
r 2
 h
 in
 1
0%
 s
er
um
 s
up
pl
em
en
te
d 
m
ed
iu
m
 (A
-E
 a
nd
 K
) o
r s
er
um
-fr
ee
 m
ed
iu
m
 (F
-
J)
 b
ef
or
e 
ad
di
tio
n 
of
 b
uf
fe
r 
in
 th
e 
ab
se
nc
e 
of
 re
co
m
bi
na
nt
 p
ro
te
in
 (B
,G
) o
r 
0.
1 
µM
 A
le
xa
 F
lu
or
-4
88
 la
be
lle
d 
TN
fn
3-
5 
(C
, H
), 
TN
fn
5-
7 
(D
, I
) o
r F
B
G
 (E
, J
). 
Fi
br
ob
la
st
s 
cu
ltu
re
d 
in
 m
ed
iu
m
 a
lo
ne
 in
 th
e 
ab
se
nc
e 
of
 re
co
m
bi
na
nt
 p
ro
te
in
 a
nd
 
bu
ffe
r w
er
e 
in
cl
ud
ed
 fo
r c
om
pa
ris
on
 (A
, F
). 
C
el
ls
 w
er
e 
cu
ltu
re
d 
fo
r a
 fu
rth
er
 2
2 
h,
 a
nd
 o
ne
 s
et
 o
f c
el
ls
 w
er
e 
ex
po
se
d 
to
 h
ig
h 
U
V
 r
ad
ia
tio
n 
to
 i
nd
uc
e 
ap
op
to
si
s 
(K
). 
 C
el
ls
 w
er
e 
ha
rv
es
te
d 
an
d 
in
cu
ba
te
d 
w
ith
 a
llo
ph
yc
oc
ya
ni
n 
(A
P
C
)-
co
nj
ug
at
ed
 A
nn
ex
in
-V
 b
ef
or
e 
FA
C
s 
an
al
ys
is
. 
 T
he
 u
pp
er
 q
ua
dr
an
ts
 r
ep
re
se
nt
 a
po
pt
ot
ic
 c
el
ls
 (
A
P
C
 +
ve
) 
w
hi
le
 t
he
 
rig
ht
 h
an
d 
si
de
 q
ua
dr
an
ts
 re
pr
es
en
t A
le
xa
 F
lu
or
-4
88
 p
os
iti
ve
 c
el
ls
.  
A
 re
pr
es
en
ta
tiv
e 
ex
pe
rim
en
t o
f t
w
o 
in
de
pe
nd
en
t 
ex
pe
rim
en
ts
 is
 s
ho
w
n.
   
                                                Results: Inhibiting FN matrix assembly independent of FN binding 
 
 189
  Cells were cultured in both serum free medium and 10% FBS containing medium to compare the 
effect serum-free medium had on cell apoptosis.  In medium containing 10% FBS or serum free 
medium alone, no cells can be observed undergoing apoptosis (upper quadrants) (Figure 5.14 A and 
F).  To confirm the efficiency of detection of apoptotic cells, UV irradiation was used to induce 
fibroblast apoptosis before staining with annexin V.  Cells treated with UV radiation show high 
levels of APC-conjugated annexin V binding (Figure 5.14 K), with the majority of cells in the upper 
quadrants (sum of both upper quadrants = 64.59%) indicating high levels of cells undergoing early 
apoptosis events.   In non-UV irradiated cells, the addition of buffer in the absence of recombinant 
protein, induced a small amount of apoptosis in cells cultured in serum (6.02%) (Figure 5.14 B) and 
a slightly higher level of apoptosis in cells in  
serum free medium (17.65%) (Figure 5.14 G).  Incubation of cells cultured in medium containing 
serum with TNfn3-5, TNfn5-7 and FBG caused no significant increase in apoptosis (6.62%, 5.83% 
and 6.82% respectively) (Figure 5.14 C-E) over addition of buffer alone.  Likewise, no apoptosis 
was induced by culturing cells in serum free medium with TNfn3-5, TNfn5-7 or FBG (15.92%, 
15.69% and 17.03%) (Figure 5.14 H-J).   
 
Consistent with FBG specifically being bound to and internalized by cells, only cells incubated with 
FBG stained positive in the 488 channel.  This was higher in cells cultured in serum (sum of both 
right-hand quadrants = 40.88%) (Figure 5.14 E) than in serum-free conditions (15.85%) (Figure 
5.14 J).  Very few cells stained positive for TNfn3-5 (10.70% and 1.55%; serum and serum-free 
conditions respectively) (Figure 5.14 C and H) and TNfn5-7 (5.58% and 2.37%; serum and serum-
free conditions respectively) (Figure 5.14 D and I).  The proportion of cells that were both apoptotic 
and fluorescently labelled with FBG (2.66% and 2.82%; serum and serum-free conditions 
respectively; Figure 5.14 E and J) was not significantly increased in proportion to the number of 
fluorescently labelled cells (38.22% and 13.03% respectively; Figure 5.14 E and J) compared to 
control cells cultured in the absence of recombinant protein (Figure 5.14 B and G) suggesting no 
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correlation between apoptosis and FBG internalization.  This indicates that the loss of FN matrix 
assembly by FBG is not caused by FBG interactions with the cell layer to activate cell signalling 
that cause cell death by apoptosis.   
 
5.2.7   FBG affects NIH 3T3 fibroblast cell morphology  
To examine the effects of FBG on fibroblast morphology in more detail, cells were plated at a lower 
cell density (1x105/ml rather than 4x105/ml as used in all previous studies), before culturing cells in 
the absence of recombinant protein or in the presence of 0.1 μM FBG and TNfn5-7.  Cells were 
cultured over time before fixing and staining for actin and cell nuclei.  Images of the cells were 
taken on a fluorescence microscope, and ImageJ image analysis software used to determine 
individual cell surface areas.   
In the absence of recombinant protein, cells start spreading to form a typical “fried-egg” shape after 
6 h total culture, and show increased spreading throughout the time course (Figure 5.15 B).  The 
mean cell area increased steadily by 50% from 1314.9 μm2 at 6 h up to 1975.8 μm2 at 24 h (Figure 
5.15 A).  TNfn5-7 had no significant effect on cell morphology over time: cells adopted a spread 
morphology and showed increased spreading over time (Figure 5.15 B); cell area increased steadily 
from 1335.3 μm2 at 6 h to 1660.7 μm2 after 24 h culture (Figure 5.15 A).  However, there is a change 
in morphology upon addition of FBG after longer periods of incubation: after 6h total culture 
fibroblasts were as well spread as the control cells cultured in the absence of recombinant protein 
and those cultured with TNfn5-7 (Figure 5.15 B).   After 10 h total culture, cells started becoming 
less spread, with some cells starting to from more angular shapes (Figure 5.15 B).  After 12 h of 
culture with FBG (14 h total culture time), the fibroblasts were obviously much less spread with 
many forming triangular shaped cells and some extending long, thin protrusions from the cell body 
(Figure 5.15 B).  After 22 h of culture with FBG (24 h total culture time), the cells adopted a thin, 
angular morphology with long protrusions extending from the cell body, which contrasted with the 
spread morphology of control cells or cells cultured with TNfn5-7 (Figure 5.15 B).  In addition, the  
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Figure 5.15   Immunofluorescent staining showing the effect of FBG on cell area and 
morphology over time 
NIH 3T3 fibroblasts were plated at 1x105/ml for 2 h in serum-free medium before addition of buffer in 
the absence of recombinant protein (-) or 0.1 μM FBG or TNfn5-7.  Cells were then incubated for a 
further 4, 8, 12 or 22 h.  Cells were fixed in 3.8% (w/v) paraformaldehyde, permeabilised with 0.2% 
Triton-X100 and stained with Alexa Fluor-568 conjugated phalloidin and DAPI.  The area of 100 
randomly chosen cells was quantified using the ImageJ program.  (A) Results show the average cell 
area +/- S.E.M. taken from a single experiment.  (B) Images were captured by fluorescence 
microscopy at x20 magnification, scale bar = 100 μm.  Representative images from 3 random fields of 
view and 2 independent experiments are shown.  
                                                Results: Inhibiting FN matrix assembly independent of FN binding 
 
 192
Figure 5.16   Immunofluorescent staining showing the effect of FBG concentration on cell 
area and morphology   
NIH 3T3s were plated at 1x105/ml for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein or 1 μM, 0.1 μM or 0.01 μM FBG and TNfn5-7.  Cells were 
incubated for a further 22 h.  Cells were fixed in 3.8% (W/v) paraformaldehyde, permeabilised with 
0.2% Triton-X100 and stained with Alexa Fluor-568 conjugated phalloidin and DAPI. Cell area was 
semi-quantified from over 100 randomly picked cells using the ImageJ program.  (A) Results show 
the average cell area +/- S.E.M. taken from a single experiment (1 μM and 0.01 μM) or from three 
independent experiments (0.1 μM). One-way ANOVA statistics were applied to compare all 
conditions with control cells cultured in the absence of recombinant protein (-), **; p<0.05, ns; no 
significant difference.  (B) Images were captured by fluorescence microscopy at x20 magnification, 
scale bar = 100 μm.  Representative images from 3 random fields of view and 2 independent 
experiments are shown.  
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mean cell area did not increase over time after treatment with FBG, but remained similar to that 
observed at 6 h total culture (cell area after 6 h culture: 1336.3 μm2; cell area after 24 h culture: 
1444.47 μm2) (Figure 5.15 A).  This difference was most apparent after 14 h of culture onwards, 
which correlated with the time point where FN matrix assembly is affected by FBG (Figure 3.17 
and Figure 5.2) and FBG levels on the cell layer were increased (Figure 5.1 B and 5.2).  
 
The effect of FBG on cell shape is also dose dependent; at higher concentrations of FBG (Figure 
5.16 B) cells had much rounder central bodies and longer, thin extensions connecting cells, when 
compared to control cells cultured in the absence of recombinant protein or in the presence of the 
same concentration of TNfn5-7.  A significant decrease in cell surface area is observed after 24 h 
culture with 0.1 μM FBG (1418.1 μm2) compared to cells cultured with buffer in the absence of 
recombinant protein (1684.7 μm2) (Figure 5.16 A).  This reduction in  
cell area is greatest at the highest concentration of 1 μM FBG, where it reduced the cell area by 38.2 
% (cell area of control cells: 1818.49 μm2; FBG treated cells: 1124 μm2) but minimal differences 
are observed at the lowest concentration of 0.01 μM (cell area of control cells: 1756 μm2; FBG 
treated cells: 2002.7 μm2) (Figure 5.16 A), although this dose response experiment has only been 
done once, which is why statistical significance could not be calculated.  These data demonstrate 
that in the presence of FBG, cells can attach and spread to a certain extent, but the cell morphology 
is altered. 
 
5.2.8   FBG induces changes in actin cytoskeleton organization and focal adhesion formation 
Actin cytoskeleton organization into stress fibres and focal adhesion formation are vital for cell 
spreading: attachment of cells via integrin ligation of the extracellular matrix initiate multiple 
signalling pathways, including activation of RhoA, which induces re-organization of the actin 
cytoskeleton and formation of focal adhesion signalling complexes.  Further focal complexes form 
along filopodial and lamellipodial membrane protrusions generated by rapid polymerization and re-
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organization of the actin cytoskeleton, which extend and probe the surrounding environment. These 
focal complexes mature into focal adhesions and actin re-organizes parallel to the cell edge 
connecting filopodia.  Focal adhesions then mature, re-orient laterally along the length of the cell 
and strengthen lateral actin stress fibres to generate cell tension (Partridge and Marcantonio, 2006).  
A major constituent of focal complexes and focal adhesions is paxillin (Geiger et al., 2001).  To 
determine if FBG induced cell rounding was accompanied by changes in actin and focal adhesion 
complexes, I followed actin organization and focal adhesion formation over time in the presence or 
absence of FBG by immunofluorescence staining for actin and paxillin. 
 
In the absence of FBG, cell actin cytoskeletal organization and focal adhesion formation follows 
that for the model of cell spreading (Figure 5.17).  After 6 h total culture actin staining shows the 
development of thick actin filaments parallel to the cell edge.  After 10 h, thinner actin filaments are 
starting to develop towards the centre of the cell.  By 14 h, an increased number of long actin stress 
fibres are developed and orient towards the centre of the cell body.  By 24 h, thick actin stress fibres 
orient along the length of the cell (Figure 5.17).  However the actin cytoskeleton is more disordered 
in the presence of FBG.  After 6 h total culture time, FBG treated cells are similar to those observed 
in control cells, with thick actin filaments present parallel to the cell periphery (Figure 5.17).  
However, by 10 h, actin cytoskeleton reorganization events are disrupted: individual actin filaments 
cannot be discerned, and strong, short actin filaments are still present at the cell periphery.  After 14 
h culture, stress fibres are only observed along the cell edge and short, actin filaments can still be 
observed generating cells with a thin, angular, protrusive morphology.  By 24 h, this thin, protrusive 
morphology is particularly evident, and although some actin stress fibres can be seen, these mainly 
seem to associate into thick cords that line the cell periphery (Figure 5.17).    
 
In the presence of FBG, paxillin staining is initially similar to control cells after 6 h, where it is 
diffuse throughout the cell and strongly stained in a perinucelar, cytoplasmic manner.  Paxillin 
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staining is also similar at 10 h where most is still located within the cytoplasm, but some localizes 
to specific focal points closer to the edges of the cell membrane.  After 14 h however, control cells 
show increased peripheral, focal paxillin staining, which orient towards the centre of the cell, co-
localizing along the actin filament, whilst cells cultured in the presence of FBG form disorganized 
clusters of paxillin staining within the central body of the cell co-localizing with the disorganized 
actin aggregates.  By 24 h, cells cultured in the absence of recombinant protein display strong, 
paxillin staining within focal adhesion structures co-localizing with the ends of the actin stress 
fibres.  Some paxillin localization can be observed at the ends of the peripheral stress fibres formed 
in FBG treated cells, but most of the paxillin remains in the body of the cell in a perinuclear fashion 
(Figure 5.17).  This suggests that FBG disrupts the actin re-organization and focal adhesion 
maturation required for cell spreading.  
 
FBG also had a dose dependent effect on paxillin staining and actin cytoskeletal organization. 0.01 
μM FBG had little effect on paxillin localization of stress factor formation.  Both 0.1 μM and 1.0 
μM completely blocked focal adhesion formation, altered paxillin to a perinuclear and cytosolic 
localization and actin became disorganized with only short fibrils observed criss-crossing the cell 
body (Figure 5.18).  These data indicate that FBG prevents cell spreading, inhibits stress fibre 
formation or maturation and causes disassembly of focal adhesions or prevents maturation of focal 
adhesions.  
 
5.2.9   FBG does not affect cell surface levels of α5β1 
Actin is required to maintain integrin clusters at the cell membrane organized in adhesive structures, 
which are important for anchoring the cells to ECM components such as FN.  The α5β1 integrins 
are important receptors involved in binding to the CBD of FN and mediating FN matrix assembly 
(Huveneers et al., 2008) (Mao and Schwarzbauer, 2005) (Wennerberg et al., 1996) (Wu et al., 1993) 
(Wu et al., 1995).  Given that I have shown loss of actin and focal adhesions then this may affect  
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Figure 5.17   Immunofluorescent staining of paxillin and actin cytosksleton in the presence of 
FBG over time  
NIH 3T3 fibroblasts were plated at 1x105/ml for 2 h in serum-free medium before addition of buffer in the 
absence of recombinant protein (-) or 0.1 μM FBG.  Cells were incubated for a further 4, 8, 12 or 22 h. 
Cells were then fixed in 3.8% (w/v) paraformaldehyde, permeabilized with 0.2% Triton-X00 and stained 
with an anti-paxillin antibody (ab32084), secondary Alexa Fluor-488 conjugated antibody and Alexa 
Fluor-568 conjugated phalloidin. Representative images from 3 random fields of view are shown:  the 
merged channels, individual actin (568 nm) and paxillin (488 nm) channels.  Images were taken by 
confocal microscopy at x60 magnification, scale bar =50 μm.   
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Figure 5.18   Immunofluorescent staining of paxillin and actin cytoskeleton in the presence of 
increasing concentrations of FBG 
NIH 3T3s fibroblasts were plated at 1x105/ml for 2 h in serum-free medium before addition of buffer 
in the absence of recombinant protein (-) or 1 μM, 0.1 μM or 0.01 μM FBG.  Cells were incubated for 
a further 22 h.  Cells were then fixed in 3.8% (w/v) paraformaldehyde, permeabilized with 0.2% 
Triton-X100 and stained with an anti-paxillin antibody (ab32084), secondary Alexa Fluor-488 
conjugated antibody and Alexa Fluor-568 conjugated phalloidin.  Representative images from 3 
random fields of view are shown:  the merged channels, individual paxillin (488 nm) and actin (568 
nm) channels.  Images were taken by confocal microscopy at x60 magnification, scale bar = 50 μm.  
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levels of integrin at the cell surface and thus explain why FN is no longer assembled or maintained 
at the cell surface.  Cell surface levels of α5β1 were monitored by FACs using an anti-α5β1 
antibody (MAB1914) and an APC-conjugated secondary (anti-rat) antibody.  Cells cultured with 
FBG (Figure 5.19 B), TNfn3-5 (Figure 5.19 C), TNfn1-5 (Figure 5.19 D) or TNfn5-7 (Figure 5.19 
E) did not show any significant effect on cell surface α5β1 levels compared to control cells cultured 
in the absence of recombinant protein (light grey line, filled histogram; Figure 5.19 A).  Rat serum 
IgG (Figure 5.19 A; dotted line) and secondary rat antibody alone (Figure 5.19 A; thin grey line) 
were included as controls and showed similar background levels as unstained samples (Figure 5.19 
A; dashed line).  These data indicate that cell surface integrin levels are not affected by TN-C 
domains including FBG. 
 
5.3   Discussion 
Whilst specific TNfn repeats and the FBG domain of TN-C both inhibited FN matrix assembly 
(Chapter 3), FBG did not bind to the FN matrix to prevent FN-cell and intermolecular FN 
interactions, unlike some of the TNfn domains (Chapter 4).  Instead, here I demonstrate that FBG 
causes disassembly of mature FN matrices.  It binds to the cell surface and is internalized by 
fibroblasts and induces significant changes to cell actin cytoskeleton and focal adhesion formation.  
 
5.3.1   FBG promotes FN matrix disassembly 
Early FN assembly events proceed normally in the presence of FBG, with thickening and 
elongation of FN fibrils occurring as observed in the control.  However, after 12 h in culture, the 
time at which FBG localization to the cells is observed, there is a striking reduction in the density of 
FN matrix assembled around fibroblasts.  Specifically, cells that exhibit a vesicular staining pattern 
of FBG are those that have less FN on the cell surface.  FBG also localized to fibroblasts after a 
mature matrix had been allowed to form, and these cells also showed reduced density of this FN 
matrix on the cell surface even after only 1 h incubation.  These data suggest FN matrix 
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disassembly is occurring.  The cells that stained positively for FBG also possessed increased 
staining of FN in intracellular vesicles compared to the control cells.  These data correlate with my 
results from chapter 3, which suggested that there was an increase in FN levels in DOC soluble 
material isolated from FBG-treated fibroblasts.  The presence of increased intracellular FN after 
treatment with FBG confirms disassembly process is occurring with subsequent FN internalization 
as reported by Bourdoulous et al., (Bourdoulous et al., 1998).   
 
5.3.2   FBG binds to, and is internalized by, fibroblasts 
FBG localization to the cell layer in freshly plated fibroblasts occurred only after 10 h incubation 
(12 h total culture).  In contrast, high levels of FBG localization to the cell layer were observed after 
only 1 h incubation if cells had already been plated for 24 h.  These results imply that FBG has 
specific requirements for cell association; it may require cells to be well spread or have well 
developed cytoskeletal architecture, or it may indicate the need for the expression of specific 
molecules at the cell surface; these may be transmembrane, cell membrane associated or matrix 
molecules.  In the previous chapter, I showed that vesicular staining by CHO cells did not require 
the presence of a FN matrix, however this does not rule out the involvement of other non-FN matrix 
components or the possibility that the mechanisms are cell type dependent.   Thus FBG association 
with cells is independent of the FN assembly process but nonetheless influences it.  
 
From the confocal z scanning images, FBG showed clear cell surface binding as well as being 
distributed intracellularly, within the cell membrane, supporting the theory that the discrete patches 
of FBG staining are likely to be vesicular in origin.  FBG internalization is also supported by the 
continued presence of vesicular FBG retained in FBG-treated fibroblasts after tryspinisation and re-
plating.    My data suggest that FBG binds to well spread cells and that it is internalized by rounded 
cells.  However, from these studies, the precise order of events cannot be deduced i.e. whether FBG 
binding to the cell surface causes cell rounding and FBG is then internalized or whether FBG 
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internalization causes cell rounding.  It is also not clear whether FBG binding or FBG uptake occurs 
simultaneously with FN internalization.  I attempted time lapse microscopy to detect FBG 
internalization in individual cells in real time, but the presence of Alexa Fluor-488 labelled FBG in 
the medium caused high background fluorescence, preventing specific FBG signals on the cell 
surface from being detected. To reduce the background, low cell densities could be pulse labelled 
with a high concentration of Alexa Fluor-488 labelled FBG and then chased with fresh medium.  
Neat experiments to try with this system include: addition of fluorescently labelled concanavalin A 
simultaneously to allow delineation of the cell surface to monitor internalization in real time; 
simultaneous inclusion of fluorescently labelled FN to cells either deficient in FN synthesis (i.e. 
CHO cells) or FN null fibroblasts and monitoring FN disassembly and internalization.   
 
FN internalization has been shown to occur via a clathrin-independent, caveolin-1 dependent 
process.  This internalization was inhibited in the presence of continuous FN polymerization (Sottile 
and Chandler, 2005).  To determine if FN internalization induced by FBG occurs in a similar 
manner, caveolae-dependent endocytosis inhibitors: β-cyclodextrin (cholesterol binding agent), 
staurosporin or genistein (kinase inhibitors) or jasplakinolide (actin filament stabilizing agent) could 
be used.  Although FN and FBG are both internalized they did not co-localize, suggesting a 
different mechanism of internalization may exist for FN and FBG.  Use of these agents to examine 
FBG uptake would confirm this.  
 
5.3.3   Comparison of fibrinogen and FBG endocytosis 
Fibrinogen is a 340-kDa soluble protein present in the blood plasma synthesised and secreted by 
hepatocytes and also extrahepatic epithelial cells at sites of inflammation.  Fibrinogen is cleaved to 
fibrin by activated thrombin on the surface of platelets during the coagulation cascade, which results 
in the formation of a fibrin-fibrinogen clot (Doolittle, 1981) (Lorenz and Longaker, 2003) into 
which plasma FN is cross-linked to form a provisional matrix (Mosher and Johnson, 1983) (Wilson 
                                                Results: Inhibiting FN matrix assembly independent of FN binding 
 
 202
and Schwarzbauer, 1992) to allow the attachment, spreading and migration of fibroblasts and other 
cell types into the wound (Colvin, 1983) (Greiling and Clark, 1997) (Kaplan and Keogh, 1982) 
(Knox et al., 1986) (Midwood et al., 2004b).  Fibrinogen is composed of 3 pairs of non-identical 
disulphide bonded polypeptide chains Aα, Bβ and γ.  The C-terminal globular domain of TN-C has 
a molecular weight of 27-kDa and is composed of 2 chemically identical amino acid sequences, 
which are organised asymmetrically, forming a funnel shaped domain with a hydrophobic centre 
(Pas et al., 2006).  The FBG of TN-C shares 40% homology to fibrinogen and is homologous to the 
β and γ chains (Doolittle, 1981) and the αvβ3-binding surface structure of these two molecules has 
also been shown to be similar (Yokoyama et al., 2000).   
 
Internalization of fibrinogen has been identified to occur via many different mechanisms in a cell-
dependent manner.  Soluble, degraded fibrinogen was shown to be internalized by phorbol 
myristate acetate (PMA)-stimulated neutrophils via only very transient associations with the cell 
layer and a non-specific pinocytic mechanism (Kirsch et al., 2002).  In contrast, immobilized 
fibrinogen has been shown to be endocytosed by lung epithelial cells by binding to αvβ3 integrins 
in an RGD-dependent, HSPG-independent manner via a non-clathrin dependent endocytosis 
pathway without requirement for plasminolysis before internalization (Odrljin et al., 2001).   
 
Soluble, plasma fibrinogen was not endocytosed by lung epithelial cells (Odrljin et al., 2001) or 
fibroblasts.  Instead soluble fibrinogen was incorporated into fibroblast FN matrices (Colvin, 1983) 
(Guadiz et al., 1997) (Pereira et al., 2002) (Rybarczyk and Simpson-Haidaris, 2000).  This FN co-
localization was only observed when fibroblasts were cultured in the presence of serum.  In the 
absence of serum or in the presence of FN assembly inhibitors, fibrinogen showed very patchy 
staining, often independent of FN staining, which Perriera et al (Pereira et al., 2002) suggest is 
localization to the cell surface.  This is comparable to what I observe in NIH 3T3 fibroblasts 
cultured with FBG in the absence of serum.  Truncated fibrinogen (partially lacking Aα and Bβ 
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chains) synthesized by breast epithelial cell line MCF-7 was also shown to bind to the cell surface 
(Rybarczyk and Simpson-Haidaris, 2000) with a punctate pattern of staining not dissimilar to the 
pattern I observed with FBG and NIH 3T3s.  It will be interesting to see if FBG binds to a FN 
matrix in my system in the presence of serum, and if so to determine what in serum causes this 
change in localization.   
 
To confirm FBG internalization, immunoelectron microscopy, which has been successfully used in 
the past to show internalization of fibrinogen into vesicular compartments (Kirsch et al., 2002) 
could be employed.  Fibroblasts could also be pre-treated with chloroquine, which is a lysosomal 
inhibitor that inhibits lysosomal protein degradation and recycling causing protein accumulation 
within the cell.  This has been used to determine internalization of fluorescently labelled fibrinogen 
via the lysosomal degradative pathway (Odrljin et al., 2001).  Co-immunofluorescence studies with 
antibodies against lysosome associated membrane protein-1 (LAMP-1) and early endosome 
antigen-1 (EEA-1) can determine whether FBG internalization follows a lysozomal or endosomal 
internalization mechanism respectively (Sottile and Chandler, 2005).   
 
5.3.4   FBG binding to fibroblasts is inhibited at 4ºC 
Endocytosis is inhibited at 4ºC due to an inability to form endocytic vesicles (Pastan and 
Willingham, 1985) (Sottile and Chandler, 2005).  Dropping the temperature of NIH 3T3 fibroblasts 
to 4ºC dramatically reduced the staining of FBG in cell cultures compared to fibroblasts maintained 
at 37ºC.  The complete inhibition of FBG cell layer association suggests FBG binding is also 
inhibited at low temperatures but makes it difficult to extrapolate these data to determine if loss of 
membrane fluidity has any effect on FBG internalization.  Cell viability of cells and the cell shape 
after incubation at 4ºC for extended time periods should also be assessed to confirm that the loss of 
binding is not due to a loss of cell viability or changes in cell morphology.   
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FBG has previously been shown to interact with two types of cell surface receptor: αvβ3 integrins 
(Yokoyama et al., 2000) and heparan sulfate proteoglycans (Aukhil et al., 1993) (Fischer et al., 
1995).  CHO cells expressing β3 integrin could adhere to culture dishes coated with FBG 
(Yokoyama et al., 2000) and this could be inhibited by the αvβ3 function-blocking antibody LM609 
and an FBG derived peptide (peptide VIII) and recombinant fibrinogen peptides derived from 
fibrinogen surface loop sequences, which have been mapped to interact with αvβ3 (LaFleur et al., 
1997).  Contrary to this, endothelial cells have been shown to interact with FBG via a cell surface 
integrin, but antisera against αvβ3 had no effect on endothelial cell adhesion (Joshi et al., 1993).  
NIL.8M hamster fibroblast adherence to FBG was shown to be mediated via a heparin sulphate 
proteoglycan (Joshi et al., 1993) (Aukhil et al., 1993), so these are possible cell surface receptor 
candidates.  The FBG domain itself possesses heparin binding activity as an individual domain 
(Fischer et al., 1995) (Aukhil et al., 1993) and within the context of the whole TN-C molecule 
(Fischer et al., 1995).   
 
To confirm the involvement of αvβ3 integrins in FBG-cell interactions, specific αvβ3 blocking 
antibodies (e.g. LM609) could be used to determine if it can prevent FBG binding to the cell 
surface.  Ligand binding and activation of αvβ3 also induces the expression of a LIBS2 epitope, 
which can be detected by flow cytometry (Yokoyama et al., 2000).  Moreover, peptide VIII, which 
is the αvβ3-interacting sequence within FBG (LaFleur et al., 1997) (Yokoyama et al., 2000) could 
be mutated to confirm whether this integrin is involved.  To determine if heparan sulphate 
proteoglycans are interacting with FBG, cells could be treated with heparinase or cultured in both 
the presence of soluble heparin and FBG.  Cells could also be pre-cultured with p-nitrophenyl-β-D-
xyloside, which inhibits GAG side chain addition to core proteins to determine if these sugars are 
essential for FBG binding.  Specific CHO cell mutants expressing defective GAGs (Chung and 
Erickson, 1997) could be used to determine if FBG binding by these cells are affected by defective 
proteoglycan GAG chains.  Furthermore, I can try to detect whether αvβ3-FBG or αvβ3-HSPG 
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cross-linked complexes can be isolated from membrane lysates.  Receptor levels should also be 
monitored over time by FACs to see if they are altered, especially 10-12 h after plating when an 
increased association of FBG with the cell layer is observed.   
 
5.3.5   FBG affects fibroblast morphology and cytoskeleton organization  
I observed that cells containing intracellular FBG showed striking changes in cell morphology that 
were not caused by changes in cell viability. When I examined cell morphology in less confluent 
cell cultures I was better able to quantify the effects.  FBG dose dependently inhibited cell 
spreading by up to 25% from 14 h onwards. Cell shape was also strikingly altered with the 
development of longer and thinner filopodial processes and more rounded, less spread central cell 
bodies in the presence of FBG but not TNfn5-7 or in the absence of recombinant protein.   This 
effect was also time dependent as freshly cultured fibroblasts exhibited normal cell morphology at 
early time points, but differences in cell shape were prominent at later time points and reflected in 
reduced cell surface area observed after 12 h culture with FBG (14 h total culture).  Again, these 
later time points are critical for FBG effects on freshly plated fibroblasts: FN matrix assembly, 
localization to the cell surface and cell morphology are all affected around this time.  
 
Culturing cells in the presence of FBG resulted in a loss of an organized actin cytoskeleton over 
time and in a dose dependent manner.  The effect of FBG on actin cytoskeletal remodelling was 
only observed 8 h after addition of FBG (10 total culture time).  FBG strongly inhibited the 
formation of actin stress fibres oriented towards and across the cell body, instead causing actin 
aggregates to form in the main cell body with only thick actin filaments along the edge of the cell 
body.  This effect was augmented by higher concentrations of FBG.   
 
Paxillin is a 68-70-kDa phosphotyrosine protein that coordinates signalling events by binding 
directly to the cytoplasmic tails of β1 and α4 integrin subunits.  It acts as an adaptor scaffold protein 
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on which multiple proteins can dock to form large protein complexes (Schaller, 2001) (Wozniak et 
al., 2004).  This protein was chosen as an indicator for focal adhesion formation.  Fibroblasts 
cultured at low densities in the presence of FBG formed small focal adhesions up to 14 h but then 
exhibited a loss of focal paxillin staining at the cell edges and very few focal adhesions or smaller 
focal adhesions, or paxillin localization to focal adhesion complexes was reduced.   
 
Cell adhesion, spreading and actin organization are key for cell-generated tension and this process is 
a pre-requisite for FN matrix assembly: ECM induced cell signalling via integrin complexes causes 
integrin clustering and assembly of specific signalling complexes containing RhoA and ROCK, 
which then feed back to activate integrins such as β1 integrins.   β1 integrins and other matrix 
assembly receptors can then bind to FN and initiate FN matrix assembly (Disatnik and Rando, 
1999) (Geiger et al., 2001) (Green et al., 2009) (Midwood et al., 2004a) (Saoncella et al., 1999) (Wu 
et al., 1995) (Yoneda et al., 2007) (Zhang and Mosher, 1996) (Zhong et al., 1998).  ECM cell 
signalling also induces actin cytoskeleton reorganization into myosin II associated filaments, which 
generate cortical cell tension.  Inhibition of cell contractility inhibits FN matrix assembly: 
disruption of the actin cytoskeleton by addition of cytochalasin D or inhibitors of contractility (e.g. 
ROCK inhibitor Y-27632) can interrupt FN unfolding (Baneyx et al., 2002) (Smith et al., 2007), FN 
fibrillar extension (Davidson et al., 2008) (Ohashi et al., 2002)  and α5β1 cross-linking and 
clustering (Friedland et al., 2009) (Ohashi et al., 2002).  Culture of cells with 2, 3-butanedione 
monoxime (BDM) myosin II inhibitor and H7, a protein kinase C (focal adhesion component) 
inhibitor, inhibits cell contractility and also inhibits FN matrix assembly (Zhong et al., 1998).   
 
FN and its assembly into a matrix have also been shown to increase actin organization (Bloom et 
al., 1999) (Gildner et al., 2004).  FN null fibroblasts showed a dose-dependent enhancement of 
biogel contraction and tensile strength in the presence of increasing concentrations of FN (Gildner 
et al., 2004).  This cell contractility has been shown to be mediated via a heparin binding region in 
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FNIII1 (III1H) (Hocking and Kowalski, 2002).  Furthermore, the loss of FN matrix assembly by 
high concentrations of another peptide derived from FNIII1 (anastellin or III1-C) correlated with a 
loss of actin stress fibres, actin formed filopodial-like structures, paxillin focal staining, FAK 
association and Rho activation (Bourdoulous et al., 1998).  This group showed the loss of FN 
matrix assembly by III1-C or blocking anti-FN antibodies was the cause for loss of the actin 
cytoskeleton organization because cell shape and cell adhesion was unaffected by these inhibitors 
when cells were plated on pre-coated ECM proteins or after treatment with III1-C for short periods 
of time (Bourdoulous et al., 1998).  However, III1-C is likely to be affecting FN-FN interactions, 
which is unlikely to be the mechanism used by FBG.   
 
The mechanism for FN matrix disassembly has not yet been elucidated.  It has been shown that 
release of cell tension and inhibition of cell contractility after a mature FN matrix has been 
assembled on the cell surface does not cause contraction and refolding of FN, but FN fibrils remain 
extended (Ohashi et al., 1999) (Smith et al., 2007).  Due to a continuous turnover of FN matrix at 
the cell surface, this FN may then be disassembled and internalized in a caveolin-1 dependent 
manner (Sottile and Chandler, 2005).  It is possible that the lack of cell tension could result in a 
more rapid disassembly of the FN matrix, resulting in a loss of FN at a more rapid rate than that 
reported by Sottile et al., (Sottile and Chandler, 2005).  FN has to be dissociated from its highly 
cross-linked matrix structure, formed by an endogenous disulphide isomerase reaction in FNI12, 
before becoming endocytosed.  It has been proposed that a reverse disulphide isomerase reaction 
may occur to allow this FN turnover (Sottile and Hocking, 2002) (Sottile and Chandler, 2005).  FN 
proteases may also be involved: highly proteolytic environments such as non-healing wounds 
contain high levels of fragmented FN (Latijnhouwers et al., 1998).   
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5.3.6   Does FBG induced FN matrix disassembly cause changes in cell phenotype or does FBG 
induced disruption of cytoskeletal architecture cause FN matrix disassembly? 
FBG association with the cell layer of freshly plated cells is most prominent after 8-10 h (10 and 12 
h total culture time).  This is the time point at which FN matrix assembly is also starting to become 
reduced and the time point at which FBG is affecting cell cytoskeletal organization.  FBG may be 
(1) directly inducing changes in the actin cytoskeleton, resulting in subsequent loss of FN matrix 
from the cell surface or (2) inducing changes in the FN matrix, the loss of which causes re-
organization of the actin cytoskeleton.  
 
5.3.6.1   FBG alters actin cytoskeletal organization to inhibit FN matrix assembly 
(A) FBG may act by binding to specific cell surface receptors to induce signalling pathways that 
directly cause changes in cell shape by inhibiting actin polymerization.  The subsequent reduction 
in cell contractility results in the loss of tension and integrin translocation required for FN matrix 
maintenance at the cell surface and thus the loss of FN matrix occurs; FN is disassembled and 
internalized.  FBG is then also cleared from the cell surface by internalization after signalling 
(Figure 5.20 A).   
 
(B) FBG binding to the cell surface may not induce signalling pathways but instead merely enable 
FBG to be internalized.  Accumulation of large amounts of intracellular FBG may then cause 
changes in cell shape and actin polymerization which results in FN disassembly (Figure 5.20 B). 
FBG can induce changes in cell morphology and actin organization.  FBG induced basic FGF-
dependent elongation of bovine aortic endothelial cells (Schenk et al., 1999).  FBG induced actin 
cytoskeleton reorganization, loss of focal phalloidin staining, the formation of membrane ruffles 
and loss of cell spreading similar to what I observed when fibroblasts were cultured with FBG.  
FBG was postulated to cause these effects by interacting and signalling via α2β1 integrins 
expressed on endothelial cells (Sriramarao et al., 1993).  Fibroblast adhesion and spreading was 
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Figure 5.20   Possible mechanisms by which FBG may be acting to inhibit cytoskeleton 
organization 
(A) FBG binds to cell surface receptors, and signals directly to inhibit actin stress fibre formation (i).  
Loss of actin cytoskeletal tension causes the loss of integrin and cell surface receptor translocation (ii) 
which inhibits FN-receptor interactions and FN is lost from cell surface (iii).  FBG is then internalized 
(iv). (B) FBG binds to cell surface receptors and is internalized (i), intracellular accumulation of FBG 
inhibits actin stress fibre formation (ii).  Loss of actin cytoskeletal tension causes the loss of integrin 
and cell surface receptor translocation (iii) which inhibits FN-receptor interactions and FN is lost from 
cell surface (iv).   
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Figure 5.21   Possible mechanisms by which FBG may be acting to inhibit FN matrix assembly 
(A) FBG binds to cell surface receptors or aggregates on the cell surface to compete directly or sterically 
hinder FN-receptor interactions.  Internalization of FBG may also remove FN receptors from cell surface (i).   
Loss of FN-receptor interactions (ii)  subsequently results in a loss of cell-ECM adhesion and this causes 
loss of actin organization, focal adhesion formation and cell contractility (iii).  (B) FBG binds to cell surface 
receptors and signals directly (i) or signals after internalization (ii) to inactivate FN matrix assembly 
receptors (iii) and thus inhibit FN matrix assembly (iv).  Loss of cell-ECM adhesion (v) causes loss of actin 
organization, focal adhesion formation and cell contractility (vi). 
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also  reduced when plated on FBG compared to FN or TNfn5-7, which was mediated by cell-
surface proteoglycans (Aukhil et al., 1993).  However, in these studies it was not determined 
whether FBG was internalized by these cells to mediate this effect.  It is not clear how internalized 
FBG may affect cytoskeletal organization, as plasma invagination and endocytosis is mediated by 
actin polymerization (Jeng and Welch, 2001) suggesting FBG internalization must occur before 
disruption of the actin cytoskeleton.   
 
5.3.6.2   FBG inhibits FN matrix assembly to affect actin cytoskeletal organization  
(A) In this model, interaction of FBG with the cell surface may inhibit FN interactions with matrix 
assembly receptors causing the loss of FN matrix: FN is then disassembled and internalized.  The 
loss of cell-ECM contacts causes inhibition of focal adhesion formation, re-organization of actin 
and loss of cell tension.  FBG may specifically interact with cell surface receptors required for 
binding to FN and thus compete for FN receptors preventing their binding to FN.  Alternatively 
FBG internalization in complex with these FN receptors may reduce the levels available at the cell 
surface.  Non-specific aggregation of FBG on the cell surface may also inhibit FN interactions with 
matrix assembly receptors (Figure 5.21 A).  High concentrations of FBG formed large aggregates 
on the cell layer, so it is possible that FBG aggregation is sterically blocking FN matrix assembly.  
As discussed before, FBG can interact with cell surface receptors including αvβ3 integrins 
(Yokoyama et al., 2000) and heparan sulfate proteoglycans (Aukhil et al., 1993) (Fischer et al., 
1995), both of which are important receptors for FN matrix assembly.  This could be tested by 
assessing the effects of blocking FBG binding to αvβ3 and HSPGs on FN matrix assembly in 
parallel with effects on cell binding as described above (Section 5.3.4: FBG binding to fibroblasts is 
inhibited at 4ºC).  
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(B) FBG binding to cell surface receptors may generate intracellular signals which down-regulate 
FN assembly receptor expression or affect their activity.  This results in the loss of FN matrix at the 
cell surface leading to re-organization of the actin cytoskeleton (Figure 5.21 B).  Integrin “cross-
talk” has been described to regulate FN matrix assembly.  Ligation of αvβ3 affected α5β1 mediated 
K562 macrophage FN-dependent phagocytosis by reducing the affinity of α5β1 integrins for FN.  
This system in macrophages required signalling via protein kinase C, integrin-associated protein 
and calcium/calmodulin-dependent protein kinase II (CamKII) (Blystone and Kaplan, 1993) 
(Blystone et al., 1999).  Plasminogen activator inhibitor-1 has also been shown to displace 
vitronectin from αvβ1, which signals to enhance α5β1 affinity and enhance FN matrix assembly 
(Vial and McKeown-Longo, 2008).  Conversely, ligation of β1 integrins have also been shown to 
negatively modulate αvβ3 activation in immortalized human bone marrow endothelial cells 
(TrHBMEC) by cAMP-dependent protein kinase (PKA) signalling pathways, which phosphorylate 
the cytoplasmic domain of β3 resulting in its deactivation (Gonzalez et al., 2008).  Although I 
demonstrated that expression levels of α5β1 remained unchanged in FBG treated cells, indicating 
that FBG binding to the cell layer does not signal to the cell to reduce α5β1 cell-surface expression, 
I did not determine whether α5β1 activation was affected.  Specific antibodies can be used, which 
specifically recognise high affinity α5β1 levels including 9EG7 and HUTS21 (Brockbank et al., 
2005).  Also I did not investigate whether αvβ3 integrin expression levels are altered.  
Unfortunately there was not enough time during this study to explore this further.  
 
5.4   Summary 
The definitive mechanism for how FBG is interacting with the cell surface, the receptors involved 
and its mechanism of cellular internalisation, its effects on cell shape and FN matrix disassembly, 
and the order by which these events occur warrant further biochemical investigations.  Whether 
FBG inhibits FN matrix assembly before disrupting the actin cytoskeleton, or whether it first 
disrupts the actin cytoskeleton before loss of the FN matrix remains to be determined.  The effect of 
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FBG on cell architecture and FN matrix assembly could be an effective mechanism to modulate 
cellular adhesion and migration through the ECM.  These results show that FBG inhibition of FN 
matrix assembly is a distinct mechanism compared to TNfn1-8 or TNfn1-3.  This supports the idea 
that within a large multi-domain protein like TN-C, individual domains possess unique activities, 
which are cryptic and buried within the full-length molecule as a further regulatory mechanism to 
control cellular processes.   
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CHAPTER 6 
The effect of TN-C domains on FN matrix 
assembly during tubulogenesis and 
angiogenesis 
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6.1   Introduction 
In chapters 3-5 I demonstrated that specific domains of TN-C inhibited FN matrix assembly in 
monolayer cultures of the NIH 3T3 mouse fibroblast cell line.  The controlled assembly of a FN 
matrix is vital for many physiological processes.  Tubule formation and branching is important for 
the development of organs such as lung and kidney.  The organization of epithelial cells into higher 
multi-cellular 3D structures involves cell adhesion, cell spreading, cell proliferation, cell migration 
and selective cell apoptosis.  Likewise, angiogenesis, the formation of neovessels from pre-existing 
vessels, proceeds via the same pathways as epithelial tubulogenesis, where a complex series of 
integrated signals induces endothelial cell adhesion, spreading, proliferation, migration and 
organization into tubular structures.  Angiogenesis and vascular remodeling are important during 
resolution of tissue injury (Tonnesen et al., 2000).  However, inappropriate angiogenesis also occurs 
in pathologies including cancer, arthritis and psoriasis and plays a vital role in driving disease 
(Carmeliet, 2003) (Zetter, 1998).   
 
The complex co-ordination of tubule/vessel formation is regulated by signaling events from cell-
ECM, cell-cell and soluble growth factor interactions (Wei et al., 2009).  FN matrix assembly is 
required for kidney epithelial cell morphogenesis in vitro (Jiang et al., 1999) (Jiang et al., 2000) and 
branching morphogenesis of the kidney and lung in vivo (Sakai et al., 2003). Furthermore, recently 
emerging data demonstrated that the assembly of a FN matrix is vital for neovessel formation by 
HUVECs cultured in 3D gels and angiogenesis in chick chorioallantoic membrane models (Zhou et 
al., 2008).  
  
TN-C expression spatially and temporally coincides with FN expression and assembly in regions of 
active tubulogenesis and angiogeneisis.  These ECM molecules are both highly expressed during 
branching morphogenesis (Gebb et al., 2005) (Roth-Kleiner et al., 2004) (Young et al., 1994), in 
development, and during angiogenesis in granulation tissue, (Betz et al., 1993) (Latijnhouwers et 
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al., 1996) (Mackie et al., 1988). In addition, in tumors, TN-C expression is increased in the ECM 
and within the extracellular space of gliomas (Zamecnik, 2005), in the tumor stroma of malignant 
mammary adenocarcinomas (Inaguma et al., 1988) (Mackie et al., 1987) and in the ECM and 
around angiogenic tumor blood vessels in soft-tissue tumors (Schnyder et al., 1997).  These are all 
areas representing high matrix turnover and likely to contain TN-C fragments (Cai et al., 2002) 
(Imai et al., 1994) (Latijnhouwers et al., 1998) (Mai et al., 2002) (Orend and Chiquet-Ehrismann, 
2006). 
 
Given that specific TN-C domains can inhibit FN matrix assembly in monolayer culture, I next 
investigated whether these domains had any effects on FN matrix assembly during tubulogenesis 
and angiogenesis.  These data may provide information about whether TN-C fragments regulate FN 
matrix assembly during physiological tubule and vessel formation in development and tissue repair, 
and may indicate whether small TN-C domains could be useful tools to inhibit inappropriate 
angiogenesis that is characteristic of many disease pathologies. 
 
6.2   Results 
 
6.2.1   TNfn1-8 and 70-kDa inhibit MDCK tubulogenesis 
To simulate 3D tubulogenesis events in vitro, Madin-Darby canine kidney (MDCK) cells are 
commonly used as a convenient model as they can be stimulated by HGF to form tubules in 3D 
collagen gels (Bird, 2006) (Borenstein and Cline., 2004; Jiang et al., 2000) (Montesano et al., 
1991).  During MDCK cell tubulogenesis cell adhesion and proliferation forms a ball of cells, 
which then selectively apoptose in the centre to form a hollow cyst.  Cells are then stimulated by 
HGF to undergo proliferation and migration to form a thick cord from the central cyst.  Cells in the 
centre of this cord are then stimulated to apoptose to form a hollow tube structure (Borenstein and 
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Cline., 2004).  FN deposition in the basal laminae is important in this process as it polarizes the 
cells and provides survival signals (Jiang et al., 1999) (Schoenenberger et al., 1994).   
 
MDCK cells cultured in 3D collagen gels in 10% serum but in the absence of HGF did not form 
tubules but cells adhere to the collagen matrix, proliferate and associate into rounded cyst-like 
clumps by d 5 (Figure 6.1) as reported before (Jiang et al., 1999).  Addition of 1 μM 70-kDa, 1 μM 
TN-C domains or an equivalent buffer volume had no effect on cyst formation (Figure 6.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  MDCK tubulogenesis in the absence of 
HGF but in the presence of TN-C domains or 70-kDa  
MDCK cells were seeded into collagen gels and cultured 
for 5 days at 37ºC in DMEM containing 10% FBS.  1 μM 
TNfn1-3, TNfn3-5, TNfn1-5, TNfn5-7, TNfn6-8, TNfn1-8, 
FBG, 70-kDa or a equivalent volume of buffer alone in 
the absence of recombinant protein (-) were added 
directly to the medium. MDCKs cultured in medium alone 
in the absence of recombinant protein and buffer were 
included for comparison (No addition). Images were 
taken by light microscopy at x10 magnification, scale bar 
= 100 μm.   
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When MDCKs were cultured in the presence of 5 ng/ml HGF, cell spreading and tubular extensions 
from a central cell clump can be seen after 2-3 d culture.  By 5 d, a complex series of branching 
tubules were formed (Figure 6.2 A) as previously described by Jiang et al., (Jiang et al., 2000).  
MDCK tubulogenesis was inhibited by the presence of 1 μM 70-kDa and TNfn1-8 producing 
aggregates of cells with only a few processes extending outwards.  Compared to cells cultured in 
the absence of recombinant protein, early stages of tubulogenesis were attenuated by 70-kDa and 
TNfn1-8, with fewer and shorter tubular structures developing from a central cluster of cells after 
only 3-4 d of culture (Figure 6.2 A).  70-kDa and TNfn1-8 also inhibited cell proliferation with a 
significant reduction in cell number after 5 d culture compared to control (Figure 6.2 B).  Incubation 
with other TN-C domains: TNfn1-3, TNfn1-5, TNfn3-5, TNfn5-7, TNfn6-8 or FBG, had no effect 
on tubulogenesis (Figures 6.3).   
 
I examined a range of doses of TN-C domains on tubulogenesis.  0.5 μM and 0.2 μM of TNfn1-8 
and 70-kDa had no discernible effects on tubulogenesis compared to cells cultured in the absence of 
recombinant protein (Figure 6.4).  Tubulogenesis was only effectively inhibited at the highest 
concentration (1 μM) by TNfn1-8 and 70-kDa.  The effect of 70-kDa on tubule formation is 
consistent with previous reports that show 1 μM 70-kDa inhibits cell proliferation and tubule 
formation (Zhou et al., 2008).  This suggests only higher concentrations of protein affect 
tubulogenesis.  Tubulogenesis was not affected by FBG, TNfn3-5 or TNfn1-3 at any concentration 
(Figure 6.4).   
 
An MTT assay confirmed TNfn1-8 and 70-kDa had no effect on MDCK cell viability suggesting 
that their inhibition of tubulogenesis is not mediated by cell death.  None of the other TN-C 
domains used in these studies showed any significant effect on cell viability (Figure 6.5).   
 
 
Results: The effect of TN-C domains on FN matrix assembly during tubule formation 
 219
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
gu
re
. 6
.2
   
M
D
C
K
 tu
bu
lo
ge
ne
si
s 
in
 th
e 
pr
es
en
ce
 o
f 7
0-
kD
a 
an
d 
TN
fn
1-
8.
   
(A
) 
M
D
C
K
s 
w
er
e 
se
ed
ed
 in
to
 3
D
 c
ol
la
ge
n 
ge
ls
 a
nd
 c
ul
tu
re
d 
fo
r 
1,
 2
, 3
, 4
 a
nd
 5
 d
 a
t 3
7º
C
 in
 D
M
E
M
 
co
nt
ai
ni
ng
 1
0%
 F
B
S
 a
nd
 s
up
pl
em
en
te
d 
w
ith
 5
 n
g/
m
l H
G
F.
  
1 
µM
 7
0-
kD
a,
 T
N
fn
1-
8 
or
 a
n 
eq
ui
va
le
nt
 
vo
lu
m
e 
of
 b
uf
fe
r 
al
on
e 
in
 th
e 
ab
se
nc
e 
of
 r
ec
om
bi
na
nt
 p
ro
te
in
 (
-)
 w
as
 a
dd
ed
 d
ire
ct
ly
 to
 th
e 
m
ed
iu
m
.  
Tu
bu
lo
ge
ne
si
s 
w
as
 m
on
ito
re
d 
ov
er
 t
im
e 
by
 li
gh
t 
m
ic
ro
sc
op
y 
at
 x
10
 m
ag
ni
fic
at
io
n,
 s
ca
le
 b
ar
 =
 1
00
 
μm
. (
B
) 
C
el
l n
um
be
r 
w
as
 d
et
er
m
in
ed
 b
y 
se
ed
in
g 
M
D
C
K
s 
in
to
 3
D
 c
ol
la
ge
n 
ge
ls
 a
nd
 c
ul
tu
rin
g 
fo
r 
5 
d 
at
 3
7º
C
 i
n 
D
M
E
M
 c
on
ta
in
in
g 
10
%
 F
B
S
 a
nd
 s
up
pl
em
en
te
d 
w
ith
 5
 n
g/
m
l 
H
G
F.
  
G
el
s 
w
er
e 
th
en
 
co
lla
ge
na
se
 d
ig
es
te
d 
fo
r 2
 h
 a
nd
 in
cu
ba
te
d 
w
ith
 tr
yp
si
n-
E
D
TA
 fo
r 2
0 
m
in
s 
be
fo
re
 re
-p
la
tin
g 
ce
lls
 o
nt
o 
a 
96
 w
el
l d
is
h.
  C
el
ls
 w
er
e 
cu
ltu
re
d 
in
 D
M
E
M
 c
on
ta
in
in
g 
10
%
 F
B
S
 fo
r 3
0 
m
in
 a
t 3
7º
C
.  
Im
ag
es
 w
er
e 
ta
ke
n 
by
 li
gh
t m
ic
ro
sc
op
y 
at
 x
10
 m
ag
ni
fic
at
io
n 
an
d 
th
e 
nu
m
be
r o
f c
el
ls
 c
ou
nt
ed
 p
er
 fi
el
d 
of
 v
ie
w
 w
ith
 
a 
m
in
im
um
 o
f 3
 fi
el
ds
 o
f v
ie
w
 p
er
 e
xp
er
im
en
t. 
 C
ou
nt
s 
w
er
e 
av
er
ag
ed
 ±
S
E
M
.  
**
*,
 p
<0
.0
01
 b
y 
on
e-
w
ay
 A
N
O
V
A
 v
er
su
s 
co
nt
ro
l (
-).
   
Results: The effect of TN-C domains on FN matrix assembly during tubule formation 
 220
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3   Tubulogenesis in the presence of TN-C domains.   
MDCK cells were seeded into collagen gels and cultured for 5 d at 37ºC in DMEM containing 5% FBS 
DMEM supplemented with 5 ng/ml HGF.  1 μM TNfn1-3, TNfn3-5, TNfn1-5, TNfn5-7, TNfn6-8, TNfn1-8, 
FBG or an equivalent volume of buffer alone in the absence of recombinant protein (-) was added directly 
to the medium. MDCKs cultured in medium alone in the absence of recombinant protein and buffer were 
included for comparison (No addition).  Images were taken at x10 magnification on a light microscope 
scale bar = 100 μm.  A representative image of 3 independent experiments is shown,  
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Figure 6.4  Actin organization and cell distribution in MDCK tubules in the 
presence of increasing concentrations of TN-C domains   
MDCK cells seeded into 3D collagen gels and cultured for 5 d at 37ºC in DMEM 
containing 10% FBS and supplemented with 5 ng/ml HGF.  1 µM, 0.5 µM or 0.2 µM 70-
kDa, TNfn1-3, TNfn3-5, TNfn1-8, FBG or an equivalent volume of buffer alone in the 
absence of recombinant protein (-) was added directly to the medium. Cells were fixed 
in 3.8% (w/v) paraformaldehyde, permeabilized in Triton X-100 and stained for actin 
(phalloidin-568) and cell nuclei (DAPI).  Images were taken on a fluorescence 
microscope at x20 magnification, scale bar = 100 μm.  A representative image is shown 
from 2 independent experiments.   
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6.2.2   TNfn1-8 and 70-kDa may inhibit FN localization 
To determine if 70-kDa and TNfn1-8 are inhibiting MDCK FN assembly in this study, FN was 
labeled with an Alexa Fluor-568 fluorescent dye (Figure 6.6 A and B).  MDCK cells were cultured 
in medium supplemented with 10% FBS that had been depleted of plasma FN but substituted with 
fluorescently labeled FN (as described (Zhou et al., 2008)) and 5 ng/ml HGF.   Zhou and coworkers 
managed to show the incorporation of fluorescently labeled FN into the basal laminae of HUVECs 
cultured in 3D fibrin gel (Zhou et al., 2008).  However, addition of fluorescently labeled FN in my 
studies could not be localized specifically to the tubular structures, but instead bound to the 3D 
collagen gel (red fluorescence in Figure 6.6 E).  Additionally, the inclusion of 25 μg/ml exogenous 
unlabeled or labeled FN seemed to suppress tubulogenesis (Figure 6.6 D and E respectively) 
compared to the control (Figure 6.6 C).  The MDCK cells cultured with FN formed only a few short 
and poorly branched tubules (Figure 6.6 D and E). 
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Figure 6.5   MDCK cell viability in the presence of TN-C domains.
1x104 MDCK cells were plated onto a 96 well dish and cultured for 5 d at 37ºC in DMEM containing 10% 
FBS (-).  After 2 h culture, 1 μM of each TN-C domain or an equivalent volume of buffer alone in the 
absence of recombinant protein (-)  was added directly to the conditioned medium.  MDCKs cultured in 
medium alone in the absence of recombinant protein or buffer were included for comparison (No 
addition)  As a control, cells were killed by culturing for 5 d  in the presence of 0.2 μM SNP (killed).  After 
5 d culture, medium was aspirated and fresh serum-free medium with MTT reagent (0.5 mg/ml) was 
applied to cells and incubated for 2 h before addition of 100 µl stop solution (0.01 M HCl in 10% SDS) 
and incubation overnight.  Plates were then read at 574 nm.  Results are shown as an average of 3 
triplicate repeats from 3 independent assays +/- SEM.  One-way ANOVA statistics were applied to 
compare all conditions with the (–) control, ***; p<0.001.   
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Indirect FN immunofluorescent staining was attempted instead.  MDCKs cultured for 5 d in 3D 
collagen gels with TNfn1-8 or buffer in the absence of recombinant protein were fixed in 
paraformaldehyde and stained with a polyclonal anti-FN antibody (F3648) and a secondary Alexa 
Fluor-488 conjugated anti-rabbit IgG antibody.  However, this again resulted in a high background 
staining that was not localized around the tubules but instead the antibody either predominantly 
stained FN deposited within the collagen gel itself or the antibody was trapped in the collagen gel 
(Figure 6.6 F).   
 
To try and detect the presence of FN around the MDCK tubules, MDCKs cultured in collagen gels 
were fixed in formalin, then sectioned and stained with a number of different anti-FN antibodies to 
determine their suitability for tubule-associated staining by immunohistochemistry.  F3648 is a 
commercially available polyclonal anti-FN antibody (Sigma).  All other antibodies screened were 
kind gifts from Jean Schwarzbauer (Princeton, N.J.).  The R39 and R184 antibodies were raised 
against full-length FN, whereas the R40 antibody specifically recognizes FNIII1-6 and R457 
recognizes the 70-kDa domain (Figure 6.7 A).  From the antibody reactivity screen, only R39 
showed strong and specific immunolocalization of FN around the tubular structures (Figure 6.7 B 
and C).  F3648 did show some staining of FN around the MDCK tubular structures, but also 
showed high background staining of the collagen gel (Figure 6.7 E) correlating with the background 
immunofluorescent staining of the collagen gel observed before (Figure 6.6 F).  R184 showed weak 
FN staining around some of the tubules (Figure 6.7 D), whereas R40 and R457 showed little 
specific FN staining (Figure 6.7 F and G respectively).  Subsequent samples were probed with the 
R39 antibody at a lower dilution (1:200) and this was found to increase the FN 
immunohistochemical staining intensity without affecting background collagen staining (Figure 6.8 
A).  All previous samples had undergone proteolytic induced epitope retrieval, and this was shown 
to be the optimal treatment method (Figure 6.8 A); heat induced epitope retrieval by pressure 
cooking enhanced the FN staining intensity but also caused an increase in non-specific background 
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color (purple in Figure 6.8 B).  Untreated samples showed very weak FN staining (Figure 6.8 C) 
compared to treated samples (Figure 6.8 A and B) suggesting that the process of fixing samples in 
formalin results in the formation of methylene bridges which mask FN epitopes.  
 
Using these optimized parameters (protease induced epitope retrieval, R39 antibody at 1:200 
dilution) the immunolocalization of FN around cultured MDCKs was examined in the presence of 
70-kDa and TNfn1-8.  Transections of MDCK cells embedded in collagen gels showed FN was 
strongly localized to individual cells as well as the ECM immediately surrounding the cells in  
MDCK cells cultured in the absence of recombinant protein and TNfn1-3 (Figure 6.9 A and C 
respectively).   Cells cultured with TNfn1-8 and 70-kDa showed slightly reduced FN staining 
around the tubular structures (Figure 6.9 B, D) but this is not as obvious at higher magnifications 
(Figure 6.9 B, D insets) and the difference in FN staining may be due to a reduced density of cells 
in each cyst and may not reflect a true reduction in the levels of FN per cell.  Unfortunately, this 
method does not allow quantitative assessment of FN levels.  
 
Together these results show that 70-kDa and TNfn1-8 inhibit MDCK cell tubulogenesis, potentially 
by reducing the deposition and assembly of FN.   
 
6.2.3   TN-C domains do not affect HUVEC tubule formation in an in vitro model of 
angiogenesis 
Zhou and coworkers showed that FN is essential for endothelial cell proliferation, migration, 
cytoskeletal organization, cell contractility and therefore tubule formation in 3D fibrin and collagen 
gels (Zhou et al., 2008).  As this group had shown that inhibitors of FN matrix assembly including 
the 70-kDa domain inhibit human endothelial cell (HUVEC) proliferation and tubule formation in a 
3D fibrin gel (Zhou et al., 2008), I wanted to determine whether the TN-C domains could also 
inhibit human endothelial cell angiogenesis and tube formation.  Angiogenesis can be simulated in  
Results: The effect of TN-C domains on FN matrix assembly during tubule formation 
 226
Figure 6.7   Immunohistochemical staining of FN in MDCK tubules
(A) The epitopes recognised by each anti-FN antibody are depicted in the schematic. (B-G) MDCK 
cells seeded into 3D collagen gels were cultured for 5 d at 37ºC in DMEM containing 10% FBS and 
supplemented with 5 ng/ml HGF. Collagen gels were fixed in formalin and stained with different anti-
FN antibodies: R39 (B, C), R184 (D), F3648 (E), R40 (F) and R457 (G) and counterstained with 
haematoxylin.  Antibodies were used in a 1:1000 dilution. Images were taken on a light microscope 
at x20 (B) and x10 (C-G) magnification, scale bars = 200 μm and 500 μm respectively.   
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Figure 6.8   Optimisation of immunohistochemical staining for FN using different antigen retrieval 
treatments   
MDCK cells seeded into 3D collagen gels were cultured for 5 d at 37ºC in DMEM containing 10% FBS and 
supplemented with 5 ng/ml HGF.  Antigen retrieval methods were applied to the fixed slides including 
protease treatment (A) and pressure cooking (B).  Samples not treated for antigen retrieval (C) and an H&E 
stain are included for comparison (D).  Images were taken on a light microscope at x20 magnification, scale 
bar = 200 μm.   
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Figure 6.9   Immunohistochemical staining of FN around MDCK tubules  
MDCKs were seeded into 3D collagen gels were cultured for 5 d at 37ºC in DMEM containing 10% FBS 
and supplemented with 5 ng/ml HGF.   Buffer alone in the absence of recombinant protein (A) or 1 μM 70-
kDa (B), TNfn1-3 (C) and TNfn1-8 (D) was added directly to the medium. Cells were then fixed in formalin 
and processed for immunohistochemical staining.  Sections of the collagen gel were protease treated for 
antigen retrieval and stained with the R39 anti-FN antibody at 1:200 dilution. All fixed samples were co-
stained with haematoxylin. Images were taken on a light microscope at x10 magnification, scale bar = 500 
μm, and higher x40 magnification images of the tubular staining can be seen in the inset of each image, 
inset length = 62 μm.  Images are representative of 2 different sections from 2 independent experiments.   
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vitro using an AngioKit™ (TCS Cellworks) where seeded human endothelial cells co-cultured with 
human mesenchymal cells form a network of tubules resembling capillary bed vessels (Beilmann et 
al., 2004).  Suramin, a known inhibitor of tubule formation in this model system and VEGF, a 
known stimulator of angiogenesis (Klein et al., 1996) and tubule formation (Beilmann et al., 2004), 
were included as controls.  Cells were also cultured in buffer alone in the absence of recombinant 
protein or with 1 μM 70-kDa, TNfn1-8, TNfn3-5 or FBG in the presence of VEGF, to determine 
their effects on VEGF-stimulated tubule formation.  Each condition was carried out in triplicate 
with one set of endothelial cells left un-stimulated to indicate the basal level of tubule formation in 
this system (denoted as “–“ in figure 6.10).  Cells were cultured as instructed for 11 d with media 
changes at d 4, d 7 and d 9.  Each time, the fresh medium was re-supplemented with the required 
stimulators, inhibitors and test compounds.  At d 11, the cells were fixed as instructed and the 
endothelial cells stained with an anti-CD31 antibody, followed by an HRP-conjugated secondary 
antibody.  A non-destructive ELISA substrate was added and the colorimetric solution transferred to 
a 96 well dish and read on an ELISA plate reader (Figure 6.10).  CD31 (also known as platelet 
endothelial cell adhesion molecule-1/PECAM-1) is a 130-kDa glycoprotein constitutively expressed 
on the surface of endothelial cells and platelets.   
 
The ELISA results show a significant reduction of tubule formation upon suramin treatment 
compared to basal (-) tubule levels, whilst VEGF significantly stimulated tubule formation (+).  
However, cells cultured in the absence of recombinant protein, 70-kDa, TNfn1-8, TNfn3-5 and 
FBG did not show any inhibition of VEGF stimulated tubulogenesis (Figure 6.10).  In fact, the 
ELISA results suggested TNfn3-5 and FBG significantly increased tubule formation levels.  
 
The ELISA substrate was washed off the tubules and a secondary staining agent applied to stain the 
tubules for image analysis.  Three random fields of view from three independent triplicate repeats of 
each condition were taken at x4 magnification on a light microscope (Figure 6.11 A).  The x4 
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images were analyzed with Image J image analysis software and the surface area of the tubules 
determined as the total number of pixels with intensities less than 100 (Figure 6.11 B). 
 
Suramin treatment showed a significant reduction in tubule surface area compared to the untreated 
control (Figure 6.11 A and B).  This reduction in tubule length, branching and density is particularly 
obvious from the tubule images.  VEGF caused a significant increase in tubule formation compared 
to the untreated control (Figure 6.11 A and B), and this VEGF-stimulated tubule formation was not 
significantly affected by addition of buffer, 70-kDa, TNfn1-8, TNfn3-5 or FBG (Figure 6.11 A and 
B).  The significant difference observed in the ELISA with TNfn3-5 and FBG may be too subtle to 
detect by this imaging method.  These data indicate that that none of the TN-C domains or the 70-
kDa domain of FN have any inhibitory effect on VEGF stimulated vessel formation in this 
angiogenesis assay. 
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Figure 6.10   Human endothelial cell tubulogenesis in the presence of TN-C domains  
Human endothelial cells were cultured in a 2D monolayer to mimic angiogenesis in vitro  20 μM 
tubulogenesis inhibitor suramin was included as a positive control to significantly inhibit endothelial cell 
tubulogenesis.  The medium was supplemented with 2 ng/ml VEGF as indicated (+) and buffer in the 
absence of recombinant protein (no add) or 1 μM 70-kDa, TNfn1-8, TNfn3-5 and FBG added directly 
into the medium.  Cells were cultured for 11 d with media changes as instructed. CD31 levels were 
quantified by ELISA with an anti-CD31 antibody, secondary alkaline-phosphatase conjugated antibody 
and non-destructive colorimetric substrate.  After colour development, the solution was transferred to a 
96 well plate and the O.D. (574nm) determined. Results are shown as mean +/- SEM:  **, p<0.01; ***, 
p<0.001 by one-way ANOVA compared to control without addition of VEGF (-) and control with 
addition of 2 ng/ml VEGF and buffer in the absence of recombinant protein (no add, +). 
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Figure 6.11   Human endothelial cell tubulogenesis in the presence of TN-C domains   
Human endothelial cells were cultured in a 2D monolayer to mimic angiogenesis in vitro.  
20 μM tubulogenesis inhibitor suramin was included as a positive control to significantly 
inhibit endothelial cell tubulogenesis.  The medium was supplemented with 2 ng/ml VEGF 
as indicated (+) and buffer in the absence of recombinant protein (no add) or 1 μM 70-
kDa, TNfn1-8, TNfn3-5 and FBG added directly into the medium.  Cells were cultured for 
11 d with media changes as instructed.  (A) Tubule structures were stained  with  an anti-
CD31 antibody, secondary alkaline-phosphatase conjugated antibody and a colorimetric 
substrate to visualize the tubules by phase microscopy at x4 magnification, scale bar = 
500 μm.  A minimum of 5 random fields of view were imaged from triplicate repeats.  A 
representative image from each condition is shown.  (B) Images were analysed by ImageJ 
for total pixel intensities <100 i.e. representing darkly stained tubules and averaged.  
Results are shown as mean +/- SEM:  **, p<0.01; ***, p<0.001 by one-way ANOVA 
compared to control without addition of VEGF (-) and control with addition of 2 ng/ml 
VEGF and buffer in the absence of recombinant protein (no add, +). 
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Although the manufacturers claim that this is a reliable model of angiogenesis, inhibitors of 
angiogenesis have been shown to have differential effects when cells have been cultured in 3D 
environments versus 2D environments (Zhou et al., 2008).  To determine if 70-kDa or the TN-C 
domains tested have differential effects in 3D cultures, HUVECs were sandwiched between 
collagen gels and stimulated with VEGF to induce tubule formation (Deroanne et al., 1996).  In the 
absence of VEGF, the cells remained round with minimal cell spreading after 2 d culture (Figure 
6.12 A).  However, in the presence of VEGF, HUVECs become well spread (Figure 6.12 B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12  HUVEC spreading in 3D collagen gel.   
HUVECs were cultured in a 3D collagen gel sandwich to mimic angiogenesis 
in vivo.  HUVECs were seeded onto collagen gels and maintained in HUVEC 
medium.  A second layer of collagen gel was then layered on top, and the 
HUVECs were cultured either in the absence of VEGF (A) or in medium was 
then supplemented with 100 ng/ml VEGF (B-F) and buffer alone (C) or 1 μM 
70-kDa (D), TNfn3-5 (E) or TNfn1-8 (F).   Cells were cultured for a further 2 d, 
before fixing in 3.8 % (w/v) paraformaldehyde, permeabilizing in 0.2 % Triton 
X-100 and staining for actin (Alexa Fluor-568 labelled phalloidin) and cell 
nuclei (DAPI).  Images were taken at x20 magnification on a fluorescent 
microscope, scale bar = 100 μm.   
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Inclusion of buffer in the absence of recombinant protein has no effect on VEGF effects on HUVEC 
spreading (Figure 6.12 C), however, the addition of 70-kDa inhibited this spread phenotype (Figure 
6.12 D).  TNfn3-5 and TNfn1-8 also caused the cells to adopt a thinner, less spread phenotype 
(Figure 6.12 E and F).  This would suggest that in 3D cultures, 70-kDa, TNfn1-8 and even TNfn3-5 
may modulate VEGF stimulated HUVEC spreading and morphology or that non-specific addition 
of any protein at high concentrations inhibits HUVEC spreading.  These HUVECs were only 
maintained for 2 d due to the time limitation of this study, and there was no opportunity to repeat 
these experiments.  For more definite results, HUVECs should be monitored for longer periods of 
time to allow 3D tubule formation.  
 
6.3   Discussion 
I have shown that TN-C domains TNfn1-8, TNfn1-3, TNfn6-8 and FBG inhibit FN matrix assembly 
by fibroblasts cultured in monolayer.  Here I show that only TNfn1-8 and 70-kDa specifically 
inhibited MDCK tubulogenesis potentially by reducing FN deposition.  Other domains, TNfn1-3, 
TNfn3-5, TNfn1-5, TNFn5-7, TNfn6-8 and FBG had no effect.  Conversely, no TN-C domains or 
70-kDa had any effect on human endothelial cell tubule formation in a 2D model of angiogenesis.  
However, 70-kDa, TNfn3-5 and TNfn1-8 reduced HUVEC spreading when cultured in a 3D 
collagen gel.  These data show that TNfn1-8 can inhibit tubulogenesis and suggest that TN-C 
domains may have differential effects on angiogenic cell processes in 3D compared to 2D cultures.   
 
6.3.1   TNfn1-8 and 70-kDa inhibit MDCK tubulogenesis 
The inhibition of MDCK tubule formation by TNfn1-8 and 70-kDa is similar to observations by 
Jiang et al., (Jiang et al., 2000) who used RGD-rhodostamin and FN antisense constructs to inhibit 
FN matrix assembly to show that the formation of tubules by HGF stimulation of MDCK cells 
cultured in 3D collagen gels requires FN matrix assembly.  TNfn1-3, TNfn6-8 and FBG did not 
affect tubulogenesis, suggesting that even though these domains can inhibit FN assembly by 
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fibroblasts cultured in a monolayer, these domains are not sufficient to inhibit FN matrix assembly 
by epithelial cells or within a 3D environment.  Both TNfn1-8 and 70-kDa inhibited early FN 
matrix assembly initiation events suggesting that FN fibrillogenesis initiation is required for tubule 
formation.  In contrast, TNfn1-3, TNfn6-8 and FBG affected later FN fibrillogenesis processes 
suggesting that even if subsequent FN disassembly occurs, the initial FN matrix assembled is 
sufficient to allow tubulogenesis to proceed.    
 
Attempts to determine FN localization in MDCK cell tubules by incubation with fluorescently 
labeled human plasma FN only resulted in background staining of the collagen gel.  Long periods of 
incubation with the fluorescent FN resulted in poorly branched structures with cells that had an 
indistinct membrane, suggestive of membrane blebbing observed when cells undergo apoptosis 
(Coleman et al., 2001).  Excess FN has been previously shown to reduce epithelial cell migration 
(Hocking and Kowalski, 2002), possibly by affecting the matrix stiffness and enhancing focal 
adhesion formation.  Furthermore, endothelial tubule formation specifically requires the expression 
of the (EDB+)FN isoform and inhibition of (EDB+)FN expression could not be rescued by addition 
of exogenous plasma (EDB-)FN (Khan et al., 2005).  This is an intuitive regulatory system to 
ensure restricted tubule formation.  This may also explain why addition of exogenous human 
plasma FN may have impeded MDCK tubulogenesis in my experiments.  This variant of FN may 
not have allowed for correct survival and migration signals in the epithelial cells leading to their 
regression and membrane blebbing.   
 
Staining of FN by indirect immunofluorescence also failed, which may be due to a lack of 
penetration by this antibody through the 3D collagen gel possibly restricted by non-specific 
interactions with the 3D collagen gel.  By immunohistochemistry, FN could only be specifically 
detected by the R39 anti-FN antibody and required proteolytic induced epitope retrieval.  The 
immunolocalization of FN did not appear to differ between treatments compared to the control.  
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TNfn1-8 and 70-kDa showed a slight reduction of FN staining around the tubules by 
immunohistochemistry.   Unfortunately, this method does not allow a quantitative assessment of FN 
levels in tubules and the resolution of these images also does not allow for determination of the 
overall FN matrix structure assembled by these cells or the intracellular or extracellular FN levels.  
The fact that there are also fewer cells in the collagen gels treated with 70-kDa and TNfn1-8 also 
means any slight reduction in overall staining intensity may not be a representation of a reduction in 
FN levels per cell per se, but that fewer cells are clustered together.   
 
Further work is required to conclusively determine whether TNfn1-8 or 70-kDa affect the amount 
of FN assembled by MDCK cells to inhibit tubulogenesis.  It is also unknown whether full-length 
TN-C affects tubulogenesis in this system.   
 
FN expression and intracellular levels can be determined by releasing cells from the collagen gel by 
collagenase digestion and probing cell lysates for FN protein (Western blotting) or isolating FN 
mRNA (Jiang et al., 1999) (Jiang et al., 2000). The conditioned medium could also be analyzed to 
determine whether higher levels of FN are secreted upon incubation with 70-kDa and TNfn1-8.  
Biochemical and quantitative analyses of the level of FN matrix assembled by these cells must be 
done, but the specific extraction of the FN matrix from the 3D collagen gel poses a challenge; 
collagenase extraction of cells may result in disruption of the basal laminae surrounding the tubules.  
It may be possible to modify the protocol for producing cell-free FN matrices (Mao and 
Schwarzbauer, 2005), whereby the cells are lysed and in a low salt detergent buffer and removed 
without disturbing the overall matrix architecture.  The amount of FN deposited within the collagen 
gel could then be determined by collagenase digestion and resolution by SDS-PAGE and Western 
blotting for FN content.  The feasibility and optimization of this process will need to be determined.  
MDCK cells could be transfected with GFP-tagged FN constructs to monitor endogenous FN 
assembly levels into the matrix in the presence or absence of recombinant TN-C domains.  
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Cryosectioned or paraffin-embedded collagen gels have also been fluorescently immunostained 
with the advantage that higher magnification confocal images can be captured allowing the 
determination of the matrix architecture (Choe et al., 2006) (Zargham et al., 2007).       
 
Finally, I used an MTT assay to asses MDCK cell viability. This was performed on cells cultured 
on a 2D plastic 96 well dish over a period of 5 d because this assay is rapid and allows multiple 
repeats without requiring large volumes of TN-C protein.  MTT assays on cells cultured in collagen 
gels are technically challenging but would help to determine cell viability and apoptosis levels of 
MDCKs cultured in a 3D environment. The MTT assay has been performed on mesenchymal stem 
cells cultured in 3D chitosan-gelatin-chondroitin scaffolds (Machado et al., 2007) or fibroblasts 
cultured in 3D Azowipe ® non-woven viscose rayon bonded with a styrene butadiene copolymer 
scaffolds (Sun et al., 2006) directly without digestion of the gel.   
 
6.3.2   Fragments of TN-C act to limit tubulogenesis during development? 
Tubule formation requires complex coordination of epithelial cell processes (Borenstein and Cline., 
2004) (Montesano et al., 1991) (Schoenenberger et al., 1994), and FN deposition in the basal 
laminae is important in this process as it polarizes the cells and provides survival signals (Jiang et 
al., 1999) (Schoenenberger et al., 1994) and also regulates cell adhesion, spreading, proliferation, 
migration and apoptosis during in vitro tubulogenesis (Jiang et al., 1999) (Jiang et al., 2000) 
(Saelman et al., 1995) (Schoenenberger et al., 1994).  FN signaling also promotes epithelial cell 
survival during tubule formation (Jiang et al., 1999) via β1 integrins (Praetorius et al., 2004) and 
focal adhesion kinase (FAK) activation (Ilic et al., 1995) (Ilic et al., 1996).  Furthermore, migrating 
MDCK cells have been shown to express (EDA+)FN isoform (Inoue et al., 2001), which has been 
shown to assemble into a FN matrix more readily and enhances cell adhesion and spreading 
(Manabe et al., 1997) (Guan et al., 1990).   
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MDCK tubulogenesis is a useful model of in vivo tubule and branching formation (Bird, 2006) 
(Borenstein and Cline., 2004) (Jiang et al., 2000) (Montesano et al., 1991).  Tubulogenesis and 
branching is vital during development.  FN and TN-C are both highly expressed in the epithelial 
cleft regions of branching tubules suggesting they are involved in directing and promoting cell 
migration and polarization during tubulogenesis.  FN has been shown to be expressed both at the 
mRNA level (laser microdissection followed by mRNA isolation) and protein level 
(immunofluorescent staining) in the cleft regions of budding submandibular gland explants (Sakai 
et al., 2003).  Inhibition of FN assembly and protein function with blocking antibodies against FN, 
α5 or β1 or FN mRNA expression with FN siRNA inhibited branching by these epithelia explants 
(Sakai et al., 2003). Similarly, TN-C is expressed at the epithelial-mesenchymal interface in 
developing epithelial clefts and the distal tips of elongating epithelium during development as 
determined by immunofluorescent staining and immunoelectron microscopy.  TN-C null mouse 
lung explants showed a 36-46% reduction in the number of branches formed, and TN-C null mice 
had enlarged airspaces reflecting reduced terminal bud branching (Roth-Kleiner et al., 2004).  TN-C 
antiserum inhibited rat fetal lung explant branching as did TN-C antisense oligonucleotides (Gebb 
et al., 2005) (Young et al., 1994).   Using recombinant TN-C domains, the TNfn6-8, TNfn1-5 and 
TNfnA-D domains were shown to inhibit branching morphogenesis in rat lung explants whereas 
FBG had no effect (Young et al., 1994).  The presence of endogenous TN-C in this system made it 
hard to discern the mechanism of action of inhibition by these TN-C domains; they may potentially 
be acting by inhibiting the stimulatory effect of TN-C on tubulogenesis during branching 
morphogenesis.   It is unknown if these domains are also affecting FN levels in this explant model 
of tubulogenesis (Young et al., 1994).  MDCK cells do not express TN-C themselves, but have been 
shown to strongly induce expression in neighboring mesenchymal cells, which in vivo may be 
involved in regulating epithelial cell growth and development (Aufderheide and Ekblom, 1988).  
This means in the MDCK tubulogenesis model I used there is no endogenous TN-C present. Thus 
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any effects caused by TNfn1-8 are not due to inhibition of TN-C function but may potentially 
inhibit FN matrix assembly. 
 
The presence of full-length TN-C here may also be involved in facilitating FN matrix assembly or 
modifying the adhesive properties of the FN matrix.   However, only TN-C is expressed in the 
epithelium of budding tips where FN levels are reduced.  This implies that TN-C may be involved 
in directing cell migration or promote secretion of proteases required for invasion at the bud tips.  
The different matrix composition in these locations must be important in directing differential cell 
activities.   
 
Given that specific domains of TN-C can inhibit tubulogenesis it is tempting to speculate that 
degradation of full-length TN-C into fragments that inhibit FN matrix assembly acts as a feedback 
mechanism to turn off or limit tubulogenesis.  Thus the ability of full-length TN-C and specific TN-
C domains to either promote or inhibit the tubulogenesis process respectively provides a further 
cryptically controlled regulatory mechanism of these modular ECM proteins which act to feedback 
and limit excessive branching during developmental events. 
 
6.3.3   Differential effects of TN-C domains on angiogenesis in a 2D model compared to 3D 
culture 
Using the in vitro AngioKit™ (TCS Cellworks), human endothelial tubule formation was not found 
to be significantly affected by 70-kDa or TNfn1-8 compared to cells cultured with VEGF alone or 
with buffer.  In contrast, TNfn3-5 and FBG did show a significant increase in CD31 levels, 
indicative of increased endothelial cell proliferation and tubule formation, but only by ELISA 
quantification.  Quantification of tubule images did not demonstrate a significant increase, which 
may be due to the ELISA being more sensitive.  CD31 may also be cleaved from the cell surface 
similar to that observed with platelets under high shear stress (Naganuma et al., 2004) and 
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neutrophils during their extravasation (Christofidou-Solomidou et al., 1997), which could contribute 
to the soluble CD31 levels.  However, the increase in tubule formation would support FBG effects 
on endothelial cell elongation as reported by Schenk et al., (Schenk et al., 1999).  It was surprising 
that TNfn3-5 had a stimulatory effect on tubulogenesis.  In this case, TNfn3-5 may affect integrin 
signaling to promote angiogenesis.   
 
Although Zhou et al., (Zhou et al., 2008) have previously shown that 70-kDa inhibits endothelial 
tube formation of HUVECs cultured in 3D fibrin gels, in the TCS angiogenesis system 70-kDa and 
TNfn1-8 had no effect.  It may be that VEGF is a very potent stimulator of human endothelial 
tubulogenesis in this Angiokit™ system in the absence of a 3D matrix imposing a chemotactic 
gradient or that the 3D environment of a fibrin or collagen gel requires different signaling events 
and matrix organization that is disturbed by these protein domains.  Zhou et al (Zhou et al., 2008) 
did show cell morphology of cells cultured in 2D could not be affected by a 70-kDa or other FN 
matrix inhibitors unlike those cultured in 3D.  As only a limited number of combinations and 
permutations could be tested in this assay, it would have been interesting to see if the suramin 
inhibitor itself could negate the effects of VEGF or whether TN-C domains could inhibit/stimulate 
angiogenesis in the absence of VEGF.   
 
The advantage of the AngioKit™ is that endothelial cells are co-cultured with mesenchymal 
(fibroblast) cells, and embedded in ECM that they assemble.  However, a limitation of this assay is 
that human endothelial cells are being co-cultured on a hard, 2D surface and cell function has been 
shown to be altered dependent on matrix stiffness (Discher, 2008) (Engler et al., 2006) (Zajac and 
Discher, 2008).  Three-dimensional models also mimic other factors required for angiogenesis 
including hypoxia (Pugh and Ratcliffe, 2003) and ECM degradation to expose cryptic chemotactic 
epitopes (Hangai et al., 2002) (Kalluri, 2003), mediated by enzymes such as MT1-MMP (Bird, 
2006) (Hiraoka et al., 1998) (Stratman et al., 2009) and MMP-1 (Guenzi et al., 2003).  To determine 
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whether 70-kDa, TNfn1-8 or TNfn3-5 have any effect on 3D angiogenesis, HUVECs were cultured 
by sandwiching between collagen gels. Migration through the collagen gels with VEGF as 
stimulation was observed after 2 d culture by immunofluorescence.  This showed that VEGF was 
stimulatory for HUVEC spreading and elongation.  This was not affected by buffer alone, but 70-
kDa, TNfn3-5 and TNfn1-8 caused cells to adopt a less spread and thinner phenotype.  This 
suggests these protein domains are affecting HUVEC interactions with the surrounding ECM to 
alter cell shape, and this may be occurring by affecting FN matrix assembly.  However, cells were 
not cultured for long enough to induce tubulogenesis, so it is not clear whether these domains affect 
the angiogenesis process overall.   
 
6.3.4   Do TN-C fragments act to limit physiological and pathological angiogenesis? 
FN and TN-C have been shown to be up-regulated in regions of active angiogenesis.  FN and TN-C 
are both highly expressed during development (Akhurst et al., 1990) (Ballard et al., 2006) (Chiquet 
and Fambrough, 1984) (Crossin et al., 1986), wound healing (Betz et al., 1993) (Latijnhouwers et 
al., 1996) (Mackie et al., 1988), in tumor stroma and around tumor blood vessels (Hanamura et al., 
1997) (Kaczmarek et al., 1994) (Schnyder et al., 1997) (Talts et al., 1999).  FN is required for 
angiogenesis: a FN fibrillar network is required for HUVEC proliferation and migration in 
developing neovessels (Zhou et al., 2008); FN enhances endothelial cell migration (Tonnesen et al., 
2000) (Feng et al., 1999) (Nicosia et al., 1993) and (EDB+)FN isoform is up-regulated in blood 
vessels of invasive breast carcinomas (Kaczmarek et al., 1994) and is required for HUVEC survival 
and neovascularisation (Khan et al., 2005).  Most of the evidence in the literature suggests that TN-
C promotes angiogenic processes including: cardiac microvascular endothelial cell migration and in 
vivo neovascularization (Ballard et al., 2006); bovine retinal endothelial cell migration (Zagzag et 
al., 2002); basic FGF-induced bovine arterial endothelial cell elongation (Schenk et al., 1999) and 
adoption of a sprouting phenotype (Canfield and Schor, 1995). The FBG domain of TN-C has been 
shown to promote this effect (Schenk et al., 1999) by reducing cell adhesion to the ECM substratum 
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and modulating cell shape (Chung et al., 1996) (Ballard et al., 2006) (Schenk et al., 1999; Zagzag et 
al., 2002).  Contrary to this, TNfnA2 has been shown to inhibit angiogenesis and human dermal 
microvascular endothelial cell migration by signaling via the β1 subunit (Saito et al., 2008) 
suggesting that different TN-C domains have differential effects on angiogenesis.  
 
These data suggest that full-length TN-C can interact via its FBG domain with αvβ3 integrins 
highly expressed on the surface of endothelial cells to promote endothelial shape changes and 
reduce focal adhesion formation required for tube formation.  This may promote angiogenesis.  
However, TN-C fragments revealed upon proteolysis (e.g. TNfn3-5, TNfn1-8 and 70-kDa) may 
inhibit angiogenesis and prevent HUVEC spreading by interfering with FN-FN interactions during 
FN matrix assembly and/or prevent cell signaling required for endothelial cell shape changes, 
proliferation, migration and survival.  The proteolysis of TN-C may again, act as a cryptically 
controlled regulatory mechanism, which limits excessive angiogenesis by regulating the FN matrix 
assembly process.   
 
6.4   Summary 
My data demonstrate that 70-kDa and TNfn1-8, which are inhibitors of FN matrix assembly, can 
inhibit MDCK tubulogenesis and prevent spreading of HUVECS in 3D collagen gels.  Whether 
these protein domains are also inhibitory for angiogenesis remains to be determined.  Further work 
needs to be done to confirm that these protein domains are affecting FN matrix assembly directly.  
These data support a matricryptic role for TN-C in regulating FN assembly during physiological 
and pathological processes.  As both tubulogenesis and angiogenesis occur in protease rich 
environments, protein domains may act to modify cell activities to provide novel regulatory systems 
for these essential processes.  The ability of these TN-C and FN domains to affect tubule forming 
processes may provide a unique tool, which can be applied to control aberrant angiogenesis that 
occurs in pathological conditions.  
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FN is an essential and ubiquitous component of the ECM.  Its assembly into a complex fibrillar 
matrix on the cell surface is essential to support tissue architecture and regulate cellular processes.  
FN has been shown to play a vital role in processes including tubulogenesis and angiogenesis by 
regulating cell migration, proliferation, morphology and survival.  FN matrix assembly occurs in a 
complex step-wise process: during early FN matrix assembly events, FN binds to cell surface 
receptors including α5β1 integrins, αvβ3 integrins and HSPGs via its 70-kDa domain, CBD and 40-
kDa (HepII) domain.  Translocation of α5β1 integrins by cytoskeletal re-organization and cell 
contractility stretches the FN molecule to expose FN-FN binding sites allowing intermolecular FN-
FN interactions.  Further stretching of the molecule and unfolding of modules reveals cryptic 
binding sites which allow further FN-FN interactions to occur.  Many soluble growth factors 
regulate FN synthesis.  However it is not clear how the complex assembly of FN into a 3D matrix is 
controlled by other components of the ECM.  In this thesis I have shown that specific domains of 
the ECM glycoprotein TN-C can regulate FN matrix assembly. 
 
7.1   Cryptic functions within TN-C regulate FN matrix assembly during tissue remodeling  
TN-C is a multimodular, multidomain ECM protein that is highly expressed during development.  It 
exhibits a restricted pattern of expression postnatally.  It is not expressed or expressed at low levels 
in healthy adult tissues but is specifically and transiently induced at sites of active tissue 
remodeling; both physiological (for example during tissue repair), and pathological (for example 
during fibrosis or in tumors) (Introduction chapter 1, Table 1.5).   Its expression spatially and 
temporally correlates with areas of FN synthesis in tissues undergoing remodeling both during 
embryogenesis and in the adult.  TN-C has the ability to localize to FN fibrillar matrices, and also to 
modify the adhesive properties of FN but its effects on FN matrix assembly were not known.     
  
I have shown that full-length TN-C does not inhibit FN matrix assembly, but individual domains 
within TN-C: TNfn1-8, TNfn1-3, TNfn6-8 and FBG possess cryptic functions that enable them to 
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inhibit FN matrix assembly.  I have also shown that specific TN-C domains can inhibit 
tubulogenesis and may affect angiogenesis by interfering with FN matrix assembly.   
 
These data confirm that individual domains of large multimodular proteins can exhibit differential 
effects on cellular processes compared to the full-length molecule (Tran et al., 2005).  TN-C may 
play proteolytically regulated roles in controlling FN matrix assembly at different stages of tissue 
remodeling.  Full-length TN-C may facilitate the correct organization of FN matrices or alter its 
properties independently of affecting assembly.  Subsequent TN-C degradation may create TN-C 
fragments that can inhibit FN matrix assembly.  For example, during wound healing, full-length 
TN-C is initially deposited at the wound edges and within the granulation tissue, which is rich with 
cellular FN deposited by fibroblasts and new blood vessels (Betz et al., 1993) (Latijnhouwers et al., 
1996) (Loots et al., 1998) (Lorenz and Longaker, 2003) (Mackie et al., 1988) (Midwood et al., 
2004) (Whitby and Ferguson, 1991).  Full-length TN-C may facilitate FN assembly and promote 
neovascularization in order to rebuild tissue lost upon injury.  TN-C expression is down-regulated 
and protein cleared from the wound during later stages of wound healing and it is absent in scar 
tissue (Betz et al., 1993) (Latijnhouwers et al., 1996) (Loots et al., 1998) (Mackie et al., 1988) 
(Whitby and Ferguson, 1991).  TN-C clearance is likely to proceed via its proteolytic degradation 
and this may create fragments that feedback to regulate FN matrix assembly and angiogenesis.  
 
This hypothesis is supported by the expression of full-length TN-C in regions of high protease 
expression and activity (Cowan et al., 1999) (Jones et al., 1995) (Jones et al., 1997) (Kalembeyi et 
al., 2003) (Mai et al., 2002).  TN-C itself can also induce the expression of MMPs by fibroblasts, 
(Tremble et al., 1994), breast epithelial cells (Kalembeyi et al., 2003) and smooth muscle cells 
(Wallner et al., 2004).  MMP-1, MMP-2, MMP-3, MMP-7, serine proteases, leukocyte elastase and 
cathepsins can degrade TN-C (Imai et al., 1994) (Latijnhouwers et al., 1998) (Mai et al., 2002) (Siri 
et al., 1995) and degradation of TN-C may reveal fragments encompassing TNfn1-8, TNfn1-3, 
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TNfn6-8 and FBG to allow the exposure of their inhibitory activity which is otherwise buried in the 
full-length protein.    
 
TN-C fragments have been found in tissues in vivo (Introduction chapter 1, section 1.3.7), although 
their identity has not been examined.  It will be interesting to characterize TN-C fragmentation 
during developmental processes, during wound healing or in pathological conditions in vivo to 
determine whether fragments possessing the actively inhibitory domains can be isolated. 
Incorporation of full length TN-C into tissue explants and analysis of soluble fragments released 
upon proteolysis would also be informative.  In vitro TN-C could also be digested with different 
proteases and the TN-C fragments generated tested for effects on FN matrix assembly to determine 
whether these digested fragments are sufficient to expose inhibitory domains.   
 
I have shown that different domains within TN-C exhibited different mechanisms of FN matrix 
assembly inhibition.  For example, my data suggest that TNfn1-8 inhibited early FN matrix 
assembly events by competing for binding to the 70-kDa and CBD domains in fibrillar FN, to 
prevent the interaction of these domains with cell surface integrins and with FN domains in 
neighbouring FN molecules.  Inhibition of FN-cell and FN-FN binding causes increased levels of 
secreted FN and loss of an organized 3D fibrillar matrix on the cell surface.   In contrast, FBG 
caused disassembly of an already mature FN matrix independent of FN binding.  FBG interacted 
with the cell surface and was internalized, resulting in actin cytoskeleton re-organization, 
internalization of FN and loss of an organized 3D fibrillar matrix at the cell surface.  These data 
imply that TN-C domains may play temporally regulated roles in regulating FN matrix assembly, 
and are able to exert control at multiple and distinct stages.  TN-C domains could act as a cue 
throughout FN fibrillogenesis to ensure the correct amount of FN matrix is laid down in the correct 
place during tissue remodeling.  The ability of FBG and TNfn1-8’s to reduce FN levels in mature 
FN matrices, suggests they can also regulate FN levels in a pre-assembled ECM.  The FN matrix 
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has been shown to be important as a scaffold protein in the incorporation of other ECM components 
such as type I collagen (Dzamba and Peters, 1991) (Sottile and Hocking, 2002) (Sottile et al., 2007) 
(Velling et al., 2002) so FBG and TNfn1-8 may act to “dispose” of excess FN scaffold after the 
assembly of other ECM proteins.    
 
TN-C null mice exhibit defects in angiogenesis and tubulogenesis (Ballard et al., 2006) (Tanaka et 
al., 2004) (Roth-Kleiner et al., 2004) and reduced FN and ECM deposition: in wound granulation 
tissue (Forsberg et al., 1996), corneal wounds (Matsuda et al., 1999), glomerulonephritis 
(Matsumoto et al., 2002) and in liver fibrosis (El-Karef et al., 2007).  These data support the idea 
that the full length form of this molecule is important in promoting these processes in vivo.  This, 
however, does make it difficult to assess the importance of TN-C fragments in vivo.  More 
information may  be generated by synthesis of a non-cleavable TN-C variant similar to non-
cleavable collagen (Wu et al., 1990) although the multiple proteases that can act on TN-C may 
make this difficult to engineer (Imai et al., 1994) (Latijnhouwers et al., 1998) (Mai et al., 2002) (Siri 
et al., 1995). 
 
In other circumstances TN-C null mice exhibit increased FN deposition, for example in tumor ECM 
(Talts et al., 1999).  This could be explained by the differential effects of full-length TN-C versus 
smaller TN-C domains and the relative importance of each in the different physiological processes.  
A balance between the different forms of TN-C in the tissue is important.  For example, although 
TN-C is persistently expressed in chronic non-healing wounds, high levels of TN-C fragments are 
observed in this highly proteolytic environment (Latijnhouwers et al., 1996) (Loots et al., 1998).  
The presence of these TN-C fragments in the wound bed could prohibit FN matrix deposition and 
perpetuate the loss of ECM within the wound.  Conversely persistent expression of TN-C in fibrotic 
diseases appears to promote disease progression.  Here, TN-C may be either more resistant to 
proteolytic degradation due to the isoform expressed or FN synthesis may be enhanced to such an 
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extent that TN-C domains are ineffective.  This model suggests TN-C plays dual but opposing roles 
depending on the precise nature and form of the molecule in the tissue, which may also act as a 
molecular indicator of the stage of the tissue remodeling process.   
 
7.2   Identification of novel binding sites for FN within TN-C  
My results revealed cryptic binding sites for specific domains of plasma FN within TN-C that are 
obscured or unavailable in the full-length molecule but which are available in the smaller domains.  
I have also shown that binding to 3D fibrillar FN has different requirements than binding to plasma 
FN coated onto ELISA dishes and I identified that small TN-C domains contain multiple binding 
sites for different domains of cellular FN.  These data raise some interesting questions as to how the 
binding of TNfn domains to FN is mediated.  Does a single TNfn domain form a separate and 
discrete FN binding site? Or are FN binding sites formed from collaborative contributions from 
multiple TNfn domains? Conversely, how does the presence of other TNfn domains mask these 
binding site(s)?  I explored this further by modeling potential FN binding sites in TNfn domains.   
 
7.3   The 3D structure of TNfn3  
Only the TNfn3 domain of TN-C has been crystallized and the structure determined by X-ray 
crystallography to 1.8 Å (pdb file: 1Ten; (Leahy et al., 1992)) (Figure 7.1 A).  The structure consists 
of seven β-strands arranged into two anti-parallel β-sheets: 3 β-strands A, B and E forming one 
sheet whereas 4 β strands C, D, G, F forming the second sheet (Leahy et al., 1992) (Pas et al., 2006) 
(Figure 7.1 B).  The β-sandwich topology of TNfn3 is homologous to that to of FNIII10 but the loop 
structures of FNIII10 are more flexible whereas those on TNfn3 are more rigid (Carr et al., 1997).  
These loop structures can possess important binding sites: the RGD sequence within FNIII10 is 
located on an exposed loop between β-strands F and G (Carr et al., 1997) and binding to this RGD 
site is promoted by PHSRN sequence located on the loop between β-strands D and E of FNIII9 
(Leahy et al., 1996).  In contrast, the RGD loop within TNfn3 is located on a shorter and more rigid 
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loop between β-strands F and G suggesting its integrin binding activity is more limited (Carr et al., 
1997) (Figure 7.1 B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.1   Multiple FN binding sites may be formed from clusters of charged residues in 
individual modules 
Ingham reported that the binding of FN and TN-C is predominantly electrostatic (Ingham et al., 
2004).  I mapped the electrostatic potential of the modular surface of TNfn3 using Pymol software 
and the 1Ten published structure.  The electrostatic potential model is an approximation of the 
electrostatic potential, which does not take into account any solvents.  This created two strongly 
negatively charged surfaces (red) on opposing sides of the TNfn3 module (Figure 7.2 A and B), 
Figure 7.1   The structure of TNfn3 
(A) The crystal structure of TNfn3 (pdb file: 1Ten).   The corresponding β-sheets are highlighted in green 
and red and the RGD sequence (ARG877, GLY878 and ASP879) is shown as stick structures on the 
loop between the β-strand E and β-strand F.  Stick structures are coloured: carbon, green; oxygen, red; 
nitrogen, blue).  The N- and C-terminals are also denoted as N and C respectively. (B) The β-strand 
structure of the FN type III fold with the two β-sheets highlighted in green and red.  Schematic is modified 
from Gao, 2003. 
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with only smaller patches of positively charged surfaces (blue) (Figure 7.2 C).  The strongly 
negatively charged surfaces were generated by a cluster of glutamate and aspartate residues, which 
have been highlighted in the primary sequence (Figure 7.3 A; 1TenA and 1TenB).  The weakly 
positively charged surfaces are created by lysine and arginine residues highlighted by in blue in the 
primary sequence (Figure 7.3 A; 1TenC).    This suggests there are two possible FN binding sites 
within TNfn3.  Each surface is formed from disparate amino acids distributed across the TNfn3 
sequence composing the exposed loops and β-strands, which come together to form large pockets of 
charge.   
 
By comparing the primary sequences for human, mouse and chick TNfn3, I found that this domain 
is highly conserved and showed 77.78% identity across these 3 species (Figure 7.3 B).   The high 
conservation of the TNfn3 suggests it plays an important function within TN-C.  Clusters of 
negatively charged residues in TNfn3, which form the electrostatically negative surfaces, are also 
well conserved across species (Figure 7.3 C).  The EBKDVTD sequence (A β-strand and loop 
region between AÆB) is fairly well conserved with only a substitution of V(811) to an A(782) in 
chick TNfn3 (Figure 7.3 C).  This substitution is likely to maintain the overall surface charge.  
Similarly, the EIDGIEL sequence is well conserved with only a substitution of G(832) to S(832) in 
mouse TNfn3 and D(832) to E(802) substitution in chick TNfn3.  These substitutions should 
maintain the overall surface charge.  The aspartate of the DTEYE sequence (loop region between 
EÆF respectively) is substituted with a histidine, H(837) in chick TNfn3, which would interrupt the 
negative charge on the surface of this TNfn domain (Figure 7.3 C).  Similarly, the IDLTEDEN 
sequence (loop region of DÆE) is strongly similar in human and chick TNfn3, but in mouse TNfn3, 
the E(853) is replaced by a positive charge H(853) (Figure 7.3 C).  This would reduce the overall 
negatively charged surface.  In each case, whether the differences in side chains affect the 
electrostatic surface charge requires mouse and chick TNfn3 structural modeling comparisons, but 
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together these data demonstrate that these acidic residues are good candidates for the FN binding 
site in TNfn3. 
 
Whilst TNfn3 is highly conserved across species, comparison of the primary sequences of TNfn1-
TNfn8 in human TN-C demonstrates only 6.45% identity (Figure 7.4 A).  The higher sequence 
diversions between different FNIII modules of the same species have been discussed before (Craig 
et al., 2004).  However, in the loop regions and β-strand sequences there are some similarly charged 
residues as those observed in TNfn3, which are highlighted in red (1TenA) and orange (1TenB) 
(Figure 7.4 B).  From this it can be seen that TNfn1, TNfn5, TNfn6 and TNfn8 have similar 
AXXXXAXXA (A, acidic residue; X, any residue) motifs: TNfn1, DLVVTEVTE; TNfn5, 
DLQVSETAE; TNfn6, EVIFSDITE and TNfn8, DLTATEVQSE.  This is similar to the TNfn3 
EVKDTVTD sequence although whether the AXXXXAXXA sequences allow the charged residues 
to be clustered enough to produce a significant electrostatically charged surface is difficult to 
predict especially as many of the residues span the length of β-strand A.    
 
Clusters of charged residues can also be observed: TNfn1, within loops AÆB (EVTEE) and loops 
EÆF (ELEPGVE); TNfn2 within loops BÆC (DPLDIAFE) and CÆD (EDEGE); TNfn6 within 
loops FÆG (FEESE).  These are highlighted in pink in figure 7.4 C.   
 
These data indicate potential FN binding sites on the exposed loops and within the β-strands of 
TNfn3, and possibly similar sites in TNfn1, TNfn2, TNfn5, TNfn6 and TNfn8.  If each TNfn 
module forms discrete and independent FN binding sites then this would suggest that TNfn1-5 has 
fewer possible FN binding sites than TNfn1-8, yet TNfn1-5 has been shown to bind to multiple FN 
domains and may do so simultaneously unlike TNfn8.  It is likely that neighboring domains may 
affect the conformational function of these binding sites instead. 
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Figure 7.3   Sequence analysis and alignments of TNfn3 
(A)  Residues that contributed to the electrostatically charged surfaces A, B and C in Figure 7.2 are 
highlighted in the TNfn3 sequence (TENA_Human (P24821) from the UniProtKB website); residues 
contributing to the negatively charged surfaces A and B are highlighted in red and orange respectively; 
residues contributing to the positively charged surface C are highlighted in blue.  (B)  Sequence alignments of 
TNfn3 modules from human, mouse and chick.  Sequence data was taken from TENA_Human (P24821), 
TENA_mouse (Q80YX1) and TENA_chick (P10039) from the UniProtKB website and compared by 
CLUSTALW online NPS@: Network Protein Sequence Analysis (TIBS 2000 March Vol. 25, No 3 [291]:147-
150, Combet C., Blanchet C., Geourjon C. and Deléage G). Residues highlighted in green are identical in all 
sequence alignments, residues highlighted in yellow are strongly similar, residues highlighted in light blue are 
weakly similar.  The RGD sequence in TNfn3 has been highlighted in red.  (C) TNfn3 from mouse and chick 
were compared for similar electrostatic residues as observed in human TNfn3: residues that matched those 
on the charged TNfn3 surfaces A and B are highlighted in red and orange respectively.  The β-strands A-G 
are shown as green rectangles and are aligned to the TNfn3 sequence as shown in Jang et al., 2004.  
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Figure 7.4   Sequence analysis and alignments of all TNfn modules 
(A) Sequence alignments of conserved TNfn modules (TNfn1-TNfn8) from the human sequence. Sequence 
data was taken from TENA_Human (P24821), from the UniProtKB website and compared by CLUSTALW 
online NPS@: Network Protein Sequence Analysis (TIBS 2000 March Vol. 25, No 3 [291]:147-150, Combet 
C., Blanchet C., Geourjon C. and Deléage G).  Residues highlighted in green are identical in all sequence 
alignments, residues highlighted in yellow are strongly similar, residues highlighted in light blue are weakly 
similar.  The RGD sequence in TNfn3 has been highlighted in red. (B) TNfn1-TNfn8 were screened for similar 
clusters of charged residues as those observed in TNfn3: residues that matched those found on the charged 
TNfn3 surfaces A and B are highlighted in red and orange respectively, as are the AXXXXAXX(X)A 
sequences and residues that are found in similar locations on the primary sequence.  (C) Possible clusters of 
negatively charged residues are highlighted in pink.  The β-strands A-G are shown as green rectangles and 
are aligned to the TNfn3 sequence as shown in Jang et al., 2004.  
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The ability of neighboring domains to influence specific sequence presentation in TNfn modules 
has been shown: the interdomain tilt between FNIII9-FNIII10 significantly affected the overall 
presented structure of the RGD repeat of FNIII10 (Altroff et al., 2004).   Mutagenesis studies of 
residues within the FNIII9 loops that form the FNIII9-FNIII10 interface showed that a mutation 
reducing interdomain mobility resulted in a loss of cell attachment and cell spreading by FNIII9-
FNIII10 and reduced the angle tilt between modules (Altroff et al., 2004).  The stabilization and 
torsional constraints by adjacent protein domains has been shown by NMR relaxation parameters, to 
arise from non-specific protein-protein interactions between the FNIII9-FNIII10 interfaces 
(Spitzfaden et al., 1997).  Furthermore, by X-ray crystallography, the presence of the EDB 
alternatively spliced module was shown to alter the angle of the interface with its neighboring 
FNIII8 domain compared to the FNIII7-FNIII8 interface causing an increased surface area exposed at 
the EDB-FNIII8 interface.  This exposed surface area and associated loop structures were highly 
acidic (Bencharit et al., 2007) and exposed adhesion promoting sequences (Chen and Culp, 1996).  
So, it is possible that the TNfn1-2 domain may stabilize a specific conformation between 
TNfn2:TNfn3 interface to expose acidic residues in the correct conformation for binding fibrillar 
FN.   
 
7.3.2   FN binding sites may be formed by disparately located charged residues contributed 
from different modules 
It is possible that FN binding sites may be formed not just by residues from a single TNfn domain 
but by cooperation of residues from other modules.  In TNfn1-5, residues located in the loops of 
adjacent domains TNfn1-2 or TNfn4-5 may be required together with the loops of TNfn3 to form 
pockets of charged residues capable of binding to FN.  Alone each domain may form no or weaker 
interactions with fibrillar FN.  In this case, residues provided by either TNfn1-2 or TNfn4-5 seem to 
be sufficient and equally effective in allowing optimal interaction of TNfn3 with soluble FN 
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whereas only TNfn1-2 orients these residues in the correct conformation for interactions with 
fibrillar FN.   
 
Upon examination of the loops in these TNfn domains, it can be seen that TNfn1-3 appears to 
possess more acidic residues in its loop structures compared to TNfn3-5 (Figure 7.5 B and C 
respectively).  The loops between the TNfn1at the TNfn1-2 interface are fairly acidic as are the 
loops of TNfn3 at the TNfn2-3 interface; some of these acidic residues also are found adjacent to 
the loop structures within the β-strands and may contribute to this negatively charged surface 
(Figure 7.5 B).  The acidic TNfn3 residues at the TNfn2-3 interface would be exposed in TNfn3-5 
and may confer its ability to bind to soluble FN (Figure 7.5 C).  In comparison, there are very few 
acidic residues in the loops between the TNfn3-4-5 interfaces.  There may be a weak negatively 
charged surface in the TNfn5 loops away from this region, but the presence of an arginine (1041) 
may reduce this overall negative charge (Figure 7.5 C).   
 
This could suggest that the binding site for soluble FN is created by the acidic residues in TNfn3, 
which are found on exposed loops in the TNfn3-5 domain and at the TNfn2-3 interface in the 
TNfn1-3 domain.  Binding to fibrillar FN may require this binding site and the interaction may be 
enhanced by residues at the TNfn1-2 interface and TNfn5 exposed loop regions.  The presence of 
TNfn1-2 alone confers the ability to bind to specific exposed cryptic binding sites in developing FN 
fibrils, whereas TNfn5 may be insufficient in combination with TNfn3 to induce binding of fibrillar 
FN.  The presence of multiple binding sites acting cooperatively to bind FN, would explain the 
strong binding observed in TNfn1-5.   
 
The TNfn5 loops may become buried in the presence of TNfn6 in TNfn1-8.  The TNfn7 loop 
sequences at the TNfn7-8 interface and TNfn8 loop sequences possess some acidic residues, but 
these may not be clustered sufficiently for optimal FN interactions.  The loop structures of TNfn6-8  
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Figure 7.5   Examination of residues in the loop regions of TNfn1-TNfn8 to highlight the 
presence or clustering of charged residues in the loop structures, which may be involved in 
electrostatic interactions 
(A) Schematic of the organization of β strands and the connecting loops in each TNfn module.  (B-
D) The amino acid sequence of the loop structures between β-strands of: (B) TNfn1, TNfn2 and 
TNfn3; (C) TNfn3, TNfn4 and TNfn5; (D) TNfn6, TNfn7 and TNfn8 are shown on their corresponding 
locations in the FN type III fold.  Acidic residues are highlighted in red whereas basic residues are 
highlighted in blue and amino acids which are in the β-strand structure flanking the loop structure 
are shown in italic.    
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do not seem strongly acidic overall (Figure 7.5 D).  This may be why TNfn1-8 shows reduced 
binding compared to TNfn1-5.  Only by investigating a series of different TNfn constructs 
including TNfn2-4 and by selective mutagenesis studies of specific residues within the loop 
structures can it be clarified which domains are important for binding to FN.  If the TNfn1-2 
interface and TNfn5 loops are important then it would be expected that TNfn1-4, TNfn2-5 and 
TNfn1-6 should have reduced associations with fibrillar FN compared to TNfn1-5. 
 
Non-contiguous sequences or multiple weak binding sites have been shown to combine to form 
strong binding sites.  The main binding site in TNfn3-5 for heparin is found in the TNfn5 module, 
but this only shows modest binding in the absence of TNfn4 module, which shows very weak 
binding to heparin by itself but enhances TNfn5 binding several fold (Jang et al., 2004).  The 
heparin binding motif BXBXBXXXXB in (chick) TNfn5: KGRHKSKPTTIK is thought to be the 
major heparin binding site (Busby et al., 1995).  A homologous lysine-rich region is found in 
human TNfn5: KGRHKSKPARVK (Jang et al., 2004).  The KEDK site in TNfn4 was shown to be 
important for enhancing TNfn5 binding and this sequence is located in the loop regions between β-
strands F and G, which face the KGR sequence (Jang et al., 2004).  Similarly, heparin binding by 
FNIII13 also depends on the cooperation of discontinuous residues to form a “cationic cradle” 
structure.  By mutational studies, the BBXB motif: Arg6-Arg7-Ala8-Arg9 and basic residues Arg23, 
Ly25 and Arg54 in FNIII13 formed a patch of positively charged residues and mutation of these 
residues caused a reduction in the affinity of FNIII13 for heparin (Busby et al., 1995).  A 
conformational binding site for heparin is also formed from non-contiguous regions of tenascin-X 
(TN-X) has also been shown (Lethias et al., 2001).  TN-X is expressed in a similar pattern as TN-C 
during development, in connective tissues and tumor tissues.  TN-X possesses 29 TNfn domains 
and molecular modeling and mutagenesis studies showed crucial residues for heparin interactions 
included Lys85 and Arg86 from TNfn10 and Lys16 in TNfn11, which are found in a loop and 
linker regions between TNfn10-1.  Although these sequences did not fit the candidate sequences 
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predicted for heparin binding, the tilt of these domains conformationally forms a cationic cradle 
(Lethias et al., 2001).   
 
From these examples, it must also be considered that residue clusters may also occur within the β-
strand sequences adjacent to the loop sequences.  Indeed many residues from the β-strands 
contribute to the electrostatic surfaces of TNfn3.  This suggests disparate amino acids residues can 
come together to form binding pockets, which are hard to predict by examination of the primary 
structure.  So it is possible that the different TNfn domains possess multiple binding sites from 
multiple charged surfaces and possibly different binding sites for soluble FN versus fibrillar FN.   
 
All of these models require the presence of neighboring domains for optimal FN binding.  This is 
further demonstrated by the fact that mixtures of TNfn1-3 and TNfn3-5 or TNfn1-5 and TNfn6-8 do 
not result in binding similar to TNfn1-5 or TNfn1-8 respectively.  This confirms the importance of 
adjacent modules in inducing conformational changes within the FN binding site(s) for optimal FN 
binding.  These conformational changes could: allow exposure and stabilization of FN binding sites; 
bring together multiple non-contiguous residues to form a binding site; bring together multiple FN 
binding sites formed from other neighboring domains; allow weaker FN binding sites from adjacent 
domains to enhance the affinity of a primary FN binding site.  Further molecular modeling and 
mutagenesis studies will need to be done to determine definitively which residues are important and 
the possible location of FN binding sites.   
    
I attempted to screen for reported FN binding motifs.  Bacterial FN adhesion proteins allow bacteria 
to bind to the ECM and facilitate colonization of the host.  Fibronectin attachment protein-A (FAP-
A) is expressed by mycobacteria including Mycobacterium Avium (Zhao et al., 1999).  Comparison 
of the FAP-A binding sequence (RWFV) with the TNfn1-TNfn8 sequences did not show any strong 
homology.  However, another protein α-Antigen (Ag) or Ag85B secreted by Mycobacterium 
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kansaii, interacts with FN via a conserved FEWYYQ sequence (Naito et al., 1998) and this did 
closely match sequences within TNfn2.  However, this sequence was not contiguous and was found 
between the loop connecting β-strands B and C, and the loop and within the E and loop between the 
E and F β-strands (Figure 7.6 A).  Furthermore, when modeled on the structure and homologous 
sequence in TNfn3 (FEWYIEL) these sequences do not form a contiguous binding site (highlighted 
green in Figure 7.6 B) suggesting this sequence may not be a major FN binding site in TNfn2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.4   Specificity of TN-C binding to FN domains 
TNfn1-5 and TNfn1-8 have been shown to bind to multiple FN domains: the 70-kDa domain, which 
is composed of FNI and FNII repeats; the CBD and 40-kDa HepII domain, which are composed of 
FNIII repeats.  This suggests that TNfn domains could bind to different modular structures.  
Modelling, mapping and determining possible key residues are yet to be done to determine where 
Figure 7.6   Modeling of TNfn3 to show the location of the corresponding FEWYYQ sequence in TNfn2
(A) Sequence alignment of the FEWYYQ sequence with TNfn1-TNfn8 modules are highlighted in green on 
TNfn2.  Sequence alignment was done using CLUSTALW online NPS@: Network Protein Sequence Analysis 
(TIBS 2000 March Vol. 25, No 3 [291]:147-150, Combet C., Blanchet C., Geourjon C. and Deléage G). 
(B)  Residues corresponding to the FEWYYQ sequence in TNfn2 (IDIYINL in TNfn3) are highlighted in green 
on the surface model of TNfn3 (pdb file: 1Ten).   
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TNfn domains could be binding within the FN domains.  It is possible that fragments of TN-C can 
interact with other FN type III repeats including other TNfn domains in a similar manner as FNIII 
domains.  However, this has not been reported and in electron microscopy images of TN-C, no 
interactions between the arms of the hexabrachion structure are observed.  The masking of loop 
structures or the presence of the EGF-L and FBG neighbouring domains may prohibit these internal 
TNfn-TNfn modular interactions.   
 
7.5   Summary 
The ECM is a complex and dynamic structure of networked proteins with multiple components and 
organizations.  Its importance in dictating cell dynamics has only been relatively recently 
established.  Deciphering how this ECM is assembled and how this 3D structure affects cell 
behaviour is essential to understand how it influences cell processes including adhesion, migration, 
proliferation, differentiation and apoptosis and help control pathological conditions in which these 
cell processes become misregulated .   
 
The ECM is formed of secreted proteins assembled by the cells and its composition can change as 
required to modulate ECM stiffness or structure.  TN-C and FN are both highly expressed in 
remodelling tissues in a temporally and spatially similar manner.  I have shown in this study that FN 
matrix assembly cannot be inhibited by full-length TN-C but can be inhibited by specific domains 
within TN-C, which may act as a cryptic regulatory mechanism to feedback and limit FN assembly 
upon its degradation.  Furthermore, specific domains of TN-C can also act to reduce mature FN 
levels suggesting it may generally limit FN levels.  These TN-C domains act via distinct 
mechanisms to inhibit FN-FN intermolecular interactions, FN-cell surface receptor interactions and 
affect actin cytoskeletal organization.  So far, I have also demonstrated that a specific TN-C domain 
can interfere with tubulogenesis and may also affect angiogenesis, which are both processes that are 
dependent on FN matrix assembly.     
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The ability of these TN-C and FN domains to regulate FN levels and its assembly, and its effects on 
tubule forming processes may provide unique tools, which can be applied to control excessive ECM 
deposition or aberrant angiogenesis that occurs in pathological conditions including tumorigenesis.    
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8.1   Confirm the mechanism of FBG inhibition 
• Is it cell surface receptor specific? 
- Internalization/effects on cell morphology competed out by  
heparin (HSPGs) 
blocking αvβ3 Ab (αvβ3) 
cyclic RGD (αvβ3) 
 
- FACs to determine α5β1 activation levels  
 
• Confirm FBG internalization by:  
- Electron microscopy 
- Co-localization with LAMP-1 (lysozomal marker) or EEA-1 (endosomal marker) 
 
• Confirm FN internalization: 
- Monitor fluorescent FN internalization by FN null fibroblasts 
- Co-localization with LAMP-1 or EEA-1 
 
• Determine FBG and confirm  FN endocytosis mechanism: 
- Cavaloe dependent endocytosis inhibitors: β-cyclodextrin (cholesterol binding agent), 
staurosporin or genistein (kinase inhibitors) or jasplakinolide (actin filament 
stabilizing agent) 
- Clathrin dependent endocytosis inhibitors:  monensin (proton gradient inhibitor),  
monodansylcadaverine (MDC) (clathrin cage stabilizer) or hyperosmolar sucrose 
(inhibits association of adaptor proteins with clathrin) 
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• Confirm the order of inhibition: 
Is it cell shape change the results in the loss of FN 
Or is it the loss of FN that results in the cell shape changes 
- Plate cells on FN/cell free FN matrix, add exogenous FBG Æ does it affect cell 
morphology? 
- Real-time lapse microscopy and pulse chase with fluorescently labelled FBG and monitor 
its entrance into cells over time 
- Real-time lapse microscopy with cells expressing a GFP-tagged actin construct  to monitor 
cell shape over time after applying a pulse chase of fluorescently labelled FBG 
- Real-time lapse microscopy with cells expressing a GFP-tagged fluorescently labelled FN 
construct to monitor FN fibrillogenesis or loss of fibrils over time 
- Treat cells with cytochalasin D or ROCK inhibitor Y-27632, which interfere with the actin 
cytoskeleton and determine whether it affects FN matrix assembly   
 
• Mutagenesis studies: 
- Mutate putative ‘active’ sites in FBG (αvβ3 or heparin binding) to confirm the requirement 
of cell surface receptors for internalization 
 
8.2   Confirm TNfn1-8 and 70-kDa inhibit tubulogenesis by inhibiting FN matrix assembly 
• Immunofluorescence: 
- Slice collagen gels by cryostat sectioning and try detecting FN by 
 immunofluorescence; screen different FN antibodies? 
- Fluorescently label TNfn1-8 and 70-kDa and look to see if they localize to the basement 
membrane around tubules 
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• FN expression levels: 
- Digest collagen gels and western blot for FN 
- Digest collagen gels and isolate FN mRNA 
 
• Apoptosis studies: 
To confirm that the loss of FN is not resulting in the loss of integrin ligation and inducing apoptosis 
(Jiang et al., 1999). 
- Digest collagen gels and western blot for caspase-3, -8 and -9 cleavage products 
- Section and stain with Annexin V 
 
8.3   Confirm effects of TN-C domains on angiogenesis 
• In vitro angiogenesis: 
- Repeat 3D collagen gel experiments 
• Ex vivo angiogenesis: 
- Chorioallantoic membrane model 
 (Zhou et al., 2008) 
• In vivo mouse model: 
- Implantation of cardiac tissue into the mouse ear  
 (Ballard et al., 2006) 
 
8.4   Confirm effects of TN-C domains on angiogenesis are specific for alterations on FN 
matrix assembly 
• Immunofluorescence: 
- Section collagen gels and chorioallatnoic membranes and stain for FN 
-  
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8.5   Mechanism of TN-C effects on angiogenesis 
• Apoptosis studies:  
To confirm that the loss of FN is not resulting in the loss of integrin ligation and inducing apoptosis 
(Jiang et al., 1999). 
- Digest collagen gels and western blot for caspase-3, -8 and -9 cleavage products 
- Section and stain with Annexin V 
 
• Mutagenesis studies: 
- Mutate putative ‘active’ sites in FBG (αvβ3 or heparin binding) or TNfn1-8 (TNfn3 
module) and determine effects on angiogenesis 
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Figure A1   Purification of recombinant TNfn1-8  
TNfn1-8 was expressed in Rosetta DE3 cells and cell lysate passed over a nickel agarose column.  (A) Eluted 
fractions were pooled and separated by SDS-PAGE (12% total acrylamide) and gels were coomassie stained. 
The arrow denotes the TNfn1-8 band at the expected molecular weight of 80-kDa and the arrow heads show 
the multiple contaminants.  (B) The pooled fractions were passed over an S-column and eluted in 1 ml fractions.  
10 μl of each fraction was resolved by SDS-PAGE (10% total acrylamide) and silver stained.  The arrow 
denotes the TNfn1-8 band and the arrow heads indicate the remaining 2 contaminants.  (C) TNfn1-8 containing 
fractions from the S-column were pooled and separated by gel filtration.  Eluted fractions were resolved by 
SDS-PAGE (10% total acrylamide) and silver stained.  The arrow denotes the TNfn1-8 band.  (D) TNfn1-8 
containing fractions without contaminants from gel filtration were combined into two pools and 1μg resolved by 
SDS-PAGE (10% total acrylamide) and silver stained.  The arrow denotes pure TNfn1-8.  Molecular weight 
markers are in kDa. 
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Figure A2  Western blots to determine that TN-C and TN-C domains are efficiently 
adsorbed onto ELISA dishes 
ELISA plates were coated with 78 nM TN-C and individual TN-C domains and incubated 
overnight at 4ºC.  The supernatant was then decanted. 10 μl of the TN-C or TN-C domain 
solution before (Lane 1) and 10 μl of the supernatant decanted after immobilisation (lane 
2) was resolved by SDS-PAGE (10% total acrylamide) and Western blotted with the anti-
His antibody (34670) and secondary AP-conjugated antibody.  Lane 3: 1 μg of purified 
protein was included as a control.  Molecular weight markers are in kDa.   
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Figure A3   Confirmation that the anti-FN antibody is used in excess in solid phase 
experiments and its specificity for FN  
(A) To  ensure excess anti-FN antibody is used in this solid phase assay: ELISA plates 
were coated with 25 μg/ml FN, 70-kDa, CBD or 40-kDa overnight at 4ºC and blocked in 
5% skimmed milk before incubating with increasing dilutions of anti-FN antibody (F3648) 
for 1 h at 37ºC.  Secondary HRP-conjugated antibody (NA9340) was applied at 1:4000 
dilution and colour developed by addition of TMB colorimetric substrate.  Representative 
results are shown as an average from triplicate repeats +/- SEM. (B) To determine that the 
anti-FN antibody is specific for FN alone: ELISA plates were coated with 25 μg/ml FN, 25 
μg/ml full-length TN-C or 78 nM TN-C domains overnight at 4ºC and blocked in 5% 
skimmed milk before incubating with 1:200 anti-FN antibody (F3648) for 1 h at 37ºC.  
Secondary HRP-conjugated antibody (NA9340) was applied at 1:4000 dilution and colour 
developed by addition of TMB colorimetric substrate.  Representative results are shown as 
an average from triplicate repeats +/- SEM.   
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Figure A4   Western blot to confirm adsorption of FN onto the ELISA 
dish  
ELISA plates were coated with 25 μg/ml human plasma FN and 
incubated overnight at 4ºC before decanting the supernatant.  Lane 2: 10 
μl of the FN solution before coating and lane 3: 10 μl of the decanted 
supernatant after immobilisation was resolved by SDS-PAGE (10% total 
acrylamide) and Western blotted with an anti-FN antibody (F3648) and a 
secondary AP-conjugated antibody.  Lane 1: 0.1 μg FN was included as 
a control.  Molecular weight markers are in kDa. 
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Figure A5   Solid phase binding assays and Western blots to confirm that anti-TN-C antibodies can detect 
their specific epitopes on TN-C and TN-C domains when immobilised onto ELISA dishes   
ELISA plates were coated with 78 nM TN-C or individual TN-C domains or 25 μg/ml FN overnight at  4ºC and 
blocked in 5% skimmed milk before incubating with a 1:200 dilution of: (A) anti-TNfn1-3 antibody (MAB1911); (B) 
anti-TNfn6-8 antibody (MAB1918); (C) anti-tetra-His tag antibody (34670).  (D) To confirm the specificity of the 
anti-TN-C antibodies 1 μg TN-C and FN were resolved by SDS-PAGE (6% total acrylamide) and Western blotted 
with an (i) anti-N-terminal TN-C antibody (MAB1908), (ii) anti-TNfn6-8 antibody (MAB1918) or as a control, (iii) 
the anti-FN antibody (F3648).  Molecular weight markers are in kDa.  
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Figure A6   Western blots to confirm TNfn1-8 domains are recognised by antibodies 
specific for TNfn1-3 and TNfn6-7 epitopes  
1 μg TN-C and individual TNfn domains were resolved by SDS-PAGE (10% total acrylamide) 
and Western blotted with an (A) anti-TNfn1-3 (MAB1911) or (B) anti-TNfn6-7 (MAB1918) and 
secondary AP-conjugated antibody. Molecular weight markers are in kDa.  
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Figure A7   Solid phase binding assays and Western blots show an absence of anti-FBG reactivity with 
an anti-FBG antibody (MAB19101) but show anti-FLAG antibody reactivity for FLAG-tagged FBG   
(A) 1 μg TN-C and FBG were resolved by SDS-PAGE (10% total acrylamide) and Western blotted with an anti-
FBG antibody (MAB19101) and secondary AP-conjugated antibody.  Molecular weight markers are in kDa.  (B)  
ELISA plates were coated with 78 nM TN-C or FBG overnight at 4ºC and blocked in 5% skimmed milk before 
incubating with a 1:200 dilution of anti-FBG antibody (MAB19101). Secondary HRP-conjugated antibody 
(NA9310) was applied at 1:4000 dilution and colour developed by addition of TMB colorimetric substrate.  
Representative results are shown as an average from triplicate repeats +/- SEM from a two independent 
experiments.  (C) 1 μg of each purified protein was resolved by SDS-PAGE (10% total acrylamide) and 
Western blotted with a an anti-FLAG antibody (F3165). The higher molecular weight band represents 
glycosylated FBG.  Molecular weight markers are in kDa.  (D) ELISA plates were coated with 78 nM FLAG-
tagged FBG overnight at 4ºC and blocked in 5% skimmed milk before incubating with 1:200 dilution of anti-
FLAG antibody (F3165).  Secondary HRP-conjugated antibody (NA9310) was applied at 1:4000 dilution and 
colour developed by addition of TMB colorimetric substrate. Representative results are shown as an average 
from triplicate repeats +/- SEM from a two independent experiments.  
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Figure A8   Fluorescent labelling of TN-C and TN-C recombinant proteins 
with Alexa Fluor-488 dye  
(1) 1 μg unlabelled protein and (2) an equivalent volume of protein after Alexa 
Fluor-488 labelling were resolved by SDS-PAGE (10% total acrylamide).  
Successful fluorescence labelling of the protein was detected by phoshoimaging 
(A) of silver stained gels (B).  To confirm the protein identity, unlabelled and 
fluorescently labelled proteins were also Western blotted with an anti-His antibody 
(34670) (C) or an anti-TNfn1-3 antibody (MAB1911) (D). Molecular weight markers 
are in kDa.  
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Fragment
OD
280 nm
A280
OD
495 nm
Amax Prot conc (μM) Dye conc (μM)
Ratio
[Dye] : [TN-Cd] 
TN-C 0.0147 0.0017 0.280754 0.119718 0.4264176
TNfn1-3 0.157 0.069 21.09715 4.859155 0.2303228
TNfn3-5 0.1562 0.1145 19.45867 8.06338 0.4143849
TNfn1-5 0.0577 0.0623 8.16 8.77 1.08
TNfn5-7 0.137 0.230 3.04 3.25 1.07
TNfn6-8 0.0621 0.0919 8.278822 6.471831 0.7817333
TNfn1-8 0.233 0.089 11.9058 6.267606 0.5264328
FBG 0.0536 0.0634 4.581958 4.464789 0.9744282
Labelling efficiency is determined from the concentration of dye : concentration of TN-C domain ratio 
([Dye] : [TN-Cd])  i.e. the number of dye molecules per protein molecule.  The concentration was 
calculated from the O.D. at 280 nm and 495 nm as described by the equations above and in materials 
and methods.   
Table A1   Alexa Fluor-488 dye labelling efficiency of TN-C and each TN-C domain 
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Figure A9   Mapping the FN domains involved in TNfn1-3, TNfn3-5 and TNfn6-8 
interactions with pre-assembled FN matrix by immunofluorescent staining in the 
presence of increasing concentrations of unlabelled CBD 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium before being further cultured 
with: buffer alone in the absence of recombinant protein (A), 250 nM CBD (B) or 100 nM 
fluorescently labelled TNfn1-3 (C, F), TNfn3-5 (D, G) or TNfn6-8 (E, H).  TNfn1-3, TNfn3-5 
and TNfn6-8 were pre-incubated for 1 h at 37ºC with buffer in the absence of CBD (C, D, E) 
or 1000 nM CBD (F,G, H). Cells were incubated for a further 1 h at 37ºC then fixed in 3.8% 
(w/v) paraformaldehyde and stained with an anti-FN antibody (F3648) and secondary Alexa 
Fluor-568 conjugated antibody.  Representative images from 3 random fields of view are 
shown.  Images were taken by confocal microscopy at x100 magnification, scale bar = 25 
μm. 
Appendix 
 296
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure A10   Mapping the FN domains involved in TNfn1-3, TNfn3-5 and TNfn6-8 
interactions with pre-assembled FN matrix by immunofluorescent staining in the 
presence of increasing concentrations of unlabelled 40-kDa 
NIH 3T3 fibroblasts were plated for 24 h in serum-free medium before being further cultured 
with:  buffer alone in the absence of recombinant protein (A), 250 nM 40-kDa (B) or 100 nM 
fluorescently labelled TNfn1-3 (C, F, I, L), TNfn3-5 (D, G, J, M) or TNfn6-8 (E, H, K, N).  TNfn1-
3, TNfn3-5 and TNfn-68 were pre-incubated for 1 h at 37ºC with buffer only (C, D, E) or 100 nM 
40-kDa (F,G H), 500 nM 40-kDa (I, J, K) or 1000 nM 40-kDa (L, M, N). Cells were incubated for 
a further 1 h at 37ºC then fixed in 3.8% (w/v) paraformaldehyde and stained with an anti-FN 
antibody (F3648) and secondary Alexa Fluor-568 conjugated antibody. Representative images 
from 3 random fields of view are shown.  Images were taken by confocal microscopy at x100, 
scale bar = 25 μm. 
